

EXHIBIT 1

1 UNITED STATES DISTRICT COURT
2 DISTRICT OF NEW JERSEY
3 CAMDEN VICINAGE

4 : MDL NO. 2875
5 IN RE: VALSARTAN, :
6 LOSARTAN, AND IRBESARTAN :
7 PRODUCTS LIABILITY :
8 LITIGATION : VIDEOTAPED DEPOSITION
9 : UPON
10 : ORAL EXAMINATION
11 : OF
12 : STEPHEN S. HECHT, PhD
13 ----- X

14 TRANSCRIPT of the stenographic notes of
15 the proceedings in the above-entitled matter, as
16 taken by and before ELLEN J. GODINO, CCR, RPR, CRCR,
17 held via ZOOM VIDEOCONFERENCE from various locations,
18 with the witness located at 2231 6th Street,
19 Minneapolis, Minnesota, on Friday, January 13, 2023,
20 commencing at 8:18 a.m. Central Time.
21
22
23
24
25

<p style="text-align: right;">Page 2</p> <p>1 APPEARANCES: 2 FOR ZHEJIANG HUAHAI PHARMACEUTICAL, CO., LTD. 3 SKADDEN ARPS SLATE MEAGHER & FLOM, LLP BY: RICHARD T. BERNARDO, ESQ. 4 JOSHUA J. SCHUCH, ESQ. JORDAN EINHSTEIN, ESQ. 5 One Manhattan West New York, New York 10001-8602 6 212-735-3000 richard.bernardo@skadden.com 7 8 FOR PLAINTIFFS: 9 MAZIE SLATER KATZ & FREEMAN BY: ADAM M. SLATER, ESQ. 10 CHRISTOPHER J. GEDDIS, ESQ. 103 Eisenhower Parkway 11 2nd Floor Roseland, New Jersey 07068 12 973-228-9898 aslater@mazieslater.com 13 cgeddis@mazieslater.com 14 15 LEVIN PAPANTONIO RAFFERTY BY: DANIEL NIGH, ESQ. 316 South Baylen St. 16 Pensacola, Florida 32502 850-435-7013 17 dnigh@levinlaw.com 18 19 HOLLIS LAW FIRM BY: C. BRETT VAUGHN, RN, BSN, ESQ. 8101 College Boulevard 20 Suite 260 Overland Park, Kansas 66210 21 913-385-5400 22 23 24 25</p>	<p style="text-align: right;">Page 4</p> <p>1 APPEARANCES (Continued): 2 FOR MYLAN PHARMACEUTICALS INC., AND MYLAN LABORATORIES, LTD.: 3 PIETRAGALLO GORDON ALFANO BOSICK & RASPANTI, LLP 4 BY: JASON M. REEFER, ESQ. One Oxford Centre 5 301 Grant Street, 38th Floor Pittsburgh, Pennsylvania 15219 6 412-263-4397 jmr@pietragallo.com 7 8 FOR TORRENT PHARMA INC. & TORRENT PHARMACEUTICALS, 9 LTD.: 10 KIRKLAND & ELLIS, LLP BY: BRITTNEY NAGLE, ESQ. 11 601 Lexington Avenue New York, New York 10022 12 212-390-4210 brittney.nagle@kirkland.com 13 14 FOR HETERO LABS, LTD: 15 HILL WALLACK, LLP BY: JOHN C. BOBBER, JR., ESQ. 16 777 Township Line Road Suite 250 17 Yardley, Pennsylvania 19067 267-759-2064 18 jbobber@hillwallack.com 19 FOR ALBERTSON'S COMPANIES, LLC: 20 BUCHANAN INGERSOLL & ROONEY, PC 21 BY: CHRISTOPHER B. HENRY, ESQ. Carillon Tower 22 227 West Trade Street, Suite 600 Charlotte, North Carolina 28202 23 704-444-3475 christopher.henry@bipe.com 24 25</p>
<p style="text-align: right;">Page 3</p> <p>1 APPEARANCES (Continued) 2 FOR TEVA PHARMACEUTICALS USA, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD., ACTAVIS PHARMA, INC., 3 AND ACTAVIS LLC: 4 GREENBERG TRAURIG, LLP BY: STEVEN M. HARKINS, ESQ. 5 VICTORIA DAVIS LOCKARD, ESQ. Terminus 200 6 3333 Piedmont Road NE, Suite 2500 Atlanta, Georgia 30305 7 678-553-2100 Harkinss@gtlaw.com 8 Lockardv@gtlaw.com 9 MARTIN, HARDING & MAZZOTTI, LLP BY: ROSEMARIE RIDDELL BOGDAN, ESQ. 10 P.O. Box 15141 23 Albany, New York 12212 11 518-724-2207 Rosemarie.bogdan@1800law1010.com 12 13 FOR HUMANA INC. & HUMANA PHARMACY, INC.: 14 FALKENBERG IVES, LLP BY: KIRSTIN B. IVES, ESQ. 15 230 W. Monroe, Suite 2220 Chicago, Illinois 60606 16 312-566-4808 kbi@falkenbergives.com 17 18 FOR PFIZER INC., VALEANT PHARMACEUTICALS INTERNATIONAL, INC., BAUSCH & LOMB INCORPORATED, AND 19 ATON PHARMA, INC.: 20 WALSH PIZZI O'REILLY FALANGA, LLP BY: CHRISTINE I. GANNON, ESQ. 21 Three Gateway Center 100 Mulberry Street, 15th Floor 22 Newark, New Jersey 07102 973-757-1100 cgannon@walsh.com 23 24 25</p>	<p style="text-align: right;">Page 5</p> <p>1 INDEX 2 3 Examinations Page 4 STEPHEN HECHT, Ph.D. 11 5 6 EXAMINATION BY MR. BERNARDO 11 7 CONTINUED EXAMINATION BY MR. BERNARDO 205 8 9 EXAMINATION BY MR. HARKINS 250 10 EXAMINATION BY MS. NAGLE 286 11 12 EXAMINATION BY MR. SLATER 291 13 EXAMINATION BY MR. BERNARDO 312 14 15 EXAMINATION BY MR HARKINS 318 16 EXAMINATION BY MR. SLATER 320 17 18 EXAMINATION BY MR. BERNARDO 322 19 EXAMINATION BY MR. SLATER 323 20 21 EXAMINATION BY MR. BERNARDO 324 22 EXAMINATION BY MR HARKINS 325 23 24 25</p>

Page 6				Page 8			
1	INDEX (Continued)			1	E X H I B I T S (Continued)		
2				2			
3	EXHIBITS			3	Number	Description	Page
4	Number	Description	Page	4	Hecht-15	English Translation of Hecht-14, Bates ZHP02630926 through 2630927	168
5	Hecht-1	Letter Report of Stephen S. Hecht, PhD, dated July 6, 2021, No Bates Stamps, 44 Pages	12	5	Hecht-16	Email Chain ending December 27, 2016, Bates ZHP0477534 through 477553	172
6	Hecht-2	Letter Report of Stephen S. Hecht, PhD, dated October 31, 2022, No Bates Stamps, 15 Pages	13	6	Hecht-17	Email Chain ending February 29, 2019, Bates ZHP02709940 through 2709984	178
7	Hecht-3	FDA Receipt Letter for ZHP Drug Master File Submission, Bates SOLCO00032578 through 32580	18	7	Hecht-18	Email Chain in Chinese Language ending February 28, 2019 previously marked ZHP-271, Bates ZHP00496153 through 496154	188
8	Hecht-4	ZHP Product Development Report for Valsartan, Bates ZHP01710663 through 1710729	22	8	Hecht-19	Document in Chinese Language previously marked ZHP-272, Bates ZHP00496155 through 496156	188
9	Hecht-5	Amendment to Drug Master File dated April 16, 2012, Bates PRINSTON00079747 through 79755	27	9	Hecht-20	English Translation of Hecht-19, previously marked ZHP-272A	188
10	Hecht-6	Amendment to Drug Master File for Valsartan dated December 10, 2013, Bates PRINSTON00073102 through 73119	34	10	Hecht-21	Email Chain ending December 22, 2016, Bates ZHP02118712 through 2118731	190
11	Hecht-7	Expert Report of Fengtian Xue, PhD dated December 22, 2022, No Bates, 107 Pages	49	11	Hecht-22	Email Chain ending April 20, 2017, Bates ZHP02118680 through 2118708	193
12	Hecht-8	United States Patent 5,502,191 Issued March 26, 1996	81	12	Hecht-23	Chart titled "D5191-15-359," Bates ZHP02118709 through 2118711	195
13				13			
14				14			
15				15			
16				16			
17				17			
18				18			
19				19			
20				20			
21				21			
22				22			
23				23			
24				24			
25				25			

Page 7				Page 9			
1	E X H I B I T S (Continued)			1	E X H I B I T S (Continued)		
2				2			
3	Number	Description	Page	3	Number	Description	Page
4	Hecht-9	FDA Statement entitled, "FDA Statement on FDA's ongoing investigation into valsartan impurities and recalls and an update on FDA's current findings" dated August 30, 2018, No Bates, Six Pages	120	4	Hecht-24	Excerpt from Purification of Laboratory Chemicals, Fourth Edition, by W.L.F. Amarego and D.D. Perrin, No Bates, 21 Pages	206
5	Hecht-10	FDA Statement entitled, "FDA Statement on the FDA's ongoing investigation into valsartan and ARB class impurities and the agency's steps to address the root causes of the safety issues," dated January 25, 2019, No Bates, Five Pages	123	5	Hecht-25	Composite Exhibit, Copies of Dr. Hecht's Exhibit Binders	225
6	Hecht-11	Article entitled "High performance mini-gas chromatography-flame ionization detector system based on micro gas chromatography column," from Review of Scientific Instruments, published April 21, 2016	136	6	Hecht-26	Curriculum Vitae of Stephen S. Hecht, PhD, Nine Pages	293
7	Hecht-12	Email Chain ending 2/28/2019 in Chinese Language, Bates ZHP02630924 through 2630925	163	7	Hecht-27	FDA Warning Letter 320-19-04 dated November 29, 2018, previously marked ZHP-213, Bates ZHP01344159 through 1344164	297
8	Hecht-13	English Translation of Hecht-12, previously marked ZHP-265A	166	8	Hecht-28	Article entitled "Identification and Control of Impurities for Drug Substance Development using LC/MS and GC/MS," from The Journal of Liquid Chromatography and Related Technologies	304
9	Hecht-14	Document in Chinese Language previously marked ZHP-266, Bates ZHP02630926 through 2630927	167	9	Hecht-29	Document entitled "Valsartan, Analysis Report for Peak Identification in GC Chromatogram Other Than Listed Solvents," Bates ZHP01746277 through 1746288	308
10				10	Hecht-30	Qualitative Reports, Bates SYNCOR00001458 through 1465	310
11				11	Hecht-31	PowerPoint Presentation dated August 23, 2012, No Bates, 19 Slides	311
12				12			
13				13			
14				14			
15				15			
16				16			
17				17			
18				18			
19				19			
20				20			
21				21			
22				22			
23				23			
24				24			
25				25			

<p style="text-align: right;">Page 10</p> <p>1 THE VIDEOGRAPHER: Good morning. We are 2 going on the record at 8:18 a.m. Central Time on 3 January 13, 2023. Please note that this deposition 4 is being conducted virtually. The quality of 5 recording depends on the quality of camera and 6 internet connection of participants. What is seen 7 from the witness and heard on screen is what will be 8 recorded. Audio and video recording will continue to 9 take place unless all parties agree to go off the 10 record. 11 This is Media Unit 1 of the 12 video-recorded deposition of Dr. Stephen Hecht in the 13 matter of In Re: Valsartan, Losartan, and Irbesartan 14 Products Liability Litigation, filed in the United 15 States District Court for District of New Jersey, 16 Camden Vicinage, MDL Number 2875. 17 My name is Lee Bowry, from the firm of 18 Veritext New Jersey, and I am the videographer. The 19 court reporter is Ellen Godino, and our concierge is 20 Justin Biley, also with Veritext. 21 I am not related to any party in this 22 action, nor am I financially interested in the 23 outcome. 24 If there are any objections to 25 proceeding, please state them at this time.</p>	<p style="text-align: right;">Page 12</p> <p>1 assume that you understand the questions I'm asking, 2 unless you ask me to clarify. Is that fair? 3 A. Okay. 4 Q. Is there anything that would prevent you 5 from providing truthful and accurate testimony today? 6 A. No. 7 Q. Okay. And I know you're -- we're all 8 doing this through technology, and I trust that 9 you're not going to communicate to anybody or look at 10 communications from anybody, either by email or chat 11 or text or otherwise, during the course of my 12 questions. Is that fair? 13 A. Yes. 14 Q. Dr. Hecht, you've written two reports in 15 this case. One is dated July 21 -- I'm sorry, 16 July 6, 2021, and one is dated October 31st, 2022. 17 Correct? 18 A. Yes. 19 MR. BERNARDO: I'd like to mark those 20 two exhibits as Hecht-1 and 2? 21 MR. SLATER: Which one is 1? 22 MR. BERNARDO: His first report -- thank 23 you, Adam -- July 6, 2021, will be 1; and 24 October 31st, 2022 will be 2. 25 (Exhibit Hecht-1, Letter Report of</p>
<p style="text-align: right;">Page 11</p> <p>1 Having heard none, counsel attending 2 remotely will be noted on the stenographic record. 3 Will the court reporter please swear in 4 the witness and then counsel may proceed. 5 STEPHEN HECHT, Ph.D., 2231 6th Street, 6 Minneapolis, Minnesota, having been duly sworn, 7 testified as follows: 8 EXAMINATION BY MR. BERNARDO: 9 Q. Good morning, Dr. Hecht. Would you 10 please state your name for the record? 11 A. Pardon? I couldn't hear you. 12 Q. Well. I'll adjust my volume. Can you 13 hear me if I speak at this volume? 14 A. Yeah. 15 Q. Okay. Would you please state your name 16 for the record? 17 A. Stephen Hecht. 18 Q. And you understand, Dr. Hecht, that 19 you're here today under oath, as if you were in a 20 courtroom, and testifying as if you were in a 21 courtroom. Correct? 22 A. Yes. 23 Q. And I know you've been deposed a number 24 of times, so I'm not going to go through the standard 25 preamble, but I just want to say that I'm going to</p>	<p style="text-align: right;">Page 13</p> <p>1 Stephen S. Hecht, Ph.D., dated July 6, 2021, No Bates 2 Stamps, 44 Pages, was received and marked for 3 identification.) 4 (Exhibit Hecht-2, Letter Report of 5 Stephen S. Hecht, Ph.D., dated October 31, 2022, No 6 Bates Stamps, 15 Pages, was received and marked for 7 identification.) 8 Q. And I understand, Dr. Hecht, you may 9 have copies of those reports with you. And just to 10 clarify the questions I'm going to ask you: I'm 11 going to be asking you about your 2022 report, 12 Exhibit 2, in its entirety, but I'm only going to be 13 asking you about certain portions of your 2021 14 report; and it would be the Section Roman II.2, 15 titled "Formation of Nitrosamines" on pages 6 to 7, 16 if you want to just take a look at that. 17 A. Yes. 18 Q. And then all of Section Roman III, 19 titled "Formation of Nitrosamines in Valsartan API." 20 (Court Stenographer clarification.) 21 Q. Section III, titled "Formation of 22 Nitrosamines in Valsartan API." 23 A. Section III? 24 Q. And I'm doing this, Dr. Hecht, just to 25 be efficient here. So when I just ask about your</p>

Page 14

1 opinions in this case or your opinions or your
2 report, I don't want to go through this
3 clarification. I just want you to assume, unless I
4 state otherwise, that those are the sections of your
5 first report and the entirety of your second report
6 about which I'm asking. Is that clear?
7 A. No.
8 Q. Okay.
9 MR. SLATER: Rich, I think this is -- I
10 get what you're saying, but I think this is very
11 confusing. Because you're going to make him think
12 he's got to go look at --
13 A. I'm not sure what you mean by "Section
14 3."
15 Q. There's a section, Roman III?
16 MR. SLATER: What page?
17 MR. BERNARDO: Give me a minute.
18 MR. SLATER: Page 18 of the first
19 report.
20 Q. And while you're looking at that,
21 Dr. Hecht, the reason I'm doing this is, I just don't
22 want there to be confusion, and this goes to a point
23 that Mr. Slater raised. I'm really here asking you
24 questions about certain opinions.
25 And I just, when I say "your opinions in

Page 15

1 this case" or "your report," I'm really referring to
2 these confines. I just want that to be clear on the
3 record, and for you to understand that so we're not
4 talking about either general caution or other issues.
5 Does that help clarify?
6 A. Yes.
7 Q. Okay. Thank you very much.
8 And Dr. Hecht, did you sign -- we're
9 going to be talking about exhibits that have been
10 marked "Confidential" in this litigation.
11 Have you signed the appropriate exhibits
12 to the protective order in this case? Are you
13 familiar with the protective order that has been
14 entered in this litigation?
15 A. No.
16 MR. SLATER: Yes, he signed it, Rich.
17 This was years ago.
18 MR. BERNARDO: Okay. I just want a
19 clarification for that on the record, and he just
20 said something different than you did.
21 Q. So let me ask you that again. There's a
22 protective order that's been entered in this case
23 that governs the use of confidential information. I
24 just want to ensure that you've read that, and that
25 you have signed on it, intending that you agree to

Page 16

1 its terms?
2 A. Okay.
3 Q. So is "okay" a "yes"?
4 A. Yes.
5 Q. Thank you.
6 Dr. Hecht, you agree ZHP used four
7 distinct manufacturing processes to produce valsartan
8 API, prior to 2018. Fair?
9 A. Yes.
10 Q. And the first one is known as the TIN
11 process?
12 A. Yes.
13 Q. And the second is known as the TEA
14 process?
15 A. Yes.
16 Q. And the third is a TEA with quenching
17 process?
18 A. Yes.
19 Q. And the fourth is the zinc chloride
20 process?
21 A. Right.
22 Q. Okay. Let's talk about those processes.
23 Let's start with the TIN process.
24 And if you need me to pull up
25 documentation in order for you to answer these

Page 17

1 questions, please ask and I'm happy to do that and
2 have that marked, but I think some of these, you
3 should be able to answer without having to look at
4 them.
5 So let's talk about the TIN process. In
6 that process -- that's what the company refers to --
7 in that process, in company documents, there is a
8 reference to "Step 4, the carbon-nitrogen group or CN
9 starting material, which was treated with sodium
10 azide to form the tetrazole compound." Is that
11 correct?
12 A. Yes.
13 Q. Okay. And in simple terms, what is a
14 tetrazole compound?
15 A. The tetrazole has four nitrogens in a
16 ring structure, and it's part of the structure of the
17 sartans.
18 Q. And the --
19 A. The sodium azide provides three of the
20 nitrogens.
21 Q. And this process was done in the
22 presence of a catalyst, [REDACTED] using
23 [REDACTED] as a solvent?
24 And pardon me if I'm not pronouncing
25 these exactly correctly, but I think you'll get the

<p style="text-align: right;">Page 18</p> <p>1 gist?</p> <p>2 A. It's [REDACTED]</p> <p>3 Q. Thank you.</p> <p>4 (Court Reporter Clarification.)</p> <p>5 MR. BERNARDO: Sure.</p> <p>6 Q. Let's switch over to the TEA process.</p> <p>7 ZHP filed a paper submission, which is</p> <p>8 called the Drug Master File, with the FDA for the TEA</p> <p>9 process in January of 2010. Correct?</p> <p>10 A. Yes.</p> <p>11 Q. Okay.</p> <p>12 MR. BERNARDO: Let's pull up on the</p> <p>13 screen and mark as Exhibit 3 company documents</p> <p>14 regarding the product development report.</p> <p>15 MR. BILY: Counsel, what tab?</p> <p>16 MR. BERNARDO: Tab 3.</p> <p>17 (Exhibit Hecht-3, FDA Receipt Letter for</p> <p>18 ZHP Drug Master File Submission, Bates SOLCO00032578</p> <p>19 through 32580, was received and marked for</p> <p>20 identification.)</p> <p>21 Q. Can you see what's on the screen?</p> <p>22 A. No, it's too small.</p> <p>23 MR. BERNARDO: Can you expand the size?</p> <p>24 Q. Does that help?</p> <p>25 A. Yeah, that's a little better.</p>	<p style="text-align: right;">Page 20</p> <p>1 A. I'm not terribly familiar with it, no.</p> <p>2 Q. Okay.</p> <p>3 A. But I can see what -- I can understand</p> <p>4 what it is.</p> <p>5 Q. So this isn't the kind of document you</p> <p>6 would have looked at to form your opinions in this</p> <p>7 case, as to the manufacturing changes or the reason</p> <p>8 for changes, or the process?</p> <p>9 MR. SLATER: Objection to the form of</p> <p>10 the question.</p> <p>11 You can answer.</p> <p>12 A. Not directly from this document. I</p> <p>13 mean, I've read descriptions of the -- you know, the</p> <p>14 processes that were used.</p> <p>15 Q. And where did you get the descriptions,</p> <p>16 and what kind of documents did you get the</p> <p>17 descriptions of the processes that were being used,</p> <p>18 Dr. Hecht?</p> <p>19 A. From the -- well, I've seen the, you</p> <p>20 know, the documents from ZHP that describe a lot of</p> <p>21 this. And also...</p> <p>22 Q. Why don't you turn to the next page --</p> <p>23 A. I don't know where I saw them.</p> <p>24 Q. If we can scroll to the next page. And</p> <p>25 further --</p>
<p style="text-align: right;">Page 19</p> <p>1 Q. Okay. Have you seen this document</p> <p>2 before?</p> <p>3 MR. SLATER: Sorry, Rich, can we see the</p> <p>4 Bates number?</p> <p>5 MR. BERNARDO: Sure.</p> <p>6 MR. SLATER: If someone can just scroll</p> <p>7 to the Bates number.</p> <p>8 MR. BERNARDO: And it's SOLCO 00032578,</p> <p>9 and we're on page 1.</p> <p>10 MR. SLATER: Thank you.</p> <p>11 A. Yeah, I don't remember.</p> <p>12 Q. You don't remember whether you've seen</p> <p>13 this document before?</p> <p>14 A. No.</p> <p>15 Q. I will represent to you that this is, as</p> <p>16 you can see from it, a document sent to the Food and</p> <p>17 Drug Administration assigning a number of a</p> <p>18 submission by ZHP on January 22nd, and the title of</p> <p>19 the submission is "Valsartan Process As</p> <p>20 Manufactured."</p> <p>21 Are you familiar with this type of</p> <p>22 document?</p> <p>23 A. With this type of document? Is that</p> <p>24 what you said?</p> <p>25 Q. Yes, that was my question?</p>	<p style="text-align: right;">Page 21</p> <p>1 MR. BERNARDO: Can we go off record for</p> <p>2 one minute.</p> <p>3 THE VIDEOGRAPHER: Going off the record.</p> <p>4 The time is 8:30 --</p> <p>5 MR. BERNARDO: Oh --</p> <p>6 THE VIDEOGRAPHER: Did you not want to</p> <p>7 go off the record?</p> <p>8 MR. BERNARDO: I think we can resolve</p> <p>9 this. I want my colleague to share the documents,</p> <p>10 not the videographer, so that I can direct and be</p> <p>11 efficient and show him pages. I also wanted to</p> <p>12 resolve it at a break, so he can look at things, so</p> <p>13 we don't have to do this, because I think these are</p> <p>14 documents with which he's familiar, and this is going</p> <p>15 to take us a long time, if this doesn't work. And I</p> <p>16 reiterate comments that Mr. Slater made earlier.</p> <p>17 THE VIDEOGRAPHER: So would you like to</p> <p>18 go off the record right now, Counsel, then?</p> <p>19 MR. SLATER: I don't understand why</p> <p>20 we're going off the record.</p> <p>21 MR. BERNARDO: I don't either. I think</p> <p>22 if -- as long as my colleague can pull up the</p> <p>23 documents and share his screen so we can show Dr.</p> <p>24 Hecht what we're talking about, I think that will be</p> <p>25 more efficient.</p>

<p style="text-align: right;">Page 22</p> <p>1 Is there a reason why we can't do that?</p> <p>2 MR. BILY: You should be able to.</p> <p>3 THE VIDEOGRAPHER: Okay.</p> <p>4 MR. BERNARDO: There we go.</p> <p>5 Q. And if you scroll through this document,</p> <p>6 this is a receipt of a document from ZHP. And if you</p> <p>7 take a look further and go through the document,</p> <p>8 let's turn to Section 3.2.</p> <p>9 MR. BERNARDO: Which is on page 29,</p> <p>10 Josh.</p> <p>11 MR. SCHOCH: Sure. This is the</p> <p>12 document.</p> <p>13 MR. BERNARDO: Okay. All right.</p> <p>14 Let's put up Tab 4, Exhibit 4.</p> <p>15 (Exhibit Hecht-4, ZHP Product</p> <p>16 Development Report for Valsartan, Bates ZHP01710663</p> <p>17 through 1710729, was received and marked for</p> <p>18 identification.)</p> <p>19 MR. BERNARDO: Yes, yes. I'd like to</p> <p>20 mark this as Exhibit 4.</p> <p>21 Q. Dr. Hecht, is this a document that</p> <p>22 you've seen before?</p> <p>23 A. I believe so.</p> <p>24 Q. Can you tell us your understanding of</p> <p>25 what this is?</p>	<p style="text-align: right;">Page 24</p> <p>1 A. Yes.</p> <p>2 Q. And that change eliminated the concern</p> <p>3 of removing any residual amount of metals during the</p> <p>4 production of valsartan, according to the company</p> <p>5 documents. Is that correct?</p> <p>6 A. Yes.</p> <p>7 Q. And the removal of metal; that would be</p> <p>8 a safety concern. Is that fair to say?</p> <p>9 MR. SLATER: Objection.</p> <p>10 You can answer.</p> <p>11 A. A safety concern, maybe an environmental</p> <p>12 concern. I don't really know.</p> <p>13 Q. Okay. But [REDACTED] has an</p> <p>14 unpleasant odor. Is that fair to say?</p> <p>15 A. I've never smelled it.</p> <p>16 Q. Okay. Would you agree that it could be</p> <p>17 harmful to employees during the manufacturing</p> <p>18 process?</p> <p>19 MR. SLATER: Objection.</p> <p>20 You can answer.</p> <p>21 A. I really don't know.</p> <p>22 Q. Okay. Isn't that something you'd want</p> <p>23 to know, to understand the nature or purpose of</p> <p>24 changes that were made that you're commenting on?</p> <p>25 MR. SLATER: Objection.</p>
<p style="text-align: right;">Page 23</p> <p>1 A. It's a product development report.</p> <p>2 Q. From ZHP?</p> <p>3 A. Yes.</p> <p>4 Q. With respect to valsartan. Correct?</p> <p>5 A. Yes.</p> <p>6 Q. All right.</p> <p>7 MR. BERNARDO: Let's go over to page 29</p> <p>8 of this.</p> <p>9 Q. And if you take a look at 3.2, "Huahai's</p> <p>10 Route," this is discussing the TEA process. And what</p> <p>11 I simply want to establish is that we agree, as</p> <p>12 described in this document, that the TEA process used</p> <p>13 triethylamine hydrochloride salt, TEA HCL, as the</p> <p>14 catalyst for the tetrazole formation, instead of</p> <p>15 [REDACTED] Is that correct?</p> <p>16 A. Correct.</p> <p>17 Q. Okay. And it's used as a catalyst in</p> <p>18 order to avoid the usage of a metal-based catalyst --</p> <p>19 sorry -- the TEA process, the tri [audio dropout]</p> <p>20 chloride was used as a catalyst, to avoid the usage</p> <p>21 of a metal-based catalyst, [REDACTED] Is</p> <p>22 that correct?</p> <p>23 A. Yes.</p> <p>24 MR. SLATER: Objection.</p> <p>25 You can answer.</p>	<p style="text-align: right;">Page 25</p> <p>1 You can answer.</p> <p>2 Argumentative.</p> <p>3 A. I thought the problem with the</p> <p>4 [REDACTED] had to do with the potential</p> <p>5 environmental aspects of its disposal.</p> <p>6 Q. Okay.</p> <p>7 A. I don't really know anything about the</p> <p>8 smell.</p> <p>9 Q. Fair. Thank you, Dr. Hecht.</p> <p>10 MR. SLATER: Hey, Rich, just do me a</p> <p>11 favor. You're jumping in a little bit when he's</p> <p>12 still talking, so please just let him finish. Thank</p> <p>13 you.</p> <p>14 MR. BERNARDO: Thanks for pointing that</p> <p>15 out, Adam, I'll try to be better.</p> <p>16 MR. SLATER: I'm your friend, I'm here</p> <p>17 for you.</p> <p>18 MR. BERNARDO: Same here, Adam.</p> <p>19 MR. SLATER: I know that.</p> <p>20 Q. And according to this document, the new</p> <p>21 catalyst, triethylamine hydrochloride salt, is also</p> <p>22 more cost-efficient than [REDACTED] Is</p> <p>23 that correct?</p> <p>24 MR. SLATER: Objection.</p> <p>25 You can answer.</p>

<p style="text-align: right;">Page 26</p> <p>1 A. I haven't seen the numbers, but I would</p> <p>2 assume so, yes.</p> <p>3 Q. And it says that in this document. Do</p> <p>4 you see, down where we're highlighting here?</p> <p>5 A. Okay, I forgot that.</p> <p>6 Q. And there's nothing wrong with a company</p> <p>7 adopting a change that improves a process, but also</p> <p>8 saves money. Is that fair?</p> <p>9 MR. SLATER: Objection.</p> <p>10 You can answer.</p> <p>11 A. It sounds logical.</p> <p>12 Q. Okay. Companies and scientists would do</p> <p>13 that all the time: They want to be more efficient</p> <p>14 and make a product, and reducing costs of making that</p> <p>15 product is an appropriate consideration. Is that</p> <p>16 fair?</p> <p>17 MR. SLATER: Objection.</p> <p>18 You can answer.</p> <p>19 A. Well, we always try to be as efficient</p> <p>20 as possible in synthesis.</p> <p>21 Q. Thank you.</p> <p>22 A. So it sounds reasonable.</p> <p>23 Q. Thank you. Let's talk about the TEA</p> <p>24 with quenching process.</p> <p>25 And do you agree that ZHP filed its</p>	<p style="text-align: right;">Page 28</p> <p>1 Q. Okay.</p> <p>2 MR. BERNARDO: And let's take a look at</p> <p>3 page 4 of this document.</p> <p>4 Q. And if you look at the bullets --</p> <p>5 MR. BERNARDO: It's page 4 -- right.</p> <p>6 Q. You'll see it talks about adding a</p> <p>7 quenching procedure after the tetrazole formation</p> <p>8 reaction in the crude valsartan, Step 4.</p> <p>9 Do you see that? It's the third bullet</p> <p>10 down under three, Step 4?</p> <p>11 A. Yeah.</p> <p>12 MR. SLATER: What's the question?</p> <p>13 MR. BERNARDO: I just want to ask if he</p> <p>14 sees there was a quenching procedure after the</p> <p>15 tetrazole reaction with the sodium nitrite solution</p> <p>16 that was added.</p> <p>17 MR. SLATER: I object; I'm not sure</p> <p>18 that's what that's talking about.</p> <p>19 Q. And it used a sodium nitrate and</p> <p>20 hydrochloric acid for that quenching, is that</p> <p>21 correct?</p> <p>22 A. That's to quench the sodium, you said?</p> <p>23 Q. Right. In the quenching procedure,</p> <p>24 after the tetrazole reaction. Correct?</p> <p>25 A. Correct.</p>
<p style="text-align: right;">Page 27</p> <p>1 original paper submission with the FDA for the TEA</p> <p>2 quenching process, in or about April of 2012?</p> <p>3 A. Yes, that sounds right.</p> <p>4 Q. Okay.</p> <p>5 MR. SLATER: When you said the quenching</p> <p>6 process, Rich, did you mean with the sodium nitrite</p> <p>7 quenching process?</p> <p>8 MR. BERNARDO: Yes.</p> <p>9 MR. SLATER: Okay.</p> <p>10 Q. And let's pull up company documentation</p> <p>11 here.</p> <p>12 MR. BERNARDO: And I want to mark an</p> <p>13 amendment to the DMF dated 4/16 as exhibit -- what</p> <p>14 are we, five? Five.</p> <p>15 (Exhibit Hecht-5, Amendment to Drug</p> <p>16 Master File dated April 16, 2012, Bates</p> <p>17 PRINSTON00079747 through 79755, was received and</p> <p>18 marked for identification.)</p> <p>19 Q. Okay. Are you familiar with this</p> <p>20 document?</p> <p>21 A. Yes.</p> <p>22 Q. Okay. And what is it, Dr. Hecht?</p> <p>23 A. This is the amendment where they're</p> <p>24 going to describe the change from [REDACTED] to</p> <p>25 triethylamine.</p>	<p style="text-align: right;">Page 29</p> <p>1 Q. Okay. If you go to page number 5, and</p> <p>2 there's a section called "Justification For --</p> <p>3 Justification and Risk Assessment."</p> <p>4 And in that section, you would agree</p> <p>5 that, according to the company, the sodium nitrate</p> <p>6 and hydrochloric acid solution was used to destroy</p> <p>7 the excess sodium azide used in the tetrazole</p> <p>8 formation reaction. Correct?</p> <p>9 A. Yes.</p> <p>10 Q. Okay. And that's because sodium azide</p> <p>11 can be explosive. Is that correct?</p> <p>12 A. Correct.</p> <p>13 Q. And it was also done to minimize the</p> <p>14 risk that sodium azide could be in the final product.</p> <p>15 Is that fair?</p> <p>16 A. Yes.</p> <p>17 Q. Okay. So that's another change that was</p> <p>18 done to enhance the safety of the process in the</p> <p>19 manufacturing environment. Is that fair?</p> <p>20 MR. SLATER: Objection.</p> <p>21 You can answer.</p> <p>22 A. I'm not sure it was just to enhance</p> <p>23 safety. I imagine that's -- that's one</p> <p>24 consideration.</p> <p>25 Q. That's a fair clarification, Dr. Hecht.</p>

<p style="text-align: right;">Page 30</p> <p>1 One of the considerations was to enhance the safety 2 of the process in the manufacturing environment with 3 the change we just discussed. Is that fair? 4 A. Yes. 5 Q. Thank you. And then the TEA with 6 quenching process also changed the molar ratio for 7 the sodium azide used in the reaction. [REDACTED] 8 [REDACTED] And you see that in that 9 bullet, under 3. Is that right? 10 A. Yes, yes. 11 Q. And that was done to decrease the 12 formation of a potential impurity known as 13 d-valsartan. Is that correct? 14 A. Yes. 15 Q. Okay. So the change with -- the change 16 to TEA with quenching, one of the purposes was to 17 reduce the amount of potential impurities. Is that 18 fair? 19 MR. SLATER: Objection. 20 You can answer. 21 A. Yeah, I -- yes. 22 Q. Okay. If you go back to page 4 in 23 Section 3 of the third bullet. The TEA with 24 quenching, it also involved the replacement of 25 [REDACTED] with [REDACTED] in the</p>	<p style="text-align: right;">Page 32</p> <p>1 nothing wrong with adopting a change that improves a 2 process, but also makes it more cost-efficient? 3 MR. SLATER: Objection. 4 You can answer. 5 A. Well, I don't know about that. I mean, 6 in this particular instance, it doesn't seem to make 7 any difference. But, you know, every -- every 8 process change that you make has to be considered 9 individually, for its potential impacts on the 10 overall process and on the overall product. So I 11 don't know whether you can just generalize, you know. 12 Every step -- every step is different. 13 Q. These changes, as part of the process, 14 were provided to the FDA in documentation. Is that 15 correct? 16 A. Yes. 17 Q. And in fact, we've looked at some of the 18 documentation that was provided to FDA. Is that 19 correct? 20 A. Yep. 21 Q. Okay. And FDA could respond to this 22 documentation once it's received, or throughout the 23 life of the product, if it has concerns. Is that 24 fair? 25 A. Yes.</p>
<p style="text-align: right;">Page 31</p> <p>1 saponification process. Is that correct? 2 A. Yes. 3 Q. And that was what is described as a 4 "nonfunctional replacement." Is that correct? 5 A. Yes. 6 Q. What's a nonfunctional replacement, what 7 does that mean? 8 A. Well, I mean, the key thing there is the 9 [REDACTED] I'm not sure, actually, why they switched 10 from [REDACTED] to [REDACTED]. I don't -- I don't 11 remember. But it doesn't matter; it's the [REDACTED] 12 that they need to saponify -- to convert the ester to 13 the acid. 14 Q. Was that done -- 15 A. Hydrolyze the ester. 16 Q. I'm sorry, say that again, I chopped 17 over you? 18 A. They need the [REDACTED] for the 19 hydrolysis of the ester. 20 Q. And was that a change that was intended 21 to make the process more cost-efficient? 22 MR. SLATER: Objection. 23 You can answer. 24 A. I imagine so. 25 Q. And again, we discussed that there's</p>	<p style="text-align: right;">Page 33</p> <p>1 MR. SLATER: Objection. 2 You can answer. 3 Q. Have you found any documentation, 4 Dr. Hecht, showing that FDA responded to ZHP to raise 5 concerns, prior to 2018, about the use of TEA? 6 A. No, I haven't seen that. 7 Q. Have you found any documentation showing 8 FDA responded to ZHP to raise any concerns about the 9 use of sodium nitrate -- nitrite and hydrochloric 10 acid solution, prior to 2018? 11 A. No, I don't think there was anything 12 before 2018. 13 Q. What about with respect to the use of 14 any particular compounds or solvents or reagents? 15 Have you seen any documentation showing that FDA 16 responded to ZHP's submission to raise any concerns 17 about that, prior to 2018? 18 A. No. 19 Q. Did FDA -- have you found any 20 documentation showing that FDA responded to ZHP to 21 raise concerns about the potential for nitrosamine 22 formation, prior to 2018? 23 A. No, I haven't seen anything. 24 Q. Have you seen any documentation 25 whatsoever, Dr. Hecht, indicating that FDA raised any</p>

<p style="text-align: right;">Page 34</p> <p>1 concerns with respect to the process change we've</p> <p>2 just discussed?</p> <p>3 MR. SLATER: Objection.</p> <p>4 A. Yes.</p> <p>5 Q. Prior to -- I'm sorry, Dr. Hecht. Prior</p> <p>6 to 2018?</p> <p>7 A. No.</p> <p>8 Q. Let's move over and talk about the last</p> <p>9 of the processes, the zinc chloride process.</p> <p>10 MR. BERNARDO: And I want to mark as</p> <p>11 Exhibit 6 the amendment to the Drug Master File, if</p> <p>12 we can pull that up.</p> <p>13 (Exhibit Hecht-6, Amendment to Drug</p> <p>14 Master File for Valsartan dated December 10, 2013,</p> <p>15 Bates PRINSTON00073102 through 73119, was received</p> <p>16 and marked for identification.)</p> <p>17 Q. ZHP filed its original paper submission</p> <p>18 with the FDA for the zinc chloride process on</p> <p>19 December 10, 2013, just as it shows right there.</p> <p>20 Correct?</p> <p>21 A. Yes.</p> <p>22 Q. And have you seen this document before?</p> <p>23 A. Yes.</p> <p>24 Q. What is its purpose?</p> <p>25 A. To describe the change in the process.</p>	<p style="text-align: right;">Page 36</p> <p>1 racemization and reduce impurities, according to the</p> <p>2 document. Is that correct?</p> <p>3 A. Yep.</p> <p>4 Q. Okay. It also reduced an EHS concern,</p> <p>5 as it states there. Correct?</p> <p>6 A. Reduced what?</p> <p>7 Q. EHS? It's on the bottom left of the</p> <p>8 block that's highlighted?</p> <p>9 MR. SLATER: You're asking, does it say</p> <p>10 that on the document?</p> <p>11 MR. BERNARDO: I'm asking first, if it</p> <p>12 says that on the document, yes.</p> <p>13 A. Oh.</p> <p>14 Q. Would it help --</p> <p>15 A. Yes, I guess it's environmental health</p> <p>16 and safety.</p> <p>17 Q. Thank you. That was going to be my</p> <p>18 question. And you raised environmental concerns</p> <p>19 before, in response to another question. Correct?</p> <p>20 A. Yes.</p> <p>21 MR. SLATER: Objection.</p> <p>22 You can answer.</p> <p>23 Q. Because sometimes, manufacturers will</p> <p>24 make changes to their processes to address</p> <p>25 environmental concerns. Is that correct?</p>
<p style="text-align: right;">Page 35</p> <p>1 Q. To whom are they describing the change</p> <p>2 in the process? Are they describing the change in</p> <p>3 the process to the FDA? Is that one of the purposes</p> <p>4 of this document?</p> <p>5 A. I do not think so.</p> <p>6 Q. Okay. It's an amendment to the Drug</p> <p>7 Master File. Correct?</p> <p>8 A. Yes.</p> <p>9 Q. And that gets submitted for a change to</p> <p>10 FDA. Correct?</p> <p>11 A. Okay, I guess that's right.</p> <p>12 Q. Okay. And you say you guess that's</p> <p>13 right, because you're -- fair to say, you're not</p> <p>14 really an expert in regulatory or FDA issues. Is</p> <p>15 that fair?</p> <p>16 A. Yes, that's correct.</p> <p>17 Q. Okay.</p> <p>18 MR. BERNARDO: Let's take a look at Page</p> <p>19 Number 2 of 16.</p> <p>20 Q. So the new process changed triethylamine</p> <p>21 hydrochloride salt to zinc chloride for the tetrazole</p> <p>22 formation. Is that correct?</p> <p>23 A. Yes.</p> <p>24 Q. And that change was to reduce -- and</p> <p>25 again, I'm sorry for my pronunciation, Dr. Hecht --</p>	<p style="text-align: right;">Page 37</p> <p>1 A. If they're forced to, sure.</p> <p>2 Q. If you turn to page 8 of 16 of the</p> <p>3 document, to the paragraph beginning "Therefore,"</p> <p>4 which we will highlight for you.</p> <p>5 Would you just please just read that</p> <p>6 paragraph into the record?</p> <p>7 A. That's going to be hard to do.</p> <p>8 MR. BERNARDO: Can you -- is there a way</p> <p>9 to blow this up a little bit. Thank you.</p> <p>10 A. "Therefore, INT3/sodium azide zinc</p> <p>11 chloride with a quantity ratio of [REDACTED] [sic] -- I</p> <p>12 don't understand that -- "is preferred and adopted</p> <p>13 for a proposed process of tetrazole forming and the</p> <p>14 output quantity with wet basis from Step 4 is</p> <p>15 increased from [REDACTED] to [REDACTED] kilograms to [REDACTED] to</p> <p>16 [REDACTED] kilograms. The process validation has been</p> <p>17 conducted and confirmed the suitability of commercial</p> <p>18 production."</p> <p>19 So in other words, they're getting</p> <p>20 better yield.</p> <p>21 Q. Thank you. That was going to be my next</p> <p>22 question. Is it fair to say that a layperson's</p> <p>23 translation of this document -- of this paragraph you</p> <p>24 just read would be that using zinc chloride as a</p> <p>25 catalyst improved the conversion of the tetrazole</p>

<p style="text-align: right;">Page 38</p> <p>1 formation reaction, and increased the crude process 2 output? Is that a fair layperson summary? 3 A. Yes, it increased the yield of the 4 tetrazole. But I don't know why -- I don't know why 5 the word "conversion" is in there. 6 Q. Okay. 7 A. It increased the yield of the tetrazole 8 formation from the precursor, in the reaction with 9 sodium azide. 10 (Court Stenographer clarification.) 11 A. It increased the yield of the conversion 12 to the tetrazole, in the reaction of the precursor 13 with sodium azide, A-Z-I-D-E. 14 Q. Is it fair to characterize this as a 15 change to optimize the manufacturing process? 16 A. Yes. 17 Q. Okay. And if you increase the yield or 18 the crude output, is it fair to say that that would 19 also therefore reduce the amount of non-valsartan 20 substances from the process? 21 A. No. I wouldn't say that. I mean, I 22 don't think you -- I don't think you can really 23 describe it that way. 24 Q. Okay. 25 A. That's a little bit -- that's a little</p>	<p style="text-align: right;">Page 40</p> <p>1 A. The goal is to -- obviously, their goal 2 is to optimize the process within the confines of 3 regulatory aspects. 4 Q. And the zinc chloride process also 5 changed the manufacturing process, so that the 6 quenching occurred in the presence of an newly-added 7 solvent -- which I'm not even going to try to 8 pronounce -- MTBE. Is that correct? 9 MR. SLATER: Objection. 10 You can answer. 11 A. Yes. 12 Q. And the change to MTBE provided better 13 solubility for the in situ intermediate, to avoid 14 emulsification, disturbing the liquid delamination 15 and separation process. Correct? 16 A. Right. 17 Q. So that change was intended to enhance 18 the separation process. Fair? 19 A. Right. 20 Q. Again, a change intended to improve the 21 overall manufacturing process? 22 A. Yep. 23 Q. Okay. That change also, to the 24 hydrolysis process, decreased the formation of the 25 impurity, d-valsartan.</p>
<p style="text-align: right;">Page 39</p> <p>1 bit too broad. 2 Q. Fair. 3 A. You'd have to look at it in detail. 4 Q. Have you done that, have you looked at 5 the change in the process in that level of detail? 6 A. No. 7 Q. Let's go back to page 2 of 16. Okay. 8 Under the "Minor Changes" section. 9 So the zinc chloride process also 10 changed the solvent for the tetrazole formation 11 reaction from toluene to dimethylformamide, or DMF. 12 Is that correct? 13 A. Yes. 14 Q. And that change was made to facilitate 15 the synthesis. Is that correct? 16 A. Yes. 17 Q. And is it fair to say, that was also a 18 change that would optimize the manufacturing process? 19 MR. SLATER: Objection. 20 You can answer. 21 A. I don't really know. 22 Q. Okay. The zinc chloride -- 23 A. Presumably it did, but that's an 24 assumption on my part. 25 Q. And if you don't know --</p>	<p style="text-align: right;">Page 41</p> <p>1 MR. BERNARDO: Do you want to put that 2 back up again, Josh? Sorry about that. Are we in 3 the right section? Okay. 4 Q. The change that we just talked about, 5 Dr. Hecht, to the hydrolysis process also helped to 6 decrease the formation of the impurity d-valsartan. 7 Is that correct? 8 A. Correct. 9 Q. So that change to the process was 10 intended to reduce the amount of potential 11 impurities. Correct? 12 MR. SLATER: Objection. 13 You can answer. 14 A. Yes. 15 MR. BERNARDO: And you can take that 16 down. 17 Q. Is it fair to say that, based on company 18 documents, the change to the hydrolysis process also 19 helped to minimize the unhydrolyzed valsartan methyl 20 ester group, to provide a better overall yield of the 21 reaction? 22 A. Yes. 23 Q. So now, we already -- I want to make 24 sure we agree that this kind of change was submitted 25 to FDA, the documentation we just looked at. You</p>

<p style="text-align: right;">Page 42</p> <p>1 have no reason to dispute that. Is that correct?</p> <p>2 A. Yes.</p> <p>3 Q. Let me ask it a different way. Are you</p> <p>4 disputing -- I think we had some double negative in</p> <p>5 there, and I just want to make sure the record is</p> <p>6 clear. Are you disputing that -- withdrawn.</p> <p>7 ZHP sent documentation of this change to</p> <p>8 FDA. Correct?</p> <p>9 A. Yes.</p> <p>10 Q. Thank you. And again, FDA could respond</p> <p>11 if it had concerns. Correct?</p> <p>12 MR. SLATER: Objection.</p> <p>13 You can answer.</p> <p>14 A. I assume so.</p> <p>15 Q. Okay.</p> <p>16 A. I don't know, really.</p> <p>17 Q. I didn't hear the last word. "I don't</p> <p>18 know," what?</p> <p>19 A. I don't know really.</p> <p>20 Q. Okay. Have you found any documentation</p> <p>21 showing FDA communicated any concerns about the use</p> <p>22 of DMF before 2018?</p> <p>23 A. No.</p> <p>24 MR. SLATER: Objection.</p> <p>25 You can answer.</p>	<p style="text-align: right;">Page 44</p> <p>1 these specific processes.</p> <p>2 MR. BERNARDO: I'm not saying you're not</p> <p>3 trying to be helpful. I'm trying to make sure I</p> <p>4 can -- I'm communicating with Dr. Hecht --</p> <p>5 MR. SLATER: Why can't you just answer</p> <p>6 my question, though? It's a yes or no, I don't</p> <p>7 understand.</p> <p>8 BY MR. BERNARDO:</p> <p>9 Q. Dr. Hecht, have you found any evidence</p> <p>10 of any communication between FDA and ZHP, expressing</p> <p>11 any concerns about ZHP's use of DMF prior to 2018?</p> <p>12 MR. SLATER: Objection.</p> <p>13 You can answer.</p> <p>14 A. No, I haven't.</p> <p>15 Q. Or its use of sodium nitrite and</p> <p>16 hydrochloric acid solution, prior to 2018?</p> <p>17 A. I haven't seen that.</p> <p>18 Q. Have you seen any documentation showing</p> <p>19 that FDA communicated, in any manner, concerns to</p> <p>20 ZHP, prior to 2019, about the potential for</p> <p>21 nitrosamine formation from the changes we've just</p> <p>22 described?</p> <p>23 MR. SLATER: Objection.</p> <p>24 A. Prior to 2019?</p> <p>25 Q. '18.</p>
<p style="text-align: right;">Page 43</p> <p>1 Q. Before 2018, have you found any</p> <p>2 documentation showing FDA communicated concerns about</p> <p>3 ZHP's use of a sodium nitrite and hydrochloric acid</p> <p>4 solution?</p> <p>5 MR. SLATER: Objection.</p> <p>6 A. No, I haven't.</p> <p>7 MR. SLATER: You're asking, Rich, about</p> <p>8 direct communications to ZHP, specific to the</p> <p>9 process. Right?</p> <p>10 MR. BERNARDO: I'm asking him if he's</p> <p>11 found any documentations at all, any kind of</p> <p>12 communication whatsoever from FDA to ZHP, expressing</p> <p>13 concerns about the use of DMF, is what we talked</p> <p>14 about.</p> <p>15 MR. SLATER: You're talking about</p> <p>16 specific to these processes. Right, prior to 2018?</p> <p>17 Q. Do you understand my questions,</p> <p>18 Dr. Hecht?</p> <p>19 MR. SLATER: Rich, why are you not</p> <p>20 answering me?</p> <p>21 (Court Stenographer clarification.)</p> <p>22 MR. SLATER: I'm not being contentious,</p> <p>23 I'm just trying to clarify that we're not talking</p> <p>24 about general communications that ZHP may have seen,</p> <p>25 as opposed to specific communications directed to</p>	<p style="text-align: right;">Page 45</p> <p>1 A. '18.</p> <p>2 Q. Correct?</p> <p>3 A. No.</p> <p>4 Q. So there's no indication whatsoever that</p> <p>5 FDA had any concern about the process change that we</p> <p>6 discussed. Correct?</p> <p>7 A. I have no idea. I haven't seen it.</p> <p>8 Q. Thank you.</p> <p>9 A. That's all I can say.</p> <p>10 Q. That's all I'm asking you to say,</p> <p>11 Dr. Hecht. Thank you.</p> <p>12 So we just we went through four</p> <p>13 different process changes that ZHP used in its</p> <p>14 manufacture of valsartan prior to 2018. I want to</p> <p>15 focus on one of them in particular, which is the last</p> <p>16 one we just discussed.</p> <p>17 So just to sort of make sure we agree:</p> <p>18 ZHP used a zinc-chloride-catalyzed tetrazole</p> <p>19 formation reaction as part of its zinc chloride</p> <p>20 manufacturing process we just discussed. Correct?</p> <p>21 A. Right.</p> <p>22 Q. And that zinc-chloride-catalyzed</p> <p>23 tetrazole formation reaction involved sodium azide as</p> <p>24 a reagent, and used DMF as a solvent. Correct?</p> <p>25 A. Yes.</p>

<p style="text-align: right;">Page 46</p> <p>1 Q. Okay. And that's the step in the</p> <p>2 process that yielded dimethylamine. Correct?</p> <p>3 MR. SLATER: Objection.</p> <p>4 You can answer.</p> <p>5 A. We don't really know that. The</p> <p>6 dimethylamine could have already been present in the</p> <p>7 dimethylformamide. I haven't seen anything in the</p> <p>8 documents that I have that indicates that ZHP ever</p> <p>9 looked into that possibility.</p> <p>10 Q. So we don't still know exactly how the</p> <p>11 dimethylamine [sic] occurred. I just want to make</p> <p>12 sure I'm understanding what you're saying. It could</p> <p>13 have occurred by degradation, or it could have</p> <p>14 occurred because it was already present in the DMF</p> <p>15 that was used. I just want to make sure that's what</p> <p>16 you just said?</p> <p>17 MR. SLATER: Objection.</p> <p>18 A. Dimethylamine, right.</p> <p>19 Q. Sorry if I --</p> <p>20 (Court Reporter Clarification.)</p> <p>21 Q. Let me try that again, since we were</p> <p>22 talking over each other.</p> <p>23 So we still don't know today whether or</p> <p>24 not the dimethylamine that was part of the</p> <p>25 nitrosamine formation process was already in the DMF,</p>	<p style="text-align: right;">Page 48</p> <p>1 You can answer.</p> <p>2 A. From what I've seen, we don't know.</p> <p>3 Q. Let me go back to where we were. So</p> <p>4 we're talking about the zinc-chloride-catalyzed</p> <p>5 tetrazole formation reaction, using sodium azide as a</p> <p>6 reagent.</p> <p>7 ZHP was not the first to use a</p> <p>8 zinc-chloride-catalyzed tetrazole formation reaction</p> <p>9 using sodium azide as a reagent. Is that correct?</p> <p>10 MR. SLATER: Objection to form.</p> <p>11 A. I don't know. I assume that this</p> <p>12 chemistry was already known. I don't think they</p> <p>13 invented it.</p> <p>14 Q. That was my question. ZHP didn't invent</p> <p>15 this reaction. Fair?</p> <p>16 MR. SLATER: Objection.</p> <p>17 You can answer.</p> <p>18 A. I don't know, really.</p> <p>19 Q. Okay.</p> <p>20 A. That would be my assumption, but I don't</p> <p>21 really know.</p> <p>22 Q. Okay. I believe, and correct me if I'm</p> <p>23 wrong, Dr. Hecht, that you've read the report of</p> <p>24 ZHP's expert, Dr. Xue? And it's spelled X-U-E, my</p> <p>25 understanding is, you pronounce it "sure," so if</p>
<p style="text-align: right;">Page 47</p> <p>1 or whether it somehow degraded and -- from the DMF to</p> <p>2 form dimethylamine. Is that fair?</p> <p>3 MR. SLATER: Objection.</p> <p>4 You can answer.</p> <p>5 A. The way you stated that, I mean,</p> <p>6 "somehow degraded"; that sounds like it's, you know,</p> <p>7 a mysterious, unexpected process. The hydrolysis of</p> <p>8 DMF to dimethylamine is absolutely basic chemistry.</p> <p>9 Q. Okay.</p> <p>10 A. So I wouldn't say -- I wouldn't put it</p> <p>11 that way at all. So no, it's not correct.</p> <p>12 Q. And well --</p> <p>13 A. The way you -- the way you stated it.</p> <p>14 Q. I appreciate that --</p> <p>15 (Court Stenographer clarification.)</p> <p>16 Q. I appreciate that qualification,</p> <p>17 Dr. Hecht. So let me ask the question in a different</p> <p>18 way.</p> <p>19 So we still don't know today whether the</p> <p>20 dimethylamine that started or was part of the process</p> <p>21 that formed nitrosamines was present in DMF that was</p> <p>22 used as a solvent, or whether it degraded during the</p> <p>23 process, the DMF degraded during the process, to form</p> <p>24 dimethylamine. Is that fair?</p> <p>25 MR. SLATER: Objection.</p>	<p style="text-align: right;">Page 49</p> <p>1 that's not --</p> <p>2 A. Yeah, I read it.</p> <p>3 Q. Okay.</p> <p>4 MR. BERNARDO: Why don't we pull that up</p> <p>5 and mark that as an exhibit. And what are we up to?</p> <p>6 MR. SCHOCH: Seven.</p> <p>7 MR. BERNARDO: Seven.</p> <p>8 (Exhibit Hecht-7, Expert Report of</p> <p>9 Fengtian Xue, Ph.D. dated December 22, 2022, No</p> <p>10 Bates, 107 Pages, was received and marked for</p> <p>11 identification.)</p> <p>12 Q. And this is the report of Dr. Fengtian</p> <p>13 Xue, dated December 22, 2022. And this is the report</p> <p>14 that we just talked about that you read. Correct?</p> <p>15 A. Yes.</p> <p>16 Q. Okay.</p> <p>17 MR. BERNARDO: If we could turn, Josh,</p> <p>18 to page 28. The middle of the first paragraph.</p> <p>19 Okay. In fact, the literature review.</p> <p>20 Q. Bear with me one minute, I'm sorry,</p> <p>21 Dr. Hecht. I just want to point you to the right</p> <p>22 place. Okay.</p> <p>23 And why don't you just take a minute to</p> <p>24 orient yourself to the topic about which Dr. Xue is</p> <p>25 talking? Are you able to read it in the size it's on</p>

<p style="text-align: right;">Page 50</p> <p>1 the screen, Dr. Hecht?</p> <p>2 A. Not when you highlight it like that, no.</p> <p>3 MR. SLATER: It's harder to read.</p> <p>4 A. It makes it harder.</p> <p>5 Q. Got it. We'll just do that to point you</p> <p>6 to that?</p> <p>7 A. Okay.</p> <p>8 Q. Why don't you just take a minute to</p> <p>9 orient yourself to where you are on the report?</p> <p>10 MR. SLATER: You want to him to read</p> <p>11 that sentence that says "in fact"?</p> <p>12 THE WITNESS: I'm reading it.</p> <p>13 A. Okay, yeah.</p> <p>14 Q. Can you just read that sentence that</p> <p>15 says "in fact" into the record.</p> <p>16 A. "In fact, a literature search related to</p> <p>17 the synthetic method to the production of tetrazoles</p> <p>18 using zinc chloride as a catalyst on SciFinder</p> <p>19 generated at least 28 reports, nine of which used DMF</p> <p>20 as a solvent for the tetrazole formation reaction.</p> <p>21 Importantly, none of these nine examples mentioned</p> <p>22 any side reaction caused by the decomposition of the</p> <p>23 DMF solvent."</p> <p>24 Q. Do you have any reason to dispute that</p> <p>25 statement that you just read, or any part of it?</p>	<p style="text-align: right;">Page 52</p> <p>1 personal. Thank you.</p> <p>2 A. Okay. No, it's not personal at all.</p> <p>3 It's just that this particular thing is irrelevant to</p> <p>4 the question, I think.</p> <p>5 Q. Well, but let me --</p> <p>6 A. It's true, I mean in his report, it's</p> <p>7 true they don't mention the decomposition, as he</p> <p>8 calls it, of the DMF solvent. That is -- that is</p> <p>9 true.</p> <p>10 But it's also true that there's no</p> <p>11 reason why they would mention it, because it's not</p> <p>12 relevant to the chemistry that's being done there,</p> <p>13 presumably. I didn't look at every report.</p> <p>14 Q. Fair. But Dr. Hecht, let's talk about</p> <p>15 that for a little bit. So if there are reports in</p> <p>16 the scientific literature using the exact same</p> <p>17 chemical formation or process, also using DMF, and it</p> <p>18 is your opinion that everybody would know that DMF</p> <p>19 would degrade during that process, wouldn't it be</p> <p>20 incumbent upon researchers either not to use it, or</p> <p>21 to report that possibility?</p> <p>22 MR. SLATER: Objection.</p> <p>23 You can answer. There's a lot in there.</p> <p>24 A. Well, it's well-established in the</p> <p>25 literature that DMF, on heating, or even crude DMF,</p>
<p style="text-align: right;">Page 51</p> <p>1 A. This is very tricky of you. No, I</p> <p>2 don't. But I mean, there was no reason -- in those</p> <p>3 studies that he quotes, there would be no reason for</p> <p>4 anybody to even think about the partial decomposition</p> <p>5 or the hydrolysis of DMF. It's not an issue, so of</p> <p>6 course it wouldn't be reported.</p> <p>7 Q. Okay. And Dr. Hecht, I just -- I'm here</p> <p>8 to ask --</p> <p>9 A. I mean, this is -- this is amazing. I</p> <p>10 mean, why are you even asking this?</p> <p>11 Q. Okay. And Dr. Hecht, first of all, I am</p> <p>12 troubled by your statement, and I just want to</p> <p>13 clarify --</p> <p>14 MR. SLATER: That's argument, that</p> <p>15 you're troubled by the statement. Let's just ask the</p> <p>16 questions, okay?</p> <p>17 Q. Dr. Hecht, I'm not here to trick you.</p> <p>18 I'm not here to do anything. I'm here to ask you</p> <p>19 questions. And I think I've been fair in asking you</p> <p>20 if you agree with them; and if you disagree with</p> <p>21 them, I'm going to ask you why you disagree.</p> <p>22 So I want to make sure we keep this in</p> <p>23 that vein. I'm not here to trick you or be tricky.</p> <p>24 A. Okay.</p> <p>25 Q. So -- okay? I don't want to make this</p>	<p style="text-align: right;">Page 53</p> <p>1 can contain small amounts of dimethylamine. That's</p> <p>2 well-established. In fact, DMF sometimes has a fishy</p> <p>3 odor due to the dimethylamine. So, you know,</p> <p>4 dimethylamine is a potential contaminant of DMF,</p> <p>5 that's well-established.</p> <p>6 Q. When was it well-established, Dr. Hecht?</p> <p>7 A. Oh, I don't remember the exact date, but</p> <p>8 it's well before 2018, that's for sure.</p> <p>9 Q. And fair to say that part of your</p> <p>10 opinion isn't just that it was well-established, but</p> <p>11 that it was widely known. Correct?</p> <p>12 A. I don't know how widely known it is.</p> <p>13 Q. Well, that's my question. Did you --</p> <p>14 let's talk about --</p> <p>15 A. I mean, what do you mean by "widely</p> <p>16 known"?</p> <p>17 Q. I'm asking you, since it was your</p> <p>18 opinion --</p> <p>19 A. Yes.</p> <p>20 Q. -- that any chemist, organic chemist</p> <p>21 looking at this should have known this, is it your</p> <p>22 opinion that any organic chemist in 2013 ought to</p> <p>23 have known the conditions under which DMF would</p> <p>24 degrade?</p> <p>25 MR. SLATER: Objection.</p>

<p style="text-align: right;">Page 54</p> <p>1 A. Any organic -- not exactly. I mean, my 2 opinion -- I'll tell you what my opinion is. Okay? 3 And then you can take it from there. 4 My opinion is that if they were using 5 sodium nitrite to -- in this reaction, then they 6 should have thought about the possibility that there 7 might be some dimethylamine present that would get 8 nitrosated under the conditions that they were doing 9 the synthesis. That's what they should have thought. 10 Q. Why should they have thought of that? 11 A. Because nitrosamines are known powerful 12 carcinogens, and they should have thought of the 13 fact -- they should have thought of the possibility 14 that, by using sodium nitrite at pH [REDACTED] which is 15 perfect conditions for nitrosamine formation, they 16 should have thought of the fact that their product 17 might have been contaminated with 18 dimethylnitrosamine. They should have thought of 19 that, absolutely. 20 Q. Okay. But what we're talking about here 21 is the first step of that; is the presence of 22 dimethylamine in the process. Correct? 23 MR. SLATER: Objection. 24 You can answer. 25 A. And they should have thought of that.</p>	<p style="text-align: right;">Page 56</p> <p>1 A. It is widely known that dimethylamine is 2 easily nitrosated to form dimethylnitrosamine, using 3 a sodium nitrite at pH [REDACTED] That is widely known. And 4 it is widely known that dimethylamine is a potential 5 contaminant in dimethylformamide, period. 6 Q. Thank you, Doctor. Again, I'm sorry -- 7 A. Furthermore, they demonstrated that this 8 was the case by forming dimethylnitrosamine in their 9 product. 10 MR. BERNARDO: Ellen, would you just 11 mind just reading the beginning of that? I 12 apologize, something got cut off here. The beginning 13 of his answer, I got the last part. 14 (Testimony read back.) 15 A. Dimethylnitrosamine. 16 Q. And again, thank you, let me just take 17 back. Because you stated, Dr. Hecht, that this is 18 your core opinion, and I appreciate that. And I 19 really want to make sure I understand it, and what 20 you did to get there. 21 And the first step I want to talk about 22 is the presence of dimethylamine, because that's 23 important that dimethylamine is part of this process 24 that resulted in the formation of nitrosamines. 25 Do you agree with that?</p>
<p style="text-align: right;">Page 55</p> <p>1 They should have thought, you know, if we use 2 dimethylformamide, there could be some dimethylamine 3 in there; we could form dimethylnitrosamine when 4 we're dumping nitrite in this reaction to decompose 5 the sodium azide at pH [REDACTED] 6 They should have thought of that. 7 That's my opinion. That's my core opinion. 8 Q. And I understand that, and I thank you 9 for clarifying that, Dr. Hecht. And I'd like to 10 explore the core opinion, because I want to 11 understand the process or steps you took to get to 12 that. 13 And the first step would be: If 14 somebody should have thought of something, is it fair 15 to say that the first step would be: It has to be 16 widely known. It has to be very knowable. It's not 17 some esoteric fact. Is that correct? 18 MR. SLATER: Objection. 19 You can answer. 20 A. It is widely know that -- 21 (Simultaneous speaking.) 22 (Court Stenographer clarification.) 23 THE WITNESS: Should I continue? 24 THE COURT REPORTER: Yes, please, 25 Doctor.</p>	<p style="text-align: right;">Page 57</p> <p>1 A. Yes. 2 MR. SLATER: Objection -- 3 A. Yes -- 4 MR. SLATER: One second, Doctor. 5 Objection to the form, compound, 6 colloquy. 7 You can answer. 8 A. Dimethylamine is part of the problem, 9 yes. 10 Q. Okay. So I really want to focus at this 11 point just on the knowledge that DMF could degrade to 12 form dimethylamine, or contains dimethylamine. 13 Do you understand where I'm trying to 14 focus? 15 A. Yes. 16 Q. Okay. And you "said it 'is' widely 17 known," or words to that effect. 18 A. Yes. 19 Q. What I want to understand is: It your 20 opinion that in 2013, it was widely known that DMF 21 could degrade under certain conditions to form 22 dimethylamine, or have dimethylamine in it? 23 A. Yes. 24 Q. Okay. What is your basis for that? 25 What steps did you take to determine what was known,</p>

<p style="text-align: right;">Page 58</p> <p>1 and how widely it was known in 2013?</p> <p>2 A. Well, I have various articles that I've</p> <p>3 looked at from the literature talking about, you</p> <p>4 know, the hydrolysis of DMF.</p> <p>5 Q. And you cited to only two of them --</p> <p>6 MR. SLATER: I'm sorry, had you</p> <p>7 finished, Dr. Hecht?</p> <p>8 MR. BERNARDO: I'm sorry, I thought he</p> <p>9 was.</p> <p>10 A. Yeah. So, you know, there's a number of</p> <p>11 different articles in the literature, and it's also</p> <p>12 described in certain texts. I've got all that --</p> <p>13 I've got all that information; they should have known</p> <p>14 that.</p> <p>15 Q. I understand you're saying they should</p> <p>16 have known, Dr. Hecht. And again, I want to</p> <p>17 understand why they should have known, and I want to</p> <p>18 understand the process.</p> <p>19 I mean, it's fair to say, Dr. Hecht,</p> <p>20 it's your opinion they should have known that. And I</p> <p>21 understand that, and you can explain that to the</p> <p>22 jury. But I want the jury to understand how it is</p> <p>23 that you got there.</p> <p>24 And I guess one thing you just said, and</p> <p>25 I want to unpackage that a bit, is it's in -- and I</p>	<p style="text-align: right;">Page 60</p> <p>1 commercially contains trace amounts of methanol,</p> <p>2 water, formic acid, and dimethylamine. 1994.</p> <p>3 Q. Okay. In that publication --</p> <p>4 A. That's one example. So I mean, you</p> <p>5 know, this is not -- this is not something recent. I</p> <p>6 mean, DMF has been around a long time.</p> <p>7 Q. Understood. And the document you just</p> <p>8 cited to is not in your -- referenced in your report</p> <p>9 or listed in the materials upon which you relied. Is</p> <p>10 that correct?</p> <p>11 MR. SLATER: Objection.</p> <p>12 A. It's not in my report, no.</p> <p>13 Q. Okay. There were only two documents in</p> <p>14 your report upon which you relied or state that you</p> <p>15 relied, in connection with your opinions that deal</p> <p>16 with dimethylamine formation in DMF. Correct?</p> <p>17 MR. SLATER: Rich, I believe that</p> <p>18 article is on the reliance list, just in case you</p> <p>19 didn't see it.</p> <p>20 MR. BERNARDO: Okay, I'll take a look.</p> <p>21 Q. Again, I want to go back to understand</p> <p>22 the steps that you took, Dr. Hecht.</p> <p>23 So your opinion is that it's widely</p> <p>24 known. And is it fair to say -- and I don't want to</p> <p>25 put words in your mouth; I just want to make sure I</p>
<p style="text-align: right;">Page 59</p> <p>1 forget the word you used, several or some</p> <p>2 publications, and I think you said a text. Is that</p> <p>3 correct?</p> <p>4 A. Yes.</p> <p>5 MR. SLATER: Objection.</p> <p>6 You can answer.</p> <p>7 (Court Stenographer clarification.)</p> <p>8 MR. SLATER: Doctor, what's happening is</p> <p>9 if you don't pause and I don't get the objection out</p> <p>10 and we talk at the same time, the court reporter is</p> <p>11 going to ask you to answer after I speak. So she</p> <p>12 just needs you to say "yes" again.</p> <p>13 THE WITNESS: Are you talking to me?</p> <p>14 MR. SLATER: Yep.</p> <p>15 A. Yes.</p> <p>16 Q. Okay. How many articles or publications</p> <p>17 are there or did you find that discuss the conditions</p> <p>18 under which DMF can degrade to form dimethylamine,</p> <p>19 such that it would be widely known?</p> <p>20 MR. SLATER: Objection.</p> <p>21 You can answer.</p> <p>22 A. There are -- there's several that I</p> <p>23 found. I don't know the exact number. Some of them</p> <p>24 are like in textbooks. For example, WHO, that's the</p> <p>25 World Health Organization, states that DMF sold</p>	<p style="text-align: right;">Page 61</p> <p>1 can understand your opinion and we can talk about the</p> <p>2 basis for it. Is it fair to say it was your</p> <p>3 opinion -- it is your opinion that in 2013, any</p> <p>4 chemist who would be working with DMF should have</p> <p>5 known that DMF could degrade to form dimethylamine?</p> <p>6 A. I don't know about "any chemist." You</p> <p>7 know, there are millions of chemists out there. Some</p> <p>8 of them aren't very smart.</p> <p>9 Q. Okay. So then who should have known, in</p> <p>10 your opinion, about the degradation of DMF, and how</p> <p>11 did you go about --</p> <p>12 A. The people at this company should have</p> <p>13 known. Absolutely, they should have known. They</p> <p>14 should have looked at it. Absolutely.</p> <p>15 Q. Okay.</p> <p>16 A. And I mean, you know, this is like</p> <p>17 textbook information. They should have thought of</p> <p>18 it.</p> <p>19 Q. Okay.</p> <p>20 A. I have no doubt about that.</p> <p>21 Q. Okay. I understand. And I'm not trying</p> <p>22 to challenge your conviction to it, Dr. Hecht. I'm</p> <p>23 trying to understand, is it -- so maybe we can cut</p> <p>24 through this.</p> <p>25 Did you go through any process</p>

<p style="text-align: right;">Page 62</p> <p>1 whatsoever to determine that this should have been 2 known to ZHP or any organic chemist using this, or is 3 it just: This is Dr. Hecht's, you know, view of DMF? 4 A. No -- 5 MR. SLATER: Objection -- 6 One second, Doctor. One second. 7 Objection. Are you saying in addition 8 to what he just told you, which is going to the 9 scientific literature, or are you saying including 10 that? What's the question? 11 MR. BERNARDO: I'm asking -- let me 12 ask -- 13 MR. SLATER: Because that question was a 14 mischaracterization, and -- 15 MR. BERNARDO: Withdrawn. 16 MR. SLATER: Wait, let me finish. 17 MR. BERNARDO: I'm withdrawing the 18 question. 19 MR. SLATER: All right, but I just want 20 to make it clear, because you're going to come back 21 to this, so I want to make sure. And you ignored 22 what you just asked him about for five or 10 minutes. 23 So I don't think it's a reasonable question. 24 MR. BERNARDO: And that's why I've 25 withdrawn it.</p>	<p style="text-align: right;">Page 64</p> <p>1 readily available scientific knowledge and 2 testing "should have been apparent to any organic 3 chemist involved in the development or assessment of 4 these processes." 5 Did I read that right? 6 A. "Any organic chemist." 7 Q. Is that -- 8 A. It should be apparent, yes, it should be 9 apparent to -- so what are you asking, exactly? 10 Q. I simply was asking -- 11 A. You're confusing me. 12 Q. -- to make sure we agree that I've read 13 this correctly. That was all. 14 MR. SLATER: Doctor, all he's asking you 15 is if he just read what your report says. 16 THE WITNESS: Yes. 17 Q. Okay. I just want to make sure we're on 18 the same page. 19 So is it correct that there are several 20 things that needed to have been known in order to 21 utilize or apply the readily-available scientific 22 knowledge? Correct? 23 MR. SLATER: Objection. 24 You can answer. 25 A. Several things? Sure.</p>
<p style="text-align: right;">Page 63</p> <p>1 Q. Dr. Hecht, in your report -- let's pull 2 up a statement in your report. Hold on. 3 Actually, why don't -- sorry. I don't 4 mean to delay this, we've been going for a little 5 over hour. Why don't we just take a brief break, and 6 we can pull up the report and we can walk through 7 that. 8 THE VIDEOGRAPHER: Okay. Going off the 9 record. The time is 9:21 a.m. Central Time. This is 10 the end of Media Unit 1. 11 (A brief recess takes place.) 12 THE VIDEOGRAPHER: We are back on the 13 record. The time is 9:33 a.m. Central Time. This 14 is the beginning of Media Unit 2. 15 BY MR. BERNARDO: 16 Q. Dr. Hecht, I'd like to pull up your 17 report from 2022 for a moment, and I'd like to focus 18 on the paragraph that's at the bottom that is being 19 highlighted here, right there. 20 And it says, "The readily available 21 scientific knowledge and testing should have been 22 applied to identify the NDMA and NDEA, even after the 23 processes were adopted." 24 This is the sentence I want to focus on, 25 Dr. Hecht. This -- presumably, you're talking about</p>	<p style="text-align: right;">Page 65</p> <p>1 Q. Okay. So first, can we agree that one 2 of the things that would have to have been known, 3 such that it would be apparent to any organic 4 chemist, is that DMF was present -- I'm sorry, is 5 that dimethylamine was present or formed during the 6 process. 7 Do you agree with that? 8 A. That it could be present, yes. 9 Q. Correct. Okay. So we do agree with 10 that. 11 A. Yes. 12 Q. And you raise two, I think, distinct 13 ways in which dimethylamine could be present in the 14 process. One would be that ZHP used DMF that was 15 contaminated with some amount of dimethylamine. Is 16 that correct? 17 A. Yes. 18 Q. Okay. Did you do anything to 19 investigate whether or not ZHP took steps to ensure 20 that the -- that the DMF it was using did not contain 21 dimethylamine? 22 A. Yeah, I looked through all the documents 23 that I have, and I couldn't find anything that 24 specifically said that they checked for the presence 25 of dimethylamine in -- in the actual process, where</p>

<p style="text-align: right;">Page 66</p> <p>1 they were doing the bulk synthesis of, you know, the</p> <p>2 valsartan.</p> <p>3 Q. Okay. Let's talk about -- sorry, go on?</p> <p>4 A. They did do one -- I did find an example</p> <p>5 of one kind of post hoc analysis that they did. Not</p> <p>6 for the process itself, but to, you know, to look</p> <p>7 into the possibility. I'd have to look again at</p> <p>8 that.</p> <p>9 Q. Do you remember what was concluded from</p> <p>10 that analysis you're referring to?</p> <p>11 A. Yes, I believe they checked the sample</p> <p>12 of DMF and -- for dimethylamine, and they didn't find</p> <p>13 any.</p> <p>14 Q. Okay.</p> <p>15 A. I think that's what they -- that's what</p> <p>16 they found. But that was -- that was not -- you</p> <p>17 know, that is the case, that's what it was. But that</p> <p>18 was not the -- that was not the DMF that was actually</p> <p>19 used in the bulk process, according to my</p> <p>20 understanding of what I read. That was like a post</p> <p>21 hoc analysis, you know, after they realized what was</p> <p>22 going on.</p> <p>23 Then they said, well, let's look at the</p> <p>24 DMF, let's look at the DMF and see if we see any</p> <p>25 dimethylamine in it. But that wasn't necessarily the</p>	<p style="text-align: right;">Page 68</p> <p>1 those eight binders?</p> <p>2 A. Some of them are company documents,</p> <p>3 yeah.</p> <p>4 Q. Okay. Outside of those eight binders</p> <p>5 that include company documents of ZHP, are there any</p> <p>6 other documents, company documents of ZHP, that you</p> <p>7 have looked at?</p> <p>8 A. Not company documents.</p> <p>9 (Simultaneous speaking.)</p> <p>10 MR. SLATER: Objection.</p> <p>11 You can answer.</p> <p>12 (Court Stenographer clarification.)</p> <p>13 A. Not -- I haven't looked at any other</p> <p>14 company documents, other than the ones that I just</p> <p>15 mentioned.</p> <p>16 MR. SLATER: Rich, just so that you know</p> <p>17 this, because I don't want you to be misled.</p> <p>18 The binders were documents that -- it's</p> <p>19 some of the documents he had, we put into binders so</p> <p>20 he would have access to them in hard copy. It's not</p> <p>21 every single document.</p> <p>22 I just want you to know that, just so</p> <p>23 that you don't have a disconnect with him, because</p> <p>24 there's no point to that.</p> <p>25 MR. BERNARDO: I appreciate that, Adam,</p>
<p style="text-align: right;">Page 67</p> <p>1 DMF that they actually used in the process. Anyhow,</p> <p>2 that's what I remember.</p> <p>3 Q. Thank you. Let me talk about the</p> <p>4 documents with you for a minute. About how many</p> <p>5 documents would you say -- well, withdrawn.</p> <p>6 Are the documents that you reviewed or</p> <p>7 considered in connection with forming your opinions</p> <p>8 those that are listed in your report, and</p> <p>9 supplemented by those that were provided to us a day</p> <p>10 or so ago? Is that the totality of documents that</p> <p>11 you reviewed?</p> <p>12 A. I don't know what was provided to you.</p> <p>13 I have no idea.</p> <p>14 Q. You don't know what was provided to us?</p> <p>15 A. I have got eight binders in my office</p> <p>16 here. And so that's what I have. I don't know what</p> <p>17 you have.</p> <p>18 Q. Understood. Let's talk about your eight</p> <p>19 binders, Dr. Hecht. Because I just -- I want to --</p> <p>20 the purpose of this is, I'm not trying to be</p> <p>21 mysterious. I just want to understand what you've</p> <p>22 looked at, to see if you've looked at other documents</p> <p>23 than I may have in mind.</p> <p>24 So you have eight binders of documents.</p> <p>25 And are those company documents pertaining to ZHP,</p>	<p style="text-align: right;">Page 69</p> <p>1 and that's what I want to explore and pin down,</p> <p>2 because I want to understand the scope of what</p> <p>3 Dr. Hecht looked at, so I can ask questions that take</p> <p>4 that into account.</p> <p>5 MR. SLATER: Yeah, he's not a -- he's</p> <p>6 not a regular litigation, do-this-all-the-time</p> <p>7 expert. So when you use terms like "materials," you</p> <p>8 know, your reliance list and things; those aren't</p> <p>9 terms that he's using every day, so it's just -- I</p> <p>10 just want you to know, you just might want to just</p> <p>11 explain what you're looking at, or what you're asking</p> <p>12 about. Because I don't want you to be, you know --</p> <p>13 MR. BERNARDO: I don't think we're near</p> <p>14 that point yet. So let me -- let's just keep going</p> <p>15 through this.</p> <p>16 Q. So Dr. Hecht, here's what I'm trying to</p> <p>17 understand.</p> <p>18 I want to understand the scope of or</p> <p>19 totality of company -- ZHP company documents that you</p> <p>20 personally reviewed, prior to forming your opinions</p> <p>21 in this case.</p> <p>22 Do you understand what I'm trying to</p> <p>23 understand?</p> <p>24 A. Yes.</p> <p>25 Q. Okay. Thank you. So I think, based</p>

<p style="text-align: right;">Page 70</p> <p>1 upon the discussion you and I just had, supplemented</p> <p>2 by what Mr. Slater told me, that some portion of</p> <p>3 those are in eight binders that you have with you</p> <p>4 today. Correct?</p> <p>5 A. Yes.</p> <p>6 Q. Could you estimate, outside of those</p> <p>7 eight binders, the number -- and I'm just looking for</p> <p>8 an estimate, like ten, a hundred, 10,000 -- the</p> <p>9 number of additional ZHP company documents that you</p> <p>10 reviewed?</p> <p>11 MR. SLATER: Please don't give him a --</p> <p>12 if you can give a reasonable estimate, you can do it,</p> <p>13 but please don't guess.</p> <p>14 A. Could you repeat the question? I mean,</p> <p>15 I --</p> <p>16 Q. Yes. Outside -- outside of those eight</p> <p>17 binders of documents?</p> <p>18 A. Yes.</p> <p>19 Q. I want to know approximately the number</p> <p>20 of ZHP company documents that you personally</p> <p>21 reviewed, prior to forming the opinions that you</p> <p>22 included in your reports in this case. Do you</p> <p>23 understand my question?</p> <p>24 A. Right. I mean, I've seen some other</p> <p>25 documents online. I don't remember -- I don't</p>	<p style="text-align: right;">Page 72</p> <p>1 you reviewed, that are with you that are company</p> <p>2 documents, roughly?</p> <p>3 A. Well, not all the binders are purely</p> <p>4 company documents. Okay? Some of them are like a</p> <p>5 mixture. But probably half of them have --</p> <p>6 Q. Okay. That's about --</p> <p>7 A. -- company-related material in them.</p> <p>8 Q. Got it. So about four binders, roughly?</p> <p>9 And again, I'm really looking to get rough --</p> <p>10 A. Very rough.</p> <p>11 Q. Okay. Outside of those four binders of</p> <p>12 company documents, about how many others? Fewer than</p> <p>13 a hundred, or more than a hundred?</p> <p>14 MR. SLATER: Objection.</p> <p>15 Q. Of company documents?</p> <p>16 MR. SLATER: Objection.</p> <p>17 A. Probably fewer than a hundred.</p> <p>18 Q. Okay, that's all I'm looking for. So</p> <p>19 the four binders, plus fewer than a hundred.</p> <p>20 Do you have any understanding of the</p> <p>21 number of company documents that were provided in</p> <p>22 this litigation by ZHP?</p> <p>23 A. I have no idea.</p> <p>24 Q. How did you come to receive those</p> <p>25 documents, the company documents that you looked at</p>
<p style="text-align: right;">Page 71</p> <p>1 remember the exact number.</p> <p>2 Q. And I don't want an exact number. What</p> <p>3 I want to get a sense of is just a range. Are we</p> <p>4 talking about fewer than a hundred?</p> <p>5 MR. SLATER: Objection.</p> <p>6 A. It depends how you define "document."</p> <p>7 Q. I'm defining it as --</p> <p>8 A. What is the definition of "document"?</p> <p>9 Q. I'm defining a document as a ZHP company</p> <p>10 document; a document kind of like what we were</p> <p>11 looking at before, that appears to have been authored</p> <p>12 by or written by ZHP, a ZHP company document.</p> <p>13 Does that help you answer the question?</p> <p>14 A. Yeah. So what was the question again?</p> <p>15 Q. The question was: Outside of the</p> <p>16 binders that we're talking about -- and I'm sorry,</p> <p>17 let me withdraw that question.</p> <p>18 The eight binders you have, I think you</p> <p>19 may have answered this, and I've forgotten already.</p> <p>20 Are those just ZHP company documents --</p> <p>21 A. No.</p> <p>22 Q. Or are there other kinds of materials?</p> <p>23 A. No, there are other materials, too.</p> <p>24 Q. Could you estimate the percentage, a</p> <p>25 quarter, half, 75 percent of the eight binders that</p>	<p style="text-align: right;">Page 73</p> <p>1 in forming your opinions?</p> <p>2 A. The law firm provided them to me.</p> <p>3 Q. Did you ask for particular documents,</p> <p>4 did you take what they sent you, something else?</p> <p>5 A. I don't really remember. I don't think</p> <p>6 I asked specifically for documents, but I don't</p> <p>7 really remember.</p> <p>8 Q. Fair. So you basically looked at the</p> <p>9 documents that plaintiff's counsel selected and</p> <p>10 provided for you. Is that a fair statement?</p> <p>11 A. Yes.</p> <p>12 Q. As you were going through those --</p> <p>13 withdrawn.</p> <p>14 I think you know that ZHP is a Chinese</p> <p>15 company, and that many of the documents are in</p> <p>16 Chinese. Is that fair?</p> <p>17 MR. SLATER: Objection.</p> <p>18 You can answer.</p> <p>19 A. Sure. But the ones I have have, you</p> <p>20 know, translations. They have English translations.</p> <p>21 Q. Because you don't speak Chinese. Fair?</p> <p>22 A. That's correct, yeah.</p> <p>23 Q. Okay. And Dr. Xue speaks -- ZHP's</p> <p>24 expert speaks Chinese. Is that correct?</p> <p>25 A. Yep.</p>

<p style="text-align: right;">Page 74</p> <p>1 Q. And in his report, he cites to other 2 documents that he states -- and I'm not asking you to 3 agree or disagree -- but that he states support his 4 opinion, that are in Chinese. Correct?</p> <p>5 A. Yes. Yeah.</p> <p>6 Q. Fair to say, you didn't look at those 7 documents, correct, because you wouldn't be able to 8 understand them?</p> <p>9 A. I didn't read them, no, because I don't 10 read Chinese.</p> <p>11 Q. Right. So you mentioned that post hoc, 12 I think that was your word, ZHP took steps to 13 determine that there was no dimethylamine in the DMF 14 it used. And it determined, in that batch that it 15 looked at post-hoc, that there was none. Correct?</p> <p>16 A. That's how I recall it.</p> <p>17 Q. Is it fair to say that you have no 18 knowledge, one way or the other, as to whether or not 19 ZHP evaluated the DMF that was used in their 20 valsartan in 2013 to ensure that there was no 21 dimethylamine?</p> <p>22 MR. SLATER: Objection.</p> <p>23 You can answer.</p> <p>24 A. I haven't seen it.</p> <p>25 Q. But we just established you've not seen</p>	<p style="text-align: right;">Page 76</p> <p>1 Q. So you don't think it really matters at 2 all as to whether you've seen the complete record, or 3 only a portion of the record?</p> <p>4 A. I don't know. I mean, you know, I've -- 5 I've seen enough to convince me that they didn't know 6 what they were doing.</p> <p>7 Q. Okay. All right. Then let me just -- 8 I think you'll agree with me on this, and then we can 9 move on, but let me just make sure. As you sit 10 here --</p> <p>11 A. I mean, they were totally oblivious. 12 You know -- okay, go ahead, sorry.</p> <p>13 Q. That's okay. As you sit here today, do 14 you agree you have no knowledge whatsoever as to 15 whether or not ZHP took steps in 2013 to ensure that 16 their DMF did not contain dimethylamine?</p> <p>17 MR. SLATER: One second. One second, 18 Doctor. Don't answer yet.</p> <p>19 I object. And I just want to say: 20 Counsel, if there are documents that you think 21 address this question specifically, and you're 22 representing it happened, I'd like to see them, 23 because they've never been produced.</p> <p>24 Q. Can you answer the question? Can you 25 answer the question?</p>
<p style="text-align: right;">Page 75</p> <p>1 all of the documents. Correct? Because some of 2 them --</p> <p>3 MR. SLATER: Objection. Objection. 4 This is argumentative. I mean, I mean -- there's -- 5 and the question -- the foundation is improper; it's 6 a misleading, mischaracterizing question. I'm happy 7 to explain to you why, if you wanted to do it without 8 Dr. Hecht. But --</p> <p>9 MR. BERNARDO: No need to explain. I 10 fully understand your objection, Adam, and I will 11 take it into account in my questions, and you can 12 address them later.</p> <p>13 Q. So Dr. Hecht, I just want -- again, for 14 purposes of understanding the basis of your opinions, 15 I want to understand what you've looked at.</p> <p>16 Because don't you think it's important 17 for the jury to understand if you've seen, you know, 18 all the materials, a portion of the materials, a few 19 selected materials? Don't you think that would be 20 important, for the jury to understand your opinions?</p> <p>21 MR. SLATER: Objection to this question. 22 I don't think he's here to be an expert on what the 23 jury needs to -- would want to see or not.</p> <p>24 You can answer.</p> <p>25 A. Right, I agree with Adam.</p>	<p style="text-align: right;">Page 77</p> <p>1 MR. SLATER: Wait, let me just finish. 2 Because you're talking about your expert 3 looking at documents in Chinese, which I don't even 4 know if we have them, I don't know if we have 5 translated versions. And I'm starting to be 6 concerned that you're suggesting something that you 7 and I know didn't happen.</p> <p>8 But you can go ahead.</p> <p>9 MR. BERNARDO: Court Reporter, would you 10 repeat the question?</p> <p>11 (The testimony is read back.)</p> <p>12 A. I don't know if they did that or not.</p> <p>13 Q. Okay. Thank you.</p> <p>14 A. I do not.</p> <p>15 Q. Let's move to the second piece. So 16 again, dimethylamine can be in DMF in, I think, two 17 ways we just discussed. One, it could be in there 18 already, and we just talked about that. Correct?</p> <p>19 A. Yes.</p> <p>20 Q. Okay. And then the second is, it could 21 degrade under certain conditions to form 22 dimethylamine. Correct?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. I want to talk about the second 25 piece only, because I've moved past the first. So I</p>

<p style="text-align: right;">Page 78</p> <p>1 want to talk about knowledge that, under certain 2 conditions, dimethylamine could degrade -- I'm sorry, 3 withdrawn. I want to talk about -- that's the 4 problem with the -- I want to talk about the 5 knowledge that was available, in your opinion, 6 regarding that, as to the degradation of DMF to form 7 dimethylamine. 8 Do you understand the very narrow 9 question that I'm going to be exploring with you? 10 A. Yes. 11 Q. Okay. I want to go back to -- 12 MR. BERNARDO: If you could pull up, 13 Josh, Dr. Hecht's statement. 14 Q. And I understand that this statement 15 doesn't say what I just said. But a piece of -- but 16 what I just said is a piece of this statement. 17 Would you agree, in order for ZHP -- if 18 there was no DMF that was in -- withdrawn. I need 19 more coffee. 20 If there was no dimethylamine in the DMF 21 that they used, they would have to know that 22 dimethylamine could form from DMF, in order to start 23 the process that resulted in nitrosamines. Is that 24 fair? 25 MR. SLATER: Objection.</p>	<p style="text-align: right;">Page 80</p> <p>1 You can answer. 2 A. No, I don't dispute that. 3 Q. Okay. And again, I'm not asking you, 4 because I know you've not looked at them, but do you 5 have any reason to dispute that none of those papers 6 mention the degradation of the DMF into 7 dimethylamine -- or to form dimethylamine? 8 MR. SLATER: Objection. 9 You can answer. 10 A. They wouldn't mention it, because it's 11 not relevant. All right? I mean, the trace amount 12 of dimethylamine that's present in the DMF only 13 becomes relevant because they're dumping sodium 14 nitrite into the reaction. 15 If it's another kind of reaction where, 16 you know, they're using DMF as a solvent, and, you 17 know, there's a certain amount of dimethylamine 18 formed, it's not relevant to the product, so it 19 wouldn't even be mentioned. 20 Q. Okay. 21 MR. BERNARDO: I want to take a look, 22 Josh, if you can pull up -- hold on the patent, what 23 number is that? 24 MR. SCHOCH: Exhibit 8. 25 Q. Okay. I want to pull up and mark as</p>
<p style="text-align: right;">Page 79</p> <p>1 You can answer. 2 A. Yes. 3 Q. Okay. And again, I want to be very 4 clear. These are not the words in there, but I want 5 to see if this is your opinion. 6 Is it your opinion that it should have 7 been apparent, to any organic chemist involved in the 8 development or assessment of this process, that DMF 9 could degrade under certain conditions, back in 2013? 10 Is that your opinion? 11 A. Yes. 12 Q. Thank you. 13 MR. BERNARDO: So you can remove that. 14 Q. So I want to -- 15 A. Especially as it relates to this 16 process. 17 Q. Sure. So I want to go back to where we 18 were before. And I don't think we need to put up 19 these articles, and I understand your views on that 20 statement. 21 But you don't dispute that there are 22 articles in the scientific literature before 2013 23 that have a similar process that formed the tetrazole 24 ring and utilized DMF. Correct? 25 MR. SLATER: Objection.</p>	<p style="text-align: right;">Page 81</p> <p>1 Exhibit 8 a March 26, 1996 United States patent. 2 Do you see what's on the screen, Doctor? 3 (Exhibit Hecht-8, United States Patent 4 5,502,191, Issued March 26, 1996, was received and 5 marked for identification.) 6 A. Yes. 7 Q. Okay. I don't -- have you seen this 8 document before? I'm guessing not, but... 9 A. I don't know. 10 MR. SLATER: What exhibit number was 11 that, I'm sorry? 12 MR. BERNARDO: Eight, Adam. 13 MR. SLATER: Thank you. 14 MR. BERNARDO: Sure. 15 MR. SLATER: We're starting to get up in 16 big numbers, so... 17 MR. BERNARDO: I know. When we hit 18 double digits, we're going to be in trouble. 19 Q. Have they fixed your Exhibit Share yet, 20 Dr. Hecht? Because I'd like you to take a moment and 21 look at this document, and then I want to ask you a 22 couple of questions about it. 23 A. Okay. 24 Q. Have they fixed your Exhibit Share so 25 that you can do that?</p>

<p style="text-align: right;">Page 82</p> <p>1 A. Well, I can see it on the Zoom screen.</p> <p>2 Q. Oh, okay. It's longer than just what's</p> <p>3 on the Zoom screen; that's why I just wanted to do</p> <p>4 it. Well, why don't I ask you the questions and you</p> <p>5 can tell me if you feel like you need to see more</p> <p>6 about it. Right?</p> <p>7 So this is a patent from, you could see</p> <p>8 on its face, March 26, 1996. Correct?</p> <p>9 A. Yes.</p> <p>10 Q. And it talks about a method -- I'm</p> <p>11 sorry, if you look at the abstract, a method for</p> <p>12 making five-substituted -- slower -- a method for</p> <p>13 making five-substituted tetrazoles of Formula I. And</p> <p>14 it shows you the tetrazole ring. Correct?</p> <p>15 A. Right.</p> <p>16 Q. Thank you. And if you -- I'll --</p> <p>17 MR. BERNARDO: Josh, if you just want to</p> <p>18 go through the next two pages and give Dr. Hecht a</p> <p>19 moment to take a look at those.</p> <p>20 Q. And it goes through the background and</p> <p>21 the summary of invention. And I'm going to give you</p> <p>22 my question on page 4, and you can tell us if you</p> <p>23 need to take a look at this more. I don't think you</p> <p>24 will, based upon your prior testimony, but I want to</p> <p>25 see.</p>	<p style="text-align: right;">Page 84</p> <p>1 acid. Do you see that?</p> <p>2 A. Uh-hum.</p> <p>3 Q. Okay. So this is a patent that is</p> <p>4 describing, in 1996, a process that is very similar</p> <p>5 to ZHP's zinc chloride process. Is that fair?</p> <p>6 MR. SLATER: Objection.</p> <p>7 You can answer.</p> <p>8 A. It is.</p> <p>9 Q. Thank you. And I will represent to you,</p> <p>10 just because we're having document issues: Nowhere</p> <p>11 in this document does it mention that DMF can</p> <p>12 degrade. Do you have any reason to dispute that?</p> <p>13 MR. SLATER: Objection, that's really</p> <p>14 not a reasonable question to ask him. It's a long</p> <p>15 document that he hasn't had a chance to read. How</p> <p>16 would he have any basis to dispute it when he hasn't</p> <p>17 read the document?</p> <p>18 MR. BERNARDO: Fair enough.</p> <p>19 Q. I will represent --</p> <p>20 MR. SLATER: If you want to represent it</p> <p>21 and ask him --</p> <p>22 MR. BERNARDO: I'm going to represent --</p> <p>23 MR. SLATER -- assuming that you're</p> <p>24 correct -- let me finish. If you want to represent</p> <p>25 it and ask him, assuming that you're correct, and</p>
<p style="text-align: right;">Page 83</p> <p>1 And if you look, part of the background</p> <p>2 gives a description of some examples of the use. And</p> <p>3 here's Example 1. Okay? Do you see that?</p> <p>4 A. Yeah.</p> <p>5 Q. And can you --</p> <p>6 MR. SLATER: And Rich, just for the</p> <p>7 record, is that pink highlighting on the document as</p> <p>8 it will be submitted as an exhibit?</p> <p>9 MR. BERNARDO: Yes.</p> <p>10 MR. SLATER: Okay.</p> <p>11 Q. And I just want to focus you on the</p> <p>12 language in the pink highlighted.</p> <p>13 A. Yep.</p> <p>14 Q. If you'd just take a minute and take a</p> <p>15 look at that.</p> <p>16 A. Okay.</p> <p>17 Q. Okay? And you see it adds some sodium</p> <p>18 azide, according to what's described there. Correct?</p> <p>19 A. Yeah.</p> <p>20 Q. And then the reaction mixture with DMF,</p> <p>21 zinc chloride, and sodium azide is heated for</p> <p>22 36 hours. Do you see that?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. And then it's cooled off and</p> <p>25 acidified with hydraulic -- I'm sorry, hydrochloric</p>	<p style="text-align: right;">Page 85</p> <p>1 then you want to ask a question based on that, I</p> <p>2 wouldn't object to that.</p> <p>3 MR. BERNARDO: That's what I was about</p> <p>4 to do, Adam.</p> <p>5 MR. SLATER: I'm here for you.</p> <p>6 BY MR. BERNARDO:</p> <p>7 Q. Dr. Hecht, I will represent to you that</p> <p>8 nowhere in this document does it mention that DMF</p> <p>9 might degrade. And before you said, in these</p> <p>10 scientific publications, they wouldn't need to,</p> <p>11 because it's the -- I think you used the dumping of</p> <p>12 acid. But this process similarly uses acid as --</p> <p>13 after it has cooled. Is that correct?</p> <p>14 MR. SLATER: Objection.</p> <p>15 One second.</p> <p>16 That mischaracterizes the prior</p> <p>17 testimony.</p> <p>18 Go ahead.</p> <p>19 A. What I said before was that there was no</p> <p>20 reason to mention it because you weren't adding</p> <p>21 sodium nitrite. You know, there was no reason to be</p> <p>22 concerned about a small amount of dimethylamine that</p> <p>23 might have formed from the DMF. There was -- you</p> <p>24 know, there was no reason to even think about that.</p> <p>25 Q. Okay. Is that your testimony with</p>

Page 86

1 respect to this as well, just so we can understand
2 that?

3 A. No --

4 MR. SLATER: Objection.

5 Stop, stop, Doctor. Doctor, one second,
6 just let me just get my objection in.

7 Objection, because this is, as well as
8 this patent, that he obviously hasn't read. So, I'm
9 just -- I just want to make it clear what the "this"
10 is.

11 Q. So Dr. Hecht, based on the description
12 that is highlighted in pink, which is similar to the
13 process that ZHP used, wouldn't you expect that if
14 the degradation of DMF to form dimethylamine was
15 widely known, that that would be referenced in here?

16 MR. SLATER: Objection.

17 You can answer.

18 A. No. Because this patent, this process,
19 doesn't say anything about adding sodium nitrite to
20 decompose the sodium azide. It doesn't go into that.

21 Q. What's the effect of --

22 A. At least not what you're showing me.

23 Q. Sure. What would be the effect of
24 adding the sodium nitrite that would cause the
25 degradation?

Page 87

1 MR. SLATER: Objection, that's a --
2 there's no foundation to that question.

3 A. I don't get the question.

4 MR. SLATER: It doesn't make sense.

5 A. I don't get your question.

6 Q. Sure. Dr. Hecht, explain to me the
7 circumstances of the zinc chloride process that set
8 the stage for the decomposition of DMF to form
9 dimethylamine?

10 A. They had added sodium nitrite to
11 decompose the excess sodium azide. The sodium azide
12 on that scale is an explosion risk, so they had to
13 add sodium nitrite to get rid of the sodium azide.
14 Sodium nitrite will react with sodium azide to
15 decompose it. So that's why they add the sodium
16 nitrite.

17 Q. And what effect did the --

18 A. But they don't talk about that here.

19 Q. What effect did the addition of the
20 sodium nitrite have on the degradation of DMF to form
21 dimethylamine?

22 MR. SLATER: Objection.

23 You can answer.

24 A. None. I mean, the dimethylamine was
25 already there. The dimethylamine formed during the

Page 88

1 heating process of the dimethylformamide.

2 So the dimethylamine was already present
3 in the reaction mixture. And then when they added
4 the sodium nitrite without extracting product out
5 first, then the dimethylnitrosamine formed and
6 contaminated the product. They could have avoided
7 the whole thing by just extracting out the product
8 first.

9 Q. So it's your opinion that the point at
10 which the dimethylamine formed was during the heating
11 process? I just want to make sure I'm understanding
12 your testimony. I don't want to put words in your
13 mouth?

14 A. No, I don't know. It could have been
15 present in the DMF to begin with. I haven't seen
16 anything that says that they tested their DMF to
17 ensure that it was free of dimethylamine.

18 Q. Okay.

19 A. I didn't see that.

20 Q. Understood.

21 A. Maybe it's in some of the other
22 documents, I don't know.

23 Q. Okay. And I don't want to go back to
24 that, and I appreciate your making that
25 qualification, because I do want to make sure your

Page 89

1 testimony is very clear.

2 So again, I want to compartmentalize
3 this so I can understand what you're saying.

4 So we're going to assume, for purposes
5 of these questions, there was no dimethylamine in the
6 DMF at the time it was used. What I want to talk
7 about is, if the dimethylamine was formed during the
8 degradation of DMF, is it your testimony that that
9 happened at the point at which the -- well, you tell
10 me: At what point in the process did that happen?

11 A. Well, if it wasn't there to begin with,
12 then it happened during the [REDACTED] hours that they heat
13 the mixture to the tetrazole formation reaction. It
14 happened during that heating process.

15 Q. Great. Thank you very much.

16 MR. BERNARDO: You can take that down.

17 A. I am sure of that.

18 Q. So I want to go back, Dr. Hecht, to --

19 MR. BERNARDO: Can you put his report
20 back up.

21 MR. SCHOCH: Uh-hum.

22 MR. BERNARDO: Yes, please.

23 Q. I want to go back to this sentence. So,
24 "it should have been apparent to any organic
25 chemist."

<p style="text-align: right;">Page 90</p> <p>1 Should it have been apparent to any</p> <p>2 organic chemist in 2013 that DMF, when heated to its</p> <p>3 boiling point, would degrade to form dimethylamine,</p> <p>4 in your opinion?</p> <p>5 MR. SLATER: Are you asking any organic</p> <p>6 chemist -- okay, go ahead. Are you saying any</p> <p>7 organic chemist --</p> <p>8 (Simultaneous speaking.)</p> <p>9 A. I don't know about any organic chemist.</p> <p>10 (Court Stenographer clarification.)</p> <p>11 MR. SLATER: Go ahead, Doctor.</p> <p>12 A. It should have been apparent.</p> <p>13 (Simultaneous speaking.)</p> <p>14 Q. And again --</p> <p>15 A. Let me --</p> <p>16 MR. SLATER: Rich, Rich. Objection to</p> <p>17 form --</p> <p>18 (Simultaneous speaking.)</p> <p>19 A. I don't know about any --</p> <p>20 (Court Reporter Clarification.)</p> <p>21 THE WITNESS: Yes.</p> <p>22 Q. I want to go back, and I think you</p> <p>23 said --</p> <p>24 MR. SLATER: You've got to stop for a</p> <p>25 second. He's still --</p>	<p style="text-align: right;">Page 92</p> <p>1 question I'm asking, but it's up to Dr. Hecht to tell</p> <p>2 me if he's not --</p> <p>3 MR. SLATER: I don't think it is clear;</p> <p>4 that's why I'm objecting.</p> <p>5 BY MR. BERNARDO:</p> <p>6 Q. Dr. Hecht, let me rephrase the question.</p> <p>7 In 2013, should it have been clear --</p> <p>8 I'm sorry. In 2013, should it have been apparent to</p> <p>9 any organic chemist involved in the development or</p> <p>10 assessment of these processes that DMF could degrade</p> <p>11 to form dimethylamine at its boiling point?</p> <p>12 A. Yes.</p> <p>13 Q. Thank you.</p> <p>14 What steps did you take to determine</p> <p>15 that in 2013, it should have been apparent to any</p> <p>16 organic chemist involved?</p> <p>17 MR. SLATER: All right, let me just --</p> <p>18 stop for a second, Doctor.</p> <p>19 You literally asked this question like</p> <p>20 an hour and a half ago, and he talked about the</p> <p>21 literature and he went through this.</p> <p>22 Is this a new question, or are you</p> <p>23 saying in addition to what he's already said? You're</p> <p>24 going over old ground already.</p> <p>25 MR. BERNARDO: I'm not going over old</p>
<p style="text-align: right;">Page 91</p> <p>1 MR. BERNARDO: No, I don't, because my</p> <p>2 question was very clear --</p> <p>3 MR. SLATER: I haven't even gotten my</p> <p>4 objection in yet.</p> <p>5 MR. BERNARDO: Adam, I'm using his</p> <p>6 language.</p> <p>7 MR. SLATER: Can I speak?</p> <p>8 (Simultaneous speaking.)</p> <p>9 MR. BERNARDO: -- fairly long. And</p> <p>10 you've been doing that throughout the deposition.</p> <p>11 MR. SLATER: Can I object? Can I place</p> <p>12 my objection or not? It was a simple question for</p> <p>13 you, when you say "any organic chemist," because</p> <p>14 you've been over this with him now four or five times</p> <p>15 already in the deposition, I was going to ask you:</p> <p>16 Are you talking about any organic chemist that was</p> <p>17 involved in the development and the oversight of the</p> <p>18 process, or are you talking about the organic chemist</p> <p>19 that's, you know, working in a high school in</p> <p>20 Kentucky right now, teaching 10th grade chemistry?</p> <p>21 Because he's already clarified that</p> <p>22 opinion multiple times already, so I'm just asking:</p> <p>23 Are you asking a different question?</p> <p>24 MR. BERNARDO: I'm not asking a</p> <p>25 different question. I think it's been clear the</p>	<p style="text-align: right;">Page 93</p> <p>1 ground, Adam, and I would appreciate it if you</p> <p>2 wouldn't feed Dr. Hecht --</p> <p>3 MR. SLATER: I'm not feeding him</p> <p>4 anything --</p> <p>5 (Simultaneous speaking.)</p> <p>6 MR. SLATER: You've literally -- well,</p> <p>7 look, you can't just keep going over the same --</p> <p>8 you've asked that question already. So I'm asking,</p> <p>9 is it a new question or the same question? Because I</p> <p>10 object to the same question being asked over and</p> <p>11 over. That's not a reasonable use of the time.</p> <p>12 Q. Dr. Hecht, would you please answer my</p> <p>13 question?</p> <p>14 MR. BERNARDO: And these are my seven</p> <p>15 hours and I have a limit of seven hours, and it's not</p> <p>16 up to you to determine what's a reasonable use of his</p> <p>17 time.</p> <p>18 A. Could you repeat the question?</p> <p>19 Q. Yes. What was the process that you went</p> <p>20 through -- now that we've established what your</p> <p>21 opinion is, which it should have been apparent to any</p> <p>22 organic chemist involved in the development or</p> <p>23 assessment of these processes, that DMF would degrade</p> <p>24 at its boiling point; what was the process you went</p> <p>25 through to determine what should or should not have</p>

<p style="text-align: right;">Page 94</p> <p>1 been apparent to any organic chemist involved in the 2 development or assessment of the process? 3 MR. SLATER: I object, asked and 4 answered. 5 You can answer again. 6 A. I looked in the literature to see 7 whether, you know, the contamination of DMF with 8 dimethylamine or the formation of dimethylamine from 9 DMF was, you know -- was reported. I mean, there's 10 no doubt that DMF can hydrolyze to dimethylamine when 11 you heat it for [REDACTED] hours at [REDACTED] degrees, or whatever 12 it was. I mean, that's like basic organic chemist -- 13 chemistry. Yeah, I mean, I think, quote, any organic 14 chemist would know that. 15 But there's also a fair amount of 16 literature on just contamination of DMF with 17 dimethylamine. I think I noted before that sometimes 18 it has a fishy odor, due to the dimethylamine. But 19 there's -- you know, there's published literature. I 20 mean, you know, I have a paragraph here from Fields, 21 you know, "methods for removing the Fmoc group." 22 (Court Reporter Clarification.) 23 A. Fmoc, F-M-O-C. In Methods in Molecular 24 Biology, Volume XXXV, Peptide Synthesis Protocols, 25 published in 1994 by Humana Press in Totowa,</p>	<p style="text-align: right;">Page 96</p> <p>1 Q. Okay. Again, I really want to try and 2 be efficient here, Dr. Hecht. I don't want to ask 3 any more questions, and I'm not intending to ask you 4 any more questions, about the presence of 5 dimethylamine in DMF. I really want to focus this 6 discussion on the knowledge, or what should or should 7 not have been known in 2013, by any organic chemist 8 involved in the development of these processes. 9 That's really what I want to focus on, Dr. Hecht. Do 10 you understand my -- 11 A. Okay, sure. 12 Q. Okay. And I understand your testimony, 13 and I'm just really trying to make sure I can 14 understand how you got there. That's really what I'm 15 trying to do. 16 And you mentioned that it's cited in 17 some literature that you found. Does the fact that a 18 concept is cited in literature mean that it should 19 have been known to any organic chemist in a process 20 that involves that constituent or process, in your 21 opinion? Does the mere citation in the literature to 22 something? 23 A. Well, yes. It's my opinion that in this 24 particular case, they definitely should have taken 25 this into account; that's my opinion. You can't</p>
<p style="text-align: right;">Page 95</p> <p>1 New Jersey. 2 And what that -- within that volume -- 3 within that volume on page 22, it says that "amine 4 impurities that could possibly remove the Fmoc group 5 include dimethylamine found in DMF," and then it 6 references Number 47. I'm not sure what 47 was. 7 But anyhow, you know, this is like -- 8 this is not something new. I mean, DMF has been 9 around a long time, and this is -- this is not new, 10 that there might be some dimethylamine in the DMF, or 11 the dimethylamine could form when you heat DMF at [REDACTED] 12 degrees for [REDACTED] hours. 13 Q. Dr. Hecht, was the example you just gave 14 me an example -- you used the word "found," I don't 15 have the article you're looking at. Was that an 16 example where DMF -- 17 MR. SLATER: It's on the reliance list, 18 the supplemental list. 19 Q. Dr. Hecht, I don't have the article in 20 front of me that you're looking at. You just used 21 the word "found." Was that an article that discusses 22 the presence of dimethylamine in DMF, or is that an 23 article that discusses the degradation at its boiling 24 point? 25 A. No, the presence.</p>	<p style="text-align: right;">Page 97</p> <p>1 change it. 2 Q. And Dr. Hecht, I wouldn't begin to try 3 to, nor is it my goal to change your opinion at all. 4 That's not what this process is about. I respect 5 your opinion, you're entitled to your opinion; I just 6 want to understand the steps you took to get there. 7 That's really the purpose. So this is not trying to 8 change your opinion. 9 So Dr. Hecht, you would agree that there 10 are -- I couldn't even begin to estimate; probably 11 tens of thousands, if not hundreds of thousands, of 12 publications in the world's scientific literature. 13 Is that a fair statement, generally? 14 A. Sure. 15 Q. Okay. And certainly, an organic chemist 16 at a company couldn't be expected to know everything 17 that's in every one of those pieces of literature. 18 Is that a fair statement? 19 A. Yes, that's correct. 20 Q. And in fact, you're a very 21 well-respected scientist, and you don't certainly 22 purport to know everything that's in the world's 23 literature. Is that fair? 24 A. Yeah, I guess. 25 Q. Okay. You'll give me that one.</p>

<p style="text-align: right;">Page 98</p> <p>1 So what I'm trying to understand -- and</p> <p>2 let me just, let me give you an example. So the --</p> <p>3 withdrawn.</p> <p>4 What I'm trying to understand is, how</p> <p>5 does a piece of information go from being referenced</p> <p>6 in an article or several articles, to being something</p> <p>7 that should be widely known by any organic chemist in</p> <p>8 the development or assessment of a process? How</p> <p>9 does -- how do you distinguish between any fact in</p> <p>10 the scientific literature, and one that is so</p> <p>11 well-established that any organic chemist involved in</p> <p>12 the development or assessment of these processes</p> <p>13 should know it? What was your process of getting</p> <p>14 there?</p> <p>15 A. The answer is awareness. Okay? If</p> <p>16 you're developing a specific process, it's your</p> <p>17 responsibility to be aware of all aspects of that</p> <p>18 process. Not only just that, "Oh, this process</p> <p>19 works, because it gives us a high yield and it's less</p> <p>20 expensive, so this is going to give us a great yield</p> <p>21 of our product." No.</p> <p>22 You have to know all possible aspects.</p> <p>23 You have to consider the possible hazards that are</p> <p>24 involved with your -- with your process, and you have</p> <p>25 to consider the possible costs that are involved with</p>	<p style="text-align: right;">Page 100</p> <p>1 scientists that it utilizes in evaluating</p> <p>2 pharmaceuticals that we all consume. Is that fair?</p> <p>3 MR. SLATER: Objection. Objection.</p> <p>4 Lack of foundation.</p> <p>5 MR. BERNARDO: I'm asking the -- I'm</p> <p>6 asking if he knows it.</p> <p>7 MR. SLATER: Well, I object to the</p> <p>8 question, the foundation and the way the question was</p> <p>9 asked. He can answer it.</p> <p>10 A. I don't know.</p> <p>11 (Court Stenographer clarification.)</p> <p>12 MR. SLATER: He said, "I don't know."</p> <p>13 A. I don't know whether the FDA has some of</p> <p>14 the world's greatest scientists.</p> <p>15 Q. Okay. Do you know if the FDA scientists</p> <p>16 were aware or not aware that DMF could degrade at the</p> <p>17 boiling point?</p> <p>18 MR. SLATER: Objection to form.</p> <p>19 A. I do not know.</p> <p>20 Q. Okay. Let me just change --</p> <p>21 MR. SLATER: You know, Rich --</p> <p>22 Q. Moving on. So Doctor -- Dr. Hecht, the</p> <p>23 valsartan, ZHP's valsartan manufacturing process is a</p> <p>24 multistep process. We can agree on that. Right?</p> <p>25 MR. SLATER: Which process are we</p>
<p style="text-align: right;">Page 99</p> <p>1 your process. You have to consider the environmental</p> <p>2 impact of the process that you're using. You have to</p> <p>3 consider whether the drug that you're making, if</p> <p>4 you're making a drug, is going to have toxicity.</p> <p>5 It all has to do with the awareness of</p> <p>6 the particular part of organic chemistry that you're</p> <p>7 working in. You can't be -- you can't know</p> <p>8 everything, but you have to be aware of the specific</p> <p>9 aspects of the process, and its possible</p> <p>10 consequences, that relate to this particular reaction</p> <p>11 conditions that you're using. It's awareness.</p> <p>12 Q. Awareness of everything that's in the</p> <p>13 scientific literature?</p> <p>14 A. No.</p> <p>15 MR. SLATER: Objection.</p> <p>16 One second, Doctor --</p> <p>17 A. Not everything.</p> <p>18 MR. SLATER: Stop. One second.</p> <p>19 A. You can't be -- it's impossible to be</p> <p>20 aware of everything. But you do -- it is your</p> <p>21 responsibility to be aware of the aspects that relate</p> <p>22 to your particular process. That is absolutely</p> <p>23 basic.</p> <p>24 Q. So, Dr. Hecht, you wouldn't dispute that</p> <p>25 the FDA has some of the world's leading chemists and</p>	<p style="text-align: right;">Page 101</p> <p>1 talking about?</p> <p>2 MR. BERNARDO: Sorry. The zinc chloride</p> <p>3 process.</p> <p>4 A. Could you repeat the question, please?</p> <p>5 Q. Sure. It's just a foundational</p> <p>6 question. I just want to -- I think we agree that</p> <p>7 there are many steps in the process of making</p> <p>8 valsartan. Whether it's the zinc chloride process or</p> <p>9 the TEA with quenching process, it's a multistep</p> <p>10 process. Is that fair?</p> <p>11 A. Yes.</p> <p>12 Q. Okay. I'm just trying to make sure I</p> <p>13 understand your opinions as to which step really</p> <p>14 matters here, for purposes of discussion. I'll give</p> <p>15 where I'm going, just to make sure that -- I think I</p> <p>16 know what your opinion is, but I want to make sure.</p> <p>17 And you believe that nitrosamines formed</p> <p>18 during the crude valsartan step. Is that correct?</p> <p>19 A. What do you mean by "the crude valsartan</p> <p>20 step"?</p> <p>21 Q. The -- do you want me to go back to our</p> <p>22 first -- Step 4, basically, that we discussed</p> <p>23 earlier?</p> <p>24 A. I don't remember --</p> <p>25 MR. SLATER: Do you want to put back up.</p>

<p style="text-align: right;">Page 102</p> <p>1 A. What you mean by "Step 4."</p> <p>2 Q. Let me do it this way.</p> <p>3 A. It forms when they dump in the nitrate.</p> <p>4 Q. Okay. Does it -- let me see if I can</p> <p>5 approach it this way.</p> <p>6 Does it form at any other step of the</p> <p>7 manufacturing process, in your opinion?</p> <p>8 A. Not before the nitrite.</p> <p>9 Q. Thank you. That's all I'm just</p> <p>10 trying to --</p> <p>11 A. I don't know about after the nitrate.</p> <p>12 Q. Fair enough. And is it your opinion</p> <p>13 that NDMA formed during that part of the process --</p> <p>14 only NDMA formed during that part of the zinc</p> <p>15 chloride process?</p> <p>16 MR. SLATER: Objection. I'm not sure I</p> <p>17 understand the question.</p> <p>18 A. I didn't get it either.</p> <p>19 Q. Sure. Do you believe that NDMA formed</p> <p>20 during any process, other than the point we just</p> <p>21 described in the zinc chloride process?</p> <p>22 MR. SLATER: Objection. When you say</p> <p>23 "the process," do you mean "step"? Isn't that the</p> <p>24 question you just asked him?</p> <p>25 Q. Dr. Hecht, can you answer?</p>	<p style="text-align: right;">Page 104</p> <p>1 degradation, and on to the risk assessment process.</p> <p>2 Are you with me?</p> <p>3 A. Yeah.</p> <p>4 Q. Great. One of your opinions is that ZHP</p> <p>5 failed to perform what you describe as a -- and I</p> <p>6 think the word you use is "straightforward" risk</p> <p>7 assessment.</p> <p>8 Do you agree with that, or do you want</p> <p>9 to see your report?</p> <p>10 A. Yes.</p> <p>11 Q. Okay. Now, you are not saying that ZHP</p> <p>12 failed to conduct any risk assessment. Correct?</p> <p>13 A. No, I'm referring to specifically the</p> <p>14 possibility of nitrosamine formation during their</p> <p>15 process.</p> <p>16 Q. Okay. So you would agree that ZHP did,</p> <p>17 in fact, conduct a risk assessment for its</p> <p>18 TEA-with-quenching process. Correct?</p> <p>19 A. You lost me.</p> <p>20 Q. Sure. Did ZHP conduct a risk assessment</p> <p>21 or not for its TEA-with-quenching process?</p> <p>22 A. With respect to what?</p> <p>23 Q. Any risk assessment whatsoever, of that</p> <p>24 process?</p> <p>25 A. Oh, I don't know risk assessment.</p>
<p style="text-align: right;">Page 103</p> <p>1 A. The NDMA -- the NDMA forms when you add</p> <p>2 the nitrite, add the sodium nitrite.</p> <p>3 Q. Okay. Do you have an opinion as to</p> <p>4 whether NDEA forms at that point?</p> <p>5 A. The NDEA was from the triethylamine</p> <p>6 process.</p> <p>7 Q. And that's what I'm trying to establish,</p> <p>8 Dr. Hecht --</p> <p>9 A. But that's a different, that's a</p> <p>10 different process.</p> <p>11 Q. Exactly. That's all I'm trying to</p> <p>12 establish. I just want to make sure that my</p> <p>13 understanding of your opinion is correct; which is</p> <p>14 that NDMA only forms during the zinc chloride</p> <p>15 process, and that NDEA forms only during the TEA with</p> <p>16 quenching process?</p> <p>17 MR. SLATER: Objection.</p> <p>18 Q. I believe that's what you're saying, but</p> <p>19 I just want to confirm that, and if it's not, I want</p> <p>20 to understand?</p> <p>21 A. Yes, I believe that's correct.</p> <p>22 Q. Okay. Thank you.</p> <p>23 (Court Reporter Clarification.)</p> <p>24 Q. Dr. Hecht, one of your opinions -- I</p> <p>25 want to move on to the -- I want to move out of DMF</p>	<p style="text-align: right;">Page 105</p> <p>1 That's a big word. You know, they have to -- they</p> <p>2 have to consider many factors before they initiate a</p> <p>3 process on that scale. There could be any number of</p> <p>4 factors. So I don't know if they considered -- you</p> <p>5 know, I don't know if they carried out a risk</p> <p>6 assessment for various different things. I have no</p> <p>7 idea.</p> <p>8 Q. I want to make sure my question is</p> <p>9 clear, because I'm not sure, based on your answer, it</p> <p>10 is, so let me just try this again. Okay?</p> <p>11 Before changing -- we talked about the</p> <p>12 four processes. Right? And the last two processes,</p> <p>13 we went through changes that the company made, and</p> <p>14 the documentation about those changes that they</p> <p>15 submitted to FDA. Right?</p> <p>16 A. Yes.</p> <p>17 Q. Okay. Before they made or proposed to</p> <p>18 make those changes, do you agree -- let's talk about</p> <p>19 the TEA quenching, the changes they made for the TEA</p> <p>20 quenching process. Do you agree or not that they</p> <p>21 conducted a risk assessment with respect to those</p> <p>22 changes?</p> <p>23 A. I don't know, because a risk assessment</p> <p>24 -- you know, what do you mean by "risk assessment"?</p> <p>25 That's a huge word.</p>

<p style="text-align: right;">Page 106</p> <p>1 Q. Can we pull up your report? Just a</p> <p>2 minute, we're going to just pull up your report,</p> <p>3 Doctor. Because I just want to make sure we're...</p> <p>4 MR. BERNARDO: It's on page 2. There</p> <p>5 you go, Josh.</p> <p>6 A. Okay.</p> <p>7 Q. Let's put it in your words.</p> <p>8 So "ZHP failed to perform a</p> <p>9 straightforward assessment of the chemistry."</p> <p>10 Do you see that?</p> <p>11 A. Yes.</p> <p>12 Q. Okay. Is it your testimony that they</p> <p>13 performed no assessment, or you just disagree with</p> <p>14 the thoroughness or detail of the assessment? That's</p> <p>15 what I'm trying to understand?</p> <p>16 A. I don't know if they -- I have no idea</p> <p>17 whether they did an assessment or not. I mean, I can</p> <p>18 only go on what's reported. Maybe they did an</p> <p>19 assessment and they -- and they decided, you know,</p> <p>20 there's no problem, so let's go forward, and it was</p> <p>21 never recorded. I don't know. Maybe they did an</p> <p>22 assessment, maybe they didn't. I have no idea.</p> <p>23 Q. Okay. So -- so your characterization of</p> <p>24 the assessment as not being straightforward; you</p> <p>25 don't know one way or the other whether they did any</p>	<p style="text-align: right;">Page 108</p> <p>1 MR. BERNARDO: I'm going --</p> <p>2 MR. SLATER: -- in general, or are you</p> <p>3 talking about an assessment of the specific parts of</p> <p>4 the reactions that Dr. Hecht has been focusing on?</p> <p>5 MR. BERNARDO: There's no question on</p> <p>6 the table to ask that about.</p> <p>7 MR. SLATER: Well, we're not trying to</p> <p>8 trick anyone we said. Right?</p> <p>9 MR. BERNARDO: Adam, there's no question</p> <p>10 on the table for which you can object.</p> <p>11 Are you going to pull up --</p> <p>12 MR. SCHOCH: Okay.</p> <p>13 Q. Okay. I'm pulling up and going to</p> <p>14 mark -- this was already marked, right? This was</p> <p>15 Exhibit 5, right? This was the amendment to the Drug</p> <p>16 Master File.</p> <p>17 I forget whether you've said you have</p> <p>18 seen this before or not. Would you refresh my</p> <p>19 recollection, Dr. Hecht?</p> <p>20 A. Maybe.</p> <p>21 Q. Maybe you've seen it. Okay. This is a</p> <p>22 document that was submitted to FDA. Correct?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. And there are multiple sections</p> <p>25 analyzing if you --</p>
<p style="text-align: right;">Page 107</p> <p>1 assessment. That's your --</p> <p>2 MR. SLATER: Objection, that's not what</p> <p>3 he said.</p> <p>4 A. No, all I know is --</p> <p>5 (Simultaneous speaking.)</p> <p>6 Q. I withdraw -- I withdraw my question.</p> <p>7 MR. SLATER: Okay.</p> <p>8 Q. Why don't we -- did you ask to see,</p> <p>9 Dr. Hecht, documents showing what ZHP did, prior to</p> <p>10 making the change, to assess the changes that were</p> <p>11 made?</p> <p>12 A. Which change are you talking about now?</p> <p>13 Q. Sorry, good question. Let's start with</p> <p>14 the TEA with quenching.</p> <p>15 Did you ask to see any documents that</p> <p>16 describe the steps that ZHP took to assess that</p> <p>17 process, prior to making the changes?</p> <p>18 A. I'm sorry, but I really don't understand</p> <p>19 what you're talking about, okay?</p> <p>20 Q. I'm asking -- let me --</p> <p>21 MR. BERNARDO: Let's pull, let's pull up</p> <p>22 one of the documents here. Let's pull up what I'll</p> <p>23 mark as --</p> <p>24 MR. SLATER: Rich, are you talking about</p> <p>25 an assessment --</p>	<p style="text-align: right;">Page 109</p> <p>1 MR. BERNARDO: Again, have we figured</p> <p>2 out if the doctor can have a look at this document on</p> <p>3 his own. This makes this sort of clunky.</p> <p>4 Q. Dr. Hecht, are you able to pull up</p> <p>5 documents, has that been sorted through?</p> <p>6 A. I haven't tried, I mean.</p> <p>7 Q. Well, let's just take a look at the</p> <p>8 changes. And the first change we discuss is on</p> <p>9 page 3 to 4, page 2 of document. Right?</p> <p>10 A. Yeah.</p> <p>11 Q. And we looked at this before. And we</p> <p>12 looked at -- if you look at Table 4 -- I'm sorry,</p> <p>13 Table 1 on page 4 of 8, right, it gives you data that</p> <p>14 the company compiled. And they used that data to</p> <p>15 determine that the process leads to equivalent yields</p> <p>16 and impurity levels.</p> <p>17 Do you see that?</p> <p>18 A. Yes.</p> <p>19 Q. And this is under --</p> <p>20 MR. BERNARDO: If you scroll back, Josh.</p> <p>21 Q. A section called "Justification and Risk</p> <p>22 Assessment." Correct?</p> <p>23 A. Yes.</p> <p>24 Q. And is it fair to say that this document</p> <p>25 demonstrates the steps that the company took to</p>

<p style="text-align: right;">Page 110</p> <p>1 determine whether this was an appropriate or 2 not-appropriate change? 3 A. Yes. 4 Q. Okay. So they did take steps, that's 5 really all I want to establish, to evaluate the 6 change. Correct? 7 A. Yes. 8 Q. Okay. And if you look -- there's 9 another assessment on page 4. Okay? And it says, 10 "After reaction" -- I'm sorry. "No adverse change in 11 qualitative and quantitative impurity profile." 12 Correct? 13 A. Yes. 14 Q. Okay. So they -- the point I'm trying 15 to make sure we agree on is that ZHP didn't simply 16 make changes to the process; but they evaluated the 17 changes they were making, to see if they were 18 appropriate changes to make. 19 Do you agree with that point? 20 A. No. 21 Q. You don't think they took any steps 22 whatsoever to evaluate the changes that they were 23 making? 24 A. They didn't take the right steps. 25 Q. Okay. Now I think I understand --</p>	<p style="text-align: right;">Page 112</p> <p>1 opinion that they were oblivious or not as to one 2 aspect, you will agree, based upon what we're looking 3 at, we could look at more if you'd like, that they 4 did take steps to evaluate the risks of the changes? 5 MR. SLATER: One second before you 6 answer, Doctor, I just want to object. 7 Because you characterized the statement 8 as "oblivious" as an opinion. I believe it's a 9 stipulated fact, per the stipulation entered into 10 this litigation, so I think that that question is 11 inappropriate. 12 MR. BERNARDO: Okay. We'll have to look 13 at the stipulation again. But that's -- despite 14 that, I think it's an appropriate question. 15 Q. And if you would answer it, Dr. Hecht? 16 A. Okay. So what's the question again? 17 MR. BERNARDO: Can you read the question 18 back, Ellen? 19 (The testimony is read back.) 20 A. No. No, that's not -- it's taken out of 21 context. That's not my opinion. It's not my opinion 22 that they were meaningless. What I said was they 23 were meaningless with respect to the formation of 24 nitrosamines in their product. 25 Q. Understood.</p>
<p style="text-align: right;">Page 111</p> <p>1 A. I can take all kinds of different steps 2 to evaluate a process that are meaningless. They 3 didn't take the critical steps. 4 Q. Okay. So it's your testimony that the 5 steps that ZHP took in the risk assessment they did 6 were meaningless? 7 A. No. They're meaningless with respect to 8 the formation of nitrosamines in their product. 9 Q. Okay. So -- 10 A. That's the risk assessment that they 11 should have taken. 12 Q. Got it. 13 A. One of them. Which they did not take. 14 Q. Okay. So that's the risk assessment, in 15 your opinion, that particular one: To evaluate DMF, 16 and whether or not it degrades or how it gets used. 17 Correct? 18 A. They should have looked for nitrosamines 19 in their product. 20 Q. Okay. But again, to clarify -- 21 A. They're using sodium nitrite. That is 22 the step that they should have taken. 23 Q. Okay. 24 A. They were oblivious. 25 Q. Okay. Dr. Hecht, whether it's your</p>	<p style="text-align: right;">Page 113</p> <p>1 A. They were not necessarily meaningless, 2 with respect to other aspects of risk. 3 Q. Correct. So they -- again, I understand 4 what you're saying: That there's one, in your view, 5 important piece that they did not look at. But 6 you're not -- it is -- would you agree that they did 7 take steps to evaluate the risks of their changes, 8 prior to making those changes, and submitted those 9 evaluations to FDA through the document that we're 10 looking at? 11 MR. SLATER: Objection to the form of 12 the question. 13 You can answer. 14 A. Yes. I don't know about risk. But 15 yeah, they submitted the changes to the FDA; they 16 have to do that. 17 Q. But they submitted more than just 18 changes, Dr. Hecht. That's what I want to see if you 19 agree or disagree on. They submitted more than -- 20 they didn't just say, "I'm changing this to this." 21 They said, "I'm changing this to this, and these are 22 the steps we took to determine that those changes are 23 appropriate." 24 Do you agree with that general 25 characterization?</p>

<p style="text-align: right;">Page 114</p> <p>1 A. Yes.</p> <p>2 MR. SLATER: Objection.</p> <p>3 You can answer.</p> <p>4 You know, Dr. Hecht, most people aren't</p> <p>5 quicker than me. You're pretty quick on the draw</p> <p>6 there.</p> <p>7 Q. I want to take a look at -- let's</p> <p>8 mark --</p> <p>9 MR. BERNARDO: Actually, why don't we --</p> <p>10 I think we've been going about an hour. Why don't we</p> <p>11 take a break before I turn to a new topic here, and</p> <p>12 cut it in the middle.</p> <p>13 THE VIDEOGRAPHER: All right. Going off</p> <p>14 the record. The time is 10:34 a.m., Central Time.</p> <p>15 This is the end of Media Unit 2.</p> <p>16 (A brief recess takes place.)</p> <p>17 THE VIDEOGRAPHER: We're back on the</p> <p>18 record. The time is 10:48 a.m. Central Time. This</p> <p>19 is the beginning of Media Unit 3.</p> <p>20 BY MR. BERNARDO:</p> <p>21 Q. Dr. Hecht, you would agree that</p> <p>22 pharmaceutical manufacturers would not be expected to</p> <p>23 test for every conceivable impurity. Is that a fair</p> <p>24 statement?</p> <p>25 MR. SLATER: Objection.</p>	<p style="text-align: right;">Page 116</p> <p>1 think you can go and give the 12 versions of what you</p> <p>2 think my question could possibly mean. Let's move</p> <p>3 on.</p> <p>4 MR. SLATER: Well, I didn't --</p> <p>5 Q. Dr. Hecht, Dr. Hecht --</p> <p>6 MR. SLATER: Hang on, hang on. Hang on,</p> <p>7 Mr. Bernardo. I'm trying to answer you. You're not</p> <p>8 going to -- I'd appreciate it. I'm not talking over</p> <p>9 you; please don't do that to me.</p> <p>10 I didn't give the 12 versions of your</p> <p>11 question. I asked you to clarify an improperly</p> <p>12 asked, lack of foundation, ambiguous question.</p> <p>13 That's what I did. And I tried to help you to make</p> <p>14 it clear, because it's not a usable question. So</p> <p>15 don't mischaracterize what I did, please.</p> <p>16 MR. BERNARDO: Adam, I would appreciate</p> <p>17 if you would be governed by what you need to do to</p> <p>18 represent your client --</p> <p>19 MR. SLATER: I am doing that.</p> <p>20 MR. BERNARDO: -- instead of -- let me</p> <p>21 finish now. Instead of helping me. Okay? I</p> <p>22 think --</p> <p>23 MR. SLATER: Do me a favor. Let's</p> <p>24 neither of us will lecture each other. I'll make my</p> <p>25 objections; you don't like what I'm doing, you</p>
<p style="text-align: right;">Page 115</p> <p>1 You can answer.</p> <p>2 A. I don't know what you mean by "every</p> <p>3 conceivable impurity." I mean, sure, there are</p> <p>4 priorities.</p> <p>5 Q. But roughly how many potential</p> <p>6 impurities could there be that could contaminate a</p> <p>7 product, in the world of impurities?</p> <p>8 MR. SLATER: Objection. Are you asking</p> <p>9 in the world of every product that is manufactured</p> <p>10 around the world? Are you talking about with this --</p> <p>11 MR. BERNARDO: I'm asking a general</p> <p>12 question.</p> <p>13 MR. SLATER: All right.</p> <p>14 So you --</p> <p>15 MR. BERNARDO: Adam -- Adam, I think the</p> <p>16 objections are getting a little over the line. I'm</p> <p>17 trying to just not go back and forth. I think</p> <p>18 there's been a hearing with the judge on this, and</p> <p>19 I'm -- you know -- let's just --</p> <p>20 MR. SLATER: I don't think --</p> <p>21 MR. BERNARDO: If the doctor has -- if</p> <p>22 the doctor has a question about my question, or</p> <p>23 thinks it's not clear, he can ask me. If you have an</p> <p>24 objection to form, you can tell me you think the</p> <p>25 question is vague, and I can go on. But I don't</p>	<p style="text-align: right;">Page 117</p> <p>1 always -- you have many -- you can do what you think</p> <p>2 you need.</p> <p>3 MR. BERNARDO: And that's what I just</p> <p>4 did. I'm telling you: I feel like you're getting,</p> <p>5 if not over the line, close to the line. I don't</p> <p>6 feel as if we need to get the Court on the phone.</p> <p>7 I'm simply, as a courtesy, telling you what my</p> <p>8 opinion is, as to the extent to which you're invading</p> <p>9 this deposition. So let's move on.</p> <p>10 BY MR. BERNARDO:</p> <p>11 Q. Dr. Hecht, do you agree that -- first of</p> <p>12 all, what I was asking when we got interrupted here,</p> <p>13 was: If you consider the world of impurities that</p> <p>14 could affect a potential pharmaceutical, a single</p> <p>15 pharmaceutical, we're talking about there could be,</p> <p>16 you know, hundreds, if not thousands, of potential</p> <p>17 impurities that could affect something or contaminate</p> <p>18 something. Is that -- is that a fair statement?</p> <p>19 MR. SLATER: Objection.</p> <p>20 You can answer.</p> <p>21 A. I don't know about the number that you</p> <p>22 gave. Of course, there can be on different</p> <p>23 impurities.</p> <p>24 Q. Okay. And --</p> <p>25 A. But I don't know about -- I wouldn't say</p>

<p style="text-align: right;">Page 118</p> <p>1 hundreds or thousands. That's -- I don't -- well, I 2 don't -- I don't think that's a good way to put it. 3 Q. Okay. Would you agree that there should 4 be a reasonable chance that an impurity can form, 5 before the pharmaceutical manufacturer, in your 6 opinion, would be expected to test for the impurity? 7 MR. SLATER: Objection. 8 You can answer. 9 A. Not in this case. You'll never get me 10 to agree to that. 11 They're dumping in nitrate at pH [REDACTED] 12 They have to test for nitrosamines, absolutely. 13 Q. In your opinion, because there was a 14 reasonable chance it could form; or just, period? 15 A. No, a reasonable chance that they could 16 form. Absolutely. 17 Q. Okay. So you would agree that, I think, 18 that there would have -- you think there was a 19 reasonable chance that nitrosamines could have 20 formed. I understand that testimony, right? 21 A. Yes. 22 Q. Okay. But that then would suggest you 23 agree with me: That in order to test for something, 24 there ought to be a reasonable chance that it could 25 form. Is that fair?</p>	<p style="text-align: right;">Page 120</p> <p>1 drug, because, you know, there are just too many. 2 So, you know, they do -- you do have to 3 be a little focused, and that's where awareness and 4 knowledge come in. That's where awareness of risk, 5 knowledge of possible risks, enter into the picture. 6 And, you know, that differentiates a responsible, 7 knowledgeable chemist from one that is unaware. 8 Q. Thank you, Dr. Hecht. 9 MR. BERNARDO: I want to put up as 10 exhibit, I'm sorry, Adam -- I don't know why I called 11 you Adam? Josh, what number are we up to? Yeah, 12 Adam is right, it's hard, it's difficult; there are 13 big numbers here. I want to mark as Exhibit 9 an 14 August 30, 2018, statement from the FDA. 15 (Exhibit Hecht-9, FDA Statement 16 entitled, "FDA Statement on FDA's ongoing 17 investigation into valsartan impurities and recalls 18 and an update on FDA's current findings" dated August 19 30, 2018, No Bates, Six Pages, was received and 20 marked for identification.) 21 Q. Okay. So Dr. Hecht, as you see, this is 22 an FDA statement, and the title is: "FDA statement 23 on FDA's ongoing investigation into valsartan 24 impurities and recalls and update on FDA's current 25 findings."</p>
<p style="text-align: right;">Page 119</p> <p>1 MR. SLATER: Objection. 2 You can answer. 3 A. I don't know about "anything." Okay? I 4 don't know why you're extending this to, you know, to 5 all things. I mean -- that's, to me is like -- 6 well, I don't know. I mean, I'm just saying that in 7 this particular case, where they're adding sodium 8 nitrite at pH [REDACTED] they should have tested for 9 nitrosamines. 10 Q. I want to give you a hypothetical, so I 11 want you to assume that -- and I know this is 12 different than your opinion, Dr. Hecht, but I want to 13 assume for my question that ZHP had no knowledge that 14 nitrosamines could form. Okay? 15 Are you with me on the assumption? 16 A. Yeah. 17 Q. Okay. Under those circumstances, you 18 would not expect them to test for it. Is that fair? 19 MR. SLATER: Objection. 20 You can answer. 21 A. Yeah, I guess. You know, if there was 22 no reason to think that nitrosamines would form, 23 then, you know, there would be -- probably would be 24 no reason to test for them. I mean, you can't test 25 for every contaminant that could possibly be in a</p>	<p style="text-align: right;">Page 121</p> <p>1 And it says, "For immediate release," 2 from -- I'm sorry, on August 30, 2018, from Scott 3 Gottlieb. Do you see that? 4 A. Yes. 5 Q. Have you seen this document before? 6 A. It does not look familiar. I don't know 7 if I've seen it. 8 Q. Okay. And are you aware that 9 Dr. Gottlieb, at the time, was the FDA Commissioner? 10 A. Yes. 11 Q. Okay. And if you -- and this is a 12 document, and if you want, you can scroll through it 13 or have us scroll for you, but I really want to focus 14 on a statement that's made at page 4 of the document? 15 A. Okay. 16 Q. And this is a document, you would agree, 17 that was issued, or a statement issued by FDA, by way 18 of follow-up to the discovery of nitrosamines in 2018 19 in valsartan. Right? 20 A. So it would appear. 21 Q. Okay. 22 MR. BERNARDO: Are we on page 4? There 23 we go. 24 Q. I want you to read the sentence, and 25 like --</p>

<p style="text-align: right;">Page 122</p> <p>1 MR. BERNARDO: Yeah, exactly. If you</p> <p>2 un-highlight it, it's easy for him, Josh.</p> <p>3 Q. My colleague highlighted the beginning,</p> <p>4 "Because."</p> <p>5 A. Yeah.</p> <p>6 Q. I'm sorry, would you read it into the</p> <p>7 record?</p> <p>8 A. Yeah. "It was not anticipated."</p> <p>9 Q. Sorry. Would you read the whole</p> <p>10 sentence into the record, and then I'll ask you a</p> <p>11 question about it?</p> <p>12 A. Okay.</p> <p>13 "Because it was not anticipated that</p> <p>14 NDMA would occur at these levels in the manufacturing</p> <p>15 of the valsartan API, manufacturers would not have</p> <p>16 been testing for it."</p> <p>17 Q. Okay. So in this document, the FDA</p> <p>18 Commissioner is explicitly stating that it was not</p> <p>19 anticipated that NDMA would occur at these levels in</p> <p>20 the manufacturing of valsartan. Correct?</p> <p>21 A. That's what he's saying.</p> <p>22 Q. And because of that, the Commissioner of</p> <p>23 the FDA was saying, and for that reason, drug</p> <p>24 manufacturers would not have been testifying --</p> <p>25 would not have been testing for it.</p>	<p style="text-align: right;">Page 124</p> <p>1 January 25, 2019.</p> <p>2 Q. And this is a statement, it looks like</p> <p>3 it's issued several months later from FDA,</p> <p>4 January 25, 2019, also from Scott Gottlieb, M.D., the</p> <p>5 Commissioner. Do you see that?</p> <p>6 A. Yep.</p> <p>7 Q. And it's another statement FDA issued as</p> <p>8 they were continuing to investigate the nitrosamine</p> <p>9 formation in valsartan. Is that correct?</p> <p>10 A. Yes.</p> <p>11 Q. Again, if you need to look at it, you'll</p> <p>12 let me know, but let's just jump ahead to page 3, and</p> <p>13 I'll show you the section about which I want to ask</p> <p>14 you a question.</p> <p>15 So where my colleague highlighted, and</p> <p>16 he'll take that off so you can better read it --</p> <p>17 MR. BERNARDO: Thank you.</p> <p>18 Q. Can you just read that sentence?</p> <p>19 A. Yeah.</p> <p>20 "Tests are selected based on assessments</p> <p>21 of what impurities may develop as a result of the</p> <p>22 manufacturing process. In other words, it generally</p> <p>23 needs to be recognized that there's a risk of an</p> <p>24 impurity occurring as a result of a manufacturing</p> <p>25 process to know the impurity should be tested for."</p>
<p style="text-align: right;">Page 123</p> <p>1 Is that what he's saying?</p> <p>2 MR. SLATER: Objection.</p> <p>3 You can answer.</p> <p>4 A. That's what the sentence appears to say.</p> <p>5 Q. Okay. Do you disagree with the FDA</p> <p>6 Commissioner's statement here?</p> <p>7 A. Absolutely disagree.</p> <p>8 Q. Okay.</p> <p>9 A. A hundred percent.</p> <p>10 Q. Okay. So you think the FDA was wrong</p> <p>11 when it said this to the public?</p> <p>12 A. Yes, it should have been testing for it.</p> <p>13 Q. Okay. So let's take a look at another</p> <p>14 statement.</p> <p>15 MR. BERNARDO: And this is marked as</p> <p>16 Exhibit 10.</p> <p>17 (Exhibit Hecht-10, FDA Statement</p> <p>18 entitled, "FDA Statement on the FDA's ongoing</p> <p>19 investigation into valsartan and ARB class impurities</p> <p>20 and the agency's steps to address the root causes of</p> <p>21 the safety issues," dated January 25, 2019, No Bates,</p> <p>22 Five Pages, was received and marked for</p> <p>23 identification.)</p> <p>24 MR. SCHOCH: Uh-hum.</p> <p>25 MR. BERNARDO: Oh, sorry, the</p>	<p style="text-align: right;">Page 125</p> <p>1 Yes, right.</p> <p>2 Q. And I think you would agree with that,</p> <p>3 based upon what you said. Correct?</p> <p>4 A. Yeah, right. They should have tested</p> <p>5 for it.</p> <p>6 Q. Okay. Is it your expectation that</p> <p>7 pharmaceutical companies generally test for NDMA or</p> <p>8 NDEA or other nitrosamines?</p> <p>9 A. Not generally, no. I don't think they</p> <p>10 do.</p> <p>11 Q. Okay. To your knowledge, prior to 2018,</p> <p>12 did pharmaceutical companies regularly test for NDMA</p> <p>13 or NDEA or other nitrosamines?</p> <p>14 MR. SLATER: Objection.</p> <p>15 You can answer.</p> <p>16 A. I do not know.</p> <p>17 Q. I'm sorry, I didn't hear your answer?</p> <p>18 A. I don't know.</p> <p>19 Q. Would that be relevant to your opinion,</p> <p>20 with respect to how widely-known, and how any chemist</p> <p>21 in a manufacturing process would be expected to know,</p> <p>22 if other manufacturers didn't test for NDMA or NDEA</p> <p>23 in pharmaceuticals?</p> <p>24 MR. SLATER: Objection.</p> <p>25 You can answer.</p>

<p style="text-align: right;">Page 126</p> <p>1 A. My opinion is based on knowledge of the 2 literature, and on decades of research on 3 nitrosamines that has established them as some of the 4 most potent carcinogens that are present in various 5 situations that humans are exposed to. So my opinion 6 is well formed on that, with respect to nitrosamines. 7 So if I were the FDA Commissioner, and I 8 saw this process, I would tell the company that they 9 had to test for nitrosamines. 10 Q. Okay. 11 A. Specifically for nitrosamines. 12 Whether nitrosamines should be tested in 13 all drug substances, it's probably not necessary; 14 because the manufacturing process, in probably the 15 vast majority of cases, would not involve the use of 16 sodium nitrite in the presence of secondary amines at 17 pH [REDACTED] 18 (Court Reporter Clarification.) 19 MR. SLATER: He said -- I'll tell you. 20 He said, "the presence of secondary amines at pH [REDACTED]" 21 A. Very few pharmaceutical companies would 22 venture to use that kind of chemistry, okay? Because 23 the people in pharmaceutical companies, they're not 24 idiots, they're aware of the literature. Okay? 25 There's hundreds of published papers on the</p>	<p style="text-align: right;">Page 128</p> <p>1 A. Sure. 2 Q. Okay. And I just want to establish: 3 What you're talking about was, generally with respect 4 to the development of nitrosamines; not specifically 5 the development of nitrosamines in pharmaceuticals. 6 Fair, in terms of the wide knowledge? 7 A. Yes, generally. But pharmaceuticals is 8 one aspect of it, okay? And people -- investigators, 9 chemists from drug companies, pharmaceutical 10 companies, attended the meetings that discussed 11 nitrosamine formation. Okay? They attend the 12 American Chemical Society meeting, where nitrosamine 13 formation, nitrosamine formation, nitrosamine 14 carcinogenicity, nitrosamine chemistry is discussed. 15 So they are aware. 16 Q. Are you aware, have there been any of 17 these types of conferences that you're aware of that 18 discussed the development of NDMA or NDEA, under the 19 conditions that were present in the processes we've 20 discussed today? 21 A. Starting in 1970, sure. 22 Q. So you're saying that the formation of 23 NDMA, for example, in a process like the zinc 24 chloride process, has been the subject of a 25 conference since the 1970s?</p>
<p style="text-align: right;">Page 127</p> <p>1 carcinogenicity of nitrosamines. There's multiple 2 reviews. There's conferences that have taken place 3 for years, okay? So this is -- this is not something 4 that's -- this is something that's widely known, 5 let's put that way. 6 And organic chemists and pharmaceutical 7 agents -- pharmaceutical companies should be aware of 8 it. They are aware of it. All right? Because I 9 mean, the FDA has had committees on nitrosamines. 10 FDA started their meetings on nitrosamines in the 11 1970s. Okay? So this is not a niche issue; this is 12 a well-known issue. But ZHP was not thinking or -- 13 whatever. I don't know. 14 Q. There are many different kinds of 15 nitrosamines in chemistry, fair to say? 16 A. Yes. 17 Q. So for example, there are 18 tobacco-specific nitrosamines; that's one kind. 19 Correct? 20 A. Yes. 21 Q. There are nitrosamines that could be 22 formed during the -- the curing or grilling of meats 23 and other foods, and nitrosamines that go in foods. 24 They're all different, and have a different mechanism 25 for formation. Is that fair?</p>	<p style="text-align: right;">Page 129</p> <p>1 MR. SLATER: Objection. 2 Q. I want to understand what you are saying 3 has been in a conference? 4 A. Not specifically -- 5 MR. SLATER: One second, Doctor -- 6 (Simultaneous speaking.) 7 A. No, not specifically for this process, 8 okay? I'm saying the general mechanism of formation, 9 okay? So that is the beauty of chemistry, okay? You 10 have certain reactions that will take place under 11 certain conditions, and it doesn't matter whether 12 that's in a food product or a pharmaceutical product, 13 or in the environment. Okay? We can predict that 14 that reaction will take place. 15 And the formation of dimethylnitrosamine 16 from dimethylamine has been known for decades. 17 Q. Okay. I want to go back to your report 18 for a moment, and we're going to put on the screen, 19 page 20. And I want to have you take a look; it's 20 about five, six lines from the bottom. 21 "In their analyses of the product, they 22 would not have identified NDMA in the chromatograms 23 unless they were specifically looking for it, because 24 the peaks would be too small." 25 Do you see that?</p>

<p style="text-align: right;">Page 130</p> <p>1 A. Yep.</p> <p>2 Q. Okay. And I understand you follow-up by</p> <p>3 saying that that's not a legitimate scientific</p> <p>4 excuse. I want to ask you a question.</p> <p>5 Hypothetically, if ZHP was not expected</p> <p>6 -- sorry. If nitrosamine formation would not be</p> <p>7 expected, you'd -- you agree, there's no reason they</p> <p>8 should have detected it in their products with the</p> <p>9 testing that was done. Correct?</p> <p>10 MR. SLATER: Objection.</p> <p>11 (Simultaneous speaking.)</p> <p>12 MR. SLATER: That doesn't make sense.</p> <p>13 A. They wouldn't have seen it. Not in</p> <p>14 routine testing.</p> <p>15 Q. Okay. And now you say ZHP should have</p> <p>16 been testing its API for both NDMA and NDEA. Is that</p> <p>17 correct?</p> <p>18 A. Yes.</p> <p>19 Q. Is it your opinion that ZHP should have</p> <p>20 been testing for all nitrosamines, or just those two?</p> <p>21 A. Well, those would be -- those would be</p> <p>22 the main two. But I mean, again, they're adding</p> <p>23 nitrite at pH [REDACTED] this is like perfect conditions for</p> <p>24 nitrosamine formation. You can read it in the</p> <p>25 literature. It's been known since the 1950s, all</p>	<p style="text-align: right;">Page 132</p> <p>1 used. Is that fair?</p> <p>2 MR. SLATER: Objection.</p> <p>3 (Simultaneous speaking.)</p> <p>4 A. Well, I know what should have been done</p> <p>5 in this case. Absolutely, I'm an expert.</p> <p>6 Q. But I'm talking about in the category of</p> <p>7 testing pharmaceuticals generally, Dr. Hecht?</p> <p>8 MR. SLATER: Objection --</p> <p>9 A. I don't know what you mean. I mean, if</p> <p>10 I saw this process, I don't care whether I'm in the</p> <p>11 pharmaceutical industry or wherever I am; I would</p> <p>12 take this material into the lab and test it for</p> <p>13 nitrosamines.</p> <p>14 Q. Okay. So gas chromatography, GC, is a</p> <p>15 type of chromatography that's used in analytical</p> <p>16 chemistry for separating and analyzing organic</p> <p>17 compounds that can be vaporized without</p> <p>18 decomposition. Is that fair?</p> <p>19 A. Yes.</p> <p>20 Q. Okay. And would you agree that -- can I</p> <p>21 just call it "GC"?</p> <p>22 A. Yes.</p> <p>23 Q. Thank you. You would agree that GC is</p> <p>24 routinely used by chemists to test the purity of a</p> <p>25 substance?</p>
<p style="text-align: right;">Page 131</p> <p>1 right?</p> <p>2 So, you know, if there were other</p> <p>3 secondary or even tertiary amines present in their</p> <p>4 reaction mixtures for whatever reasons, then other</p> <p>5 nitrosamines possibly could have formed.</p> <p>6 Q. Now fair to say, Doctor, you've never</p> <p>7 worked at a pharmaceutical company. Correct?</p> <p>8 A. Yes.</p> <p>9 Q. That's correct, you haven't worked at</p> <p>10 one. Right?</p> <p>11 A. Correct.</p> <p>12 Q. Thank you. And you've never done any</p> <p>13 kind of systemic evaluation of the kind of testing or</p> <p>14 testing program that a pharmaceutical company does.</p> <p>15 Correct?</p> <p>16 A. That's correct.</p> <p>17 Q. Okay. So fair to say, you're not an</p> <p>18 expert in testing pharmaceuticals for impurities?</p> <p>19 MR. SLATER: Objection.</p> <p>20 A. Well, I know how to do it. All right?</p> <p>21 I just haven't worked in that area. But I certainly</p> <p>22 know how to do it.</p> <p>23 Q. Right. But you're not an expert in</p> <p>24 terms of what is done or what should be done, or the</p> <p>25 types of equipment that are typically used or not</p>	<p style="text-align: right;">Page 133</p> <p>1 A. Yes.</p> <p>2 Q. Okay. And GC can be followed by a</p> <p>3 couple detectors, such as a flame ionization</p> <p>4 detector?</p> <p>5 A. Correct.</p> <p>6 Q. Okay. Which I'm going to refer to as</p> <p>7 FID, if that's okay?</p> <p>8 A. Right.</p> <p>9 Q. And the FID is an analytic instrument</p> <p>10 that measures analytes in a gas stream?</p> <p>11 A. Yes.</p> <p>12 Q. And FID functions by detecting ions that</p> <p>13 are formed during combustion of organic compounds in</p> <p>14 a hydrogen flame?</p> <p>15 A. Yes.</p> <p>16 Q. And you agree that the combination,</p> <p>17 which I'll refer to as GC-FID, is commonly used by</p> <p>18 chemists in separating and analyzing organic</p> <p>19 compounds that can be vaporized without</p> <p>20 decomposition?</p> <p>21 A. Yes.</p> <p>22 Q. And you agree that GC-FID can detect</p> <p>23 almost all carbon-containing organic molecules?</p> <p>24 A. I wouldn't go that far.</p> <p>25 Q. Where do we depart?</p>

<p style="text-align: right;">Page 134</p> <p>1 A. They have to be volatile.</p> <p>2 Q. Okay. That would be your qualifier?</p> <p>3 A. Well, the detection method is pretty</p> <p>4 general, but it wouldn't work unless you -- you have</p> <p>5 to convert the analyte into the gas stream of the --</p> <p>6 of the GC. If it's not volatile, it wouldn't go</p> <p>7 through the GC.</p> <p>8 Q. Thank you. And you would agree that</p> <p>9 there are articles that have been published in the</p> <p>10 peer-reviewed scientific literature about GC-FID as</p> <p>11 an analytic tool. Correct?</p> <p>12 A. Yes.</p> <p>13 Q. Okay. Would you agree that it's become</p> <p>14 the most widely-used tool for volatile organic</p> <p>15 compound detection?</p> <p>16 A. It's one of the most volatile --</p> <p>17 volatile? It's one of the most widely used.</p> <p>18 Q. Okay. But if there's an article --</p> <p>19 again, I'm trying to just be efficient and not have</p> <p>20 to go through it -- that stated that it's become the</p> <p>21 most widely-used tool for VOC detection, you wouldn't</p> <p>22 have a reason to dispute that. Correct?</p> <p>23 A. Yes.</p> <p>24 MR. SLATER: Objection.</p> <p>25 Q. You -- I think you agreed with me,</p>	<p style="text-align: right;">Page 136</p> <p>1 question. Okay?</p> <p>2 MR. SLATER: I get it, but I'm asking</p> <p>3 you to show him the article, rather than asking him</p> <p>4 to assume that articles say things.</p> <p>5 MR. BERNARDO: Okay.</p> <p>6 Q. Dr. Hecht, first of all, you agree what</p> <p>7 we're looking at really should be -- what we're</p> <p>8 evaluating should be what was in use in 2000 --</p> <p>9 before 2018. Correct? Because that's the period of</p> <p>10 time that we're talking about. Is that fair?</p> <p>11 A. Right.</p> <p>12 Q. Okay.</p> <p>13 MR. BERNARDO: So why don't we pull it.</p> <p>14 I was trying to be efficient. Why don't we just mark</p> <p>15 this.</p> <p>16 (Exhibit Hecht-11, Article entitled</p> <p>17 "High performance mini-gas chromatography-flame</p> <p>18 ionization detector system based on micro gas</p> <p>19 chromatography column," from Review of Scientific</p> <p>20 Instruments, published April 21, 2016, was received</p> <p>21 and marked for identification.)</p> <p>22 Q. And this is a 2016 article entitled,</p> <p>23 "High-performance mini-gas chromatography-flame</p> <p>24 ionization detector system based on micro gas</p> <p>25 chromatography column."</p>
<p style="text-align: right;">Page 135</p> <p>1 Dr. Hecht, but I just want to make sure?</p> <p>2 A. It's one of the most widely used. I</p> <p>3 don't know if it's the most widely used anymore. But</p> <p>4 it's definitely one of the most widely used. But you</p> <p>5 know, GC mass spec has taken over.</p> <p>6 Q. And --</p> <p>7 A. You know, there's always evolution of</p> <p>8 analytical methods. And, you know, the older ones</p> <p>9 fall by the wayside, new ones come along. And the</p> <p>10 new ones are usually pretty expensive at first, but,</p> <p>11 you know, as further advances are made, they also</p> <p>12 become cheaper and they take over. It's just like</p> <p>13 any product.</p> <p>14 Q. Sure. As science evolves, so too does</p> <p>15 technology. Right?</p> <p>16 A. Yep.</p> <p>17 Q. And again, I'm just trying to be</p> <p>18 efficient, because if you do disagree, we can pull it</p> <p>19 up and take a look at it. But if there were an</p> <p>20 article that were published that -- in 2016. And by</p> <p>21 the way, let me take a step --</p> <p>22 MR. SLATER: I'm sorry, can you show him</p> <p>23 the article? I don't really understand what you're</p> <p>24 doing here.</p> <p>25 MR. BERNARDO: I'm just asking a</p>	<p style="text-align: right;">Page 137</p> <p>1 I'll ask the question, but I can't</p> <p>2 imagine you'll remember.</p> <p>3 Do you know if you've had occasion to</p> <p>4 review this article before?</p> <p>5 A. Have I what?</p> <p>6 Q. Had occasion to review this article</p> <p>7 before, if you know?</p> <p>8 A. No, I haven't seen this one.</p> <p>9 Q. Okay. Why don't we just take a look at</p> <p>10 the second page, the bottom left. Okay. I simply --</p> <p>11 and again, you're welcome to look at as much or as</p> <p>12 little of this off the record as you'd like. But I</p> <p>13 just want to see if you have any reason to dispute --</p> <p>14 you see this --</p> <p>15 MR. BERNARDO: You want to get the</p> <p>16 bottom left since the N --</p> <p>17 Q. If you look at that last paragraph --</p> <p>18 whoops, there we go, the last paragraph on the</p> <p>19 left-hand column that begins "Since the advent"?</p> <p>20 A. Yup.</p> <p>21 Q. Okay. Can you just read that?</p> <p>22 A. "Since the advent of the flame</p> <p>23 ionization detector, it has become the most</p> <p>24 widely-used tool for VOC detection."</p> <p>25 Q. As you sit here today, Dr. Hecht, I just</p>

<p style="text-align: right;">Page 138</p> <p>1 want to understand: Do you have any reason to 2 dispute that conclusion? 3 MR. SLATER: Objection. 4 Q. This is a 2016 article? 5 MR. SLATER: Objection. 6 You can answer. 7 Asked and answered. 8 You can answer again. 9 A. Yeah, I have reason to dispute it, 10 because I think GC mass spec might be just as widely 11 used. I don't know, I don't have the figures before 12 me. But, you know, GC mass spec is certainly widely 13 used. I think all universities have it, and I'm sure 14 all pharmaceutical companies have it. And all 15 industry has it. 16 I mean, you know, it's hard to imagine 17 doing analytical chemistry these days without a GC 18 mass spec or LC mass spec. 19 Q. And -- 20 A. So yeah, whether GC-FID is more widely 21 used than GC mass spec, I'm really not sure. 22 Q. Thank you, that's all I'm asking. And 23 this -- I just want to make sure we're on the same 24 page, literally. That we're in -- this is an article 25 in 2016, I'm not asking you about today, I'm asking</p>	<p style="text-align: right;">Page 140</p> <p>1 impurities using GC-FID? 2 A. Yes. 3 Q. Have you ever tested for impurities 4 using GS [sic] mass spectrometry? 5 A. Yes. 6 Q. I want to go back to Dr. Xue's report, 7 which we'll put on the screen? 8 MR. BERNARDO: And if Josh, you could 9 turn to page 53. 10 Q. And I'll just tell you in advance: The 11 purpose of this question, Dr. Hecht, is just to get 12 an understanding. I think there's certain things 13 that you and Dr. Xue agree with, and I know there's 14 certain things you disagree with, and I just -- I'm 15 trying to distinguish or understand the difference. 16 So page 53, the last line, it says, "The 17 five methods" -- I'm sorry. 18 "Plaintiff's experts also state that 19 five testing methods for nitrosamines were available, 20 and any reasonable organic chemist would have used 21 one of them to test valsartan API for nitrosamines." 22 That's a fair characterization. 23 Correct? 24 MR. SLATER: I'm sorry. One second, 25 Doctor.</p>
<p style="text-align: right;">Page 139</p> <p>1 you about 2016. 2 Is your answer the same for 2016 as you 3 just gave me. Correct? 4 A. Yes. 5 Q. Okay. Thank you. Would you agree that 6 there are actually times when -- 7 MR. BERNARDO: You could take that down. 8 Q. When GC-FID is, in fact, the best method 9 for testing? 10 MR. SLATER: Objection. 11 You can answer. 12 A. That's a really hard question to answer. 13 I mean, I don't know what you're driving at. The 14 best method? I mean, the best method for what? 15 Q. Fair enough. I'm simply asking whether 16 you would acknowledge that there are circumstances in 17 which this could be the best method to use. I'm not 18 asking you to delineate them. 19 And if you don't know, you don't know? 20 MR. SLATER: Objection. 21 You can answer. 22 A. Yes, I suppose there are circumstances 23 where GC-FID could be a better method than GC mass 24 spec. 25 Q. Have you, Dr. Hecht, ever tested for</p>	<p style="text-align: right;">Page 141</p> <p>1 Are you saying, did you read the 2 statement correctly? 3 MR. BERNARDO: I'm asking if it's a fair 4 characterization. 5 Q. Do you agree with that characterization 6 of the plaintiff's experts, in what they say? 7 MR. BERNARDO: So, no, Adam, I'm not 8 asking if I read it correctly. 9 A. Five methods. 10 Q. No, I'm just on the first -- oh, yeah. 11 MR. SLATER: Are you including the 12 footnote to that sentence? 13 MR. BERNARDO: Yes. 14 A. Okay. Five methods, I can't read the 15 footnote, but I don't know -- 16 MR. BERNARDO: Can you blow that up, 17 Josh. Blow it up a little more. Thanks. 18 A. Yeah, I guess these are -- these are the 19 five methods they -- that he's mentioning. 20 Q. Right. Okay. Just going on the 21 carryover sentence, Dr. Xue says, "The five methods 22 identified by plaintiff's experts include the 23 combined head space method" -- and I'm going to skip 24 over the abbreviations -- "combined direct injection 25 method, direct injection, head space, and LC-HRMS</p>

<p style="text-align: right;">Page 142</p> <p>1 method."</p> <p>2 Did I read that correctly?</p> <p>3 A. Yeah, that sounds right.</p> <p>4 Q. And those are the five methods that</p> <p>5 plaintiff's experts have pointed to. Is that fair?</p> <p>6 A. Yep.</p> <p>7 Q. Okay.</p> <p>8 MR. BERNARDO: And can you move it up a</p> <p>9 little bit, Josh -- sorry. Sorry, I want to continue</p> <p>10 reading, thank you.</p> <p>11 Q. And he also says, "All of these methods</p> <p>12 use MS," or mass spectrometry, "as a detector."</p> <p>13 Do you agree with that?</p> <p>14 A. Yes, that's right.</p> <p>15 Q. Okay. Here's the part I want to see if</p> <p>16 you agree with.</p> <p>17 "Although these methods" -- sorry.</p> <p>18 "Although these MS-based methods are</p> <p>19 sensitive toward the nitrosamines NDMA and NDEA,</p> <p>20 I" -- and he's saying Dr. Xue -- "have not seen any</p> <p>21 evidence that they were the standard in the industry</p> <p>22 at the time when the zinc chloride process and the</p> <p>23 TEA process with quenching were being utilized for</p> <p>24 the production of valsartan API. And as I've</p> <p>25 explained above, ZHP did not have a scientific reason</p>	<p style="text-align: right;">Page 144</p> <p>1 investment, and it's not always easy for academic</p> <p>2 institutions to acquire them, because they can be</p> <p>3 quite expensive. But industry certainly, the</p> <p>4 pharmaceutical industry, absolutely, a hundred</p> <p>5 percent, has these instruments available.</p> <p>6 I don't know where this guy gets his</p> <p>7 information from. It's absolutely wrong. Okay?</p> <p>8 Q. And to be clear, Dr. Xue is saying he's</p> <p>9 not seeing evidence. And what you're pointing me to,</p> <p>10 if I understand, is commentary from your students.</p> <p>11 So this commentary from your students is from 2013 or</p> <p>12 prior?</p> <p>13 A. I can't tell you exactly when it's from.</p> <p>14 Q. I'm just trying --</p> <p>15 A. Look, I know the pharmaceutical industry</p> <p>16 definitely is well-equipped for mass spectrometry.</p> <p>17 There's no doubt.</p> <p>18 Q. In 2013?</p> <p>19 A. Yes, in 2013. No doubt.</p> <p>20 Q. Okay. And I understand you have no</p> <p>21 doubt. I'm trying to understand the reason you have</p> <p>22 no doubt, and you've told me because students you've</p> <p>23 had have come back and told you. Is there any --</p> <p>24 A. That's not a good example, okay?</p> <p>25 Q. Okay.</p>
<p style="text-align: right;">Page 143</p> <p>1 to be looking for NDMA or NDEA in valsartan API at</p> <p>2 that time."</p> <p>3 Did I read that correctly? That's all</p> <p>4 I'm --</p> <p>5 A. Yes, you did.</p> <p>6 Q. Okay. I want to eliminate the last</p> <p>7 part, because I know your position on there. I want</p> <p>8 to ask, Dr. Hecht, if you have identified evidence,</p> <p>9 and if so, what it is, that these methods that were</p> <p>10 described above were standard in the industry at the</p> <p>11 time when the zinc chloride process and the TEA</p> <p>12 process with quenching were being utilized for the</p> <p>13 production of valsartan API?</p> <p>14 MR. SLATER: Objection.</p> <p>15 A. Absolutely. GC-MS and LC-MS are</p> <p>16 standard in the industry. Absolutely, a hundred</p> <p>17 percent.</p> <p>18 Q. And what is -- can you point me to</p> <p>19 something that would help us understand where you get</p> <p>20 to that conclusion?</p> <p>21 A. I know from -- from my students or post</p> <p>22 docs that have gone into industry, they come back and</p> <p>23 tell me how well-equipped these pharmaceutical</p> <p>24 industries, pharmaceutical companies are. Okay? I</p> <p>25 mean, a mass spectrometer is a significant</p>	<p style="text-align: right;">Page 145</p> <p>1 A. A better example is from, you know, I</p> <p>2 attend conferences every year of the American</p> <p>3 Chemical Society. I see the hundreds of papers that</p> <p>4 are presented, many of them from the industry, okay?</p> <p>5 I attend the conference, the American Society for</p> <p>6 Mass Spectrometry, ASMS, that happens every year,</p> <p>7 okay? They have hundreds of presentations, many of</p> <p>8 which are from industry, and all use these methods.</p> <p>9 So I mean, I don't know where this guy</p> <p>10 gets his information from. It's wrong. It's</p> <p>11 absolutely wrong.</p> <p>12 Q. Okay. I'm not asking whether or not</p> <p>13 they were used. I'm asking whether or not they were</p> <p>14 the standard in the industry, and I'm trying to</p> <p>15 understand --</p> <p>16 A. Yes, they are the standard.</p> <p>17 Q. Let me just finish. I understand that's</p> <p>18 your opinion, Dr. Hecht.</p> <p>19 A. It's more than an opinion; it's a fact.</p> <p>20 Q. Okay. I'm trying --</p> <p>21 A. To be clear, okay? This is a fact.</p> <p>22 Q. Okay. Is it a fact because you say it's</p> <p>23 a fact, or is it a fact because you can point me to a</p> <p>24 process to be determined --</p> <p>25 (Simultaneous speaking.)</p>

<p style="text-align: right;">Page 146</p> <p>1 (Court Stenographer clarification.)</p> <p>2 Q. Wait. Wait, Dr. Hecht --</p> <p>3 A. Go to the abstracts of the American</p> <p>4 Society For Mass Spectrometry, ASMS, which are</p> <p>5 published every year. Look at the hundreds of</p> <p>6 abstracts and where they come from.</p> <p>7 Q. Okay.</p> <p>8 A. And you'll find your answer.</p> <p>9 Q. Okay. I don't want to -- I don't intend</p> <p>10 personally to research this. I'm simply trying to</p> <p>11 ask if you've done: -- have you done anything to</p> <p>12 research this, or are you saying it based upon your</p> <p>13 observations?</p> <p>14 A. It's based on my observations. I've</p> <p>15 attended the ASMS meetings.</p> <p>16 You know, I was editor-in-chief of</p> <p>17 Chemical Research and Toxicology for five years, so I</p> <p>18 see all the papers that are submitted, many of which</p> <p>19 come from industry, and they use this technology.</p> <p>20 Q. Dr. Hecht, what did you do to prepare</p> <p>21 for your deposition today?</p> <p>22 A. I studied the binders.</p> <p>23 Q. And the binders are the ones that you</p> <p>24 referred me to that include approximately four</p> <p>25 binders of ZHP documents, and some other materials?</p>	<p style="text-align: right;">Page 148</p> <p>1 used, and then, you know, he showed the various</p> <p>2 different peaks that you could get from GC-FID, and,</p> <p>3 you know, the peaks were very small for NDMA, and</p> <p>4 blah-blah-blah, and -- whatever. It's irrelevant, I</p> <p>5 mean -- well, it's not irrelevant. It's relevant.</p> <p>6 But the point is that, in order to get a</p> <p>7 firm handle on the quantitation of NDMA or NDEA at</p> <p>8 these levels, you're talking about like an average of</p> <p>9 65 parts per million or whatever, you're going to</p> <p>10 have to use a mass spec detector, a GC-MS.</p> <p>11 Q. Yeah, I'm on a different topic,</p> <p>12 Dr. Hecht, just let me help here. So I moved past</p> <p>13 the testing methodology, and I really want to just</p> <p>14 understand what you, Dr. Hecht, did to form your</p> <p>15 opinions in this case.</p> <p>16 And remember, I'm talking about your</p> <p>17 opinions in your December 2022 or your October '22</p> <p>18 report and just a portion of your 2021 report that we</p> <p>19 talked about earlier. Are you with me?</p> <p>20 A. Yep.</p> <p>21 Q. Okay. Before you formed your opinions</p> <p>22 as to what ZHP did or didn't do, or knew or should</p> <p>23 know, those opinions, did you review testimony of ZHP</p> <p>24 employees?</p> <p>25 MR. SLATER: Objection.</p>
<p style="text-align: right;">Page 147</p> <p>1 A. Yes.</p> <p>2 Q. Okay. Generally, in respect to forming</p> <p>3 your opinions in this case, did you read deposition</p> <p>4 testimony?</p> <p>5 A. Yes, I did read a couple.</p> <p>6 Q. And did you read the depositions in</p> <p>7 their entirety, or did you read -- read portions of</p> <p>8 them?</p> <p>9 A. I don't really know.</p> <p>10 Q. Okay. Well, you cite to some of them,</p> <p>11 so I'm trying to understand a little bit better.</p> <p>12 A. Yes, so I mean, I have the deposition</p> <p>13 of -- I don't know. The guy...</p> <p>14 MR. SLATER: Take your time, there's no</p> <p>15 rush.</p> <p>16 Q. Let's do it this way, Dr. Hecht. You've</p> <p>17 cited to certain ones, and we don't need to get into</p> <p>18 the specifics. I'm really just trying to get a</p> <p>19 general sense.</p> <p>20 A. Yeah, well, I'm looking for the</p> <p>21 deposition of -- I don't know; I can't find it right</p> <p>22 now.</p> <p>23 Q. Okay.</p> <p>24 A. Anyhow, there's a guy from industry that</p> <p>25 talked about the various analytical methods that were</p>	<p style="text-align: right;">Page 149</p> <p>1 You can answer.</p> <p>2 A. Could you rephrase that? I mean,</p> <p>3 that's --</p> <p>4 Q. I'm simply asking --</p> <p>5 A. I don't really know -- try to rephrase</p> <p>6 it, okay?</p> <p>7 Q. Of course. In connection with the</p> <p>8 portion of your report we've talked about, okay? I</p> <p>9 just want to make this a simpler question.</p> <p>10 So you do remember our discussion at the</p> <p>11 beginning of this deposition, that I'm only asking</p> <p>12 you questions about your ZHP-specific opinions, the</p> <p>13 ones that are in your 2022 report, and in a portion</p> <p>14 of your 2021 report. Are you with me on that?</p> <p>15 A. Yeah.</p> <p>16 Q. Okay. So those opinions, in connection</p> <p>17 with forming those opinions, did you review</p> <p>18 testimony, deposition testimony, of ZHP company</p> <p>19 employees?</p> <p>20 MR. SLATER: Objection.</p> <p>21 You can answer.</p> <p>22 A. Yes.</p> <p>23 Q. Okay. Approximately how many employees'</p> <p>24 depositions did you read?</p> <p>25 A. I don't know.</p>

<p style="text-align: right;">Page 150</p> <p>1 Q. Okay. Do you know if you read the 2 entire testimony of the employee, a portion of the 3 testimony of the employee? Like, did you sit down 4 and say, "Here, I'm going to read this particular 5 person from cover to cover"; or did you just look at 6 portions of it? 7 A. Portions. 8 Q. Okay. How did you identify which 9 portion to take a look at? 10 A. You know, I have binders that have 11 portions of testimony in them. 12 Q. Okay. And who selected -- 13 A. That were sent to me. 14 Q. So you didn't select the portions of the 15 testimony that you were going to review; somebody 16 else selected them for you. Is that fair? 17 A. Yes. 18 Q. Okay. About how much time would you say 19 you spent, just looking at deposition testimony? 20 A. Oh, I don't know. Several hours. 21 Q. Okay. 22 A. I don't know. 23 Q. Did you -- it's fair to say -- I'm 24 sorry? 25 A. Yeah, go ahead.</p>	<p style="text-align: right;">Page 152</p> <p>1 MR. SLATER: Really? Do you want us to 2 ask your experts -- 3 MR. BERNARDO: Adam -- 4 MR. SLATER -- who wrote their reports? 5 MR. BERNARDO: Adam, let's just have 6 some ground rules. You don't -- I don't interrupt 7 you when you're talking, let me finish my response, 8 and then you can respond to that. It will make this 9 much easier. 10 We will move on. I disagree with you. 11 Let's move on. 12 MR. SLATER: Okay. And what I was 13 saying, before you interrupted my interruption of 14 your interruption of my interruption of you, was 15 that's -- we're not going to be asking your experts 16 that either, because it's clearly off-limits under 17 the federal rules of civil procedure and the case 18 law. Come on. 19 MR. BERNARDO: I disagree with that, but 20 I'm happy to move on. 21 MR. SLATER: Okay. Are you suggesting 22 when we depose your experts, we can ask them who had 23 input into the writing of their reports? 24 Q. Dr. Hecht -- 25 MR. BERNARDO: Adam, you're eating into</p>
<p style="text-align: right;">Page 151</p> <p>1 Q. Fair to say, you didn't interview any 2 company employees yourself. Correct? 3 A. Correct, yes. 4 Q. Did you ask Mr. Slater if you could? 5 A. No. 6 Q. And did you write your report yourself, 7 or did somebody else write it for you? What would -- 8 help me understand the process? 9 A. I wrote the draft. 10 MR. SLATER: Wait, wait, time out. Time 11 out. Stop for a second. 12 I got distracted for a second. 13 Objection. You're not going to ask these questions. 14 It's off limits, it's the work product. You're not 15 asking about the writing of the report. You're not 16 asking who wrote, who did what. That's it. Move on 17 to the next subject. 18 MR. BERNARDO: I'm not asking anything 19 about lawyers, I'm simply asking if Dr. Hecht wrote 20 it or if he had somebody else write it. I think -- 21 MR. SLATER: Objection. You can go to 22 the Court. It's work product. How the report is 23 written is work product; you know better. Come on. 24 MR. BERNARDO: Okay. I disagree with 25 your characterization.</p>	<p style="text-align: right;">Page 153</p> <p>1 my time, let's move on. 2 BY MR. BERNARDO: 3 Q. Dr. Hecht, did you read Dr. Bain's 4 expert report? 5 A. Spell it? 6 Q. B-A-I-N? I think it might be it's 7 B-A-I-N-S, but -- 8 A. I don't know. What was it about? I 9 don't remember. 10 Q. Okay. You answered my question. 11 So you don't know if you reviewed 12 Dr. Bain's report before your report was written. 13 Correct? 14 MR. SLATER: He doesn't know if he even 15 saw it. 16 A. I don't know. I may have. I mean, I 17 don't know how to answer it, because you have to tell 18 me what was his report about. I don't remember the 19 name necessarily. Who is Dr. Bain? I mean... 20 Q. You've answered my question. Thank you. 21 MR. BERNARDO: So Adam, I'm about to 22 turn to a section that's not going to get done in a 23 few minutes. It's 12:35, we're a little shy of an 24 hour, but I'm thinking maybe now is a good time to 25 take a lunch break. But that depends. We're an hour</p>

<p style="text-align: right;">Page 154</p> <p>1 behind for Dr. Hecht, so maybe --</p> <p>2 MR. SLATER: So hang on, hang on. This</p> <p>3 is what I'd like to do. I want to leave it up to</p> <p>4 Dr. Hecht. We're not doing an eleven --</p> <p>5 MR. BERNARDO: Yeah, of course.</p> <p>6 MR. SLATER: Because what I'm not doing</p> <p>7 is an 11-and-a-half-hour deposition today, like</p> <p>8 happened last night. You were fortunate enough not</p> <p>9 to be on the deposition. It went 'til 8:30; it</p> <p>10 started at 9:00 in the morning here on the East</p> <p>11 Coast. It went on forever.</p> <p>12 So I just -- whatever breaks we take, I</p> <p>13 don't want to take them just for the sake of taking</p> <p>14 them. So I would ask the doctor if he wants to take</p> <p>15 a break, when he wants to take it, how long he needs.</p> <p>16 Because I really don't want to have this deposition</p> <p>17 going to 8 o'clock tonight.</p> <p>18 MR. BERNARDO: I don't expect it will</p> <p>19 be, unless you have many hours of questions. I'm</p> <p>20 simply acknowledging that at some point in time, even</p> <p>21 if the doctor doesn't, there are other lawyers,</p> <p>22 myself included, who would want to take a break for</p> <p>23 lunch.</p> <p>24 MR. SLATER: Well, I think the other</p> <p>25 lawyers, frankly, between you and me, they can eat</p>	<p style="text-align: right;">Page 156</p> <p>1 MR. SLATER: What report did you say,</p> <p>2 Rich, the 2022?</p> <p>3 MR. BERNARDO: Yes.</p> <p>4 MR. SLATER: Thank you.</p> <p>5 MR. BERNARDO: And it's on the screen.</p> <p>6 Q. I want to focus, Dr. Hecht, on what is</p> <p>7 on the screen, which is your report that says, "A</p> <p>8 series of customer complaints was received by ZHP</p> <p>9 with regard to the unknown peak or aberrant peaks on</p> <p>10 the chromatography. And this includes" -- and then</p> <p>11 you list six -- seven pieces there.</p> <p>12 Do you see that where I am?</p> <p>13 A. Yes.</p> <p>14 Q. Okay. And I think you refer to these as</p> <p>15 "customer complaints." Correct?</p> <p>16 A. Yes.</p> <p>17 Q. And you cite to various documents and</p> <p>18 testimony. Do you see that?</p> <p>19 A. Yes.</p> <p>20 Q. And this is -- these are -- well, let me</p> <p>21 go back.</p> <p>22 So the deposition testimony just has</p> <p>23 excerpts. So for example, the first one says,</p> <p>24 "Quiangming Li," and it gives the date of the depo,</p> <p>25 and it has page 130, line 7, through 170, line 11.</p>
<p style="text-align: right;">Page 155</p> <p>1 while they watch. So I'm not --</p> <p>2 MR. BERNARDO: I can't, and I'm not --</p> <p>3 MR. SLATER: Look, it's 11:30 where he</p> <p>4 is. If Dr. Hecht is okay to keep going, we'd like to</p> <p>5 keep going.</p> <p>6 MR. BERNARDO: Okay. Let's take, then,</p> <p>7 a brief bio break, and then we'll go for another</p> <p>8 hour, and then we'll decide about lunch. How's that?</p> <p>9 Q. Does that work for you, Dr. Hecht?</p> <p>10 A. Yes.</p> <p>11 Q. Okay, thank you.</p> <p>12 THE VIDEOGRAPHER: Going off the record.</p> <p>13 The time is 11:36 a.m. Central Time. This is the end</p> <p>14 of Media Unit 3.</p> <p>15 (A brief recess takes place.)</p> <p>16 THE VIDEOGRAPHER: We're back on the</p> <p>17 record. The time is 11:46 a.m., Central Time. This</p> <p>18 is the beginning of Media Unit 4.</p> <p>19 BY MR. BERNARDO:</p> <p>20 Q. Dr. Hecht, I want to change topics here,</p> <p>21 and we want to put back a copy of your report, or if</p> <p>22 you could take a look at a look at your report at</p> <p>23 pages 6 to 7. I just want to refresh your</p> <p>24 recollection about the subject I'm going to be</p> <p>25 talking about. Okay?</p>	<p style="text-align: right;">Page 157</p> <p>1 Correct?</p> <p>2 A. Yeah.</p> <p>3 Q. And those are ones I think we talked</p> <p>4 about earlier, is that the same thing here: Those</p> <p>5 are ones that plaintiff's counsel selected for you to</p> <p>6 take a look at?</p> <p>7 A. Yes.</p> <p>8 MR. SLATER: Objection.</p> <p>9 You can answer.</p> <p>10 A. Yes.</p> <p>11 Q. And did you ask to look at any other</p> <p>12 parts of the deposition of those witnesses you cite,</p> <p>13 for context or other information?</p> <p>14 A. I'm not sure I understand your question.</p> <p>15 Q. Sure. I'll rephrase it. When you</p> <p>16 looked at, for example, the first reference we have</p> <p>17 under Number 1, it has, it looks like, 40 pages,</p> <p>18 maybe, right --</p> <p>19 A. Sure.</p> <p>20 Q. -- of testimony? When you read that,</p> <p>21 did you ask, based upon your reading of that, to see</p> <p>22 other testimony that would be relevant to that</p> <p>23 particular topic, or did you limit your review to</p> <p>24 those pages?</p> <p>25 MR. SLATER: Objection.</p>

<p style="text-align: right;">Page 158</p> <p>1 You can answer.</p> <p>2 A. No, I didn't ask for more.</p> <p>3 Q. And you cite to -- again, I'm just going</p> <p>4 to do it by way of example. For the first one, you</p> <p>5 cite to a single document.</p> <p>6 Is it fair to say that that's the only</p> <p>7 document from the company that you looked at with</p> <p>8 respect to that particular issue?</p> <p>9 MR. SLATER: Objection.</p> <p>10 You can answer.</p> <p>11 Q. I'm sorry, I didn't hear your answer,</p> <p>12 Doctor?</p> <p>13 A. Yes.</p> <p>14 Q. So, as you were looking at these, you</p> <p>15 didn't look at other documents that might pertain to</p> <p>16 the same circumstance. Correct?</p> <p>17 MR. SLATER: Objection.</p> <p>18 You can answer.</p> <p>19 A. As far as I recall.</p> <p>20 Q. Okay. And did you do any -- did you</p> <p>21 take any other steps to investigate the circumstances</p> <p>22 regarding the seven, I'll call them, as you do,</p> <p>23 customer complaints that are listed in your report,</p> <p>24 than look at the deposition excerpt and the documents</p> <p>25 cited?</p>	<p style="text-align: right;">Page 160</p> <p>1 Novartis was the one that identified it, as far as I</p> <p>2 know. So I'm not sure. I don't think the other</p> <p>3 ones -- I mean the other complaints, I think, had to</p> <p>4 do also with a lot of other peaks that were in the</p> <p>5 chromatograms.</p> <p>6 Q. Explain to me, setting aside Number 7,</p> <p>7 how Numbers 1 through 6 play into your opinion or a</p> <p>8 factor or something you considered? Explain to me</p> <p>9 what the relevance of them is?</p> <p>10 MR. SLATER: Objection.</p> <p>11 You can answer.</p> <p>12 A. Well, I think, you know, they indicated</p> <p>13 a general lack of care on the part of the</p> <p>14 manufacturer.</p> <p>15 Q. Explain to me how they demonstrate a</p> <p>16 lack of care on the part of the manufacturer?</p> <p>17 A. Well, I think they saw other peaks in</p> <p>18 the chromatograms. You know, I don't think -- I</p> <p>19 don't think the NDMA and NDEA had been identified at</p> <p>20 that time. But, you know, they saw -- they saw other</p> <p>21 peaks in the chromatograms, as far as I recall,</p> <p>22 that -- you know, that they didn't think they should</p> <p>23 be there. They indicate lack of purity.</p> <p>24 Q. So the fact that there were other peaks</p> <p>25 indicates a lack of care of the company? I just want</p>
<p style="text-align: right;">Page 159</p> <p>1 A. Any other steps with respect to what?</p> <p>2 Q. Did you take -- did you take any other</p> <p>3 steps to investigate what was done in connection, or</p> <p>4 said in connection, with those customer complaints?</p> <p>5 A. Well, all the material that I reviewed</p> <p>6 was related to these complaints. So I mean, I don't</p> <p>7 really know what you're getting at.</p> <p>8 Q. I'm really --</p> <p>9 A. The whole thing I related. They're all,</p> <p>10 they're all related.</p> <p>11 Q. Okay.</p> <p>12 A. So yeah, I did take other steps. I</p> <p>13 read, you know, all the other reports.</p> <p>14 Q. Right. Let me be more -- we'll get into</p> <p>15 one or two of these with specifics, and then we can</p> <p>16 pursue that.</p> <p>17 We know that the seventh one was the</p> <p>18 identification of NDMA -- or NDEA. Correct? The</p> <p>19 Novartis, Number 7?</p> <p>20 A. Yes.</p> <p>21 Q. Did the other six pertain to customer</p> <p>22 complaints that were received with respect to</p> <p>23 nitrosamines?</p> <p>24 A. I don't think they had identified the</p> <p>25 nitrosamines at that time. I'm not sure. I mean --</p>	<p style="text-align: right;">Page 161</p> <p>1 to make sure I'm not putting words in your mouth, and</p> <p>2 I want to understand what you just said?</p> <p>3 A. No, a lack of -- lack of purity, I said.</p> <p>4 Not lack of care, lack of purity.</p> <p>5 So, you know, they're getting the API</p> <p>6 from ZHP, they're going to check it and make sure</p> <p>7 it's pure. And that's not what they saw.</p> <p>8 Q. So is it possible that there could be</p> <p>9 impurities that don't cause concern, and that, after</p> <p>10 investigation, are perfectly okay? Or is it your</p> <p>11 opinion that any impurity whatsoever demonstrates a</p> <p>12 lack of care?</p> <p>13 A. No, there could be impurities that are,</p> <p>14 you know, not a -- not a matter for concern.</p> <p>15 Q. And do you know whether any of these</p> <p>16 examples that you identified concluded that the peaks</p> <p>17 related to impurities that were of no concern? Do</p> <p>18 you -- do you understand my question?</p> <p>19 A. I don't remember what all the peaks</p> <p>20 were, to tell you the truth. We'd have to go through</p> <p>21 them one by one. So, you know, some things would be</p> <p>22 concerning and others would not. But, you know, if I</p> <p>23 were one of these companies, I wouldn't want to see a</p> <p>24 lot of other peaks in stuff that's supposed to be</p> <p>25 pure.</p>

<p style="text-align: right;">Page 162</p> <p>1 Because, you know, I'm going to</p> <p>2 incorporate this into my product; I'm going to check</p> <p>3 and make sure that it's pure.</p> <p>4 Q. Would it change your opinion if the</p> <p>5 company addressed them and looked into them, and</p> <p>6 found that they were of no concern; or that the</p> <p>7 person who or customer who complained about them was</p> <p>8 satisfied? Would that -- would that change your</p> <p>9 opinion?</p> <p>10 MR. SLATER: Objection.</p> <p>11 You can answer.</p> <p>12 A. Nothing is going to change my opinion</p> <p>13 about what happened in this main issue.</p> <p>14 Q. I'm sorry.</p> <p>15 A. Nothing will change my opinion about</p> <p>16 that. I can guarantee you that.</p> <p>17 Q. You pointed out a problem with my</p> <p>18 question. Thank you, Dr. Hecht.</p> <p>19 I meant would it change your opinion as</p> <p>20 to the relevance of -- to your opinions, of these</p> <p>21 particular customer complaints? In other words, if</p> <p>22 these customer complaints were investigated, and it</p> <p>23 was determined what these issues were, and it was</p> <p>24 resolved to the customers' satisfaction, would these</p> <p>25 complaints have any relevance, or factor into your</p>	<p style="text-align: right;">Page 164</p> <p>1 Q. Do you know what Vertex is, Dr. Hecht?</p> <p>2 A. They're a pharmaceutical company.</p> <p>3 Q. Do you know where they fit, in terms of</p> <p>4 their relationship with ZHP? Are they a customer of</p> <p>5 ZHP?</p> <p>6 A. I believe they are.</p> <p>7 Q. Okay.</p> <p>8 MR. BERNARDO: I'm sorry, Josh, I want</p> <p>9 to take a look at the document, Tab 22.</p> <p>10 Q. And I want to show you the first</p> <p>11 document that you have cited in your report. It may</p> <p>12 be helpful, Dr. Hecht, if you have -- and I think you</p> <p>13 said you did have -- your report handy, just so you</p> <p>14 could just take a look at numbers, if you have your</p> <p>15 report handy and can be on the page we were just</p> <p>16 looking at. Which was --</p> <p>17 MR. BERNARDO: Josh, what page?</p> <p>18 MR. SCHOCH: Page 6.</p> <p>19 Q. Which is page 6 of your 2022 report.</p> <p>20 Tell me when you're there.</p> <p>21 A. Yeah.</p> <p>22 Q. Okay. So we're going to pull up -- we</p> <p>23 have pulled up --</p> <p>24 MR. BERNARDO: If you scroll down to</p> <p>25 show the Bates number, Josh.</p>
<p style="text-align: right;">Page 163</p> <p>1 opinion anymore? That's just what I'm trying to find</p> <p>2 out?</p> <p>3 MR. SLATER: Objection.</p> <p>4 You can answer.</p> <p>5 A. Yeah, I mean, they saw some peaks. And,</p> <p>6 you know, if the peak turned out to be something</p> <p>7 that's, you know, of no concern, then, you know,</p> <p>8 there wouldn't be a problem.</p> <p>9 Q. And you -- I think you said, you didn't</p> <p>10 do anything to investigate each of these six</p> <p>11 circumstances, other than to look at the excerpts and</p> <p>12 documents that you were provided. Is that fair?</p> <p>13 A. Yes, that's correct.</p> <p>14 Q. Okay. Why don't we just take one of</p> <p>15 them.</p> <p>16 MR. BERNARDO: And let's pull up, what</p> <p>17 exhibit number are we at?</p> <p>18 MR. SCHOCH: 12.</p> <p>19 MR. BERNARDO: Okay, that works out.</p> <p>20 Let's take -- well, first of all, let's take the, I</p> <p>21 think it's called Vertex.</p> <p>22 (Exhibit Hecht-12, Email Chain ending</p> <p>23 2/28/2019 in Chinese Language, Bates ZHP02630924</p> <p>24 through 2630925, was received and marked for</p> <p>25 identification.)</p>	<p style="text-align: right;">Page 165</p> <p>1 Q. The first one that you have cited there.</p> <p>2 Correct?</p> <p>3 A. Yep.</p> <p>4 Q. Okay. And you can scroll through, it's</p> <p>5 a two-page document. Presumably you reviewed this,</p> <p>6 since it's cited in your report. Is that fair?</p> <p>7 MR. SLATER: I don't think Dr. Hecht is</p> <p>8 looking at the screen. I think he's looking for</p> <p>9 something.</p> <p>10 A. Okay. Go ahead.</p> <p>11 Q. Sure. This is the first document that</p> <p>12 you cite on Number 4, Vertex.</p> <p>13 Do you agree with me? If you look at --</p> <p>14 A. At Vertex, right.</p> <p>15 Q. Okay. And I just want to understand</p> <p>16 what, if anything, in connection with this particular</p> <p>17 customer complaint you got from this particular</p> <p>18 document?</p> <p>19 A. I don't remember. I'd have to look at</p> <p>20 it.</p> <p>21 Q. We're looking at it now. It's --</p> <p>22 A. Yeah, okay, I know, but you didn't show</p> <p>23 me anything so far.</p> <p>24 Q. I guess that's my point. Is there</p> <p>25 anything substantively that you could derive from</p>

<p style="text-align: right;">Page 166</p> <p>1 this document?</p> <p>2 A. I don't remember. I have to look at it.</p> <p>3 Q. I'm asking you to do that. Has your --</p> <p>4 A. I'm looking at it, right. But it</p> <p>5 doesn't show anything. It's just like two pages.</p> <p>6 Q. Okay.</p> <p>7 MR. BERNARDO: Can you expand the size,</p> <p>8 Josh? Okay.</p> <p>9 Q. My point -- and I think you're agreeing</p> <p>10 -- well, first of all, there are portions of this</p> <p>11 document that are in Chinese. That's fair, and we'll</p> <p>12 look at the translation?</p> <p>13 A. Yeah.</p> <p>14 Q. Okay. But I just want to confirm, you</p> <p>15 agree, and I think you just said that: This document</p> <p>16 doesn't tell you anything that would explain to you</p> <p>17 what happened with respect to this Vertex customer</p> <p>18 complaint. I think --</p> <p>19 A. Not these -- not these two pages, no.</p> <p>20 MR. SLATER: Objection.</p> <p>21 Q. Thank you, okay.</p> <p>22 MR. BERNARDO: Let's look at the</p> <p>23 translation of these two pages, Josh, which is 265A.</p> <p>24 (Exhibit Hecht-13, English Translation</p> <p>25 of Hecht-12, previously marked ZHP-265A, was received</p>	<p style="text-align: right;">Page 168</p> <p>1 the English translation?</p> <p>2 (Exhibit Hecht-15, English Translation</p> <p>3 of Hecht-14, Bates ZHP02630926 through 2630927, was</p> <p>4 received and marked for identification.)</p> <p>5 Q. Okay. And this is the other document</p> <p>6 that you have cited. Correct?</p> <p>7 A. Yes.</p> <p>8 Q. Okay. What did you glean from this</p> <p>9 document that supports your opinion that these</p> <p>10 customer complaints showed a lack of care of ZHP?</p> <p>11 And we can scroll through; just tell us when to</p> <p>12 scroll down, Dr. Hecht, if you'd like?</p> <p>13 A. Well, there's --</p> <p>14 MR. SLATER: One second. One second.</p> <p>15 Doctor, one second.</p> <p>16 Objection to the question. The</p> <p>17 foundation, the mischaracterization, and the method</p> <p>18 that you're proceeding through these documents, and</p> <p>19 the way you're asking the questions.</p> <p>20 Now you can answer.</p> <p>21 A. There are solvent residues -- in the,</p> <p>22 you know, in the API.</p> <p>23 Q. And you agree, at least what I see,</p> <p>24 where you're looking at the top, am I correct, you're</p> <p>25 looking at the, "Samples provided found solvent</p>
<p style="text-align: right;">Page 167</p> <p>1 and marked for identification.)</p> <p>2 Q. Okay. This is the translation that has</p> <p>3 been used or provided.</p> <p>4 MR. SLATER: It's cut off.</p> <p>5 MR. BERNARDO: That's exactly how it was</p> <p>6 provided and used as a deposition exhibit. And this</p> <p>7 is the document, if you look the reference that's</p> <p>8 cited in his report. I didn't create this.</p> <p>9 A. Well, there's nothing useful here.</p> <p>10 Q. Okay. Let's take a look at the other</p> <p>11 exhibit, which is ending in Bates 926.</p> <p>12 MR. BERNARDO: And we'll mark that as</p> <p>13 exhibit, whatever number we're up to.</p> <p>14 (Exhibit Hecht-14, Document in Chinese</p> <p>15 Language previously marked ZHP-266, Bates ZHP02630926</p> <p>16 through 2630927, was received and marked for</p> <p>17 identification.)</p> <p>18 Q. And this document is also in Chinese, so</p> <p>19 I'll just tell you there's an English translation</p> <p>20 that was used, and that is part of this, so we'll</p> <p>21 just turn to that.</p> <p>22 A. Yeah.</p> <p>23 MR. SLATER: Objection.</p> <p>24 A. I see it.</p> <p>25 MR. BERNARDO: Do you want to pull up</p>	<p style="text-align: right;">Page 169</p> <p>1 residues not contained"?</p> <p>2 A. What?</p> <p>3 Q. Where did you conclude from this page</p> <p>4 that there were solvent residues?</p> <p>5 A. Just go back to the previous page.</p> <p>6 Q. This is page 1. There we go.</p> <p>7 A. Okay. Go down --</p> <p>8 MR. SLATER: Can you make it bigger,</p> <p>9 please?</p> <p>10 MR. BERNARDO: Sure.</p> <p>11 Am I understanding that Dr. Hecht's</p> <p>12 document share still doesn't work?</p> <p>13 A. I can see it. I can see it fine. They</p> <p>14 said -- yeah. They found solvent residues.</p> <p>15 Q. Okay.</p> <p>16 A. "Not contained in the following Russian</p> <p>17 giant registration document." I'm not sure what that</p> <p>18 means.</p> <p>19 Q. Okay. But based upon --</p> <p>20 A. But on the previous page or the next</p> <p>21 page, I saw a list of solvents.</p> <p>22 Q. Okay. Let's take a look at that.</p> <p>23 MR. BERNARDO: Let's go to the next</p> <p>24 page.</p> <p>25 A. Maybe it was the previous page, I don't</p>

<p style="text-align: right;">Page 170</p> <p>1 know. I saw it. So, you know, they didn't want to 2 have solvent residues in their -- in their API. 3 Q. Dr. Hecht, do you know what steps, if 4 any, ZHP took in response to the issue that you're 5 describing? 6 A. To the solvent residues? 7 Q. Yes. 8 A. I really don't remember. 9 Q. Do you know if they did -- 10 A. They might have -- they might have done 11 some analyses of the solvent residues that were 12 mentioned, and I don't remember. 13 Q. Okay. So as you sit here today, you're 14 not in a position to explain what the circumstances 15 were, with respect to the fourth item on page 6 that 16 you describe as "customer complaints." Is that fair? 17 MR. SLATER: Objection. 18 You can answer. 19 A. No, I wouldn't say that. I mean, there 20 were definitely aberrant peaks in the chromatograms 21 that they obtained when they analyzed the API, so I 22 mean, that -- you know, that was a problem. 23 Q. Okay. 24 A. I can't say exactly what these peaks 25 were, and I don't recall exactly what the resolution</p>	<p style="text-align: right;">Page 172</p> <p>1 Q. Okay. They show a lack of -- 2 A. And that's -- that's pertinent to the 3 big issue. 4 Q. Okay. 5 MR. BERNARDO: Let's pull up Tab 26. Or 6 Document 26. 7 (Exhibit Hecht-16, Email Chain ending 8 December 27, 2016, Bates ZHP0477534 through 477553, 9 was received and marked for identification.) 10 Q. Okay. I'm showing you a document that 11 I've marked as Exhibit 16, a December 27th, 2016, 12 email from Sophie Lee to a variety of recipients. 13 A. Okay. 14 Q. Do you see that? And why don't we pull 15 up -- this is another document that's in Chinese, so 16 we will pull up the English translation that was 17 provided. 18 MR. SLATER: I'm sorry, I totally got 19 spaced. Did you say that you pulled up deposition 20 testimony? Because I see a document. 21 MR. BERNARDO: No, I said I pulled up a 22 document, Adam, and I identified the document for the 23 record. And I'm about to ask him if he's seen it, 24 but I want to pull up. 25 Or is that the English? Oh, sorry.</p>
<p style="text-align: right;">Page 171</p> <p>1 of the thing was. Because I think around that same 2 time then, that's when Novartis discovered the NDMA, 3 and that kind of made all this other stuff 4 irrelevant. Because then, as ZHP had to go back and 5 analyze their 5,000 batches, and they found NDMA in 6 all of them. So I mean, that kind of made all these 7 complaints totally irrelevant. 8 Q. Well, then, if you think these 9 complaints are irrelevant, then I don't want to spend 10 time going through them and understanding your 11 knowledge, Dr. Hecht. But they're listed in your 12 report, and I'm trying to understand why you listed 13 them, the points that you're trying to make about 14 them and the extent to which you rely on them. If 15 they're irrelevant -- 16 A. Because -- because -- 17 MR. SLATER: One second, Doctor. 18 Doctor. 19 Objection to the question. You've 20 cherry-picked one thing without other parts. You 21 haven't asked about the rest of the citation in that 22 number, including the deposition testimony. The 23 foundation is very misleading. You have his report. 24 You can answer the question. 25 A. They show a lack of care.</p>	<p style="text-align: right;">Page 173</p> <p>1 Hold on a second. 2 Q. So Dr. Hecht, this is not -- 3 MR. BERNARDO: Let's pull this back up. 4 Q. This is not a document -- 5 MR. BERNARDO: Let's go back to the 6 beginning, Josh. 7 Q. This is not a document that was listed 8 in your report. Is it fair to say, therefore, that 9 you did not see this document, or you don't have a 10 recollection of having seen this document, in 11 connection with the points that you were making on 12 page 6 of your report? 13 A. I don't remember if I've seen this or 14 not. Maybe I did, maybe I didn't. 15 Q. If you did, and you were using it to 16 make your point, wouldn't you have listed it in 17 connection with the fourth item, as being pertinent 18 to that? 19 A. I don't know. 20 Q. You don't know whether you would have 21 identified it? Okay. So -- 22 A. I don't know. I don't see the relevance 23 of this whole thing. So, you know, what are you 24 trying to get at? 25 Q. If you go to page 4 of this document.</p>

<p style="text-align: right;">Page 174</p> <p>1 Okay? We see a December 22nd, 2016, email. Right?</p> <p>2 A. Yeah.</p> <p>3 Q. Okay. In which Jenny Liu writes that,</p> <p>4 and why don't you -- yeah.</p> <p>5 "It seems that your product cannot fully</p> <p>6 comply with ND for residual solvents before two to</p> <p>7 three years ago. Vertex claimed that there were</p> <p>8 additional peaks appeared which was not indicated in</p> <p>9 ND. So I'm worried if your product can fully comply</p> <p>10 with ND and if you can sign on it. Please recheck."</p> <p>11 Do you see that?</p> <p>12 A. Yeah.</p> <p>13 Q. Okay. That's from Jenny Liu at Shanghai</p> <p>14 Pharmtech Company. Correct?</p> <p>15 A. Yes.</p> <p>16 Q. And who -- who is Shanghai Pharmtech</p> <p>17 Company?</p> <p>18 A. It's one of their customers.</p> <p>19 Q. Okay. And then, if you continue on, she</p> <p>20 says, "We haven't received any complaint."</p> <p>21 So do you have any reason to dispute</p> <p>22 that this line of communication pertains to the same</p> <p>23 Vertex issue that we've been talking about,</p> <p>24 Dr. Hecht?</p> <p>25 MR. SLATER: Objection. This entire</p>	<p style="text-align: right;">Page 176</p> <p>1 said that these show an absence of care.</p> <p>2 And I'm trying to determine whether or</p> <p>3 not other documents that you did not look at, or do</p> <p>4 not appear to know about, or have seen, or don't</p> <p>5 remember having seen, have impacted that. I just</p> <p>6 want to explain to you what I'm doing, to make this a</p> <p>7 little bit simpler --</p> <p>8 MR. SLATER: Yeah, I object to your</p> <p>9 colloquy; I object to everything else you're saying.</p> <p>10 MR. BERNARDO: Okay.</p> <p>11 Q. And it says, "Dear Jenny, we haven't</p> <p>12 received any complaint from other Russian clients for</p> <p>13 valsartan quality. If it's problem for Vertex, then</p> <p>14 we have to withdraw the signed ND."</p> <p>15 Do you see that?</p> <p>16 A. Yeah.</p> <p>17 Q. Okay. And then Jenny Liu responds, and</p> <p>18 we'll look at that.</p> <p>19 And it says, "Good morning. Last time</p> <p>20 you provided three batch samples of valsartan and I</p> <p>21 just asked the test results about the solvents. Here</p> <p>22 is the reply. Please comment. It seems there are</p> <p>23 many additional peaks which did not indicate in ND."</p> <p>24 Do you know what the "ND" is?</p> <p>25 A. No, what is "ND"?</p>
<p style="text-align: right;">Page 175</p> <p>1 line of questioning, it's just being --</p> <p>2 A. What same Vertex issue?</p> <p>3 MR. SLATER: Let me finish, Doctor.</p> <p>4 Doctor, let me finish.</p> <p>5 The foundation for this whole entire</p> <p>6 line of questioning is completely misleading, and</p> <p>7 it's just completely inappropriate, the way this is</p> <p>8 being approached.</p> <p>9 You can answer the questions as best you</p> <p>10 can. I'll clean it up later.</p> <p>11 MR. BERNARDO: I'll give you a running</p> <p>12 objection on that.</p> <p>13 MR. SLATER: I don't want a running</p> <p>14 objection to this, honestly, because I want to be</p> <p>15 able to place the objections as you go. Because what</p> <p>16 you're doing here, with the cherry-picking, is</p> <p>17 really, really misleading.</p> <p>18 Q. Dr. Hecht, I'm showing you documents</p> <p>19 that you have not cited to, that pertain to the very</p> <p>20 same specific circumstances that, I will represent to</p> <p>21 you, Dr. Hecht, show the investigation that was done</p> <p>22 and the description of what those unknown peaks are.</p> <p>23 I will tell you right now, that's what</p> <p>24 I'm trying to do here, through documents that you</p> <p>25 didn't look at. Your counsel is objecting, and you</p>	<p style="text-align: right;">Page 177</p> <p>1 Q. That's what I'm asking, if you know what</p> <p>2 "ND" means.</p> <p>3 A. What is this? Tell me what it is?</p> <p>4 Q. Okay. So it's what is referred to as a</p> <p>5 normative document. Do you know the purpose of a</p> <p>6 normative document?</p> <p>7 A. To -- it's a validation document for the</p> <p>8 material.</p> <p>9 Q. Okay. So what they're saying is they</p> <p>10 found things which were not in the normative</p> <p>11 document. Correct?</p> <p>12 A. Yes.</p> <p>13 Q. Okay. And if you look at what is listed</p> <p>14 below, none of them are nitrosamines. Correct?</p> <p>15 A. That is correct.</p> <p>16 Q. Okay. And it says, "Please provide</p> <p>17 justification of appearances of these peaks."</p> <p>18 Correct?</p> <p>19 A. Yep.</p> <p>20 Q. Okay. So this communication is not</p> <p>21 about a complaint with respect to unknown peaks that</p> <p>22 were nitrosamines. Is that fair?</p> <p>23 MR. SLATER: Objection.</p> <p>24 You can answer.</p> <p>25 A. What do you mean? What do you mean,</p>

<p style="text-align: right;">Page 178</p> <p>1 "unknown peaks"?</p> <p>2 Q. What they determined are that these are</p> <p>3 the peaks that they found. Correct?</p> <p>4 A. This is what they found, right.</p> <p>5 Q. Right. Okay. Do you know what ZHP did</p> <p>6 to investigate this, to come to this conclusion?</p> <p>7 A. No. I mean, I'm not sure I understand</p> <p>8 your question.</p> <p>9 Q. Okay. Did you know that -- and you have</p> <p>10 not read this; but did you understand, either through</p> <p>11 the testimony or through the document that we're</p> <p>12 looking at, that it was determined that Vertex wasn't</p> <p>13 actually using the right valsartan ND?</p> <p>14 A. No. I don't -- I don't know.</p> <p>15 Q. Okay.</p> <p>16 MR. BERNARDO: Let's take a look at the</p> <p>17 document with the Bates number ending in 2709940,</p> <p>18 which we'll mark as Exhibit 17.</p> <p>19 (Exhibit Hecht-17, Email Chain ending</p> <p>20 February 29, 2019, Bates ZHP02709940 through 2709984,</p> <p>21 was received and marked for identification.)</p> <p>22 Q. Okay. And this is another email --</p> <p>23 MR. BERNARDO: Go to the front page,</p> <p>24 okay.</p> <p>25 Q. This is another email that's part of</p>	<p style="text-align: right;">Page 180</p> <p>1 been talking about?</p> <p>2 A. No.</p> <p>3 Q. Okay. If we go through, and we can</p> <p>4 scroll through the document, I want you to take a</p> <p>5 look. And you can see that ZHP worked with Jenny Liu</p> <p>6 and Shanghai Pharmtech to try and figure out what was</p> <p>7 going through with these peaks. And we'll scroll</p> <p>8 through. Okay?</p> <p>9 So Dr. Hecht, do you have any</p> <p>10 disagreement that this document, which is a 45-page</p> <p>11 document -- and again, you're free to pull this up,</p> <p>12 and your counsel can send it to you at a break, and</p> <p>13 we thought we had technology that allowed you to do</p> <p>14 it. I just want to have you look at it.</p> <p>15 This shows that they were looking at</p> <p>16 this from December 2016, into well into 2017. Do you</p> <p>17 have any reason to dispute that?</p> <p>18 A. No.</p> <p>19 Q. Okay. And if you look at the email at</p> <p>20 the bottom of page 3, it says that Vertex is not</p> <p>21 asking ZHP to remove the peaks, because Vertex</p> <p>22 already defined what the peaks were. Is that</p> <p>23 correct?</p> <p>24 A. Yeah.</p> <p>25 Q. Okay. They just wanted an explanation</p>
<p style="text-align: right;">Page 179</p> <p>1 this chain. And if you go down to page 7, you can</p> <p>2 see -- you see the same chain that we just looked at,</p> <p>3 Dr. Hecht?</p> <p>4 A. No.</p> <p>5 Q. Okay. So you can see that this includes</p> <p>6 her last email about the peaks issue. Right?</p> <p>7 A. Yeah.</p> <p>8 Q. Okay. And this is another document that</p> <p>9 you do not cite in your report. Is that correct?</p> <p>10 A. Right.</p> <p>11 Q. Okay. And you would agree, if you look</p> <p>12 at it, this relates to the issue we've been</p> <p>13 discussing. Correct?</p> <p>14 A. I would agree with what?</p> <p>15 Q. You would agree that this particular</p> <p>16 email chain relates to the issue that we've just been</p> <p>17 discussing with respect to Vertex, that's cited on</p> <p>18 page 4 of your report. Correct?</p> <p>19 MR. SLATER: Objection, foundation.</p> <p>20 You can answer.</p> <p>21 A. I don't know. I suppose so.</p> <p>22 Q. Well, I guess let me ask it a different</p> <p>23 way. Based upon the context and what is in this</p> <p>24 document, do you have any reason to disagree that</p> <p>25 this appears to relate to the same issue that we've</p>	<p style="text-align: right;">Page 181</p> <p>1 about the nature of the peaks. Right?</p> <p>2 A. Yeah.</p> <p>3 Q. And then there's some back-and-forth</p> <p>4 about the testing that was done by Vertex to find the</p> <p>5 peaks. Correct?</p> <p>6 A. Yeah.</p> <p>7 Q. Now, if you go to the top of the first</p> <p>8 page of the document, which would bring you to sort</p> <p>9 of the last-in-time email, ZHP responds that Vertex</p> <p>10 was using the wrong normative document.</p> <p>11 Do you see that? It says -- and it</p> <p>12 gives a number, "Is not our valsartan ND number. Our</p> <p>13 valsartan ND number is," and then they provide --</p> <p>14 they provide that. Do you see that?</p> <p>15 A. Okay, yes.</p> <p>16 Q. Okay? So ZHP says that the valsartan ND</p> <p>17 is actually different. Is that fair?</p> <p>18 A. That's what they're saying.</p> <p>19 Q. So there's clearly some confusion going</p> <p>20 on at Vertex, pertaining to this whole circumstance.</p> <p>21 Is that fair?</p> <p>22 A. Yeah.</p> <p>23 Q. And I raise this, Dr. Hecht -- and I'm</p> <p>24 not going to go through all of these. Is it fair to</p> <p>25 say, this is an example of how, if you look at other</p>

<p style="text-align: right;">Page 182</p> <p>1 documents that provide context for the documents that</p> <p>2 you cite, they may provide additional explanation</p> <p>3 that's inconsistent with what might appear on the</p> <p>4 face of the document that you cite?</p> <p>5 MR. SLATER: Objection.</p> <p>6 You can answer.</p> <p>7 A. I don't know what you're talking about.</p> <p>8 Q. Well, having --</p> <p>9 MR. SLATER: You're arguing with him. I</p> <p>10 mean --</p> <p>11 MR. BERNARDO: I'm not.</p> <p>12 MR. SLATER: It's not -- come on.</p> <p>13 Q. Dr. Hecht, let me ask you a question.</p> <p>14 Having walked through this document, do you think</p> <p>15 this is an example of ZHP not caring, as you</p> <p>16 described, these are examples?</p> <p>17 MR. SLATER: Objection.</p> <p>18 You can answer.</p> <p>19 A. Did I say that, not caring?</p> <p>20 Q. That was your word, Dr. Hecht.</p> <p>21 A. Yeah. No, sure, they -- they have to</p> <p>22 care about it. I mean, this is their product, so.</p> <p>23 Q. So is it fair to say that -- again, and</p> <p>24 you're welcome to look at as much or as little of</p> <p>25 this as you want to to answer my questions, and</p>	<p style="text-align: right;">Page 184</p> <p>1 were unknown peaks, and, you know, the nitrosamines</p> <p>2 were also in there. And --</p> <p>3 Q. But the --</p> <p>4 (Simultaneous speaking.)</p> <p>5 MR. SLATER: I'm sorry, Mr. Bernardo,</p> <p>6 you're interrupting him.</p> <p>7 A. By the time -- by the analyst. So I</p> <p>8 don't think I should answer that.</p> <p>9 Q. Okay. But the unknown -- the unknown</p> <p>10 peaks turned out not to be nitrosamines. Correct?</p> <p>11 MR. SLATER: Objection.</p> <p>12 A. The ones they're listing here were not</p> <p>13 nitrosamines, but that doesn't mean that there were</p> <p>14 not nitrosamines in there.</p> <p>15 Q. And I'm not --</p> <p>16 A. So there might be other unknown peaks</p> <p>17 that they didn't even see, or they didn't mention or</p> <p>18 they didn't look at. So they were just probably</p> <p>19 looking at the bigger peaks.</p> <p>20 So, you know, these solvent-related</p> <p>21 compounds are going to give larger peaks in the</p> <p>22 chromatograms than the ones of interest here, the</p> <p>23 nitrosamines. Nitrosamine peaks will be very small</p> <p>24 compared to these, by the -- by the method they're</p> <p>25 using. If that's what you're trying to get at.</p>
<p style="text-align: right;">Page 183</p> <p>1 you'll tell me if you need to look at more.</p> <p>2 Do you agree that, based upon what I've</p> <p>3 tried to walk you through, that this demonstrates</p> <p>4 that ZHP took the customer complaints seriously?</p> <p>5 MR. SLATER: Objection.</p> <p>6 You can answer.</p> <p>7 A. I don't know if they took the customer</p> <p>8 complaints seriously or not, really. I mean, yeah,</p> <p>9 this would indicate that they do. And they have to</p> <p>10 do that.</p> <p>11 Q. Let me ask it a different way, because</p> <p>12 that's a fair point.</p> <p>13 Does this demonstrate that they</p> <p>14 appropriately responded to an inquiry about unknown</p> <p>15 peaks?</p> <p>16 MR. SLATER: Objection.</p> <p>17 You can answer.</p> <p>18 A. It seems to, yes.</p> <p>19 Q. Okay. And it shows that the unknown</p> <p>20 peaks had nothing to do with nitrosamine development.</p> <p>21 Is that fair?</p> <p>22 MR. SLATER: Objection.</p> <p>23 You can answer.</p> <p>24 A. I don't know about that. I mean, I</p> <p>25 don't want to answer that. I mean, you know, there</p>	<p style="text-align: right;">Page 185</p> <p>1 Q. I'm not trying to get at anything,</p> <p>2 Dr. Hecht, I'm simply trying to ask the question.</p> <p>3 Now that we've been through at least</p> <p>4 some additional communications pertaining -- and to</p> <p>5 be clear, I'm not representing that this is the</p> <p>6 totality either. I'm just trying to show that this</p> <p>7 is an example of, there are additional</p> <p>8 communications.</p> <p>9 But now that we've walked through this,</p> <p>10 do you think that this example should be on your list</p> <p>11 of examples that are pertinent to your opinion?</p> <p>12 MR. SLATER: Objection.</p> <p>13 You can answer.</p> <p>14 A. I don't think this is pertinent to my</p> <p>15 opinion at all.</p> <p>16 Q. Okay. And that's because --</p> <p>17 A. I think it's irrelevant.</p> <p>18 Q. Okay. Thank you, Dr. Hecht.</p> <p>19 Let's take a look at another one, let's</p> <p>20 look at Number 5, and Number 5 is Glenmark.</p> <p>21 Do you see that on your report,</p> <p>22 Dr. Hecht?</p> <p>23 A. Yes, Glenmark.</p> <p>24 Q. Okay. And have you look at the</p> <p>25 documents. So there are three documents cited with</p>

<p style="text-align: right;">Page 186</p> <p>1 respect to Number 5. Do you see those?</p> <p>2 A. Yes.</p> <p>3 Q. Okay. And I take it you've looked at</p> <p>4 those documents?</p> <p>5 A. Probably.</p> <p>6 Q. Can you -- can you, as you sit here</p> <p>7 today, explain to me the circumstances with Glenmark,</p> <p>8 such that it's an example of one of the customer</p> <p>9 complaints you're pointing to in your report?</p> <p>10 A. No, I don't remember --</p> <p>11 MR. SLATER: Do you want him to give</p> <p>12 the --</p> <p>13 A. I don't remember the details.</p> <p>14 MR. SLATER: I'm sorry. Do you want to</p> <p>15 give him the documents and the deposition testimony</p> <p>16 that's cited in the report?</p> <p>17 MR. BERNARDO: I want to ask him</p> <p>18 questions without being interrupted, but I don't</p> <p>19 think that's going to happen.</p> <p>20 Q. So as you sit here today, you're not</p> <p>21 recalling, Dr. Hecht? Is that fair?</p> <p>22 MR. SLATER: Objection.</p> <p>23 Q. I just want to understand, as you sit</p> <p>24 here today, what you can tell me, without looking at</p> <p>25 documents. That's all I'm trying to get at. If it's</p>	<p style="text-align: right;">Page 188</p> <p>1 A. My opinion will not change.</p> <p>2 Q. Thank you.</p> <p>3 A. I don't care what you bring up.</p> <p>4 Q. Okay.</p> <p>5 A. My opinion is solid.</p> <p>6 (Exhibit Hecht-18, Email Chain in</p> <p>7 Chinese Language ending February 28, 2019 previously</p> <p>8 marked ZHP-271, Bates ZHP00496153 through 496154, was</p> <p>9 received and marked for identification.)</p> <p>10 Q. The first document you cite that is not</p> <p>11 testimony is ZHP-271. And this looks like it's in</p> <p>12 English. And again, there's nothing -- do you want</p> <p>13 to flip through the document? There's nothing of</p> <p>14 substance; this is just a cover transmittal. Is that</p> <p>15 fair?</p> <p>16 A. Yes.</p> <p>17 Q. Okay. Let's bring up the second one,</p> <p>18 which is ZHP-272.</p> <p>19 (Exhibit Hecht-19, Document in Chinese</p> <p>20 Language previously marked ZHP-272, Bates ZHP00496155</p> <p>21 through 496156, was received and marked for</p> <p>22 identification.)</p> <p>23 Q. And that one is in Chinese, so we're</p> <p>24 going to bring up 272A, which is in English.</p> <p>25 (Exhibit Hecht-20, English Translation</p>
<p style="text-align: right;">Page 187</p> <p>1 nothing, it's nothing. That's fine.</p> <p>2 MR. SLATER: Yeah, objection.</p> <p>3 You can answer.</p> <p>4 A. I don't remember the specifics of this</p> <p>5 document.</p> <p>6 Q. Okay.</p> <p>7 MR. BERNARDO: Let's pull up the first</p> <p>8 document that's cited.</p> <p>9 MR. SLATER: Well, first -- are you</p> <p>10 talking about under Glenmark in the report? The</p> <p>11 first document cited was deposition testimony. So I</p> <p>12 assume you're going to the second document cited,</p> <p>13 which is not the deposition testimony?</p> <p>14 MR. BERNARDO: I'm referring to</p> <p>15 documents, separate and distinct from testimony.</p> <p>16 MR. SLATER: Right.</p> <p>17 Q. Okay. And let me ask, since Mr. Slater</p> <p>18 raised that. Do you recall anything, or can you</p> <p>19 point to anything in testimony with respect to the</p> <p>20 first document -- or the first circumstance we did</p> <p>21 with respect to Vertex, that would somehow change</p> <p>22 your opinion, having now looked at the underlying</p> <p>23 documents?</p> <p>24 MR. SLATER: Is the question without</p> <p>25 looking at the testimony?</p>	<p style="text-align: right;">Page 189</p> <p>1 of Hecht-19, previously marked ZHP-272A, was received</p> <p>2 and marked for identification.)</p> <p>3 MR. BERNARDO: I'm sorry. Thank you.</p> <p>4 MR. SLATER: By the way, Mr. Bernardo, I</p> <p>5 think, but I could be wrong, because I wasn't in this</p> <p>6 deposition. But my understanding is Mr. Lee was</p> <p>7 deposed about the Chinese documents, and the English</p> <p>8 translations were given to counsel. I could be</p> <p>9 wrong; but you -- I just want to make that clear.</p> <p>10 You could probably look at the testimony to figure</p> <p>11 that out.</p> <p>12 MR. BERNARDO: You very well may be</p> <p>13 right, and you can certainly make that point.</p> <p>14 I'm simply trying to understand the</p> <p>15 extent to which Dr. Hecht has looked at these</p> <p>16 materials.</p> <p>17 BY MR. BERNARDO:</p> <p>18 Q. So can you -- so this is a three-page</p> <p>19 document. If we just take a minute and scroll</p> <p>20 through, can you explain to me what this is, and how</p> <p>21 it impacts your opinion? With respect to the 2016</p> <p>22 complaint in December, from Glenmark?</p> <p>23 A. I can't read that fast, sorry.</p> <p>24 Q. No, no, no.</p> <p>25 A. So, you know, apparently, there's some</p>

<p style="text-align: right;">Page 190</p> <p>1 solvent peaks similar to the other one.</p> <p>2 Q. Okay. So is there anything you can tell</p> <p>3 us about this document that's somehow relevant to</p> <p>4 your inclusion of the Glenmark customer complaint,</p> <p>5 and what you -- what, if anything, you derive from</p> <p>6 it?</p> <p>7 A. I can't derive much from this document.</p> <p>8 Q. Okay.</p> <p>9 MR. BERNARDO: Let's look at the third</p> <p>10 and last document, which is Tab 34. What number is</p> <p>11 that?</p> <p>12 MR. SCHOCH: Twenty-one.</p> <p>13 MR. BERNARDO: Which is Exhibit 21. And</p> <p>14 how many pages is that?</p> <p>15 (Exhibit Hecht-21, Email Chain ending</p> <p>16 December 22, 2016, Bates ZHP02118712 through 2118731,</p> <p>17 was received and marked for identification.)</p> <p>18 Q. Okay. And this is, again, a much longer</p> <p>19 document, right? And it's from Francis D'Souza to a</p> <p>20 number of individuals.</p> <p>21 Do you know who Francis D'Souza is?</p> <p>22 A. I do not.</p> <p>23 Q. Okay. And here, Francis D'Souza is</p> <p>24 identifying some unknown peaks, and asking ZHP for</p> <p>25 their justification and origin.</p>	<p style="text-align: right;">Page 192</p> <p>1 A. Right.</p> <p>2 Q. And then on December 22nd, Francis</p> <p>3 D'Souza responds with some more questions. Do you</p> <p>4 see those?</p> <p>5 A. Yep.</p> <p>6 Q. Okay. And if we go back to what we just</p> <p>7 looked at, that was Exhibit 20, that's -- was marked</p> <p>8 278, that's the summary of communications between ZHP</p> <p>9 and Glenmark about the unknown peak. Is that fair?</p> <p>10 A. Yes.</p> <p>11 Q. Okay. And you can see the first</p> <p>12 communication that's up there on the upper left is</p> <p>13 December 19, 2016. That's the email we just looked</p> <p>14 at. Right?</p> <p>15 A. Yeah.</p> <p>16 Q. And then there's some responses from ZHP</p> <p>17 and Glenmark on December 22nd, 2016, and that's in</p> <p>18 the summary, you'll see those?</p> <p>19 A. Yeah.</p> <p>20 Q. Okay. Those are the ones that we just</p> <p>21 looked at. Then the summary goes on with</p> <p>22 communications back and forth for another couple of</p> <p>23 pages. Right?</p> <p>24 A. Yes.</p> <p>25 Q. Okay. It goes all the way until April,</p>
<p style="text-align: right;">Page 191</p> <p>1 A. Right.</p> <p>2 Q. Is that fair?</p> <p>3 A. Same deal.</p> <p>4 Q. Right. If you go to the third page of</p> <p>5 this email chain.</p> <p>6 MR. BERNARDO: Sorry, scroll back a</p> <p>7 little, there we go.</p> <p>8 Q. There appears to be a preliminary</p> <p>9 analysis, some of Glenmark's preliminary analysis of</p> <p>10 what the peaks are. Do you see that?</p> <p>11 A. Yes.</p> <p>12 Q. Okay. So they aren't totally unknown.</p> <p>13 Correct? There's some at least initial analysis of</p> <p>14 what these peaks are. Is that correct?</p> <p>15 A. Right, right.</p> <p>16 Q. And Glenmark is really asking ZHP to</p> <p>17 confirm their identities and justify the origin.</p> <p>18 Correct?</p> <p>19 A. Yep.</p> <p>20 Q. Okay. And then ZHP responds on</p> <p>21 December 22nd, do you see that, saying they're</p> <p>22 investigating, and asking for the chromatograph for</p> <p>23 further investigation.</p> <p>24 A. Yep.</p> <p>25 Q. Right?</p>	<p style="text-align: right;">Page 193</p> <p>1 2017. Is that correct?</p> <p>2 A. Yes.</p> <p>3 Q. Okay. That's the last entry, and it</p> <p>4 says ZHP responded to Glenmark about Glenmark's</p> <p>5 replies. Right? And "there was no further feedback</p> <p>6 from subsequent customer and there's no follow-up."</p> <p>7 Do you see that?</p> <p>8 A. Yep.</p> <p>9 MR. BERNARDO: Let's take a look at the</p> <p>10 April 20, 2017, communication.</p> <p>11 (Exhibit Hecht-22, Email Chain ending</p> <p>12 April 20, 2017, Bates ZHP02118680 through 2118708,</p> <p>13 was received and marked for identification.)</p> <p>14 Q. And again, this was not listed in your</p> <p>15 materials, so I take it this is not something that</p> <p>16 you looked at, or you just don't know?</p> <p>17 MR. SLATER: What exhibit number is</p> <p>18 this?</p> <p>19 MR. BERNARDO: 22.</p> <p>20 MR. SLATER: Exhibit 22. And what is</p> <p>21 it, it's an April 20, 2017 email?</p> <p>22 MR. BERNARDO: Yes.</p> <p>23 A. Yeah.</p> <p>24 Q. Okay. And it has the same subject line:</p> <p>25 "Unknown peaks of residual" -- or attachments.</p>

<p style="text-align: right;">Page 194</p> <p>1 A. Right.</p> <p>2 Q. Okay. So it's no question but that it</p> <p>3 relates to the issue we've been talking about?</p> <p>4 MR. SLATER: Objection.</p> <p>5 A. I don't really agree with that.</p> <p>6 Q. Okay. Fair enough. It appears to</p> <p>7 relate, from the text of this, and the description --</p> <p>8 A. I don't know if it really relates.</p> <p>9 Q. Okay. Let's go through the email -- I</p> <p>10 don't want to go through each page, and you'll see</p> <p>11 that ZHP and Glenmark are talking about these peaks.</p> <p>12 MR. BERNARDO: Is the attachment part of</p> <p>13 this, Josh?</p> <p>14 MR. SCHOCH: Yeah.</p> <p>15 MR. BERNARDO: Okay.</p> <p>16 Q. Do you agree that -- and you'll see this</p> <p>17 particular one, this is the one we just looked at a</p> <p>18 minute ago. They're talking about the three unknown</p> <p>19 peaks. Correct?</p> <p>20 A. Yes.</p> <p>21 Q. And this email has an attachment?</p> <p>22 MR. BERNARDO: Let's bring that up,</p> <p>23 which is 23.</p> <p>24 MR. SLATER: Are we still on Exhibit 22?</p> <p>25 MR. BERNARDO: We're moving to</p>	<p style="text-align: right;">Page 196</p> <p>1 Q. Okay. And the control mechanism for the</p> <p>2 impurities. Is that correct?</p> <p>3 A. Yes.</p> <p>4 Q. And then the limitation standard for</p> <p>5 those impurities?</p> <p>6 A. Right.</p> <p>7 Q. Okay. And this is the last</p> <p>8 communication in the summary correspondence, and</p> <p>9 Glenmark actually identifies each of the unknown</p> <p>10 peaks, and gives more information about each peak.</p> <p>11 Is that fair?</p> <p>12 A. Yep.</p> <p>13 Q. And again, these are not nitrosamines.</p> <p>14 Right?</p> <p>15 A. Right.</p> <p>16 Q. Okay. So looking at again, all of the</p> <p>17 communications -- and I'm not representing this is</p> <p>18 the entirety; I'm just saying these are more than</p> <p>19 what was listed in your report or listed in your</p> <p>20 reliance materials -- you would agree, wouldn't you,</p> <p>21 that it shows that ZHP was working with its customer</p> <p>22 to address and understand the origin of unknown</p> <p>23 peaks?</p> <p>24 MR. SLATER: Objection.</p> <p>25 You can answer.</p>
<p style="text-align: right;">Page 195</p> <p>1 Exhibit 23.</p> <p>2 (Exhibit Hecht-23, Chart titled</p> <p>3 "D5191-15-359," Bates ZHP02118709 through 2118711,</p> <p>4 was received and marked for identification.)</p> <p>5 MR. SLATER: 23, okay.</p> <p>6 Q. And the attachment -- and this is an</p> <p>7 attachment from April 20, 2017. And the attachment</p> <p>8 actually lists all of the peaks that Glenmark raised.</p> <p>9 Correct?</p> <p>10 MR. SLATER: Objection.</p> <p>11 A. Yep.</p> <p>12 Q. Okay. And you can see it identifies</p> <p>13 each of the peaks in the one, two, three, four, fifth</p> <p>14 column?</p> <p>15 MR. SCHOCH: Page 6.</p> <p>16 MR. BERNARDO: Under "Library Search,"</p> <p>17 do you see that?</p> <p>18 A. Yes.</p> <p>19 Q. And none of those is nitrosamines. Is</p> <p>20 that correct?</p> <p>21 A. Yes.</p> <p>22 Q. Okay. And the table also includes</p> <p>23 the -- see that column that's highlighted in yellow</p> <p>24 and blue, that says "Origin of Impurities"?</p> <p>25 A. Yep.</p>	<p style="text-align: right;">Page 197</p> <p>1 A. It appears that way, yes.</p> <p>2 Q. Okay. Would you therefore take this off</p> <p>3 of your list of examples of the customer complaints</p> <p>4 that are relevant to your opinion on page 6?</p> <p>5 MR. SLATER: Objection.</p> <p>6 A. No, I would not.</p> <p>7 Q. Why not?</p> <p>8 A. Well, because, you know, these are</p> <p>9 instances of impurities being found in the -- in the</p> <p>10 API that these companies were purchasing from ZHP, so</p> <p>11 naturally, it's a concern.</p> <p>12 Q. Is it a concern if they're within the</p> <p>13 limitation standard?</p> <p>14 MR. SLATER: Objection.</p> <p>15 You can answer.</p> <p>16 A. When you see the peaks, the first thing</p> <p>17 you have to do is identify them, and then the second</p> <p>18 thing you have to do is quantify them. And then when</p> <p>19 that work is complete, then you can decide, you know,</p> <p>20 whether it's a problem or not.</p> <p>21 Q. And is it fair to say, from the</p> <p>22 communications we just looked at, that that's in fact</p> <p>23 what happened: They were both investigated and</p> <p>24 quantified?</p> <p>25 A. Well, it seems to be -- that, you know,</p>

<p style="text-align: right;">Page 198</p> <p>1 that appears to be the intent.</p> <p>2 Q. Okay. On page 7 of your report, on the</p> <p>3 top page, you'll see another customer complaint,</p> <p>4 Number 7. And it's Novartis, and that's the one in</p> <p>5 which nitrosamines or NDMA was identified. Is that</p> <p>6 correct?</p> <p>7 A. Yes.</p> <p>8 Q. Okay. In your report, you say --</p> <p>9 MR. BERNARDO: You want to pull it down,</p> <p>10 just a little further.</p> <p>11 Q. I'm in the third line, Dr. Hecht,</p> <p>12 beginning "Novartis."</p> <p>13 "Novartis investigated the unknown peaks</p> <p>14 to determine what was causing them, and identified</p> <p>15 the NDMA in ZHP API manufactured with the zinc</p> <p>16 chloride process."</p> <p>17 What do you mean when you say, Novartis</p> <p>18 investigated and identified NDMA?</p> <p>19 A. How could it be clearer than that?</p> <p>20 Q. Well, how about this. Let me ask --</p> <p>21 A. They investigated, and they identified</p> <p>22 it.</p> <p>23 Q. Okay. Walk me through the steps that</p> <p>24 Novartis took. And was it Novartis, was it a third</p> <p>25 party, when did it occur? I just want to</p>	<p style="text-align: right;">Page 200</p> <p>1 took?</p> <p>2 A. I don't know. I read it, okay? I</p> <p>3 didn't make it up. It's in the material that I have.</p> <p>4 Q. I'm not suggesting you made it up, I'm</p> <p>5 just trying to understand, so I can --</p> <p>6 A. Yeah.</p> <p>7 Q. -- see how --</p> <p>8 MR. SLATER: Objection to form.</p> <p>9 A. It's in the -- it's in one of the</p> <p>10 binders. I have the -- I have something from</p> <p>11 Novartis, from this guy, Kevin O'Mahoney in Ireland,</p> <p>12 that, you know, identified the NDMA.</p> <p>13 And I don't think the document that I</p> <p>14 have actually goes into the origin of it, but he</p> <p>15 figured it out. And the reason he was able to figure</p> <p>16 it out was, I'm sure, although I don't know if it's</p> <p>17 in the documents, is that he looked at the process.</p> <p>18 And once you look at the process, then you're going</p> <p>19 to figure it out.</p> <p>20 Q. So you just said you're sure, but you</p> <p>21 don't know if it's in the documents. If it's not in</p> <p>22 the documents, how else would you be sure that they</p> <p>23 looked at the --</p> <p>24 A. Okay, I don't know that. Maybe I'm not</p> <p>25 sure.</p>
<p style="text-align: right;">Page 199</p> <p>1 understand --</p> <p>2 A. As far as I know, it was Novartis in</p> <p>3 Ireland, someone named Kevin O' Mahoney, or something</p> <p>4 like that, that, you know, first suspected, and then</p> <p>5 figured out that it was NDMA.</p> <p>6 And as far as I remember, that person</p> <p>7 took a look at the process that ZHP was using, and</p> <p>8 that gave him the hint that this -- that there could</p> <p>9 be NDMA in there. And then, and then he, they,</p> <p>10 confirmed it, Novartis confirmed it.</p> <p>11 I believe that's the sequence of events.</p> <p>12 But, you know, I could be a little bit off.</p> <p>13 Q. Okay.</p> <p>14 A. Novartis went into a little more detail,</p> <p>15 I believe. You know, they actually looked at the</p> <p>16 process and, you know, they figured out that -- what</p> <p>17 could be going on here, because of the use of</p> <p>18 nitrite.</p> <p>19 Q. Okay.</p> <p>20 A. That's my understanding of it.</p> <p>21 Q. And how did you get that understanding?</p> <p>22 A. By reading. Reading the reports,</p> <p>23 reading the binders and everything.</p> <p>24 Q. So you're saying the binders contain</p> <p>25 information that delineate the steps that Novartis</p>	<p style="text-align: right;">Page 201</p> <p>1 Q. Okay. Again, I'm just trying to</p> <p>2 understand. So --</p> <p>3 A. I read this, I definitely read that</p> <p>4 Novartis figured it out. And as far as I know, it</p> <p>5 was by someone named Kevin O'Mahoney. And that's --</p> <p>6 somewhere in -- somewhere in these binders is that.</p> <p>7 I can't remember exactly where it is.</p> <p>8 Q. Do you know --</p> <p>9 A. But I couldn't make something like that</p> <p>10 up.</p> <p>11 Q. I'm not suggesting you did, Dr. Hecht.</p> <p>12 Do you know if Novartis did the testing</p> <p>13 themselves, or if they retained a third party to do</p> <p>14 the testing?</p> <p>15 A. I don't remember.</p> <p>16 Q. Okay. Do you know if Novartis conducted</p> <p>17 any other tests previously to this, and the results</p> <p>18 of those tests?</p> <p>19 A. I don't -- I don't know. I don't</p> <p>20 remember how much Novartis did.</p> <p>21 Q. Okay. Do you know the circumstance of</p> <p>22 why Novartis was testing?</p> <p>23 A. Yes.</p> <p>24 Q. What were they?</p> <p>25 A. They looked at the procedure.</p>

<p style="text-align: right;">Page 202</p> <p>1 Q. Why were they looking --</p> <p>2 A. And they saw -- I mean, how many times</p> <p>3 do I have to repeat it? They saw how they decomposed</p> <p>4 the sodium azide by dumping in nitrite at pH [REDACTED] in the</p> <p>5 presence of the product. And then the light bulb</p> <p>6 went off.</p> <p>7 Q. Do you know how long Novartis, if they</p> <p>8 were, were testing API from ZHP?</p> <p>9 A. No, I don't know how long.</p> <p>10 Q. Okay. And as we just identified before,</p> <p>11 you will agree that sometimes additional documents or</p> <p>12 additional communications can shed more light on</p> <p>13 communication that you're looking at. Correct?</p> <p>14 MR. SLATER: Objection.</p> <p>15 You can answer.</p> <p>16 A. Sure. The more information we have, the</p> <p>17 better off we'll be. I don't know what your point</p> <p>18 is.</p> <p>19 Q. You answered my question. That was my</p> <p>20 only point.</p> <p>21 A. All right.</p> <p>22 Q. Do you know whether Novartis did any</p> <p>23 testing of valsartan, prior to May of 2018?</p> <p>24 A. Not that I'm aware of.</p> <p>25 Q. But you don't know, one way or the</p>	<p style="text-align: right;">Page 204</p> <p>1 the guy at Novartis was smart enough to look at the</p> <p>2 procedure, and he saw how ZHP dumped in nitrite at</p> <p>3 pH [REDACTED] and then he said, well, there might be</p> <p>4 nitrosamines here, so let's look at NDMA. That's</p> <p>5 what happened.</p> <p>6 Q. I want to shift gears to -- and if we</p> <p>7 turn to your report --</p> <p>8 MR. SLATER: If we're going to a</p> <p>9 different area, now would probably be a good time to</p> <p>10 eat.</p> <p>11 MR. BERNARDO: No, I'm thinking -- yeah,</p> <p>12 right. I was going to say, I could do this pretty</p> <p>13 quickly. Why don't we do that, Adam.</p> <p>14 MR. SLATER: I mean, now it's late</p> <p>15 enough.</p> <p>16 MR. BERNARDO: Yeah, yeah.</p> <p>17 MR. SLATER: How much time does</p> <p>18 everybody want to take?</p> <p>19 THE VIDEOGRAPHER: Should we go off the</p> <p>20 record first, Counsel?</p> <p>21 MR. BERNARDO: Sure, please.</p> <p>22 THE VIDEOGRAPHER: Going off the record.</p> <p>23 The time is 12:45 Central Time. This is the end of</p> <p>24 Media Unit Number 4.</p> <p>25 (A luncheon recess takes place.)</p>
<p style="text-align: right;">Page 203</p> <p>1 other?</p> <p>2 A. No, I don't know.</p> <p>3 Q. Do you have any reason to dispute that</p> <p>4 Novartis conducted testing on valsartan API, prior to</p> <p>5 2018?</p> <p>6 A. I don't know.</p> <p>7 Q. Okay. Hypothetically --</p> <p>8 A. I don't know whether they did or they</p> <p>9 didn't. That's my answer.</p> <p>10 Q. Hypothetically -- understood.</p> <p>11 Hypothetically, if Novartis did conduct testing on</p> <p>12 valsartan API prior to May 2018, and did not find</p> <p>13 NDMA, would that factor into your consideration and</p> <p>14 the forming of your opinion?</p> <p>15 A. No, because in order to find NDMA in the</p> <p>16 testing, you need to be looking for it. All right?</p> <p>17 The peaks -- the NDMA peak would be too small for it</p> <p>18 to stand out. That's why some of these companies</p> <p>19 missed it, because they looked at the solvents, the</p> <p>20 ones we were just talking about. They're going to be</p> <p>21 like relatively larger peaks. The NDMA peak is going</p> <p>22 to be very small.</p> <p>23 So you wouldn't see it. You wouldn't</p> <p>24 notice it unless you were actually looking for it.</p> <p>25 And that's why only Novartis figured it out, because</p>	<p style="text-align: right;">Page 205</p> <p>1 THE VIDEOGRAPHER: We're back on the</p> <p>2 record. The time is 1:27 p.m. Central Time. This is</p> <p>3 the beginning of Media Unit 5.</p> <p>4 CONTINUED EXAMINATION BY MR. BERNARDO:</p> <p>5 Q. Good afternoon -- yeah, it's afternoon</p> <p>6 in Minnesota, yes. Good afternoon, Dr. Hecht. We've</p> <p>7 had a little lunch break here.</p> <p>8 I want to go back to further discuss a</p> <p>9 topic we talked about this morning, the decomposition</p> <p>10 of DMF. And again, for purposes of these questions,</p> <p>11 Dr. Hecht, I want to clarify: I understand your</p> <p>12 opinion that there may have been dimethylamine in DMF</p> <p>13 already, but I want to assume there was not. I want</p> <p>14 to assume that whatever contribution of DMF came</p> <p>15 through degradation, for purposes of these questions.</p> <p>16 Do you understand what I'm saying?</p> <p>17 A. Yes.</p> <p>18 Q. Okay. So if the DMF degraded to form</p> <p>19 dimethylamine, it's my understanding from your</p> <p>20 earlier testimony that it's your opinion that that</p> <p>21 occurred when the process was heated to [REDACTED] degrees</p> <p>22 celsius. Is that correct?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. Is there any other point in the</p> <p>25 process you believe that if degradation was what</p>

<p style="text-align: right;">Page 206</p> <p>1 resulted in the formation of dimethylamine, that that</p> <p>2 would have occurred?</p> <p>3 A. This was -- this would be the most</p> <p>4 likely.</p> <p>5 Q. Okay. Well, you say "it would be the</p> <p>6 most likely." I just -- I just want to understand,</p> <p>7 so we can talk about others, if there are others.</p> <p>8 A. I don't have any others in mind.</p> <p>9 Q. Okay.</p> <p>10 MR. BERNARDO: I want to pull up -- I</p> <p>11 don't think we've marked it already, have we, Josh?</p> <p>12 Q. Okay. One of the publications you cite</p> <p>13 to -- and I'm not sure exactly how to pronounce it,</p> <p>14 so I'll just call it Armarego, if that is right.</p> <p>15 MR. BERNARDO: And let's mark that as</p> <p>16 exhibit -- what are we up to? 24.</p> <p>17 (Exhibit Hecht-24, Excerpt from</p> <p>18 Purification of Laboratory Chemicals, Fourth Edition,</p> <p>19 by W.L.F. Amarego and D.D. Perrin, No Bates, 21</p> <p>20 Pages, was received and marked for identification.)</p> <p>21 MR. SLATER: Doctor, if you have that</p> <p>22 there, you can pull up the hard copy too, if you need</p> <p>23 to.</p> <p>24 Q. And before we get into -- so this is --</p> <p>25 what I've marked as Exhibit 24 is a book called</p>	<p style="text-align: right;">Page 208</p> <p>1 want to find out more about it. So in the lab, we</p> <p>2 would have, you know, bookshelves -- or not in the</p> <p>3 lab, necessarily, but, you know, in the area,</p> <p>4 where -- like a reference library. And you know, you</p> <p>5 would go to a book like this to find out more about a</p> <p>6 particular solvent or process that you were using.</p> <p>7 These kinds of books are very useful.</p> <p>8 Now they're probably all online. But in</p> <p>9 the past, it would be typical to have, you know,</p> <p>10 bookshelves with relevant references available.</p> <p>11 MR. BERNARDO: If we can go to the</p> <p>12 preface of this. Okay. And if you go down to --</p> <p>13 Josh, if you can find that, "to keep this book in a</p> <p>14 convenient size, portions." Josh? Oh.</p> <p>15 Q. Okay. This -- and we'll undo it,</p> <p>16 because I know this makes it harder for you to look,</p> <p>17 but I just wanted to point out to you where I'm</p> <p>18 looking.</p> <p>19 It says, "To keep this book a convenient</p> <p>20 size, and bearing in mind that its most likely users</p> <p>21 will be laboratory trained, we've omitted</p> <p>22 manipulative details with which they can be assumed</p> <p>23 to be familiar, and also detailed theoretical</p> <p>24 discussions."</p> <p>25 Do you see what I just read?</p>
<p style="text-align: right;">Page 207</p> <p>1 Purification of Laboratory Chemicals, Fourth Edition.</p> <p>2 And you're familiar with this book.</p> <p>3 Correct, Dr. Hecht?</p> <p>4 A. Right.</p> <p>5 Q. When did you first become familiar with</p> <p>6 this publication?</p> <p>7 A. Oh, this is like a standard in the --</p> <p>8 you know, there's a whole shelf full of standard kind</p> <p>9 of laboratory -- not manuals, exactly, but different</p> <p>10 books that collect laboratory methods that are, you</p> <p>11 know, relevant to those that are commonly used in</p> <p>12 organic chemistry laboratories. So, you know, this</p> <p>13 is one of those.</p> <p>14 Q. When did you first -- do you have a copy</p> <p>15 of this?</p> <p>16 A. I do not.</p> <p>17 Q. Okay. When is the first time that you</p> <p>18 saw this?</p> <p>19 A. Probably about 40 years ago. I don't</p> <p>20 know; I don't remember.</p> <p>21 Q. What would be the circumstances for</p> <p>22 which you would consult this type of publication?</p> <p>23 A. Well, if we're doing a process in the</p> <p>24 lab, and, you know, we had to use a solvent or</p> <p>25 reagent that we hadn't used before, and, you know, we</p>	<p style="text-align: right;">Page 209</p> <p>1 A. Yes.</p> <p>2 Q. So this book is not intended to</p> <p>3 communicate information with which a lab technician</p> <p>4 would be assumed to be familiar; they omitted that,</p> <p>5 to help the size of the book. Is that a fair</p> <p>6 interpretation of what's being said there?</p> <p>7 MR. SLATER: Objection.</p> <p>8 You can answer.</p> <p>9 A. Well, yeah, I mean, that's what it says.</p> <p>10 But, you know, that's a matter of opinion, obviously.</p> <p>11 So, you know, what to include and what not to</p> <p>12 include. You don't know what a person's likely to be</p> <p>13 familiar with or not. I mean, it's all a matter of</p> <p>14 opinion.</p> <p>15 Q. Of course, it is. But it's the opinion</p> <p>16 of the authors and people who had responsibility for</p> <p>17 this book, that this book only includes things with</p> <p>18 which people would not be expected to be familiar.</p> <p>19 That's what they're saying here. Is that fair?</p> <p>20 MR. SLATER: Objection.</p> <p>21 You can answer.</p> <p>22 A. Probably.</p> <p>23 Q. Okay. And if you go back to the preface</p> <p>24 to the fourth edition -- or go to the preface to the</p> <p>25 fourth edition. It says on the bottom, you see it,</p>

<p style="text-align: right;">Page 210</p> <p>1 there's a total of --</p> <p>2 MR. SLATER: Wait, I'm sorry, Rich. Is</p> <p>3 this a different edition? Because that was the</p> <p>4 preface, I might have just blanked it?</p> <p>5 MR. BERNARDO: No, we're in the same --</p> <p>6 the same edition that I've been showing him, and this</p> <p>7 is the same thing that's been cited, as far as I'm</p> <p>8 aware. I haven't left the same book.</p> <p>9 MR. SLATER: Got it. Got it. It</p> <p>10 confused me, because it looked like there were two</p> <p>11 prefaces.</p> <p>12 Q. The authors point out that there's a</p> <p>13 total of 5,700 entries. Correct?</p> <p>14 A. That's what it says.</p> <p>15 Q. And this book is -- if I'm correct,</p> <p>16 Dr. Hecht, it's not a textbook; it's a compendium,</p> <p>17 listed alphabetically, of various chemical -- I don't</p> <p>18 know whether they're called compounds, or -- but</p> <p>19 there's -- it's almost like -- a little bit more of</p> <p>20 an encyclopedia. Is that fair?</p> <p>21 A. Yeah, you could say that.</p> <p>22 Q. Okay. And is it also fair to say that</p> <p>23 you wouldn't expect that any lab chemist would</p> <p>24 commonly know every one of the 5700 entries in this</p> <p>25 book? Can you agree with that?</p>	<p style="text-align: right;">Page 212</p> <p>1 MR. BERNARDO: Would you read back the</p> <p>2 question?</p> <p>3 Q. Because I don't think that's the</p> <p>4 question I asked, Dr. Hecht?</p> <p>5 (The testimony is read back.)</p> <p>6 MR. SLATER: Objection.</p> <p>7 You can answer.</p> <p>8 A. It may or may not be widely known. I</p> <p>9 was certainly aware of it.</p> <p>10 Q. Okay. Fair --</p> <p>11 A. I don't know whether it's widely known</p> <p>12 or not. But I repeat: If I were doing this on the</p> <p>13 scale that they're doing it, I would certainly look</p> <p>14 into it.</p> <p>15 Q. And Dr. Hecht, and I -- we've done a</p> <p>16 search; I mean, you've written several hundred</p> <p>17 articles. Is that fair to say?</p> <p>18 A. Yes.</p> <p>19 Q. We didn't find any citation of this</p> <p>20 portion of this publication discussing degradation of</p> <p>21 DMF in any of your writings. Is that consistent with</p> <p>22 your expectation?</p> <p>23 A. I'm surprised you went through all of</p> <p>24 them, but --</p> <p>25 Q. We didn't read them all, but that's what</p>
<p style="text-align: right;">Page 211</p> <p>1 I think we agree from your response, but</p> <p>2 I'd like you to confirm?</p> <p>3 A. Probably.</p> <p>4 Q. In fact, you don't know if -- I would</p> <p>5 assume -- every one of the 5700 entries in here, and</p> <p>6 what they say?</p> <p>7 A. That's a good chance that's correct.</p> <p>8 Q. So the fact that it is in this book does</p> <p>9 not mean that information about the conditions under</p> <p>10 which DMF could degrade would be widely known. Is</p> <p>11 that fair?</p> <p>12 MR. SLATER: Objection.</p> <p>13 A. Well, you know, if I were making</p> <p>14 kilograms of valsartan, I would certainly check into</p> <p>15 every reagent that's being used in that process.</p> <p>16 Absolutely. This not like a casual experiment, you</p> <p>17 know, that you do, "oh, let's try this and see if it</p> <p>18 works." You know, this is an industrial process</p> <p>19 where the materials are going to be distributed</p> <p>20 worldwide.</p> <p>21 So I would make damn sure that</p> <p>22 everything that I used, everything that I did in this</p> <p>23 process, was bulletproof.</p> <p>24 MR. BERNARDO: Ellen --</p> <p>25 A. So yeah, I would look at it.</p>	<p style="text-align: right;">Page 213</p> <p>1 computers are for.</p> <p>2 A. I don't -- I don't think we used DMF</p> <p>3 that much.</p> <p>4 Q. Okay.</p> <p>5 A. In the studies we did. But I was</p> <p>6 certainly familiar with the fact that DMF, you know,</p> <p>7 could have dimethylamine in it, or could be</p> <p>8 hydrolyzed into dimethylamine. I mean, that's like</p> <p>9 basic chemistry.</p> <p>10 Q. And again, I just want to understand</p> <p>11 this book.</p> <p>12 MR. BERNARDO: If you can go back to the</p> <p>13 first page again, Josh, please.</p> <p>14 Q. You would agree, this is not what you</p> <p>15 would characterize as a textbook; it's not something</p> <p>16 that would be used to teach organic chemistry or</p> <p>17 chemistry. Is that fair?</p> <p>18 MR. SLATER: Objection.</p> <p>19 You can answer.</p> <p>20 A. Well, that depends. I mean, if you're</p> <p>21 teaching a laboratory course, you might very well use</p> <p>22 this book.</p> <p>23 Q. Okay. Do you know whether anybody</p> <p>24 teaching a lab report -- laboratory course does use</p> <p>25 this book?</p>

<p style="text-align: right;">Page 214</p> <p>1 A. I have no idea.</p> <p>2 Q. Okay. And again, it's talking about</p> <p>3 "Purification of Laboratory Chemicals." If you're</p> <p>4 purchasing -- like if you're using DMF that you</p> <p>5 purchased, and if you took steps to -- or your</p> <p>6 quality steps ensure that it didn't contain</p> <p>7 dimethylene -- dimethylamine, would there be any</p> <p>8 reason for you to consult this purification of DMF --</p> <p>9 consult this purification manual to determine how to</p> <p>10 purify DMF?</p> <p>11 Let me -- and that was a bad question,</p> <p>12 Dr. Hecht, I'm sorry.</p> <p>13 I want you to assume the following. I</p> <p>14 want you to assume that a manufacturer uses DMF</p> <p>15 that's purchased, and that it's purchased pursuant to</p> <p>16 specifications to ensure its purity. If that were</p> <p>17 the case, would there be a reason for somebody to</p> <p>18 look up how to purify, or the purification of DMF, in</p> <p>19 this particular book that we're looking at here?</p> <p>20 MR. SLATER: Objection.</p> <p>21 You can answer.</p> <p>22 A. No, I mean, you know, if the -- if the</p> <p>23 standards were given by the person selling it -- by</p> <p>24 the company selling it, you know, and dimethylamine</p> <p>25 was one of those standards, I don't think there would</p>	<p style="text-align: right;">Page 216</p> <p>1 screen?</p> <p>2 A. Yes.</p> <p>3 Q. Okay. Thank you. And it says -- what</p> <p>4 are the various abbreviations up front, the M, the B,</p> <p>5 the 153 degrees, what does that all mean?</p> <p>6 A. The M is the molecular weight --</p> <p>7 (Court Reporter Clarification.)</p> <p>8 A. Molecular weight. B is the boiling</p> <p>9 point, at two different pressures. D is the density,</p> <p>10 and N25 is the refractive index, I believe.</p> <p>11 Q. When you say it's two different</p> <p>12 pressures, give me a little bit more understanding of</p> <p>13 what you mean by that, with respect to the boiling</p> <p>14 point?</p> <p>15 A. Well, boiling point is a function of</p> <p>16 pressure. So, you know, if you go on a camping trip</p> <p>17 and you go up to the top of a mountain and boil your</p> <p>18 water, you'll find that it's not a hundred degrees;</p> <p>19 it's less. So as the pressure goes down, so does the</p> <p>20 boiling point.</p> <p>21 Q. And what does the 153 degrees represent</p> <p>22 there, with respect to pressure?</p> <p>23 A. So 153 is the boiling point at</p> <p>24 atmospheric pressure, 760 millimeters.</p> <p>25 Q. And then what's the 76 degrees; what</p>
<p style="text-align: right;">Page 215</p> <p>1 be a reason to necessarily look into it.</p> <p>2 But -- you know, again, I would</p> <p>3 certainly -- well, if I were using the process that</p> <p>4 they were using, I would have checked to make sure</p> <p>5 there's no dimethylamine; either in the DMF to begin</p> <p>6 with, or that's not formed during the process.</p> <p>7 Q. What would you have checked --</p> <p>8 A. That's my bottom line.</p> <p>9 Q. Understood. What would you have</p> <p>10 checked?</p> <p>11 MR. SLATER: Objection.</p> <p>12 You can answer.</p> <p>13 A. I would check the DMF for dimethylamine.</p> <p>14 That's easy to do by GC-MS.</p> <p>15 Q. Okay.</p> <p>16 A. Or I would also look into the formation</p> <p>17 of dimethylamine, under the conditions that I was</p> <p>18 doing the synthesis.</p> <p>19 Q. Thank you.</p> <p>20 MR. BERNARDO: Let's turn to page, is it</p> <p>21 192, yes. Can you make that a little bit bigger?</p> <p>22 That's good.</p> <p>23 Q. And this is the paragraph of this book</p> <p>24 that we've been looking at that's relevant to your</p> <p>25 testimony. Is that fair, the one that's on the</p>	<p style="text-align: right;">Page 217</p> <p>1 pressure is that?</p> <p>2 A. 39 millimeters of mercury.</p> <p>3 Q. And what would have been the conditions</p> <p>4 and pressure at the step in the valsartan</p> <p>5 manufacturing process where you say that DMF could</p> <p>6 have degraded?</p> <p>7 A. That would be the 153.</p> <p>8 Q. Okay. So --</p> <p>9 A. I mean, the pressure would be the 760.</p> <p>10 Q. Thank you. I understood what you meant,</p> <p>11 but thank you for that clarification.</p> <p>12 So it says here that -- can I just refer</p> <p>13 to it as "DMF"?</p> <p>14 "DMF decomposes slightly at its normally</p> <p>15 boiling point" -- and that, we just discussed, was</p> <p>16 153 degrees celsius. Correct? You're nodding, but</p> <p>17 please --</p> <p>18 A. Yes.</p> <p>19 Q. Thank you.</p> <p>20 "To give small amounts of dimethylamine</p> <p>21 and carbon monoxide."</p> <p>22 But I thought we just talked about the</p> <p>23 temperature when heated in the valsartan</p> <p>24 manufacturing process was [REDACTED] degrees celsius.</p> <p>25 Correct?</p>

Page 218

1 A. For [REDACTED] hours.
2 Q. Understood.
3 A. For [REDACTED] hours.
4 Q. Understood. Let me ask my question,
5 then. I just want to make -- we agree that for --
6 put aside the time; we'll talk about that in a
7 minute. It was not for [REDACTED] hours maintained at a
8 boiling point, or even reaching a boiling point; it
9 was many degrees lower than a boiling point. Is that
10 fair?
11 MR. SLATER: Objection.
12 You can answer.
13 A. [REDACTED] degrees lower.
14 Q. [REDACTED] degrees celsius lower?
15 A. Correct.
16 Q. Which is about -- I'm really bad at
17 this, about [REDACTED] degrees Fahrenheit lower?
18 A. That's about right, yep.
19 Q. Okay. So sort of the difference
20 between, you know, [REDACTED] degrees and [REDACTED] degrees
21 Fahrenheit, just for a reference point. Is that
22 right?
23 A. Yep.
24 Q. Okay. Does it say anyplace in here that
25 the duration of time at a lower boiling point could

Page 219

1 increase the risk of degradation to form
2 dimethylamine?
3 A. No, it doesn't go into that, but I can
4 tell you from experience that it -- you're going to
5 get some dimethylamine, if you heat DMF at [REDACTED]
6 degrees for [REDACTED] hours. You're going to get some
7 dimethylamine.
8 Q. And you say from -- I think you said
9 from experience. Tell me what experience you have at
10 heating dimethylamine at [REDACTED] degrees celsius for
11 [REDACTED] hours, or some --
12 A. You mean heating dimethylformamide.
13 Q. Sorry. Heating DMF. Sorry. Let me --
14 A. No, I don't have specific experience
15 with dimethylformamide that I can recall, but I have
16 lots of experience with organic chemistry and organic
17 synthesis. And, you know, just because the -- this
18 difference between 153 versus [REDACTED] degrees, especially
19 given the timeframe of [REDACTED] hours; I can guarantee you
20 that some dimethylamine is going to be formed. I'd
21 stand by it.
22 Q. I appreciate that you stand by it. And
23 I'm trying to just understand why you do, and how you
24 do. I'm not trying to challenge you, Dr. Hecht; I'm
25 just trying to understand.

Page 220

1 So your standing by that is not based
2 upon your experience of heating DMF to [REDACTED] degrees
3 for [REDACTED] hours -- [REDACTED] hours. Correct?
4 A. Not specifically with DMF, but it is
5 based on my experience with organic chemical
6 reactions. And I can guarantee you, a hundred
7 percent, that some dimethylamine will be formed if
8 you heat dimethylformamide for the length of time
9 they said in the thing -- I just blanked on. But
10 you're going to get some.
11 Q. Okay. But again --
12 A. Because that's how organic chemistry is.
13 Okay? It's not -- so I disagree with the other --
14 with the guy, Xue, on this. I mean, he goes into
15 that in his report, but I think he's wrong there. I
16 disagree with that.
17 Q. Understood.
18 A. Because he says specifically that no, we
19 didn't heat it to 153; we only heated it -- they only
20 heated it to [REDACTED].
21 When I read that, I thought to myself,
22 is he kidding? I mean, that's not enough of a
23 difference. Okay? You're going to get some
24 dimethylamine. And they proved that by finding
25 dimethylnitrosamine when they added nitrite.

Page 221

1 Q. What did they prove? Wasn't the
2 dimethylamine already formed when they added the
3 nitrite, in your opinion?
4 MR. SLATER: Objection,
5 mischaracterization.
6 You can answer.
7 A. I'm not sure what you're asking. But I
8 do know that when they added nitrite and they got
9 dimethylnitrosamine, which everybody agrees happened,
10 that that demonstrates that there was dimethylamine
11 in there. Because that's one way you identify
12 secondary amines: By making the nitrosamine.
13 Q. And I'm not questioning you as to what
14 did or didn't actually happen. What I'm questioning
15 you about is the knowledge that somebody might have.
16 And nothing in what we're looking at on
17 the screen here, which is the purifications book that
18 we've been talking about, says that if you heat it to
19 [REDACTED] centigrade for [REDACTED] hours, it will degrade. Is
20 that fair?
21 MR. SLATER: Objection.
22 You can answer again.
23 A. That's fair. But listen; this is a
24 professional outfit that is producing materials by
25 organic synthesis, okay? They know this. All right?

<p style="text-align: right;">Page 222</p> <p>1 What they didn't know, what they were non-aware of, 2 was that formation of nitrosamine under their 3 conditions would even be a problem. They never 4 thought about that. 5 Q. Dr. Hecht -- 6 A. That, that is where they fell down. 7 Q. The process -- 8 A. I mean, they're oblivious. 9 Q. The process that we've been talking 10 about of NDMA formation during the zinc chloride 11 process, I want to talk about that a little bit. 12 Would you agree that there are multiple 13 steps that have to occur in the NDMA formation 14 process following the formation of dimethylamine from 15 DMF? 16 A. Well, there's basically one step. I 17 don't know multiple steps. 18 So you have nitrite in there; you're at 19 pH 12. So what happens is that you form N2O3, and 20 N2O3 reacts with the amine to get the nitrosamine. 21 Q. Thank you. You saved me a lot of 22 questions. That's what I was really trying to get 23 at: Were the steps that was necessary for it to 24 form, and you just explained them. Thank you. 25 A. It's a simple reaction, okay? It's not</p>	<p style="text-align: right;">Page 224</p> <p>1 MR. BERNARDO: Yeah, we can -- I want to 2 discuss this -- 3 MR. SLATER: Let me finish. Let me 4 finish. It's a PDF with the index. Do you want to 5 put a sticker on them? I have no idea -- and then 6 what do you want to do, send them out to have 7 someone -- 8 MR. SCHOCH: Each binder is a separate 9 PDF. 10 MR. SLATER: Yes, each binder is a 11 separate PDF. We can send them to you; but if you 12 don't trust us and you want to have stickers put on 13 the binders, we can do that too. 14 MR. BERNARDO: This isn't a lack of 15 trust or not, and we can talk at a break as to how to 16 do it; I just want to have the inventory of what's in 17 there be part of the record, and we can discuss the 18 best logistical way to do that at a break. We don't 19 need to -- 20 MR. SLATER: I'm just offering you that 21 we have PDFs of every single binder that we can just 22 give to you, and then you can just mark them as 23 exhibits and attach them right now. 24 MR. BERNARDO: Perfect. I don't want to 25 go through that right now. We don't need to do that</p>
<p style="text-align: right;">Page 223</p> <p>1 complicated. It's one of the simplest reactions in 2 chemistry. That's why there's so much concern about 3 it, and that's why there's so much contamination of 4 various items. Because it's a very simple reaction, 5 not complicated. 6 Q. I'd like to, Dr. Hecht -- and we can 7 talk with you after the deposition to figure out the 8 best way to coordinate that, mark the binders that 9 you've got with you in your office? 10 MR. SLATER: You have them. Rich, you 11 have them. 12 Oh, didn't you send them all to him 13 already? Oh, we can -- I thought that they were 14 already sent to you. We can electronically send them 15 to you right now. 16 MR. BERNARDO: Sure. I just -- Adam, 17 and we can discuss this after the deposition, I 18 simply just want to have them be part of the record, 19 so we have like an understanding on the record of 20 exactly what they are. So I just want to mark -- 21 I'm going to reserve -- 22 MR. SLATER: Oh, so you don't want us to 23 send them to you electronically so you can actually 24 mark them? Because everything he was sent, we have 25 electronically --</p>	<p style="text-align: right;">Page 225</p> <p>1 right now. 2 And I'm just going to reserve -- and 3 we'll do it as one composite exhibit that we can just 4 call Exhibit 25, which are the binders that Dr. Hecht 5 has. 6 And I will accept Mr. Slater's 7 representation that the copy he provides will be the 8 copy -- or identical to the copy that Mr. -- that 9 Dr. Hecht has. 10 (Exhibit Hecht-25, Composite Exhibit, 11 Copies of Dr. Hecht's Exhibit Binders, was received 12 and marked for identification.) 13 BY MR. BERNARDO: 14 Q. I want to talk about another topic, 15 Dr. Hecht. And I want to go back to your report at 16 pages 7 to 8. 17 A. Which one? 18 Q. I'm sorry, the October -- the 19 October 31st, 2022, report, and I want you to turn to 20 page 7 to 8. 21 A. Okay. 22 Q. There we go. My colleague just 23 highlighted, and we'll take it off; I just want to 24 draw your attention to the section that I'm pointing 25 out, which is, "Of note, and perhaps not a</p>

<p style="text-align: right;">Page 226</p> <p>1 coincidence, the July 27, 2017, email written by</p> <p>2 Jinsheng Lin, Ph.D. confirming that there was NDMA in</p> <p>3 ZHP's valsartan API caused by the quenching with</p> <p>4 sodium nitrite was written during the same month."</p> <p>5 Do you see that?</p> <p>6 A. Yep.</p> <p>7 Q. Have you reviewed that email, Dr. Hecht?</p> <p>8 A. Pardon me?</p> <p>9 Q. Have you reviewed that email?</p> <p>10 A. Yes.</p> <p>11 Q. Okay. And I take it that was part of</p> <p>12 the materials that you were sent to review. Correct?</p> <p>13 A. Yes.</p> <p>14 Q. And the version that was sent to you was</p> <p>15 in English. Is that correct?</p> <p>16 A. No, it was in Chinese.</p> <p>17 Right.</p> <p>18 Q. I'm simply asking, Dr. Hecht --</p> <p>19 A. Okay. Yeah, it was in English.</p> <p>20 Q. Okay. I understand you know this and I</p> <p>21 know this, but we just need to make things clear on</p> <p>22 the record. That's why I'm asking you this.</p> <p>23 A. Okay.</p> <p>24 Q. And you know that the document was</p> <p>25 originally written in Chinese. Correct?</p>	<p style="text-align: right;">Page 228</p> <p>1 actually accurately translating what was said in</p> <p>2 Chinese?</p> <p>3 MR. SLATER: Objection.</p> <p>4 A. I have some Chinese colleagues in my</p> <p>5 lab. I could easily find out.</p> <p>6 Q. I'm not asking you if you could find</p> <p>7 out; I'm asking if you've done that?</p> <p>8 MR. SLATER: Objection.</p> <p>9 You can answer.</p> <p>10 A. I have not.</p> <p>11 Q. Okay. And we know already that you've</p> <p>12 read Dr. Xue's export report. Correct?</p> <p>13 A. Yes.</p> <p>14 Q. And in his report, he addresses this</p> <p>15 email. Do you recall that?</p> <p>16 A. Yes.</p> <p>17 Q. Okay. And, you know, I think, because</p> <p>18 he says it, that Dr. Xue is a native Chinese speaker.</p> <p>19 Correct?</p> <p>20 A. Yes.</p> <p>21 Q. And he obviously also speaks English.</p> <p>22 Correct?</p> <p>23 A. Yes.</p> <p>24 Q. And he's also a chemist. Correct?</p> <p>25 A. Right.</p>
<p style="text-align: right;">Page 227</p> <p>1 A. Yes.</p> <p>2 Q. Okay. And it was produced in the</p> <p>3 litigation also in Chinese, as it was maintained in</p> <p>4 the ordinary course of business. Is that correct?</p> <p>5 A. I guess so, yeah.</p> <p>6 Q. Okay. And I think we established that</p> <p>7 you don't speak or read Chinese. Correct?</p> <p>8 A. Correct.</p> <p>9 Q. And are you aware that there are</p> <p>10 different English translations of this e-mail?</p> <p>11 MR. SLATER: Objection.</p> <p>12 You can answer.</p> <p>13 A. No.</p> <p>14 Q. Okay. Do you know -- and you've read</p> <p>15 one translation. Correct?</p> <p>16 A. Yes.</p> <p>17 Q. Okay. And obviously, you would not</p> <p>18 understand the original Chinese if you read it.</p> <p>19 Fair?</p> <p>20 A. That's fair to say.</p> <p>21 Q. So you relied on the English translation</p> <p>22 that was provided to you. Fair?</p> <p>23 A. I did.</p> <p>24 Q. Okay. Do you agree that you, sitting</p> <p>25 here, have no way of knowing if that translation is</p>	<p style="text-align: right;">Page 229</p> <p>1 Q. So fair to say, he's probably in the</p> <p>2 best position to understand what is said in here,</p> <p>3 because he has both native Chinese speaking skills,</p> <p>4 and a deep understanding of chemistry?</p> <p>5 MR. SLATER: Objection. Compared to</p> <p>6 who?</p> <p>7 A. Yeah, I don't know about that.</p> <p>8 Q. A better understanding --</p> <p>9 A. First of all, I don't know -- I don't</p> <p>10 know anything about his Chinese skills, even though</p> <p>11 he says it's his native language. You know, there</p> <p>12 are different dialects and stuff. So I really don't</p> <p>13 know. I have no idea.</p> <p>14 Q. Okay. It's fair to say --</p> <p>15 A. His chemistry, I think, is probably</p> <p>16 pretty strong.</p> <p>17 Q. Okay. Fair to say that minor</p> <p>18 distinctions in wording, in science in particular,</p> <p>19 can result in different meanings?</p> <p>20 MR. SLATER: Objection.</p> <p>21 A. It's possible.</p> <p>22 Q. Okay. And do you have any reason, as</p> <p>23 you sit here today, to dispute his conclusion that</p> <p>24 when you read the document in its original Chinese,</p> <p>25 the email makes no reference to possible nitrosamine</p>

<p style="text-align: right;">Page 230</p> <p>1 formation, from the TEA process with quenching or the</p> <p>2 zinc chloride process, for valsartan API?</p> <p>3 MR. SLATER: Objection.</p> <p>4 A. Well, the email talks about nitrosamine</p> <p>5 formation.</p> <p>6 Q. I'm asking if you have any reason to</p> <p>7 challenge or dispute his conclusion that it makes no</p> <p>8 reference, when you read the original Chinese, to</p> <p>9 possible nitrosamine formation from the TEA process</p> <p>10 with quenching, or the zinc chloride process for</p> <p>11 valsartan?</p> <p>12 MR. SLATER: Objection.</p> <p>13 You can answer.</p> <p>14 A. I haven't tried to read it in Chinese,</p> <p>15 so I have no idea.</p> <p>16 Q. So that's -- you don't have, as you sit</p> <p>17 here today, a basis to dispute that. Is that fair?</p> <p>18 MR. SLATER: Objection.</p> <p>19 You can answer.</p> <p>20 A. What I have is an English translation.</p> <p>21 Okay? So, you know, the person who translated it</p> <p>22 maybe didn't translate it correctly, it's possible.</p> <p>23 But I have an English translation. I didn't look at</p> <p>24 the memo, the email in Chinese. Even if I had done</p> <p>25 that, I would have no idea what it said.</p>	<p style="text-align: right;">Page 232</p> <p>1 saying it's going to shut down. One second here.</p> <p>2 MR. SLATER: The time has come.</p> <p>3 MR. BERNARDO: What have you done to my</p> <p>4 computer, Adam?</p> <p>5 MR. SLATER: I released -- I have other</p> <p>6 people, though. I have people in there.</p> <p>7 Q. Sorry. Have you done anything to</p> <p>8 research the structural differences between</p> <p>9 irbesartan and valsartan API?</p> <p>10 A. I don't have to research it. It's</p> <p>11 obvious. I mean, if you look at the structure,</p> <p>12 they're different.</p> <p>13 Q. You say in your report at -- and again,</p> <p>14 I'm sorry, to be clear, your October 2022 report at</p> <p>15 page 2.</p> <p>16 MR. BERNARDO: If you want to pull that</p> <p>17 up.</p> <p>18 Q. That "ZHP acknowledged the possibility</p> <p>19 of cross-contamination of valsartan API on shared</p> <p>20 product production lines."</p> <p>21 Do you see that?</p> <p>22 MR. SLATER: Hey, I'm sorry, what page</p> <p>23 are you on, in which report? Last year's?</p> <p>24 MR. BERNARDO: Correct, Adam, yes.</p> <p>25 MR. SLATER: Which page, I'm sorry?</p>
<p style="text-align: right;">Page 231</p> <p>1 So I'm depending on what I have in my</p> <p>2 hand.</p> <p>3 Q. Do you know what --</p> <p>4 A. Which is an English translation.</p> <p>5 Q. I'm sorry to interrupt.</p> <p>6 A. That's pretty clear. Right?</p> <p>7 Q. Do you know what irbesartan is?</p> <p>8 A. Yes, it's another -- another sartan.</p> <p>9 Q. And have you studied irbesartan, as you</p> <p>10 have valsartan?</p> <p>11 A. Have I studied it? I don't know what</p> <p>12 you mean by that.</p> <p>13 Q. Have you -- have you investigated the</p> <p>14 potential or not of nitrosamine formation in</p> <p>15 irbesartan?</p> <p>16 MR. SLATER: Stop for a second.</p> <p>17 Are you asking if he's done anything --</p> <p>18 Well, you know what, you can just go</p> <p>19 ahead and answer the question. I don't care.</p> <p>20 A. Only in this email.</p> <p>21 Q. Okay. And is it fair to say, or do you</p> <p>22 not know, that irbesartan is a different drug</p> <p>23 molecule from the generic valsartan API?</p> <p>24 A. Yes, for sure, it's different.</p> <p>25 Q. Just a moment here, my computer is</p>	<p style="text-align: right;">Page 233</p> <p>1 MR. BERNARDO: On page 2, I believe.</p> <p>2 MR. SLATER: Page 2.</p> <p>3 MR. BERNARDO: We'll highlight the</p> <p>4 language for you.</p> <p>5 MR. SLATER: No, it's all right. I just</p> <p>6 wanted to make sure I was in the right place.</p> <p>7 BY MR. BERNARDO:</p> <p>8 Q. Do you see that, Dr. Hecht?</p> <p>9 A. Yep.</p> <p>10 Q. Okay. And you say that "ZHP</p> <p>11 acknowledged the likely occurrence of</p> <p>12 cross-contamination." Correct?</p> <p>13 A. Yes.</p> <p>14 Q. Have you investigated whether in fact</p> <p>15 any kind of cross-contamination occurred?</p> <p>16 MR. BERNARDO: Can you hold -- can we go</p> <p>17 off the record?</p> <p>18 THE VIDEOGRAPHER: Going off the record.</p> <p>19 The time is 2:04 p.m. Central Time.</p> <p>20 (A brief recess takes place.)</p> <p>21 THE VIDEOGRAPHER: We are back on the</p> <p>22 record. The time is 2:12 p.m. Central Time.</p> <p>23 BY MR. BERNARDO:</p> <p>24 Q. Dr. Hecht, we were talking about</p> <p>25 cross-contamination. I don't think we got very far,</p>

<p style="text-align: right;">Page 234</p> <p>1 but I think the only point I wanted to establish is,</p> <p>2 you say that ZHP acknowledged the -- and I think the</p> <p>3 words you used are "likely occurrence" of</p> <p>4 cross-contamination. Right?</p> <p>5 A. Yes.</p> <p>6 Q. Okay. Did you do anything to</p> <p>7 investigate whether cross-contamination did, in fact,</p> <p>8 occur?</p> <p>9 A. Well, it's in the documents. With</p> <p>10 the -- they go into a great deal of detail about the</p> <p>11 cross-contamination of the lines that were used in</p> <p>12 various processes, which is one way that the</p> <p>13 dimethylnitrosamine ended up in one of the products</p> <p>14 that also had diethylnitrosamine.</p> <p>15 In other words, from the -- I think</p> <p>16 there was cross-contamination between the TEA process</p> <p>17 and the later processes. I'm not exactly sure, but I</p> <p>18 know, from what I read, there was some</p> <p>19 cross-contamination in the lines. ZHP mentions that.</p> <p>20 And that was the source, I believe.</p> <p>21 Q. That was my --</p> <p>22 A. Of part of the dimethylnitrosamine that</p> <p>23 they found in the TEA process.</p> <p>24 Q. And I think you answered my question,</p> <p>25 but let me just make sure.</p>	<p style="text-align: right;">Page 236</p> <p>1 about something different. So what's going on here?</p> <p>2 Q. I switched -- I finished that topic and</p> <p>3 moved to this topic.</p> <p>4 A. Okay.</p> <p>5 Q. And then asked --</p> <p>6 A. You didn't ask anything about it.</p> <p>7 Q. Well, let me start over. I think we've</p> <p>8 completed the questions I wanted to ask you, and I</p> <p>9 think you've answered them. I can go back, but I</p> <p>10 don't see a need to, unless there's -- you disagree</p> <p>11 with any of the testimony you've given.</p> <p>12 Let me do it this way, so the record is</p> <p>13 clear.</p> <p>14 A. You're asking the questions, so that's</p> <p>15 fine. It just confused me --</p> <p>16 Q. Yeah, I'm sorry --</p> <p>17 A. That you jumped from one thing to</p> <p>18 another, without any notice.</p> <p>19 Q. Without a transition. Let me just</p> <p>20 summarize this, because I think the record is clear,</p> <p>21 but just to make sure.</p> <p>22 You talk about cross-contamination on</p> <p>23 this page of your report; that's in the first line.</p> <p>24 Correct?</p> <p>25 A. Yes.</p>
<p style="text-align: right;">Page 235</p> <p>1 The basis for your understanding of what</p> <p>2 did or didn't occur with respect to</p> <p>3 cross-contamination is the document you have cited</p> <p>4 there, the ZHP deviation investigation report. Is</p> <p>5 that correct?</p> <p>6 A. Which document are you talking about</p> <p>7 now?</p> <p>8 Q. The one that's cited that we'll</p> <p>9 highlight for you in a moment. Right there?</p> <p>10 A. Yeah.</p> <p>11 Q. Okay. And I just simply want to make</p> <p>12 sure that that's the totality of what you're relying</p> <p>13 on with respect to the contamination issue; that you</p> <p>14 did not do anything to investigate it, additional</p> <p>15 from that?</p> <p>16 MR. SLATER: Additional from reading the</p> <p>17 documents, is that what you're asking?</p> <p>18 MR. BERNARDO: That's exactly what I'm</p> <p>19 asking.</p> <p>20 A. I guess I'm a little confused. Because</p> <p>21 I mean, before your computer went down, we were</p> <p>22 talking about something different. We were talking</p> <p>23 about the irbesartan.</p> <p>24 Q. We were, and right before --</p> <p>25 A. Then all of a sudden, you're talking</p>	<p style="text-align: right;">Page 237</p> <p>1 Q. And then you cite to -- and you</p> <p>2 explained a little bit about what you think happened,</p> <p>3 with respect to cross-contamination. Right?</p> <p>4 A. Yeah.</p> <p>5 Q. And I simply wanted to confirm that the</p> <p>6 basis of your understanding is the document that you</p> <p>7 cite; that you didn't do anything on your own</p> <p>8 otherwise to investigate the cross-contamination.</p> <p>9 And I think you confirmed that, too?</p> <p>10 A. Right.</p> <p>11 Q. That's all I wanted to do.</p> <p>12 I'm going to switch topics, to give</p> <p>13 you -- we're done with cross-contamination.</p> <p>14 Prior to your involvement in this case,</p> <p>15 Dr. Hecht, had you ever done any research on</p> <p>16 impurities in pharmaceuticals in particular?</p> <p>17 A. No, not pharmaceuticals.</p> <p>18 Q. Okay. And in particular, I think this</p> <p>19 is consistent with what you just said, but just to be</p> <p>20 sure. So you've never researched the development of</p> <p>21 nitrosamines in pharmaceuticals, prior to your</p> <p>22 involvement in this case. Correct?</p> <p>23 A. Yes.</p> <p>24 Q. Fair to say, therefore, you've never</p> <p>25 taught on that subject; the subject being the</p>

<p style="text-align: right;">Page 238</p> <p>1 formation of -- let me start with impurities in 2 pharmaceuticals? 3 A. Not in pharmaceuticals. I mean -- 4 Q. Yeah, I'm purely asking about 5 pharmaceuticals? 6 A. We did do a study on dishwashing 7 liquids. And of course, we've done a lot on tobacco, 8 but we haven't done pharmaceuticals. 9 Q. And you've never performed any 10 evaluation of a manufacturer's compliance with CGMP 11 manufacturing practices with respect to 12 pharmaceuticals. Is that fair? 13 A. Yes, correct. 14 Q. And you've never conducted testing of 15 any kind for a pharmaceutical company of any of its 16 products. Is that correct? 17 A. Correct. 18 Q. And you've never conducted an assessment 19 of a pharmaceutical product. Correct? 20 A. What do you mean by "assessment"? 21 Q. Well, I was going to use risk 22 assessment, but you didn't like that phrase earlier? 23 A. No. 24 Q. You've never studied a pharmaceutical, 25 previously to this case, to determine what risks the</p>	<p style="text-align: right;">Page 240</p> <p>1 A. That would probably be about 20 years 2 ago. 3 Q. And in -- what about a class in organic 4 chemistry, how long ago was that? 5 A. No, I never taught -- oh, no, that's not 6 true. I taught organic chemistry at Haverford 7 College in 1969. 8 Q. And when was the last time that you 9 personally utilized gas chromatography? 10 A. Personally? 11 Q. Yes. 12 A. Probably in about 1994. 13 Q. And what about gas chromatography with 14 flame ionization detector? 15 A. Yes, the same. 16 Q. The same answer, okay. 1994? 17 A. Right. 18 Q. And what about gas chromatography with 19 mass spectrometry? 20 A. GC-MS? Personally, you mean I injected 21 the sample? 22 Q. Correct. 23 A. No, I worked with -- side by side with 24 somebody else who injected the sample? 25 Q. Correct?</p>
<p style="text-align: right;">Page 239</p> <p>1 pharmaceutical might present. Is that fair? 2 A. Correct. 3 Q. Okay. And you have no experience with 4 respect to pharmaceutical regulation and enforcement. 5 Fair? 6 A. Correct. 7 Q. And outside of litigation, you've never 8 reviewed any pharmaceutical regulatory filings. 9 Correct? 10 A. Correct. 11 Q. Okay. 12 MR. BERNARDO: And this is where the 13 word comes up, Adam. 14 Q. You're not an epidemiologist. Is that 15 fair? 16 A. I'm not what? 17 Q. An epidemiologist? 18 A. That's correct; I'm not an 19 epidemiologist. 20 Q. And therefore, you don't consider 21 yourself to be an expert in the field of 22 epidemiology. Correct? 23 A. That's correct. 24 Q. When was the last time you taught a 25 full-time university course, Dr. Hecht?</p>	<p style="text-align: right;">Page 241</p> <p>1 A. I injected the sample? 2 Q. Yes, that's what I'm asking. 3 A. Okay. 1995. 4 Q. And let's ask the question that you're 5 trying to qualify. Explain when was the last time 6 you did what you were describing, where maybe you 7 were standing next to somebody who was doing it? 8 A. Well, we're still doing it in the lab. 9 So, you know, we use GC-MS and LC-MS every day. We 10 have 15 instruments. 11 Q. New topic. This is going to be a 12 transition. I want to talk about your invoices. But 13 I can bring them up if you need to refer to them, or 14 we could talk generally. 15 Let me ask my question, and then you can 16 tell me whether we need to refer to them. 17 Looking at your most recent invoice that 18 was provided here, it appears that you last billed 19 time, other than one hour that was recently billed, 20 in July of 2021. Is that correct? 21 MR. SLATER: What he's asking is, what 22 you've invoiced us for. 23 A. Yeah, I guess that's correct. 24 Q. How much time since July of 2021 have 25 you devoted to work on this case, just roughly? And</p>

<p style="text-align: right;">Page 242</p> <p>1 July of 2021; I'm asking that, because that's the 2 date of your report? 3 A. I don't know. Maybe 30 hours or so? I 4 haven't added it all up yet. 5 Q. Okay. So you've just not billed that 6 time. Is that fair? 7 A. Yeah, that's right. 8 Q. Got it. Okay. And Dr. Hecht, I think 9 we talked about this before. You have a lot of 10 experience studying nitrosamines. I understand that; 11 that's fair? 12 A. Right. 13 Q. And you've published hundreds of 14 articles about nitrosamines. Correct? 15 A. Correct. 16 Q. And given presentations -- and I'm 17 talking generally, nitrosamines? 18 A. Yes. 19 Q. And many of them, if I recall, are 20 focused on NNN or NNK, tobacco-specific nitrosamines. 21 Is that correct? 22 A. Right. 23 Q. And you've taught university students 24 about nitrosamines generally. Correct? 25 A. Yes.</p>	<p style="text-align: right;">Page 244</p> <p>1 conference calls, and also at a symposium. So I 2 participated in all that, I don't remember the exact 3 details. But it was either 2020 or 2021. 4 Q. Okay. You were retained in 2019. 5 Correct? 6 A. Yes. 7 Q. So I was asking you whether you've done 8 any of this prior to your retention as an expert in 9 this litigation. 10 A. Done any of what? 11 Q. Sorry. The panel you're talking about, 12 you were answering my question -- 13 A. No, that was after. 14 Q. Okay. So the example you just gave was 15 after you were retained as an expert in litigation? 16 A. Yes, that's right. 17 Q. Okay. Thank you. Dr. Hecht, during 18 your last deposition, you were asked about whether or 19 not you disclosed your work for plaintiffs in this 20 case when you participated in that FDA panel. 21 I don't want to re-hash that; I just 22 want to ask if you recall that questioning? 23 A. Not really. 24 Q. Okay. Is it fair to say that you did 25 not disclose your work for plaintiffs, prior to</p>
<p style="text-align: right;">Page 243</p> <p>1 Q. Okay. Now, is it fair to say that 2 you've never published anything or taught anything 3 with respect to the formation of NDMA in a 4 pharmaceutical product? 5 A. I don't know about "never." But in 6 general, you know, it's not one of the main topics, 7 for sure. But I mean, there could have been an 8 example in -- I can't think of any offhand. So I'd 9 say yes, it's fair to say. 10 Q. Okay. And prior to this litigation, 11 fair to say you've never had any discussions with 12 regulators about how DMF can degrade and form 13 nitrosamines in a pharmaceutical product? 14 A. No, that's not true. Because I was on 15 the FDA panel that looked into this. So there's 16 plenty of discussion. 17 Q. And when was that? 18 A. 2021? 19 Q. I was asking prior to the litigation, 20 Dr. Hecht? 21 A. Yeah, prior to the litigation. So the 22 FDA panel was established or reenergized around the 23 time when all this was happening, so I forget the 24 exact date. It's either 2020 or 2021. So I mean, I 25 was on that panel. So I participated in a few</p>	<p style="text-align: right;">Page 245</p> <p>1 participating in that panel? 2 MR. SLATER: Objection. 3 You can answer. 4 A. You mean disclose to the FDA? 5 Q. Correct. As a potential conflict of 6 interest. 7 A. I really don't remember. 8 Q. Okay. Do you agree that it's important 9 to provide disclosure about whatever kind of work 10 you're doing in connection with papers or 11 publications or panels, so that the people listening 12 to you have an understanding of what role you have? 13 I mean, you have your education; but whether or not 14 you do work for plaintiffs or otherwise? Do you 15 think that's important? 16 A. Yes -- 17 MR. SLATER: Objection. 18 You can answer. 19 Q. I didn't hear your -- 20 A. Yes, it's important. 21 Q. Okay. And you've previously had issues 22 brought to your attention where you in fact did not 23 disclose your work for plaintiffs in litigation, 24 where you should have. Do you recall that? 25 MR. SLATER: Objection.</p>

<p style="text-align: right;">Page 246</p> <p>1 A. There might have been -- there might</p> <p>2 have been one or two.</p> <p>3 Q. Okay. And an example of one of them is</p> <p>4 a paper you wrote with respect to smokeless tobacco,</p> <p>5 with an author called Dr. Boffetta.</p> <p>6 Do you recall that?</p> <p>7 MR. SLATER: Objection.</p> <p>8 A. I remember the paper for sure.</p> <p>9 Q. But you don't remember whether or not</p> <p>10 you disclosed?</p> <p>11 MR. SLATER: Objection.</p> <p>12 A. Disclosed what?</p> <p>13 Q. The fact that you were a paid expert in</p> <p>14 smokeless tobacco litigation for plaintiffs?</p> <p>15 A. Oh, yeah, right.</p> <p>16 MR. SLATER: One second, Doctor.</p> <p>17 Objection to this whole line of</p> <p>18 questioning.</p> <p>19 You can answer.</p> <p>20 A. I was, yeah. I guess I -- maybe I</p> <p>21 didn't disclose it, I don't know. I don't know.</p> <p>22 Q. And you later --</p> <p>23 A. This was like -- this was 20 years ago.</p> <p>24 Q. Okay. And you later issued an errata,</p> <p>25 as a result of being asked to disclose your --</p>	<p style="text-align: right;">Page 248</p> <p>1 A. So I --</p> <p>2 MR. SLATER: Let him finish the answer,</p> <p>3 please.</p> <p>4 A. I did write to the journal and disclose</p> <p>5 that I was a witness in testimony about this subject.</p> <p>6 Q. What were the circumstances that caused</p> <p>7 you to do that, if you recall?</p> <p>8 A. Yeah, Slater reminded me.</p> <p>9 Q. Okay.</p> <p>10 MR. BERNARDO: Reserving time for</p> <p>11 redirect, and turning it -- oh, I'm sorry, one last</p> <p>12 question.</p> <p>13 Q. Dr. Hecht, we've gone through your two</p> <p>14 reports; a portion of your 2021 report and the</p> <p>15 entirety of your 2022 report, and talked about a lot</p> <p>16 of topics.</p> <p>17 I want to just ask you: Are there any</p> <p>18 points about which you expect to testify pertaining</p> <p>19 to the subjects we discussed that we haven't talked</p> <p>20 you about here today?</p> <p>21 MR. SLATER: Objection.</p> <p>22 You could answer.</p> <p>23 A. No. But -- no. Something else could</p> <p>24 come up, I mean....</p> <p>25 Q. But as you sit here today, there's</p>
<p style="text-align: right;">Page 247</p> <p>1 A. Yeah.</p> <p>2 Q. -- relationship.</p> <p>3 A. Right.</p> <p>4 Q. Okay.</p> <p>5 A. And I probably neglected to disclose it</p> <p>6 when we wrote the paper. I probably forgot about it.</p> <p>7 Q. Okay. You recently published a paper</p> <p>8 that talks about NDMA forming in valsartan, within</p> <p>9 the last year, I believe. Correct?</p> <p>10 A. Yep.</p> <p>11 Q. And it's entitled "Metabolic activation</p> <p>12 and DNA interactions with carcinogenic n-nitrosamines</p> <p>13 to which humans are commonly exposed"?</p> <p>14 A. Yep.</p> <p>15 Q. Okay. And do you agree that in that</p> <p>16 paper, you also did not disclose that you're a</p> <p>17 retained expert in litigation involving that very</p> <p>18 subject?</p> <p>19 MR. SLATER: Objection.</p> <p>20 You can answer the question.</p> <p>21 A. Yeah, actually I did write to the</p> <p>22 journal afterwards. I did forget to add it in the</p> <p>23 paper itself, but I did write to the journal</p> <p>24 afterwards. I can read you the email.</p> <p>25 Q. No. I appreciate --</p>	<p style="text-align: right;">Page 249</p> <p>1 nothing else that you can think of. Is that fair?</p> <p>2 MR. SLATER: Objection.</p> <p>3 You can answer.</p> <p>4 A. Right. I said that.</p> <p>5 MR. BERNARDO: I don't have any further</p> <p>6 questions at this time. I turn it over to my</p> <p>7 colleagues for other counsel. And as I mentioned a</p> <p>8 few minutes ago, obviously, I'm reserving the</p> <p>9 remainder of my time for any redirect, of course, to</p> <p>10 the extent Mr. Slater does direct.</p> <p>11 MR. SLATER: When you say the remainder</p> <p>12 of your time?</p> <p>13 MR. BERNARDO: The remainder of the</p> <p>14 seven hours that haven't been used, after the other</p> <p>15 folks ask their questions. I'm trying to make it</p> <p>16 clear: I may not be done. I have seven hours, and I</p> <p>17 may ask questions after you're asking them. I think</p> <p>18 that was pretty clear, but.</p> <p>19 All right. Do you want to take a break,</p> <p>20 Dr. Hecht, before somebody else comes, or should we</p> <p>21 let -- it looks like maybe Mr. Harkins will ask</p> <p>22 questions.</p> <p>23 THE WITNESS: Yeah, let's keep going.</p> <p>24 MR. HARKINS: Can we just take a quick</p> <p>25 five-minute break or do you want to keep going?</p>

<p style="text-align: right;">Page 250</p> <p>1 THE WITNESS: Let's take a break then.</p> <p>2 THE VIDEOGRAPHER: Going off the record.</p> <p>3 The time is 2:32 p.m. Central Time. This is the end</p> <p>4 of Media Unit 5.</p> <p>5 (A brief recess takes place.)</p> <p>6 THE VIDEOGRAPHER: We're back on the</p> <p>7 record. The time is 2:41 p.m. Central Time. This is</p> <p>8 the beginning of Media Unit 6.</p> <p>9 EXAMINATION BY MR. HARKINS:</p> <p>10 Q. Good afternoon, Dr. Hecht.</p> <p>11 A. Good afternoon.</p> <p>12 Q. My name is Steven Harkins with the law</p> <p>13 firm of Greenberg Traurig, and I represent the Teva</p> <p>14 defendants.</p> <p>15 You're familiar with the Teva defendants</p> <p>16 and their role as a finished-dose manufacturer in</p> <p>17 this case. Right?</p> <p>18 A. Yes.</p> <p>19 Q. The main thrust of my questioning is</p> <p>20 going to be find out, in your supplemental report and</p> <p>21 in the one section of your report submitted in 2021,</p> <p>22 if you have any criticisms or opinions about the</p> <p>23 finished-dose manufacturers.</p> <p>24 And when I say "finished-dose</p> <p>25 manufacturers," unless otherwise indicated, I'm</p>	<p style="text-align: right;">Page 252</p> <p>1 to -- well, I don't know. I mean, someone along the</p> <p>2 line has to figure out that, you know, this process</p> <p>3 that was being used was not correct. And, you know,</p> <p>4 that it presents the potential problem of nitrosamine</p> <p>5 contamination.</p> <p>6 Q. And we'll go through this; I'll give you</p> <p>7 more opportunities to talk about specific sections of</p> <p>8 that report. But I just want to generally, you know,</p> <p>9 see if you agree that the main thrust of your report,</p> <p>10 your supplemental report, are criticisms of ZHP, and</p> <p>11 there are some areas that might apply to the</p> <p>12 finished-dose manufacturers?</p> <p>13 I just want to understand if that's</p> <p>14 fair?</p> <p>15 A. Right, that's correct.</p> <p>16 Q. Then looking at the report that you</p> <p>17 submitted on July 6, 2021, I believe that's already</p> <p>18 been marked as Exhibit 1. Do you have that report</p> <p>19 with you as well?</p> <p>20 A. Yeah.</p> <p>21 Q. There is a section that starts on</p> <p>22 page 25 of your report, under the Heading 6, and it's</p> <p>23 titled "Nitrosamines in the Teva Finished Dose</p> <p>24 Formulation"?</p> <p>25 A. Yes.</p>
<p style="text-align: right;">Page 251</p> <p>1 referring to both Teva and Torrent, who were the two</p> <p>2 finished-dose manufacturers involved here. Okay?</p> <p>3 A. Okay.</p> <p>4 Q. Is that a yes?</p> <p>5 A. Yes.</p> <p>6 Q. Can you hear me okay?</p> <p>7 A. Yes.</p> <p>8 Q. All right. Generally speaking, you</p> <p>9 understand that this upcoming trial involves the ZHP</p> <p>10 API that was used by both Teva and Torrent in their</p> <p>11 finished-dose valsartan drug product. Right?</p> <p>12 A. Yes.</p> <p>13 Q. And looking at your supplemental report</p> <p>14 that was submitted back in October of 2022. Do you</p> <p>15 have a copy of that, or would it be helpful for me to</p> <p>16 share that?</p> <p>17 A. Yes.</p> <p>18 Q. In this report, are you intending to</p> <p>19 offer any opinions with regard to the finished-dose</p> <p>20 manufacturers?</p> <p>21 MR. SLATER: Objection.</p> <p>22 You can answer.</p> <p>23 A. No. I mean, they received the material</p> <p>24 from ZHP. ZHP created the faulty material. And I</p> <p>25 guess it's -- you know, it's their responsibility</p>	<p style="text-align: right;">Page 253</p> <p>1 Q. And I just want to make sure that we</p> <p>2 understand if there's anything in this report that we</p> <p>3 need to address, I want you to take a moment and look</p> <p>4 at the first paragraph of this section, and read</p> <p>5 through it quickly. And -- or I'm sorry; read</p> <p>6 through it at your own pace, and let me know when</p> <p>7 you're finished.</p> <p>8 (Brief pause in proceedings.)</p> <p>9 A. Yeah.</p> <p>10 Q. Am I correct that this paragraph</p> <p>11 describes the product that is manufactured by API</p> <p>12 received from ZHP and Mylan by Teva. Correct?</p> <p>13 A. Right.</p> <p>14 Q. It's a factual paragraph?</p> <p>15 A. Yes.</p> <p>16 Q. It wasn't intended to be an opinion or</p> <p>17 criticism of Teva's conduct. Right?</p> <p>18 A. Correct.</p> <p>19 Q. The next paragraph, I believe, indicates</p> <p>20 levels of NDMA identified by Teva in their valsartan</p> <p>21 product, testing on the ZHP product. Go ahead and</p> <p>22 take a look at it, and just -- my question is: Is</p> <p>23 this just another factual paragraph describing that</p> <p>24 topic?</p> <p>25 A. Yes.</p>

<p style="text-align: right;">Page 254</p> <p>1 Q. This paragraph doesn't contain any</p> <p>2 opinions or criticisms of Teva's conduct. Right?</p> <p>3 A. Right.</p> <p>4 Q. And the final paragraph, again, just</p> <p>5 to -- I'm sorry, the third paragraph, again, just to</p> <p>6 go through, is discussing the NDEA testing levels in</p> <p>7 the Mylan product, and is similarly just a factual</p> <p>8 paragraph. Right?</p> <p>9 A. Right.</p> <p>10 Q. It doesn't contain any opinions or</p> <p>11 criticisms with respect to Teva?</p> <p>12 A. Right.</p> <p>13 Q. Then the final paragraph says, "These</p> <p>14 contamination levels caused an unreasonably dangerous</p> <p>15 and unacceptable risk of causing or substantially</p> <p>16 contributing to the causation of cancer for those</p> <p>17 ingesting the valsartan sold by Teva."</p> <p>18 A, did I read that correctly?</p> <p>19 A. Yes.</p> <p>20 Q. And B, that was part of your general</p> <p>21 causation opinion that you previously provided.</p> <p>22 Correct?</p> <p>23 A. Right.</p> <p>24 Q. So Dr. Hecht, turning back to the report</p> <p>25 that you submitted in October of this case, and</p>	<p style="text-align: right;">Page 256</p> <p>1 A. Yep.</p> <p>2 Q. And the statement that you're making</p> <p>3 with regard to Teva and Torrent here is just to</p> <p>4 report the levels of impurities that were found in</p> <p>5 their finished dose product. Correct?</p> <p>6 A. Right.</p> <p>7 Q. And similar to the question I was asking</p> <p>8 with the other report, this paragraph is not intended</p> <p>9 to contain any opinions or criticisms of the</p> <p>10 finished-dose manufacturers; it's factual?</p> <p>11 A. It's just facts.</p> <p>12 Q. Right. Dr. Hecht, to make sure that we</p> <p>13 cover anything that may fall into that gray area</p> <p>14 where you were talking about obligations the</p> <p>15 finished-dose manufacturers might have, can you turn</p> <p>16 back to your first report, the July 6 -- 2021,</p> <p>17 apologies, report, and go to page 18?</p> <p>18 A. Okay.</p> <p>19 Q. And this is a statement that you</p> <p>20 discussed already, and I just want to clarify a few</p> <p>21 things about it from the finished-dose manufacturers'</p> <p>22 perspective.</p> <p>23 At the end of that paragraph, you</p> <p>24 indicate "a qualified organic chemist in industry</p> <p>25 would be aware of this literature."</p>
<p style="text-align: right;">Page 255</p> <p>1 looking at the first paragraph?</p> <p>2 A. Yeah.</p> <p>3 Q. And I believe you said this generally,</p> <p>4 but I just want to be clear.</p> <p>5 In the first paragraph here, you state</p> <p>6 that the purpose of this report is to provide further</p> <p>7 discussion of your conclusions as what ZHP -- I'm</p> <p>8 sorry; to supplement your opinions with respect to</p> <p>9 ZHP. Is that correct?</p> <p>10 A. Yes.</p> <p>11 Q. And the second paragraph indicates a</p> <p>12 summary of your supplemental opinions and conclusions</p> <p>13 as what ZHP could or should have done?</p> <p>14 A. Yes.</p> <p>15 Q. You don't mention either of the</p> <p>16 finished-dose manufacturers, including Teva, anywhere</p> <p>17 in those two paragraphs. Right?</p> <p>18 A. Right.</p> <p>19 Q. And turning down through your report --</p> <p>20 and I'm happy to let you take more time to look. But</p> <p>21 I will say, the only place in your report, the</p> <p>22 supplemental report submitted in October, that I see</p> <p>23 a reference to Teva and Torrent in the body of the</p> <p>24 report is at the bottom of page 10; if you can turn</p> <p>25 to that.</p>	<p style="text-align: right;">Page 257</p> <p>1 A. Where is this now?</p> <p>2 Q. Sorry. The bottom of the first full</p> <p>3 paragraph, on page 18?</p> <p>4 A. Oh, okay. Oh. Yes.</p> <p>5 Q. And I'm not going to go back over it,</p> <p>6 but this is the statement that you were discussing</p> <p>7 with Mr. Bernardo, about the literature that you may</p> <p>8 have reviewed in connection with coming to this -- to</p> <p>9 forming this opinion. Right?</p> <p>10 A. Yes.</p> <p>11 Q. Does this opinion in your report apply</p> <p>12 equally to the organic chemists working for the</p> <p>13 finished-dose manufacturers, like Teva and Torrent?</p> <p>14 MR. SLATER: Objection.</p> <p>15 You can answer.</p> <p>16 A. Yeah, I would think that anybody doing</p> <p>17 organic chemistry should have at least a passing</p> <p>18 knowledge of what the hazards of various compounds</p> <p>19 are, yeah. And of their place in the overall</p> <p>20 firmament of organic compounds. And, you know,</p> <p>21 nitrosamines have a special place.</p> <p>22 Q. And I think I understand your testimony</p> <p>23 on this from earlier today, so I'm not going to go</p> <p>24 back over that. I just want to clarify a few things</p> <p>25 that I don't know if they were exactly clear on the</p>

<p style="text-align: right;">Page 258</p> <p>1 record, in a slightly narrower fashion.</p> <p>2 You discussed the world of literature,</p> <p>3 and sort of the body of scientific knowledge</p> <p>4 surrounding these issues. I just want to confirm:</p> <p>5 You are not aware of any literature, prior to June</p> <p>6 2018, that discussed the potential for nitrosamine</p> <p>7 impurities, specifically in valsartan API or</p> <p>8 valsartan drug products. Correct?</p> <p>9 MR. SLATER: Objection.</p> <p>10 You can answer.</p> <p>11 A. Published literature, or any --</p> <p>12 Q. Published literature?</p> <p>13 A. Published literature. That specifically</p> <p>14 related to valsartan?</p> <p>15 Q. Yes.</p> <p>16 A. Is that the question?</p> <p>17 Q. Yes.</p> <p>18 A. No, I don't think there was any, unless</p> <p>19 I'm forgetting something.</p> <p>20 Q. And in your review of material in this</p> <p>21 case, you haven't seen any document that indicates</p> <p>22 that Teva specifically was aware of the potential for</p> <p>23 nitrosamine formation in valsartan API or valsartan</p> <p>24 drug product, prior to June 2018. Correct?</p> <p>25 A. Prior to when?</p>	<p style="text-align: right;">Page 260</p> <p>1 included on the list of supplemental materials</p> <p>2 reviewed. Correct?</p> <p>3 A. Right.</p> <p>4 Q. And Dr. Hecht, turning now back to your</p> <p>5 July report, there is an exhibit that has a similar</p> <p>6 list of the materials that you reviewed. I believe</p> <p>7 it's Exhibit -- I believe it's Exhibit 2 to your</p> <p>8 July 7, 2021 report. If you could go ahead and take</p> <p>9 a look at that.</p> <p>10 A. Which exhibit is it?</p> <p>11 Q. It's Exhibit 2?</p> <p>12 A. All right.</p> <p>13 Q. And I believe it's unnumbered.</p> <p>14 A. Okay. "Documents Reviewed."</p> <p>15 Q. And there's a header --</p> <p>16 A. What's your question?</p> <p>17 Q. Sure. I just want to confirm: There's</p> <p>18 a header for ZHP documents again, and that goes on</p> <p>19 until the third page --</p> <p>20 A. Right.</p> <p>21 Q. -- of this exhibit. Then there are</p> <p>22 Hetero and Mylan documents?</p> <p>23 A. Right.</p> <p>24 Q. And then there's a list of 13 Teva</p> <p>25 documents. Do you see that?</p>
<p style="text-align: right;">Page 259</p> <p>1 Q. June of 2018?</p> <p>2 A. Correct.</p> <p>3 Q. And Dr. Hecht, one more thing as we're</p> <p>4 just kind of cleaning up stuff on your report, I just</p> <p>5 want to make sure that I'm clear.</p> <p>6 Looking at the supplemental report that</p> <p>7 you submitted, the October 31st, 2022, report, and</p> <p>8 specifically going to the list of supplemental</p> <p>9 materials reviewed that begins on Exhibit A. Let me</p> <p>10 know when you're there.</p> <p>11 A. Yeah.</p> <p>12 Q. So the first page of this is all under a</p> <p>13 heading that includes ZHP documents. Correct?</p> <p>14 A. Yes.</p> <p>15 Q. And then on the second page, there are a</p> <p>16 handful of Torrent documents as well. Correct?</p> <p>17 A. Yes.</p> <p>18 Q. And then there are four deposition</p> <p>19 transcripts here.</p> <p>20 A. Yeah?</p> <p>21 Q. And I believe all four of those</p> <p>22 deposition transcripts are ZHP witnesses. Is that</p> <p>23 correct?</p> <p>24 A. I think so, yeah.</p> <p>25 Q. There are no additional Teva documents</p>	<p style="text-align: right;">Page 261</p> <p>1 A. Right.</p> <p>2 Q. And just so I'm clear: In forming your</p> <p>3 opinions, both in your initial report and in your</p> <p>4 supplemental report, these are the only 13 Teva</p> <p>5 documents that you reviewed?</p> <p>6 A. Correct.</p> <p>7 Q. All right. Dr. Hecht, if you could turn</p> <p>8 back to the body of your July 6, 2021, report. Oh, I</p> <p>9 apologize. The supplemental report.</p> <p>10 MR. SLATER: What did you say? I lost</p> <p>11 it, I missed it?</p> <p>12 MR. HARKINS: I identified the wrong</p> <p>13 report. The next question is about the supplemental</p> <p>14 October report.</p> <p>15 A. Okay.</p> <p>16 Q. Strike that again. I'm getting my</p> <p>17 reports mixed up.</p> <p>18 I apologize, Dr. Hecht. This question</p> <p>19 is about the July report, and specifically on page 23</p> <p>20 of that report.</p> <p>21 A. Okay.</p> <p>22 Q. So at the top of that, there's a</p> <p>23 paragraph that starts in the middle, and beginning in</p> <p>24 the second line, you have a sentence after a comma,</p> <p>25 I'm happy to read the beginning of it. It says,</p>

<p style="text-align: right;">Page 262</p> <p>1 "Thereafter, when aberrant peaks demonstrated 2 unaccounted-for impurities, the nitrosamine 3 contamination could have been easily discovered, 4 based on knowledge of the potential chemical 5 reactions and application of GC-MS to identify 6 potential NDMA/NDEA." 7 Did I read that correctly? 8 A. Yes. 9 Q. And then it says, "This was identified 10 by Novartis, even without the full information 11 available to ZHP." 12 Did I read that correctly as well? 13 A. Yes. 14 Q. At the end of that statement, you say, 15 "the full information available to ZHP." 16 What do you mean by that? 17 A. Well, it took -- according to my 18 understanding, ZHP never thought of the possibility 19 that dimethylnitrosamine could form in this process. 20 Of if they had thought of it, they never mentioned 21 it. But Novartis, the guy at Novartis, figured it 22 out by, you know, taking into consideration the 23 process. 24 So, you know, he's the one, according to 25 my understanding, he's the one that figured out</p>	<p style="text-align: right;">Page 264</p> <p>1 A. Well, I can imagine what it -- what it 2 would be, but I don't have a -- I mean, when you say 3 do I have an understanding; sure, I have an 4 understanding if it -- you know, if somebody would 5 show it to me and discuss it with me. I mean, it's 6 not something that's forefront in my mind. 7 Q. You don't have an opinion generally 8 about what types of information a finished-dose 9 manufacturer has access to, in submitting an ANDA 10 that refers to a DMF. Right? 11 A. You're saying I don't have an opinion? 12 Q. I guess before I get to this specific 13 question, I was hoping to ask a more general one. 14 The specific question is going to be: 15 Have you reviewed documents to determine what 16 information on the ZHP process was available to the 17 finished-dose manufacturers, when they submitted 18 their ANDAs for the valsartan product prior to 2018? 19 A. No, I haven't. 20 Q. And then the more general question is: 21 Do you generally have an opinion or knowledge of what 22 types of information is available to a finished-dose 23 manufacturer, in that type of situation? 24 A. No. 25 Q. So I understand, and correct me if I'm</p>
<p style="text-align: right;">Page 263</p> <p>1 dimethylamine could have been formed from DMF, and, 2 you know, once he saw that, then obviously the light 3 bulb went off. 4 Q. Doctor, are you familiar with the FDA's 5 review process for approving DMFs and ANDA 6 applications? 7 A. Not very. 8 Q. So would you say you have an 9 understanding of what information in the Drug Master 10 File is or is not available to a finished-dose 11 manufacturer when they submit an ANDA? 12 A. It's not my area. 13 Q. And you haven't reviewed Teva's ANDAs 14 that were submitted in this case? 15 A. Pardon? 16 Q. Sorry. You have not reviewed the ANDA 17 files submitted by the finished-dose manufacturers, 18 Teva and Torrent, in this case, have you? 19 A. No. 20 Q. Do you have any understanding -- I 21 believe you may have already answered this, but just 22 to be clear -- do you have any opinion or 23 understanding as to what a finished-dose manufacturer 24 like Teva does or does not have access to, in the ZHP 25 DMF when they submit those ANDAs?</p>	<p style="text-align: right;">Page 265</p> <p>1 mischaracterizing, that it's your opinion ZHP should 2 have recognized the potential for nitrosamine 3 formation in the API, based on the information that 4 was available to ZHP. Correct? 5 A. Yes. 6 Q. But you have not undertaken to analyze 7 whether the finished-dose manufacturers, including 8 Teva, should have recognized the potential for 9 nitrosamine formation, based on the information that 10 was available to them about ZHP's process at the time 11 they submitted their ANDAs? 12 A. No, I haven't looked at that. 13 Q. I believe you testified earlier that -- 14 though I understand you think differently about what 15 ZHP should have done -- you testified that if ZHP had 16 no reason to think nitrosamines could form, there 17 would be no reason for ZHP to test for nitrosamines. 18 Is that accurate? 19 MR. SLATER: Objection. 20 You can answer. 21 A. Could you repeat that? 22 Q. Sure. I believe you testified earlier 23 today that, assuming ZHP had no reason to think 24 nitrosamines could form, there would not be a reason 25 for them to test for nitrosamines in their valsartan</p>

<p style="text-align: right;">Page 266</p> <p>1 drug product?</p> <p>2 MR. SLATER: Objection.</p> <p>3 You can answer.</p> <p>4 A. That question doesn't make sense to me.</p> <p>5 I mean, I don't see how they could assume that.</p> <p>6 Q. Sure?</p> <p>7 A. Considering in the process they used. I</p> <p>8 mean, that's the whole basis of my testimony. I</p> <p>9 don't see how they could possibly assume that.</p> <p>10 Q. And I understand that, Dr. Hecht. And I</p> <p>11 believe the exact way the question was phrased to you</p> <p>12 is: Understanding that you think they should have</p> <p>13 had a reason to think nitrosamines could form, asking</p> <p>14 for purposes of the question that to -- I'm sorry.</p> <p>15 You were asked, for purposes of the</p> <p>16 question, to assume that they had no reason to think</p> <p>17 that they would form. I'm just confirming that your</p> <p>18 testimony from today was: If, assuming ZHP had no</p> <p>19 reason to think nitrosamines could form, there would</p> <p>20 be no reason for them to test for nitrosamines?</p> <p>21 MR. SLATER: Objection.</p> <p>22 You can answer.</p> <p>23 A. I guess so, but I'm really not sure.</p> <p>24 Because -- you know, I have trouble with the first --</p> <p>25 your assumption, your presumed assumption, I have</p>	<p style="text-align: right;">Page 268</p> <p>1 API. So really, that's a little surprising to me</p> <p>2 that only Novartis could think of this. I don't</p> <p>3 really know what's wrong with the other ones.</p> <p>4 Q. Apologies; I just want to make sure</p> <p>5 you're finished?</p> <p>6 A. I'm finished.</p> <p>7 Q. I just want to clarify the last</p> <p>8 response, just so I'm sure.</p> <p>9 You just stated that you assume they</p> <p>10 have some information about the API process, but I</p> <p>11 believe you just testified that you have not reviewed</p> <p>12 documents to form an opinion about what information</p> <p>13 from ZHP's DMF on the process was available to the</p> <p>14 finished-dose manufacturers. Correct?</p> <p>15 A. Yeah, that's true, I -- I don't know</p> <p>16 what was available. Yeah, it's just an assumption on</p> <p>17 my part.</p> <p>18 Q. Dr. Hecht, turning to just another one</p> <p>19 of these statements I want to make sure we don't</p> <p>20 miss. On your initial July report, on page 11 --</p> <p>21 MR. SLATER: The 2022 report, you said?</p> <p>22 MR. HARKINS: Yes.</p> <p>23 MR. SLATER: Okay.</p> <p>24 A. Yep.</p> <p>25 Q. So I've got -- I must have mixed these</p>
<p style="text-align: right;">Page 267</p> <p>1 real trouble with that. I have trouble getting my</p> <p>2 mind around the fact that they could possibly have</p> <p>3 not thought of this, even though they didn't.</p> <p>4 So you're asking me to assume that they</p> <p>5 didn't think of it. So I guess, yeah, if they didn't</p> <p>6 think of it, you know, then -- you know, the second</p> <p>7 part would make sense. But I can't see how they</p> <p>8 couldn't think of that. Does that make sense?</p> <p>9 Q. Yes, Doctor. And I understand your</p> <p>10 concern, and that you disagree with the premise that</p> <p>11 I'm asking you to assume for the question. I totally</p> <p>12 understand that.</p> <p>13 My next question is: Would that same</p> <p>14 logic hold true for the finished-dose manufacturers?</p> <p>15 If the finished-dose manufacturers had no reason to</p> <p>16 think that nitrosamines could form in the valsartan</p> <p>17 drug substance, there would be no reason for the</p> <p>18 finished-dose manufacturers to test for nitrosamines?</p> <p>19 MR. SLATER: Objection.</p> <p>20 You can answer.</p> <p>21 A. That's probably true. I mean, I think I</p> <p>22 have more sympathy with the finished-dose</p> <p>23 manufacturers than I do with the ZHP. But of course,</p> <p>24 the finished-dose manufacturers, I'm sure, are well</p> <p>25 aware of the procedures that are used to prepare the</p>	<p style="text-align: right;">Page 269</p> <p>1 two up. I apologize. The supplemental report on</p> <p>2 page 11?</p> <p>3 MR. SLATER: The October 2022 report,</p> <p>4 right?</p> <p>5 MR HARKINS: Yes.</p> <p>6 A. Okay.</p> <p>7 Q. This is into your Conclusions section</p> <p>8 here, Dr. Hecht, and I just want to understand the</p> <p>9 conclusion sentence here that starts with, "The</p> <p>10 available knowledge and technology should have been</p> <p>11 applied to add straightforward testing for NDMA and</p> <p>12 NDEA of each batch of API and finished dose</p> <p>13 manufactured using the API with these processes,</p> <p>14 which would have revealed the process of NDMA and</p> <p>15 NDEA."</p> <p>16 Did I read that correctly?</p> <p>17 A. Yes.</p> <p>18 MR. SLATER: Objection. I think you</p> <p>19 might have missed a couple of words.</p> <p>20 Q. Dr. Hecht, this statement includes the</p> <p>21 finished-dose manufacturer. Is this intended to be</p> <p>22 an opinion about testing that the finished-dose</p> <p>23 manufacturers should have also added to their</p> <p>24 manufacture of valsartan finished product?</p> <p>25 A. Yes.</p>

<p style="text-align: right;">Page 270</p> <p>1 Q. And my question, generally speaking, is:</p> <p>2 What guidances or standards do you feel should have</p> <p>3 caused the finished-dose manufacturers to add this</p> <p>4 type of testing to their product, to the extent that</p> <p>5 you reviewed it and considered it in forming that</p> <p>6 opinion?</p> <p>7 A. Well, the finished-dose manufacturer, I</p> <p>8 assume, is familiar with the process that was used to</p> <p>9 prepare the API. That's my assumption; that they</p> <p>10 certainly ought to be aware of that. And of course,</p> <p>11 they also do testing of the API before they put it</p> <p>12 into the finished dose.</p> <p>13 So again, I come back to Novartis. I</p> <p>14 mean, Novartis thought of this. So I don't see why</p> <p>15 somebody at Teva or one of these other companies that</p> <p>16 use the API couldn't think of it.</p> <p>17 Q. So -- and Doctor, I just want to make</p> <p>18 sure I understand the two areas you talked about</p> <p>19 there. One was their analysis of the process for the</p> <p>20 manufacturing of the API; and I believe the other one</p> <p>21 you said was their own testing, the finished-dose</p> <p>22 manufacturers' testing of the API that they're using.</p> <p>23 Are those the two areas? Did I get that right?</p> <p>24 MR. SLATER: Objection.</p> <p>25 You can answer.</p>	<p style="text-align: right;">Page 272</p> <p>1 MR. SLATER: Tell me what page again,</p> <p>2 Steve?</p> <p>3 MR HARKINS: 20.</p> <p>4 MR. SLATER: 20, thank you.</p> <p>5 A. Okay.</p> <p>6 Q. If I have this backwards again, I'm</p> <p>7 going to be...</p> <p>8 At the bottom of this page, I believe it</p> <p>9 is the third-to-last sentence, it says, "In their</p> <p>10 analyses of the product, they would not have</p> <p>11 identified NDMA in the chromatograms unless they were</p> <p>12 specifically looking for it, because the peaks were</p> <p>13 too small."</p> <p>14 Did I read that correctly?</p> <p>15 A. Right.</p> <p>16 Q. That's an opinion about ZHP. Correct?</p> <p>17 A. Yes.</p> <p>18 Q. And from your testimony earlier today,</p> <p>19 you agree that, in order to find NDMA in valsartan</p> <p>20 testing, you need to be looking for it.</p> <p>21 A. Right.</p> <p>22 Q. And you testified that ZHP would not</p> <p>23 have identified NDMA through routine chromatography</p> <p>24 testing of the API?</p> <p>25 A. Most likely.</p>
<p style="text-align: right;">Page 271</p> <p>1 A. Well, yeah. Both.</p> <p>2 Q. So turning to the first one that you</p> <p>3 discussed, the analysis by the finished-dose</p> <p>4 manufacturers of the API process. I believe we've</p> <p>5 already set out and established that you did not</p> <p>6 undertake to review what, if anything, about that</p> <p>7 process was known to the finished-dose manufacturers.</p> <p>8 Correct?</p> <p>9 A. Could you repeat that?</p> <p>10 Q. It's the same question we were going</p> <p>11 over. You did not review what information was</p> <p>12 available to the finished-dose manufacturers when</p> <p>13 they were evaluating ZHP's process. Correct?</p> <p>14 A. Right. No, I didn't review that.</p> <p>15 Q. And you don't have opinions on what is</p> <p>16 generally available, as part of that review process,</p> <p>17 to a finished-dose manufacturer. Correct?</p> <p>18 A. I don't know much about it. But, you</p> <p>19 know, it's my assumption that the basic methodology</p> <p>20 to prepare the API would be made clear to the</p> <p>21 finished-dose manufacturer. That's my assumption.</p> <p>22 Q. Turning to the second area that you</p> <p>23 talked about, their testing of the API, I'd like to</p> <p>24 refer you to page 20 of your initial report, the July</p> <p>25 report.</p>	<p style="text-align: right;">Page 273</p> <p>1 Q. And I apologize; I want to make sure.</p> <p>2 Were there peaks, or would there be peaks, in routine</p> <p>3 chromatography testing of the API that would be large</p> <p>4 enough for ZHP to have identified it?</p> <p>5 A. There were small peaks. But they didn't</p> <p>6 further investigate the small peaks.</p> <p>7 Q. Were the peaks large enough that they</p> <p>8 would have been noticeable, and allowed detection of</p> <p>9 NDMA on routine chromatography testing?</p> <p>10 A. Probably not. Again, you know, with a</p> <p>11 peak that size, you have to develop a method to look</p> <p>12 for it specifically. You know, like a routine GC-MS</p> <p>13 analysis or LC-MS analysis, you know, it would just</p> <p>14 appear as a small peak.</p> <p>15 So, you know, unless you were -- unless</p> <p>16 you had some knowledge, like the guy at Novartis, to</p> <p>17 look for it specifically, then you wouldn't -- you</p> <p>18 probably -- you might not even notice it. So no, you</p> <p>19 would focus on the larger peaks, which were all like</p> <p>20 solvent residues and stuff.</p> <p>21 Q. My question is just that the same holds</p> <p>22 true for the finished-dose manufacturers: They would</p> <p>23 not have identified NDMA in the chromatograms of API</p> <p>24 unless they were specifically looking for it, because</p> <p>25 the peaks would be too small?</p>

<p style="text-align: right;">Page 274</p> <p>1 A. Probably. But Novartis did. So.</p> <p>2 Q. And as far as testing -- apologies, were</p> <p>3 you finished?</p> <p>4 A. Yep.</p> <p>5 Q. And as far as testing of the</p> <p>6 finished-dose product itself; again, the</p> <p>7 finished-dose manufacturers looking at chromatograms</p> <p>8 on the finished-dose product would not have</p> <p>9 identified NDMA unless they were specifically looking</p> <p>10 for it. Correct?</p> <p>11 A. Probably.</p> <p>12 Q. And I just want to make sure I'm getting</p> <p>13 the terminology right.</p> <p>14 When you say, "identified NDMA in the</p> <p>15 chromatograms," are you talking about analysis of the</p> <p>16 raw data and imaging that results from</p> <p>17 chromatography?</p> <p>18 A. I don't know about imaging. But I mean,</p> <p>19 you get a chromatogram, which is a series of peaks.</p> <p>20 Okay? And the NDMA peak, when it's detected by flame</p> <p>21 ionization detection in this circumstance, would be</p> <p>22 quite small. So since there were larger peaks in the</p> <p>23 same chromatogram, you know, you might ignore the</p> <p>24 small NDMA peak.</p> <p>25 Does that answer your question?</p>	<p style="text-align: right;">Page 276</p> <p>1 they might ignore it completely.</p> <p>2 Q. And I think I understand your opinion</p> <p>3 with regard to other ways that it could have been</p> <p>4 identified; I just want to be clear. Analysis of</p> <p>5 chromatography from the routine testing by the</p> <p>6 finished-dose manufacturers, just that piece, would</p> <p>7 not have identified NDMA, because the peak is too</p> <p>8 small?</p> <p>9 A. Well, no, that's not true. I mean, if</p> <p>10 they used GC -- if they had used GC-MS, for example,</p> <p>11 or LC-MS, rather than GC-FID, you know; or LC with UV</p> <p>12 detection; in other words, if they used a more</p> <p>13 specific method, like Novartis did, then they would</p> <p>14 have seen it clearly.</p> <p>15 Q. And Dr. Hecht, I just want to be clear.</p> <p>16 I'm not talking about other investigational methods,</p> <p>17 or other ways that they could have identified it.</p> <p>18 I'm just -- I'm just trying to clarify, because I</p> <p>19 think I used the wrong term.</p> <p>20 It's your opinion that use of the</p> <p>21 routine detection method from chromatography by the</p> <p>22 finished-dose manufacturers on the valsartan API in</p> <p>23 this case would not have identified NDMA, because the</p> <p>24 peaks generated by that testing would be too small?</p> <p>25 MR. SLATER: Objection.</p>
<p style="text-align: right;">Page 275</p> <p>1 Q. I think so, and I think I probably just</p> <p>2 said it inartfully.</p> <p>3 When you talk about what would be shown</p> <p>4 in the chromatograms, we're talking about the data,</p> <p>5 and then the graphical representation of the peaks?</p> <p>6 A. Yes. The graphic -- the chromatogram is</p> <p>7 a graphical representation of the peaks. You know,</p> <p>8 there's a baseline, and it goes up, and it comes down</p> <p>9 again, and it goes up again and comes down again.</p> <p>10 It's like a mountain range. Not exactly, but, you</p> <p>11 know, the peaks are -- that's why they're called</p> <p>12 "peaks."</p> <p>13 Q. And the review of that chromatography</p> <p>14 data in the graph by the finished-dose manufacturers</p> <p>15 would not have identified NDMA unless they were</p> <p>16 looking for it, because the peaks were too small?</p> <p>17 A. Well, I can't exclude the fact that it</p> <p>18 could have been identified. All right? I'm just</p> <p>19 saying that in the absence of other information, when</p> <p>20 they looked at the chromatogram, the NDMA peak is</p> <p>21 going to be quite small compared to the other peaks.</p> <p>22 So they would not have first noticed it. All right?</p> <p>23 They would -- they'd look at the big</p> <p>24 peaks first; I mean, anybody would do that. So there</p> <p>25 would be a small peak that was actually the NDMA, but</p>	<p style="text-align: right;">Page 277</p> <p>1 You can answer.</p> <p>2 A. Well, that depends on how you define</p> <p>3 "routine." So --</p> <p>4 Q. Doctor --</p> <p>5 A. If they used GC mass spec, and they</p> <p>6 monitored multiple different ion transitions in the</p> <p>7 same run, which is definitely possible, then they</p> <p>8 might have seen a larger peak for NDMA. But you</p> <p>9 know, if they used GC-FID, then the peak is going to</p> <p>10 be quite small, compared to like solvent residue</p> <p>11 peaks. So you know, it depends on how they did this,</p> <p>12 how they did the work.</p> <p>13 Q. And Dr. Hecht --</p> <p>14 (Court Reporter Clarification.)</p> <p>15 Q. And Doctor, I apologize if I've confused</p> <p>16 the question.</p> <p>17 You're aware that GC-FID was the</p> <p>18 detection method -- you're aware of the detection</p> <p>19 method that was approved in the ANDA specifications</p> <p>20 for performing chromatography on valsartan API in the</p> <p>21 relevant ANDAs, or are you not?</p> <p>22 A. No, I don't know what the approved</p> <p>23 method was. Was it GC-FID, or, I don't know. Or was</p> <p>24 it GC-MS?</p> <p>25 Q. I'll represent to you that it was not</p>

<p style="text-align: right;">Page 278</p> <p>1 GC-MS.</p> <p>2 Using the methods that you discussed</p> <p>3 previously with reference to the ZHP API that we were</p> <p>4 talking about, where you indicated that using that</p> <p>5 method of routine chromatography testing, ZHP would</p> <p>6 not have detected NDMA in their API on routine</p> <p>7 chromatography testing; I'm asking you to assume the</p> <p>8 same method of routine chromatography testing for the</p> <p>9 finished-dose manufacturers. Do you understand?</p> <p>10 A. Yeah, right.</p> <p>11 Q. Using that method of chromatography</p> <p>12 testing to analyze raw chromatography data on the</p> <p>13 incoming API, the finished-dose manufacturers would</p> <p>14 not have identified the NDMA because the peaks would</p> <p>15 have been too small?</p> <p>16 A. Well, I mean, I have to say that really</p> <p>17 depends on the operator. Okay? I mean, I've had</p> <p>18 years of experience with this. And, you know, I'm in</p> <p>19 the office, the guy who's running things in the lab.</p> <p>20 So there are differences, you know.</p> <p>21 Some people in the lab will look at</p> <p>22 every small peak, and question it. Others will say,</p> <p>23 oh, that's just a small peak; we don't have to worry</p> <p>24 about it. So it really depends to some extent on the</p> <p>25 operator, and also on the question that's being</p>	<p style="text-align: right;">Page 280</p> <p>1 A. No.</p> <p>2 Q. Do you have any understanding of what</p> <p>3 Mr. Russ's opinions are?</p> <p>4 A. I don't know Mr. Russ. I don't think</p> <p>5 I've read anything by Mr. Russ.</p> <p>6 Q. I'm going to ask you to assume for the</p> <p>7 purposes of the next question that Mr. Russ has</p> <p>8 testified that the specifications in place for</p> <p>9 release of valsartan API would not have been exceeded</p> <p>10 by any of the ZHP API used in manufacturing by any of</p> <p>11 the finished-dose manufacturers.</p> <p>12 Can you assume that, just for purposes</p> <p>13 of this question?</p> <p>14 MR. SLATER: Objection.</p> <p>15 You can answer.</p> <p>16 A. Could you repeat that?</p> <p>17 Q. You've testified that you don't know the</p> <p>18 standards that are applicable to determining whether</p> <p>19 to release and use the API under either the ANDAs,</p> <p>20 ICH, or any of those other guidances. Right?</p> <p>21 A. Yeah, right.</p> <p>22 Q. I'm going to ask you to assume, for</p> <p>23 purposes of this question, that plaintiff's expert,</p> <p>24 Philip Russ, has testified that none of the ZHP API</p> <p>25 used by any of the finished-dose manufacturers would</p>
<p style="text-align: right;">Page 279</p> <p>1 asked.</p> <p>2 Q. Doctor, are you familiar with the</p> <p>3 release standards for valsartan API, as far as</p> <p>4 identification of unknown impurities that show up on</p> <p>5 chromatograms?</p> <p>6 A. No.</p> <p>7 Q. That's not something you reviewed in</p> <p>8 connection with your work in this case?</p> <p>9 A. Not specifically, no.</p> <p>10 Q. Are you familiar with the specifications</p> <p>11 put in place in the ANDAs for approving use of APIs,</p> <p>12 based on levels of unknown impurities that are</p> <p>13 identified in that API?</p> <p>14 A. It's not really my area. I'm not that</p> <p>15 familiar with it.</p> <p>16 Q. Are you familiar with the ICH guidances</p> <p>17 that set certain target standards for the</p> <p>18 pharmaceutical industry as a whole to use in</p> <p>19 evaluating unknown impurities in their API?</p> <p>20 A. No.</p> <p>21 Q. Are you familiar with a plaintiff's</p> <p>22 expert who testified last week named Philip Russ?</p> <p>23 A. No.</p> <p>24 Q. Have you reviewed anything that Mr. Russ</p> <p>25 has submitted in connection with this case?</p>	<p style="text-align: right;">Page 281</p> <p>1 have exceeded the minimum specifications for unknown</p> <p>2 impurities, like NDMA, in any of the products used to</p> <p>3 manufacture their finished dose.</p> <p>4 I'm going to ask you to assume that, for</p> <p>5 purposes of my next question. Okay?</p> <p>6 A. All right.</p> <p>7 MR. SLATER: And I'm objecting to it,</p> <p>8 because there's serious issues with that question.</p> <p>9 I'm not going to speak about it, but I have serious</p> <p>10 issues with that question.</p> <p>11 Q. So Dr. Hecht, assuming that the routine</p> <p>12 chromatogram did not exceed any of the specifications</p> <p>13 in place, that operator would have no reason to think</p> <p>14 that nitrosamines specifically were forming, based on</p> <p>15 their review of the chromatograms in testing that</p> <p>16 API?</p> <p>17 MR. SLATER: Objection.</p> <p>18 You can answer.</p> <p>19 A. Right. If the operator didn't know</p> <p>20 anything else, you know, there would be no reason for</p> <p>21 them to suspect that the small peak was NDMA. You</p> <p>22 know, if they're -- if they didn't know anything</p> <p>23 about the process used to manufacture the API.</p> <p>24 Q. All right. Dr. Hecht, I believe you</p> <p>25 testified that your opinions about how prevalent</p>

<p style="text-align: right;">Page 282</p> <p>1 GC-MS is in the pharmaceutical industry are based, at 2 least in part, on discussions with former students 3 and colleagues who have gone and worked in the 4 pharmaceutical industry. Is that right? 5 MR. SLATER: Objection. 6 You can answer. 7 A. I mentioned that, but really, a much 8 better example is the ASMS meetings. There you will 9 see literally hundred of papers from the 10 pharmaceutical industry using mass spectrometry, 11 LC-MS and GC-MS. That's really a much better example 12 than, you know, what my former students might have 13 said. That wasn't really a very good example, 14 although it has happened. 15 But the ASMS is really the right answer 16 to that. 17 Q. And Doctor -- 18 A. ASMS is the American Society For Mass 19 Spectrometry. They have an annual meeting. 20 Q. And Dr. Hecht, my next question, just -- 21 I know this is not the main thing you're saying 22 you're relying on. Are any of those students 23 currently, or have they worked, for any of the 24 defendants in this case, if you know? 25 A. Not for -- oh, no. I don't think so,</p>	<p style="text-align: right;">Page 284</p> <p>1 that for purposes of this question, okay? 2 A. Okay. 3 Q. Are you aware of how many of those over 4 5,000 monographs require testing with GC-MS to 5 perform a specified assay? 6 A. I have no idea. 7 Q. And Dr. Hecht, again, for purposes of 8 this question, I'll represent to you that of those 9 over 5,000 monographs, only four require the use of 10 GC-MS to perform a specified assay. 11 A. Yeah. 12 Q. Assuming that's accurate, just for 13 purposes of this question, would that change your 14 opinion in any way on how regularly GC-MS is used in 15 the pharmaceutical industry? 16 A. No. 17 Q. Okay. And I believe I -- I believe I 18 heard you correctly today that there's nothing we 19 could show you on that that would change any of your 20 opinions today. Correct? 21 A. Well, I wouldn't say nothing, but -- 22 MR. SLATER: Objection to the form. 23 A. You know, well, okay. I don't know 24 about the whole pharmaceutical industry, but. So 25 you're the expert.</p>
<p style="text-align: right;">Page 283</p> <p>1 no. 2 Q. And just because we have a couple of 3 different entities; the Teva entities include Teva, 4 Actavis, Watson and Aero are all sort of involved? 5 A. No, no. 6 Q. Doctor -- I'm sorry, Dr. Hecht, 7 apologies. Are you familiar with USP monographs? 8 A. USP monographs? 9 Q. Yes. 10 A. No. 11 Q. Do you understand what is set out in the 12 USP monographs, as far as testing that's performed on 13 drugs and drug substances? 14 A. No, I'm not familiar with it. 15 Q. Are you aware of the types of tests that 16 are specified to perform specific assays in 17 connection with USP monographs? 18 A. No. 19 Q. Are you aware of how many USP monographs 20 there are? 21 A. No. 22 Q. I'll represent to you that in the 23 plaintiff's expert report, Laura Plunkett's report, 24 she identifies over 5,000 such monographs that are 25 currently approved by USP. I would ask you to assume</p>	<p style="text-align: right;">Page 285</p> <p>1 Q. No, I promise you I'm not, Dr. Hecht. I 2 just want -- 3 A. Well, I mean, I don't know, you know, 4 what percentage of all drug companies actually have 5 mass spectrometry. I really don't know. It's my 6 assumption that it's very widely used in the 7 pharmaceutical industry. I'd be shocked if that's 8 not the case. But that's just an opinion. I 9 don't -- I don't really have facts to back that up. 10 MR. HARKINS: All right. Dr. Hecht, 11 those are all the questions that I have for you. I 12 believe one of the other defendants may have some 13 questions. 14 It might help to take a quick break just 15 to clear that up? 16 THE WITNESS: Okay. 17 THE VIDEOGRAPHER: All right. Going off 18 the record. The time is 3:35 p.m. Central Time. 19 This is the end of Media Unit 6. 20 (A brief recess takes place.) 21 THE VIDEOGRAPHER: We're back on the 22 record. The time is 3:49 p.m. Central Time. This is 23 the beginning of Media Unit 7. 24 MR. BERNARDO: Dr. Hecht, during the 25 break, Mr. Slater and I were doing a little bit of</p>

<p style="text-align: right;">Page 286</p> <p>1 housekeeping, and I just want to the record to 2 reflect the accurate numbers, so we can have the 3 proper exhibit marked. 4 Earlier, when I asked you how many 5 binders you had with you, your answer was eight. And 6 we got copies of them from Mr. Slater, and there were 7 only seven. And I understand during the break you 8 went back and recounted, and there were, in fact, 9 seven binders you have with you, not eight. Is that 10 correct? 11 THE WITNESS: Yeah, it only seems like 12 eight. Yes, seven is correct. 13 MR. BERNARDO: Okay, thank you. 14 Brittney? 15 MS. NAGLE: All right. 16 EXAMINATION BY MS. NAGLE: 17 Q. Hi, Dr. Hecht. My name is Brittney 18 Nagle, and I represent the Torrent defendants. I'm 19 going to be asking you a brief set of questions just 20 to wrap up on behalf of Torrent today. 21 Dr. Hecht, first I want to look at your 22 July report, July 2021. 23 A. Yeah. 24 Q. And I'd like to draw your attention to 25 Section 7, which begins on page 26 of the report.</p>	<p style="text-align: right;">Page 288</p> <p>1 A. Well, the first three paragraphs are 2 statements of fact. I believe that the fourth 3 paragraph is also a statement of fact. 4 Q. Okay. So this section just contains 5 factual information with respect to Torrent's 6 finished drug product? 7 A. Correct. 8 Q. Okay. 9 (Court Reporter Clarification.) 10 MS. NAGLE: Finished drug product. 11 Q. And while we're looking at the July 12 report, Dr. Hecht, can we turn your attention to 13 Exhibit 2 of your report, which is your "Materials 14 Relied Upon" list? 15 A. What page? 16 Q. I am looking at a version that has been 17 broken out separately, and it is at the bottom of 18 page 4 out of 6. 19 A. I'm confused now, now what are you -- 20 Q. Exhibit 2? 21 A. Exhibit 2. 22 Q. Exhibit 2 to your July report? 23 A. Yes. 24 Q. It's "Documents Reviewed," and if you 25 scroll down --</p>
<p style="text-align: right;">Page 287</p> <p>1 MR. SLATER: You said 27? 2 MS. NAGLE: It's Section 7, page 26. 3 MR. SLATER: Oh, got it. 4 Q. Dr. Hecht, do you see the Section 7 is 5 entitled, "Nitrosamines In the Torrent Finished-Dose 6 Formulation." Correct? 7 A. Yeah. 8 Q. And Dr. Hecht, a few minutes ago, do you 9 recall Mr. Harkins asked you some questions about the 10 section that precedes this section about Teva? 11 A. Yes. 12 Q. Do you remember that? 13 A. Yes. 14 Q. So Dr. Hecht, I just want to confirm, in 15 line with how you testified earlier, that the 16 information contained in this section is intended to 17 be like factual information. Is that correct? 18 A. Yes. 19 Q. And this section isn't offering 20 commentary on Torrent's conduct. Correct? 21 MR. SLATER: Objection. 22 You can answer. 23 A. I have to read over it. Just hold on a 24 second. 25 Q. Of course.</p>	<p style="text-align: right;">Page 289</p> <p>1 A. Oh, right. 2 Q. Look at the fourth page? 3 A. Yeah, okay. 4 Q. Okay. And you see the section labeled 5 "Torrent Documents"? 6 A. I'm not there yet. 7 Q. Okay. 8 A. Okay. 9 Q. Okay. So Dr. Hecht, this lists seven 10 documents. Correct? 11 A. Exhibit 2 of -- Exhibit 2, yes -- seven 12 documents. 13 Q. All right. And Dr. Hecht, do you recall 14 if you reviewed any additional Torrent documents that 15 are not included on this list, in connection with 16 your July report? 17 A. No. No additional. 18 Q. Okay. All right. So Dr. Hecht, let's 19 take -- or let's turn to your October 2022 report, 20 please. 21 A. Okay. 22 Q. And similarly, I want to look at the 23 Exhibit A to your report, which is the "Supplemental 24 List of Materials Reviewed." Can you let me know 25 when you're there?</p>

<p style="text-align: right;">Page 290</p> <p>1 A. Yes.</p> <p>2 Q. Okay. So on this list, we see that</p> <p>3 there's a section labeled "Torrent Documents," and it</p> <p>4 includes four documents?</p> <p>5 A. Yes.</p> <p>6 Q. Are there any other documents that you</p> <p>7 reviewed with respect to Torrent that are not listed</p> <p>8 here?</p> <p>9 A. No.</p> <p>10 Q. And Dr. Hecht, in your review of</p> <p>11 materials in this case, you haven't identified any</p> <p>12 document that indicates that Torrent was aware of a</p> <p>13 potential nitrosamine formulation in the valsartan</p> <p>14 API or valsartan drug product, prior to June 2018.</p> <p>15 Correct?</p> <p>16 A. Correct.</p> <p>17 MS. NAGLE: Dr. Hecht, that is all the</p> <p>18 questions I have for you today. Thanks very much.</p> <p>19 THE WITNESS: Okay.</p> <p>20 MR. SLATER: All right. So let's take</p> <p>21 a -- let's go off and take about ten, 15 minutes. I</p> <p>22 hope -- if we come back quicker, we'll be back</p> <p>23 quicker. But when we come back, I'll have a few</p> <p>24 questions. And I understand all defense counsel has</p> <p>25 finished their questioning for now, subject to what I</p>	<p style="text-align: right;">Page 292</p> <p>1 MR. SLATER: We're up to 26?</p> <p>2 MR. BERNARDO: I believe so.</p> <p>3 (A discussion is held off the record.)</p> <p>4 MR. SLATER: Whoever is the technical</p> <p>5 person running this, can you allow Chris to share his</p> <p>6 screen to put a document up, or upload it or</p> <p>7 whatever?</p> <p>8 MR. GEDDIS: It's uploading. I can</p> <p>9 screen share.</p> <p>10 MR. BILY: You should be able to screen</p> <p>11 share.</p> <p>12 MR. GEDDIS: Do want me to put it on the</p> <p>13 screen?</p> <p>14 MR. SLATER: Yeah, I mean, put it up.</p> <p>15 But we've got to get it to everybody.</p> <p>16 You're saying you're not able to share</p> <p>17 it in your share file?</p> <p>18 He's having trouble getting into the</p> <p>19 share folder. He doesn't have permission to upload.</p> <p>20 MR. BILY: I'll put my email in the</p> <p>21 chat. Just quickly send it to me, and I can upload</p> <p>22 it.</p> <p>23 MR. SLATER: All right. If there comes</p> <p>24 a point, Counsel, when you say, "Hey, we need that</p> <p>25 document," Chris will just pause to send you</p>
<p style="text-align: right;">Page 291</p> <p>1 ask. So hopefully, we won't be too long and we can</p> <p>2 get it done.</p> <p>3 THE VIDEOGRAPHER: All right. Going off</p> <p>4 the record. The time is 3:55 p.m. Central Time.</p> <p>5 (A brief recess takes place.)</p> <p>6 THE VIDEOGRAPHER: We're back on the</p> <p>7 record. The time is 4:12 p.m. Central Time.</p> <p>8 EXAMINATION BY MR. SLATER:</p> <p>9 Q. Doctor, I just have a few questions on a</p> <p>10 couple of things you were asked about, and one or two</p> <p>11 things I'd like to confirm. Okay?</p> <p>12 A. Okay.</p> <p>13 Q. First of all, all the opinions you've</p> <p>14 offered today in your testimony; have they all been</p> <p>15 offered to a reasonable degree of scientific</p> <p>16 certainty?</p> <p>17 A. Yes.</p> <p>18 Q. And does the same hold true for all the</p> <p>19 opinions set forth in your reports?</p> <p>20 A. Yes.</p> <p>21 MR. SLATER: And Chris, why don't we</p> <p>22 mark as the next exhibit, which I think is 25,</p> <p>23 Dr. Hecht's CV.</p> <p>24 MR. BERNARDO: I think we're up to 26,</p> <p>25 Adam.</p>	<p style="text-align: right;">Page 293</p> <p>1 whatever.</p> <p>2 Most of what I'm asking about is things</p> <p>3 you have, and I'm only going to use a couple</p> <p>4 documents. But obviously, stop us if you need</p> <p>5 something; we'll get it to you.</p> <p>6 MR. BERNARDO: Will do, thank you.</p> <p>7 MR. SLATER: All right. So first of</p> <p>8 all, that's the CV. I assume I don't need to get</p> <p>9 that to you guys before we ask some questions about</p> <p>10 it?</p> <p>11 MR. BERNARDO: Correct.</p> <p>12 MR. SLATER: Okay. But for the record,</p> <p>13 the CV will be Exhibit 26.</p> <p>14 (Exhibit Hecht-26, Curriculum Vitae of</p> <p>15 Stephen S. Hecht, Ph.D., Nine Pages, was received and</p> <p>16 marked for identification.)</p> <p>17 Q. Doctor, on the screen what we have is</p> <p>18 Exhibit 26, and that's the CV you just provided us, I</p> <p>19 think a few days ago.</p> <p>20 Is that your up-to-date curriculum</p> <p>21 vitae?</p> <p>22 A. Yes.</p> <p>23 Q. And does it describe your education,</p> <p>24 professional experience, publications, and other</p> <p>25 professional accomplishments?</p>

<p style="text-align: right;">Page 294</p> <p>1 A. Yes.</p> <p>2 Q. Okay. All right.</p> <p>3 MR. SLATER: Let's take that down.</p> <p>4 Q. Now, the next thing I would like to do</p> <p>5 is ask you just a couple of questions. You were</p> <p>6 asked some questions about what ZHP or others would</p> <p>7 be expected to know, and I just want to ask you one</p> <p>8 or two things along those lines. Okay?</p> <p>9 A. Okay.</p> <p>10 Q. With regard to those chemists who were</p> <p>11 involved in developing and assessing and managing the</p> <p>12 TEA with sodium nitrite quenching and zinc chloride</p> <p>13 manufacturing processes, if they had performed -- and</p> <p>14 I'm quoting now -- "a sound scientific appraisal of</p> <p>15 the chemical reactions involved in the synthesis,</p> <p>16 impurities associated with raw materials that could</p> <p>17 contribute to the impurity profile of the new drug</p> <p>18 substance, and possible degradation products," would</p> <p>19 that, in your opinion, have encompassed the</p> <p>20 information you've told us throughout your deposition</p> <p>21 that should have been known to the people who</p> <p>22 developed and assessed this process, these processes?</p> <p>23 A. Yes.</p> <p>24 Q. And is that for the reasons you told us</p> <p>25 earlier, about the availability of this information</p>	<p style="text-align: right;">Page 296</p> <p>1 failure to evaluate the potential presence of amines,</p> <p>2 that would then be impacted by the sodium nitrite to</p> <p>3 create nitrosamines?</p> <p>4 A. Yes.</p> <p>5 MR. BERNARDO: Object to form.</p> <p>6 A. When they decided to use nitrite in the</p> <p>7 reaction mixture, they should have thought about</p> <p>8 nitrosamine formation.</p> <p>9 Q. I'm now going to ask you about a</p> <p>10 document I know you've seen, which is the FDA warning</p> <p>11 letter, November 29, 2018. And I'm going to go to</p> <p>12 the fourth page of that.</p> <p>13 In the context of the questioning that</p> <p>14 defense counsel asked you, about what the FDA's views</p> <p>15 on this situation are and were. Do you remember, you</p> <p>16 were asked some questions about that earlier?</p> <p>17 A. Yes.</p> <p>18 Q. I'm going to read now from the FDA</p> <p>19 warning letter.</p> <p>20 MR. BERNARDO: Adam, which one?</p> <p>21 MR. SLATER: Sorry. This is the FDA</p> <p>22 warning letter dated November 29, 2018, which is</p> <p>23 whatever exhibit we're up to now, which is I guess</p> <p>24 27, which was marked as ZHP Exhibit 213 during</p> <p>25 discovery.</p>
<p style="text-align: right;">Page 295</p> <p>1 in the scientific literature?</p> <p>2 A. Yes.</p> <p>3 MR. BERNARDO: Object to the form of the</p> <p>4 question.</p> <p>5 Q. Similar question, if the people who</p> <p>6 were -- the chemists who were involved in these</p> <p>7 processes had applied science-based decision-making</p> <p>8 with respect to the potential risks of those</p> <p>9 processes, would have, in your opinion, encompassed</p> <p>10 the information you've told us throughout the</p> <p>11 deposition that they -- that ZHP's chemists, you told</p> <p>12 us during the deposition, should have understood?</p> <p>13 And I think you used the word "awareness"?</p> <p>14 A. Yes.</p> <p>15 Q. Okay. In your opinion, did the chemists</p> <p>16 that were involved in the development and assessment</p> <p>17 and oversight of this process -- these processes,</p> <p>18 both of them; in your opinion, did they apply sound</p> <p>19 scientific evaluation and appraisal of these</p> <p>20 processes in evaluating the risks?</p> <p>21 MR. BERNARDO: Object to the form of the</p> <p>22 question. Vague, compound.</p> <p>23 A. No.</p> <p>24 Q. And is that for the reasons you've told</p> <p>25 us throughout the deposition, in terms of their</p>	<p style="text-align: right;">Page 297</p> <p>1 (Exhibit Hecht-27, FDA Warning Letter</p> <p>2 320-19-04 dated November 29, 2018, previously marked</p> <p>3 ZHP-213, Bates ZHP01344159 through 1344164, was</p> <p>4 received and marked for identification.)</p> <p>5 Q. And one of the things the FDA said in</p> <p>6 that letter to ZHP was, "You failed to adequately</p> <p>7 assess the potential formation of mutagenic</p> <p>8 impurities when you implemented the new process,"</p> <p>9 and they're talking there about the zinc chloride</p> <p>10 process.</p> <p>11 "Specifically, you did not consider the</p> <p>12 potential for mutagenic or other toxic impurities to</p> <p>13 form from DMF degradants, including the primary DMF</p> <p>14 degradant, dimethylamine."</p> <p>15 I'm going to stop there. Do you agree</p> <p>16 with that, that there was a failure to adequately</p> <p>17 assess?</p> <p>18 MR. BERNARDO: Object to the form of the</p> <p>19 question, foundation.</p> <p>20 A. Yes, I agree.</p> <p>21 Q. And with regard to the TEA process with</p> <p>22 sodium nitrite quenching, would your opinion be the</p> <p>23 same with regard to the substances used in that</p> <p>24 process?</p> <p>25 A. Yes.</p>

<p style="text-align: right;">Page 298</p> <p>1 Q. The FDA also said to ZHP directly in the 2 warning letter to ZHP, "You also failed to evaluate 3 the need for additional analytical methods to ensure 4 that unanticipated impurities were appropriately 5 detected and controlled in your valsartan API before 6 you approved the process change. You are responsible 7 for developing and using suitable methods to detect 8 impurities when developing, and making changes to, 9 your manufacturing processes. If new or higher 10 levels of impurities are detected, you should fully 11 evaluate the impurities, and take action to ensure 12 the drug is safe for patients." I'm going to stop 13 there. 14 Are you in agreement with that? 15 A. Yes. 16 MR. BERNARDO: Object to the form -- 17 Doctor, just give me a minute to put my objection on 18 the record. 19 Object to the form of the question, 20 foundation. 21 Go ahead. 22 Q. Is that fully consistent with your 23 opinion that ZHP failed to ensure that they 24 anticipated and detected the NDMA and NDEA that came 25 from their -- these two processes we're talking</p>	<p style="text-align: right;">Page 300</p> <p>1 FDA, if ZHP had performed the assessment that you 2 have testified in your opinion they should have, 3 would they have identified the NDMA and NDEA from 4 these two processes from the very beginning, before 5 they even went to market? 6 MR. BERNARDO: Same objection. 7 A. Yes, they would have. 8 Q. And if they had applied that assessment 9 with regard to every batch manufactured going 10 forward, would they have also, in your opinion, 11 identified the NDMA and NDEA from these processes? 12 A. Yes. 13 Q. Let's go to your report of July 6, 2021, 14 page 19, please. Okay. Looking at the bottom of 15 page 19 of your July 6, 2021, report, you state, 16 "Once the presence of NDMA was discovered, it was not 17 difficult to determine the root cause. A July 27, 18 2017, email within ZHP refers to the root cause: 19 Specifically, the fact that NDMA was known to occur 20 in valsartan as a result of the use of sodium nitrite 21 in the sodium azide quenching process, and that there 22 was a need for 'the optimization of the valsartan 23 sodium azide quenching process.'" 24 Do you see that? 25 A. Yes.</p>
<p style="text-align: right;">Page 299</p> <p>1 about? 2 MR. BERNARDO: Same objection. 3 A. Yes. 4 Q. The FDA then said, "Your response," 5 referring to the response from ZHP to the 483 letters 6 that they got from the FDA, "Your response states 7 that predicting NDMA formation during the valsartan 8 manufacturing process required an extra dimension 9 over current industry practice, and that your process 10 development study was adequate. We disagree." 11 So I'm going to stop there. Do you also 12 disagree with that position taken by ZHP, and their 13 expert, for that matter? 14 MR. BERNARDO: Same objection. 15 A. Yes. 16 Q. And is that for the reasons you're 17 explained during the deposition, in terms of what you 18 thought they should have done in their assessment? 19 A. They should have known. 20 Q. And then the FDA says, "We remind you 21 that common industry practice may not always be 22 consistent with Current Good Manufacturing Practice 23 requirements, and that you are responsible for the 24 quality of drugs you produce." 25 With regard to that statement by the</p>	<p style="text-align: right;">Page 301</p> <p>1 Q. And there's a reference there, 91; and 2 I'm going to 91, which is "Min Li deposition 3 transcript, April 20, 2021, page 82, line 14 to 4 page 90, line 2." 5 And I just want to confirm that the -- 6 am I correct that the source of that information was 7 the sworn testimony of Min Li, who, during the 8 deposition, confirmed what that email from Jin Shiang 9 Lin said? 10 A. Yes. 11 Q. And the fact stated in that email that 12 the sodium nitrite -- let me -- one second, let me 13 just catch my -- new question. 14 Looking at the email itself, as 15 discussed by Min Li, where it states that "there's 16 n-nitrosodimethylamine that occurs in valsartan when 17 quenched with sodium nitrite, and its structure is 18 very toxic." 19 With regard to that statement in terms 20 of the root cause for the creation of NDMA in 21 valsartan, is that a correct statement of why it 22 occurred, in terms of the quenching with sodium 23 nitrite? 24 A. Yes. 25 Q. And with regard to the TEA process with</p>

<p style="text-align: right;">Page 302</p> <p>1 sodium nitrite quenching, would the same hold true in</p> <p>2 terms of the root cause?</p> <p>3 A. Yes.</p> <p>4 Q. Now, what I'd like to do is put up on</p> <p>5 the screen an article.</p> <p>6 MR. SLATER: And my guess is, we're</p> <p>7 going to need to give this to the defense lawyers,</p> <p>8 because I don't think that you've seen this. It's</p> <p>9 something that we --</p> <p>10 MR. GEDDIS: I'm putting it in the</p> <p>11 Dropbox link, and I'm putting it in the chat.</p> <p>12 MR. SLATER: Oh, good. Is that okay,</p> <p>13 everybody?</p> <p>14 You are muted, my friend.</p> <p>15 MR. BERNARDO: I can see it, but I'd</p> <p>16 like to have a copy so I can --</p> <p>17 MR. SLATER: Yeah, Chris just said he</p> <p>18 dropped it into the chat, I think.</p> <p>19 MR. GEDDIS: No, Dropbox, and I put the</p> <p>20 DropBox link and in the chat.</p> <p>21 MR. SLATER: He's putting in the Dropbox</p> <p>22 in the chat.</p> <p>23 (A discussion is held off the record.)</p> <p>24 MR. SLATER: Yep. Do you want us to</p> <p>25 wait a second while you access that?</p>	<p style="text-align: right;">Page 304</p> <p>1 we're supplementing it through this deposition.</p> <p>2 MR. HARKINS: Sorry. I have a folder for</p> <p>3 that.</p> <p>4 MR. SLATER: Is it all right if I</p> <p>5 proceed now? Hearing no objection, okay.</p> <p>6 BY MR. SLATER:</p> <p>7 Q. Doctor --</p> <p>8 MR. SLATER: This is Exhibit 28, you</p> <p>9 said, Chris?</p> <p>10 (Exhibit Hecht-28, Article entitled</p> <p>11 "Identification and Control of Impurities for Drug</p> <p>12 Substance Development using LC/MS and GC/MS," from</p> <p>13 The Journal of Liquid Chromatography and Related</p> <p>14 Technologies, was received and marked for</p> <p>15 identification.)</p> <p>16 BY MR. SLATER:</p> <p>17 Q. Doctor, what we've put on the screen as</p> <p>18 Exhibit 28 is an article that frankly, we pulled</p> <p>19 during your deposition when you were being questioned</p> <p>20 about whether or not drug companies would be expected</p> <p>21 to have LC-MS and GC-MS methodologies available to</p> <p>22 them, and the equipment to perform that, prior to</p> <p>23 2011, 2012, 2013; the time period when the</p> <p>24 development of these processes occurred. And</p> <p>25 thereafter.</p>
<p style="text-align: right;">Page 303</p> <p>1 MR. BERNARDO: Yes, please.</p> <p>2 MR. SLATER: Yeah, no problem.</p> <p>3 MR. HARKINS: Sorry. I'm getting content</p> <p>4 blocking trying to open that in Dropbox. Is there</p> <p>5 anywhere else that we've gotten this?</p> <p>6 (Court Stenographer clarification.)</p> <p>7 MR. HARKINS: Apologies, this is Steve</p> <p>8 Harkins for Teva.</p> <p>9 I'm getting a content filtering message</p> <p>10 for your Dropbox. I'm just wondering if there was</p> <p>11 anywhere that this is, or has been sent.</p> <p>12 MR. BILY: It's marked on Exhibit Share</p> <p>13 now, Exhibit 28.</p> <p>14 MR. SLATER: Let me know when you all</p> <p>15 are able to see it. Any luck?</p> <p>16 MR. BERNARDO: I have it.</p> <p>17 MR. SLATER: Okay, great. Is it okay if</p> <p>18 I proceed?</p> <p>19 MR. BERNARDO: From my perspective.</p> <p>20 I'll defer to my co-defendants.</p> <p>21 MR. SLATER: Steve, is it okay if I get</p> <p>22 moving?</p> <p>23 MR. HARKINS: Sorry, I'm still not happy.</p> <p>24 This isn't on the doctor's reliance list, is it?</p> <p>25 MR. SLATER: No, it's not. Although</p>	<p style="text-align: right;">Page 305</p> <p>1 On the screen is an article titled</p> <p>2 "Identification and Control of Impurities For Drug</p> <p>3 Substance Development Using LC-MS and GC-MS," which</p> <p>4 was published in 2008, in The Journal of Liquid</p> <p>5 Chromatography and Related Technologies.</p> <p>6 Do you see that?</p> <p>7 A. Yes.</p> <p>8 Q. And the authors, Heewon Lee, Sherry</p> <p>9 Shen, and Nelu Grinberg, apparently worked in the</p> <p>10 Chemical Development Department at Boehringer</p> <p>11 Ingelheim Pharmaceuticals in Ridgefield, Connecticut.</p> <p>12 Do you see that?</p> <p>13 A. Yes.</p> <p>14 Q. And the abstract -- and I'm only going</p> <p>15 to ask you about the first page, frankly -- says at</p> <p>16 the top, in the beginning, "Identification and</p> <p>17 control of impurities for drug substances is a</p> <p>18 critical task in pharmaceutical process development</p> <p>19 for quality and safety."</p> <p>20 And just that general principle you</p> <p>21 agree with. Correct?</p> <p>22 A. Yes.</p> <p>23 MR. BERNARDO: Object to form -- let me</p> <p>24 just put my objection on to the use of an article</p> <p>25 that was pulled -- and we'll determine who pulled</p>


<p style="text-align: right;">Page 306</p> <p>1 it -- during Dr. Hecht's deposition, that was not 2 part of his reliance material, or otherwise disclosed 3 in advance of the deposition. But go on, Adam. 4 MR. SLATER: Yeah. The article was 5 pulled by Christopher Geddis, who is the lawyer who's 6 working on this deposition with me, while Dr. Hecht 7 was being questioned. 8 It's a line of questioning that we 9 didn't really anticipate, so we addressed it while 10 the deposition was happening. 11 BY MR. SLATER: 12 Q. Now, looking at the abstract, at the 13 last five lines, it says, "Three case studies are 14 described where unknown process impurities were 15 analyzed for identification using LC-MS and GC-MS 16 methodologies. It is demonstrated that 17 identification of the unknown impurity enabled 18 chemists to pinpoint the chemical step of impurity 19 generation, aiding the effort to reduce or even 20 eliminate the impurity in the drug substances." 21 Do you see what I just read? 22 A. Yes. 23 Q. Is this the type of literature you were 24 stating that you believed was readily available in 25 the scientific literature, demonstrating that drug</p>	<p style="text-align: right;">Page 308</p> <p>1 Dropbox first, then he'll put it on the screen, so 2 that you guys can get it, and then when you have it, 3 I can start asking about it. 4 (Exhibit Hecht-29, Document entitled 5 "Valsartan, Analysis Report for Peak Identification 6 in GC Chromatogram Other Than Listed Solvents," Bates 7 ZHP01746277 through 1746288, was received and marked 8 for identification.) 9 MR. SLATER: Great. Is this Exhibit 29? 10 Great. 11 Q. So we're marking this as Exhibit 29. 12 It's titled, "Valsartan analysis report for peak 13 identification in GC chromatogram, other than listed 14 solvents." And I can represent to you, based on the 15 metadata, that this goes back to 2009, this document. 16 And you can see, you'll be able -- 17 defense counsel will be able to see that there's 18 actually the chromatograms that are discussed go back 19 to -- they're dated; you can see the dates in 2009. 20 MR. SLATER: And if we go now to the 21 second page of this, which is page 2 of 12, please. 22 Let's blow that up, because that is small. Great. 23 Q. In this analysis report from 2009 at 24 ZHP, it states that "For residual solvent method, 25 observed extra peaks in the region of about six to</p>
<p style="text-align: right;">Page 307</p> <p>1 companies did actually maintain LC-MS and GC-MS 2 technology, prior to the development of the TEA with 3 sodium nitrite quenching and zinc chloride processes 4 were developed? 5 A. Yes. 6 MR. BERNARDO: Object to the form of 7 the -- 8 A. Absolutely, this is the type of 9 literature. There's no doubt that drug companies had 10 this technology available. 11 MR. BERNARDO: Object to the form of the 12 question, and object to the characterization of the 13 prior testimony. 14 A. It's absolutely consistent with what I 15 was saying. 16 MR. SLATER: Chris, let's go to the next 17 document, which will be the valsartan analysis report 18 for peak identification. 19 MR. BERNARDO: I'm sorry, can you repeat 20 what we're going to? 21 MR. SLATER: I'm talking to Chris. He's 22 going to bring it up on the screen and give it to you 23 all. 24 (A discussion is held off the record.) 25 MR. SLATER: He's putting it in the</p>	<p style="text-align: right;">Page 309</p> <p>1 eight minutes, which are observed in GC chromatogram 2 available in valsartan batch analysis. The 3 identification of extra peaks, other than listed 4 solvent peaks, are conducted by" -- ZHP. 5 "The analytical method for residual 6 solvents determination was developed by a head-space 7 GC method. Based on actual two peaks raised at five 8 to seven minutes, we have performed GC-MS, and got 9 the same value of 102 with reference to the solvents' 10 structure." And I'm going to just stop there. 11 Does this confirm, based on what the 12 language says right there, that ZHP in 2009 had GC-MS 13 technology available to it? 14 MR. BERNARDO: Object to the form of the 15 question, lack of foundation. 16 Go ahead. 17 A. Yes, it confirms. 18 Q. And is that consistent with your opinion 19 that you would expect a company like ZHP to have had 20 this technology? 21 A. Yes. 22 MR. HARKINS: Object to form, leading. 23 MR. SLATER: Let's go now to the next 24 one, the qualitative report, please. And we'll make 25 that Exhibit 30.</p>

<p style="text-align: right;">Page 310</p> <p>1 (Exhibit Hecht-30, Qualitative Reports, 2 Bates SYNCOR00001458 through 1465, was received and 3 marked for identification.) 4 (Court Stenographer clarification.) 5 MR. BERNARDO: Richard Bernardo did. 6 MR. SLATER: I think Steve Harkins had 7 one too. 8 MR. HARKINS: Yes, Steve Harkins for 9 Teva. 10 (Court Stenographer clarification.) 11 MR. SLATER: It was Mr. Bernardo, and 12 also Steve Harkins objected. 13 I'm here for you, Steve, just like I'm 14 here for Rich. 15 MR. BERNARDO: And we so appreciate it, 16 Adam. 17 MR. SLATER: Okay. 18 BY MR. SLATER: 19 Q. Looking at Exhibit 30, which is a 20 qualitative report dated November -- November 19, 21 2012, does this show a printout of GC-MS 22 chromatograms? Do you see the GC-MS method is 23 indicated at the top? 24 A. Yes. 25 Q. So does this show, consistent with your</p>	<p style="text-align: right;">Page 312</p> <p>1 have had available to it? 2 A. Yes. 3 Q. And Doctor, I just want to make one more 4 thing clear. Today you were asked a lot of questions 5 about the zinc chloride process. 6 With regard to your fundamental opinions 7 about why it happened, the availability of the 8 literature, if a reasonable scientific review was 9 done in order to understand the risks of that 10 procedure, and the methodology and capability to test 11 for NDMA and NDEA; would all of your opinions, as you 12 gave them regarding the zinc chloride process, apply 13 to the TEA with sodium nitrite quenching process? 14 A. Yes. 15 MR. SLATER: I have no other questions, 16 thank you. 17 MR. BERNARDO: Dr. Hecht, just a few 18 follow-ups. 19 EXAMINATION BY MR. BERNARDO: 20 Q. First, I want to talk about the 21 July 2017 Jin Shiang Lin memo that Mr. Slater was 22 asking about a moment ago. Do you know what document 23 I'm talking about? 24 A. Yep. 25 Q. Okay. And you cite to testimony of one</p>
<p style="text-align: right;">Page 311</p> <p>1 understanding, that ZHP had GC-MS technology 2 available to it, at least as of 2012? 3 A. Yes. 4 Q. Okay. 5 MR. SLATER: Let's take that down, and 6 let's go to the next exhibit, which is going to be a 7 PowerPoint. And I'll just say for the record, the 8 Bates number is SOLCO 00027588. And it's a 9 PowerPoint dated August 23, 2012, from ZHP. 10 (Exhibit Hecht-31, PowerPoint 11 Presentation dated August 23, 2012, No Bates, 19 12 Slides, was received and marked for identification.) 13 MR. SLATER: And let's go to -- I don't 14 know how to number the pages, but it's I think the 15 fourth or fifth to last page, which has a listing of 16 research and development capabilities, listing 17 analytical instruments and capabilities at ZHP. 18 Q. And if you look down, it says "mass 19 spectrometry." And do you see it lists two different 20 types of mass spectrometry? 21 A. Yes. 22 Q. "LC-MS Agilent 1100, GC-MS Agilent 23 7890A." Are those both mass spectrometers of the 24 nature -- of the type that you would have expected, 25 as you testified earlier, a company like ZHP would</p>	<p style="text-align: right;">Page 313</p> <p>1 individual, Min Li. Correct? 2 A. Yes. 3 Q. And what's your understanding -- first 4 of all, did Min Li write that document? The July -- 5 A. No, I think Jin Shiang Lin wrote it. 6 Q. Did you read any testimony or 7 interviews, or otherwise have any understanding of 8 what Jin Shiang Lin's statements as to the meaning of 9 that memo would be? 10 MR. SLATER: Objection. 11 You could answer. 12 A. I don't remember. 13 Q. Okay. What is your understanding or 14 recollection of what Dr. Li testified, what's your 15 understanding of that memo, from Dr. Li's testimony? 16 MR. SLATER: Objection, it's ambiguous. 17 A. This is from Jin Shiang Lin. I'm lost 18 here. I mean, what are you asking me? 19 Q. Mr. Slater was pointing out to you that 20 in your report, you're citing to testimony of Dr. Li 21 as to what that memo means. Is that right? 22 A. Yes. 23 Q. And I'm asking you, what is your 24 understanding, based upon the testimony of Dr. Li, of 25 what that memo means?</p>

<p style="text-align: right;">Page 314</p> <p>1 A. Well --</p> <p>2 Q. And you can use your report, Doctor.</p> <p>3 You can also reference that if you want to?</p> <p>4 A. I mean, what it means is that, you know,</p> <p>5 there was -- that they had identified</p> <p>6 dimethylnitrosamine in valsartan. I mean, that's</p> <p>7 what this says.</p> <p>8 Q. And that's your understanding of what</p> <p>9 Dr. Li testified about?</p> <p>10 A. Yeah.</p> <p>11 Q. And Dr. Li didn't write the memo. Is</p> <p>12 that fair?</p> <p>13 A. No, the memo was written by Lin.</p> <p>14 Q. And did you read any testimony of any</p> <p>15 other individuals at ZHP who testified about what</p> <p>16 that memo means?</p> <p>17 A. I don't remember.</p> <p>18 Q. Well, okay. Mr. Slater -- different</p> <p>19 topic. Mr. Slater pulled up an article during your</p> <p>20 deposition with respect to a couple of the issues</p> <p>21 about which we've talked. I want to talk about the</p> <p>22 first article that was pulled up.</p> <p>23 MR. BERNARDO: And if we could pull that</p> <p>24 one up again, Adam or Chris, whoever was pulling that</p> <p>25 up.</p>	<p style="text-align: right;">Page 316</p> <p>1 instrumentation was widely available in the</p> <p>2 pharmaceutical industry at the time when all this was</p> <p>3 happening, that's a fact. And this just confirms it.</p> <p>4 Q. It confirms that it was available,</p> <p>5 Dr. Hecht, but does it confirm that it would be the</p> <p>6 type of testing or spectrometry that would be used,</p> <p>7 under the circumstances of the type of testing that</p> <p>8 was being done by ZHP or any other manufacturer?</p> <p>9 A. Of course it would be used.</p> <p>10 Q. Well, let me --</p> <p>11 A. Because it's -- you know, it's better</p> <p>12 than just GC-FID, and it's better than LC with UV</p> <p>13 detection. So of course it would be used.</p> <p>14 Q. In certain types of circumstances, it</p> <p>15 would be better. Correct?</p> <p>16 A. Yes.</p> <p>17 MR. SLATER: Objection.</p> <p>18 You could answer.</p> <p>19 A. Right, that's true.</p> <p>20 Q. So neither this article nor the other</p> <p>21 documents that Mr. Slater showed you from ZHP's files</p> <p>22 would necessarily show that this was the better type</p> <p>23 to use, under the type of testing that was being done</p> <p>24 of valsartan in the routine testing. Is that fair?</p> <p>25 MR. SLATER: Objection to the question.</p>
<p style="text-align: right;">Page 315</p> <p>1 MR. SLATER: Yeah, sure, let's pull it</p> <p>2 up.</p> <p>3 Q. And this is not an article that you read</p> <p>4 or relied on in connection with your report or your</p> <p>5 opinions previous to today. Is that fair?</p> <p>6 A. Correct.</p> <p>7 Q. And this is a report that talks about</p> <p>8 the availability of this type of testing. Is that</p> <p>9 correct?</p> <p>10 A. Instrumentation, yes.</p> <p>11 Q. Correct, okay. But it doesn't speak to</p> <p>12 what would be used in what circumstances, or what was</p> <p>13 standard in the industry to use in particular</p> <p>14 circumstances. Is that fair?</p> <p>15 MR. SLATER: Objection.</p> <p>16 You can answer.</p> <p>17 A. Well, I haven't read the article, but...</p> <p>18 Q. So if you haven't read the article, then</p> <p>19 it's clearly not something you're relying with</p> <p>20 respect to your testimony. It's something that</p> <p>21 Mr. Slater just showed you here. Correct?</p> <p>22 MR. SLATER: Objection.</p> <p>23 You can answer.</p> <p>24 A. I'm relying on my knowledge of the field</p> <p>25 of mass spectrometry. And when I said that this</p>	<p style="text-align: right;">Page 317</p> <p>1 You can answer.</p> <p>2 A. Novartis used it, so I mean...</p> <p>3 Q. In 2018?</p> <p>4 A. This is really -- I mean -- professional</p> <p>5 chemists want to use the best available technology,</p> <p>6 and the industry certainly wants to get the best</p> <p>7 available technology to analyze their products.</p> <p>8 And, you know, what this says is that</p> <p>9 technology was clearly available in -- when was this</p> <p>10 published? 2009.</p> <p>11 This is just consistent with what I've</p> <p>12 been saying all along: That the technology has been</p> <p>13 available since the early 2000s. The LC-MS</p> <p>14 technology -- after electro-spray came out, LC-MS</p> <p>15 took off, all right? And, you know, before that, I</p> <p>16 mean, GC-MS was available since the 1970s.</p> <p>17 So I mean, to propose that the</p> <p>18 pharmaceutical industry didn't have access to this</p> <p>19 instrumentation is almost laughable.</p> <p>20 Q. Dr. Hecht, we're not talking about what</p> <p>21 was available; we're talking about what would have</p> <p>22 been typically used, under the type of testing that</p> <p>23 was done. Right?</p> <p>24 A. Yep.</p> <p>25 Q. And this -- neither this article nor the</p>















<p style="text-align: right;">Page 318</p> <p>1 documents from ZHP show that this type of technology, 2 despite its availability, would have been industry 3 standard to use, in the type of testing that was 4 being done; rather, it would show that it was 5 available technology. Is that fair? 6 MR. SLATER: Objection. 7 You can answer. 8 A. If it's available, it will be used, 9 believe me. 10 Q. All right. 11 MR. SLATER: I don't have any further 12 questions, Dr. Hecht. 13 MR HARKINS: I'm sorry. Just one 14 clarification for the record, Dr. Hecht. 15 EXAMINATION BY MR HARKINS: 16 Q. Looking at that article that you 17 reviewed, or I'm sorry, that article that you did not 18 review; can you read the second sentence from the 19 abstract? 20 A. No, you have to make it larger. 21 Q. I apologize, I don't have control of it. 22 A. The second sentence says, "The most 23 commonly used analytical technique for impurity 24 analysis in drug substances and drug products is 25 undoubtedly the chromatographic method, namely HPLC."</p>	<p style="text-align: right;">Page 320</p> <p>1 have to have a detection system. So this is not 2 saying, you know, what the detection system is. 3 HPLC stands for high-performance liquid 4 chromatography; that's the separation system. Then 5 the HPLC has to be connected to a detector of some 6 sort. And that could be UV detection, or that could 7 be mass spec detection. 8 MR HARKINS: No questions. 9 MR. SLATER: I just have one follow-up. 10 Chris, could you scroll to the next 11 page, please. Yes, perfect. 12 EXAMINATION BY MR. SLATER: 13 Q. Doctor, at the middle of the second page 14 of this article, which is page 2236, it states, 15 "Identification and tracking of organic impurities 16 using LC-MS-related technologies for drug substance 17 and drug product development is well-documented in 18 the literature," and you see that there's citations 19 from 3 to 12 and 13 to 16. Do you see that? 20 A. Yep. 21 Q. And is that consistent with your opinion 22 that the use of this technology would have been 23 well-documented in the literature? 24 A. Absolutely. 25 Q. And that's -- it states "for drug</p>
<p style="text-align: right;">Page 319</p> <p>1 Q. Do you dispute that sentence? 2 A. Not at all, because most -- 3 MR HARKINS: That's all I have. 4 A. Most things that they would be analyzing 5 for -- not most things, but many things that they 6 would not -- that they would be analyzing for, you 7 couldn't do by GC, because they're not volatile. So 8 that's why LC-MS, the use of it, exploded after the 9 development of the electro spray interface, which was 10 around 2000, which I believe somebody got the Nobel 11 Prize for. So, you know, LC-MS took over the field 12 after electro spray came along. 13 So, you know, those are just the facts. 14 And I mean, to propose that the industry didn't have 15 this instrumentation is nonsense. 16 Q. Dr. Hecht, my question was just: Do you 17 agree with the statement in this article that -- 18 while you have not read, you are apparently relying 19 on for your opinion -- that "the most commonly-used 20 analytical technique for impurity analysis in drug 21 substances and drug products is undoubtedly a 22 chromatographic method, namely high-performance 23 liquid chromatography, HPLC." 24 Do you agree with that? 25 A. Yes, HPLC, yeah. Coupled -- I mean, you</p>	<p style="text-align: right;">Page 321</p> <p>1 substance and drug product development." That would 2 apply to what we're talking about in this case. 3 Right? 4 A. Yes. 5 Q. And if we go to the next page, 2237, the 6 second full paragraph, the end of that paragraph. 7 MR. SLATER: Scroll up a little bit, 8 Chris. All right, perfect. No, no, don't go any 9 further. Yeah, a little more. I want to see more of 10 the bottom of the page. Okay, perfect. 11 Q. Towards the bottom of the page, there's 12 a paragraph that starts "most drug substances." 13 Do you see that? 14 A. Yes. 15 Q. The last sentence of that paragraph 16 says, "Especially, GC-MS is a powerful analytical 17 technique for identification of unknowns, due to the 18 availability of vast and accessible spectral 19 libraries." 20 What does that mean, that there are 21 "vast and accessible spectral libraries" available, 22 as they're stating there? 23 MR. BERNARDO: Object to the form of the 24 question, foundation. 25 A. Exactly what it says. I mean, there are</p>

<p style="text-align: right;">Page 322</p> <p>1 vast libraries that show the mass spec fragmentation 2 pattern of, you know, thousands of compounds. So you 3 can take your output from the GC-MS, which will be a 4 mass spectrum, and compare to the database to, you 5 know, get a possible match. 6 Q. And again, is that consistent with the 7 opinion you provided in your deposition that, to your 8 understanding, that this technology was available and 9 utilized in the drug development and drug 10 manufacturing industry, before the TEA with sodium 11 nitrite and zinc chloride processes were developed, 12 and all throughout the time that they were used, up 13 until 2018? 14 A. Yes, it was available. 15 MR. SLATER: I have no other questions. 16 MR. BERNARDO: I have one last. 17 EXAMINATION BY MR. BERNARDO: 18 Q. Dr. Hecht, I just want to clarify 19 something for the record, because I don't think those 20 words came out of your mouth; but rather, plaintiff's 21 counsel's mouth. 22 The article that we're looking at is not 23 one that you researched and identified, for purposes 24 of your opinion or forming your opinions. Correct? 25 A. Correct.</p>	<p style="text-align: right;">Page 324</p> <p>1 confirming -- confirmatory of the opinion you gave 2 earlier in the deposition, regarding the availability 3 and use of these technologies? 4 A. Yes. 5 Q. And now that you have the article, is it 6 something that you would rely on, if you testified at 7 trial, to support that opinion? 8 A. Yes. 9 MR. SLATER: No other questions. 10 MR. BERNARDO: I don't want to take some 11 time. 12 EXAMINATION BY MR. BERNARDO: 13 Q. But Dr. Hecht, you have not read this 14 article in the last few minutes that we've been 15 talking about it. Correct? 16 A. I saw the abstract. 17 Q. You read the abstract? 18 A. Yes. 19 Q. Wouldn't you first want to read the 20 entire article, to determine if it's one on which you 21 would rely to form your opinion, or do you just read 22 an abstract and determine that this is -- 23 A. No, I could read the whole article. 24 Q. But you didn't read the whole article. 25 Correct?</p>
<p style="text-align: right;">Page 323</p> <p>1 Q. It's one that plaintiff's counsel, 2 during your deposition, found and is asking you 3 questions about, because they're asking you questions 4 to determine whether this article is consistent with 5 your testimony. Is that correct? 6 MR. SLATER: Objection. 7 A. Yeah, I didn't need the article. I 8 mean, I've been doing this 40 years. 9 Q. I just want to clarify -- 10 A. I know the field. I didn't need to read 11 this article to tell me that the pharmaceutical 12 industry has mass spectrometers. 13 Q. I didn't ask that question. I simply 14 wanted to know, from a logistical standpoint, that 15 this was something that you didn't identify, but 16 plaintiff's counsel identified for you, during your 17 deposition. Is that correct? 18 A. Correct. 19 MR. BERNARDO: Thank you. I have no 20 further questions and -- 21 MR. SLATER: One last question. 22 EXAMINATION BY MR. SLATER: 23 Q. Now that you've seen this -- well, 24 rephrase. Just to be very clear. 25 Is this article consistent and</p>	<p style="text-align: right;">Page 325</p> <p>1 A. No, I didn't read the whole article. I 2 didn't need to, because I know this stuff. I could 3 have written that article. 4 Q. But you didn't? 5 A. No. 6 Q. And you didn't read the article? 7 A. No, I didn't read the article. 8 MR. BERNARDO: Sorry, Steve. 9 MR. HARKINS: No. 10 EXAMINATION BY MR. HARKINS: 11 Q. Just to confirm, Dr. Hecht, are you able 12 to identify any article that you have actually read, 13 either in your materials cited in support of your 14 opinions, or that you can identify to us now, in 15 support of this point? 16 A. Well, much of my work that's cited in my 17 CV, which I think you have, relies on these methods. 18 I'm not in the pharmaceutical industry, but it's the 19 same thing: You're looking at complex mixtures by 20 GC-MS or LC-MS to identify specific substances, 21 including dimethylnitrosamine. 22 So no, I don't work in the 23 pharmaceutical industry; and no, I didn't use GSMC 24 and LC-MS to identify compounds, contaminants, minor 25 constituents of pharmaceutical products; but I used</p>

<p style="text-align: right;">Page 326</p> <p>1 it for -- to identify minor constituents of other 2 products, like tobacco. So it's the same principle. 3 And, you know, I was at a small 4 foundation. We had to stretch to spend the money to 5 get the instrumentation, GC-MS and LC-MS. You know, 6 to propose that the pharmaceutical industry did not 7 have access to this instrumentation at the time when 8 all this was going is -- it's absolutely wrong. They 9 absolutely had access, and used it. 10 Q. Doctor, I think you might have been 11 confused by my question. I'm asking if you can 12 identify, or have identified in connection with 13 either of your reports, any article that you have 14 actually read to support the proposition that this 15 was widespread in the pharmaceutical industry? 16 A. No, I did not. 17 MR HARKINS: No further questions. 18 MR. SLATER: I have no other questions. 19 MR. BERNARDO: Thank you very much, 20 Dr. Hecht, for your time. I hope your snow 21 dissipates. 22 THE WITNESS: Thank you. 23 THE VIDEOGRAPHER: We're off the record 24 at 4:55 p.m. Central Time, and this concludes today's 25 testimony given by Dr. Stephen Hecht. The total</p>	<p style="text-align: right;">Page 328</p> <p style="text-align: center;">J U R A T</p> <p>I DO HEREBY CERTIFY that I have read the foregoing transcript of my deposition testimony and I certify that is it true and correct to the best of my knowledge.</p> <p>_____ STEPHEN HECHT</p> <p>Subscribed and sworn to before me this __ day of _____, 2023.</p> <p>_____ Notary public</p>
<p style="text-align: right;">Page 327</p> <p>1 number of media used was seven, and will be retained 2 by Veritext. 3 (The proceedings concluded at 4:55 p.m. 4 CST.)</p>	<p style="text-align: right;">Page 329</p> <p style="text-align: center;">C E R T I F I C A T E</p> <p>I, ELLEN J. GODINO, LICENSE NO. X101618, a Certified Shorthand Reporter of the State of New Jersey, do hereby certify that prior to the commencement of the examination, STEPHEN HECHT, Ph.D. was duly sworn by me to testify the truth, the whole truth and nothing but the truth. I DO FURTHER CERTIFY that the foregoing is a true and accurate transcript of the testimony as taken stenographically by and before me at the time, place and on the date hereinbefore set forth, to the best of my ability. I DO FURTHER CERTIFY that I am neither a relative nor employee nor attorney nor counsel of any of the parties to this action, and that I am neither a relative nor employee of such attorney or counsel, and that I am not financially interested in the action.</p> <p> ELLEN J. GODINO CERTIFIED COURT REPORTER State of New Jersey DATED: 1/18/23</p>

[& - 2]

Page 1

&	10:34 114:14	136 7:13	
& 2:3,9 3:9,13 3:18 4:3,8,10 4:20	10:48 114:18	14 7:22 8:4 167:14 168:3 301:3	 
0	11 5:4,6 7:13 136:16 154:7 156:25 268:20 269:2	1465 9:22 310:2	1800law1010... 3:11
00027588 311:8 00032578 19:8 07068 2:11 07102 3:22	1100 311:22 11:30 155:3 11:36 155:13 11:46 155:17	15 6:9 8:4 13:6 168:2 241:10 290:21 15141 3:10 15219 4:5	188 8:11,14,16 19 8:14,16 9:24 188:19 189:1 192:13 300:14 300:15 310:20 311:11
1	12 6:5 7:18,20 116:1,10 163:18,22 166:25 308:21 320:19	153 216:5,21,23 217:7,16 219:18 220:19 15th 3:21 16 6:16 8:6 27:16 35:19 37:2 39:7 172:7,11 320:19	190 8:18 19067 4:17 192 215:21 193 8:21 195 8:23 1950s 130:25 1969 240:7 1970 128:21 1970s 127:11 128:25 317:16
1 6:5 10:11 12:20,21,23,25 19:9 63:10 83:3 109:13 157:17 160:7 169:6 252:18 	120 7:4 12212 3:10 123 7:8 12:35 153:23 12:45 204:23 13 1:15 6:8 7:20 10:3 166:24 260:24 261:4 320:19 130 156:25 1344164 9:12 297:3      	163 7:18 166 7:20 167 7:22 168 8:4 17 8:8 178:18 178:19 170 156:25 1710729 6:14 22:17 172 8:6 1746288 9:20 308:7 178 8:8  	199 8:18 19067 4:17 192 215:21 193 8:21 195 8:23 1950s 130:25 1969 240:7 1970 128:21 1970s 127:11 128:25 317:16 1994 60:2 94:25 240:12 240:16 1995 241:3 1996 6:24 81:1 81:4 82:8 84:4 1:27 205:2
1.5. 30:8 1/13/2023 330:3 1/18/23 329:15 10 6:18 7:8 34:14,19 62:22 123:16,17 255:24 10,000 70:8   10001-8602 2:5 10022 4:11 102 309:9 103 2:10 107 6:22 49:10			2 2 6:8 12:20,24 13:4,12 30:8 35:19 39:7 63:14 106:4 109:9 114:15 232:15 233:1,2

[2 - 230]

Page 2

260:7,11	57:20 58:1	2019 7:11 8:9	190:15 206:19
288:13,20,21	61:3 74:20	8:11 44:20,24	2118708 8:22
288:22 289:11	76:15 79:9,22	123:21 124:1,4	193:12
289:11 301:4	90:2 92:7,8,15	178:20 188:7	2118711 8:24
308:21	96:7 144:11,18	244:4	195:3
2/28/2019 7:18	144:19 304:23	2020 243:24	2118731 8:19
163:23	2016 7:16 8:6	244:3	190:16
[REDACTED]	8:19 135:20	2021 6:6 12:16	212-390-4210
[REDACTED]	136:20,22	12:23 13:1,13	4:12
[REDACTED]	138:4,25 139:1	148:18 149:14	212-735-3000
[REDACTED]	139:2 172:8,11	241:20,24	2:6
[REDACTED]	174:1 180:16	242:1 243:18	213 9:12
[REDACTED]	189:21 190:16	243:24 244:3	296:24 297:3
[REDACTED]	192:13,17	248:14 250:21	22 6:13,21 8:18
[REDACTED]	2017 8:21	252:17 256:16	8:21 49:9,13
[REDACTED]	180:16 193:1	260:8 261:8	95:3 148:17
[REDACTED]	193:10,12,21	286:22 300:13	164:9 190:16
[REDACTED]	195:7 226:1	300:15 301:3	193:11,19,20
[REDACTED]	300:18 312:21	2022 6:9,21	194:24
200 3:5	2018 7:6 9:11	12:16,24 13:5	2220 3:15
2000 136:8	16:8 33:5,10	13:11 49:9,13	2231 1:14 11:5
319:10	33:12,17,22	63:17 148:17	2236 320:14
2000s 317:13	34:6 42:22	149:13 156:2	2237 321:5
2008 305:4	43:1,16 44:11	164:19 225:19	225 9:7
2009 308:15,19	44:16 45:14	232:14 248:15	227 4:22
308:23 309:12	53:8 120:14,19	251:14 259:7	22nd 19:18
317:10	121:2,18	268:21 269:3	174:1 191:21
2010 18:9	125:11 136:9	289:19	192:2,17
2011 304:23	202:23 203:5	2023 1:15 10:3	23 3:10 8:23
2012 6:16 9:24	203:12 258:6	328:15	9:24 194:23
27:2,16 304:23	258:24 259:1	205 5:7	195:1,2,5
310:21 311:2,9	264:18 290:14	206 9:4	261:19 311:9
311:11	296:11,22	21 7:16 8:18	311:11
2013 6:19	297:2 317:3	9:5 12:15	230 3:15
34:14,19 53:22	322:13	136:20 190:13	

[24 - 477553]

Page 3

24 9:4 206:16 206:17,25	271 8:12 188:8 188:11	[REDACTED]	32502 2:16
25 7:11 9:7 123:21 124:1,4 225:4,10 252:22 291:22	272 8:14 188:18,20	[REDACTED]	32580 6:11 18:19
250 4:16 5:9	272a 8:17 188:24 189:1	[REDACTED]	3333 3:6
2500 3:6	278 192:8	3.2 23:9	34 6:18 190:10
26 6:24 9:9 81:1,4 82:8 172:5,6 286:25 287:2 291:24 292:1 293:13 293:14,18	27th 172:11	3.2. 22:8	36 83:22
260 2:20	28 8:11 9:14 49:18 50:19 188:7 303:13 304:8,10,18	30 7:6 9:22 120:14,19 121:2 242:3 309:25 310:1 310:19	38th 4:5
2630925 7:19 163:24	28202 4:22	301 4:5	39 217:2
2630927 7:23 8:4 167:16 168:3	286 5:10	30305 3:6	3:35 285:18
265a 7:21 166:23,25	2875 1:3 10:16	304 9:14	3:49 285:22
266 7:23 167:15	29 8:8 9:11,18 22:9 23:7 178:20 296:11 296:22 297:2 308:4,9,11	308 9:18	3:55 291:4
267-759-2064 4:17	291 5:12	31 6:8 9:24 13:5 311:10	4
27 6:15 8:6 9:11 172:8 226:1 287:1 296:24 297:1 300:17	293 9:9	310 9:22	4 6:13 17:8 22:14,14,15,20 28:3,5,8,10 30:22 37:14 82:22 101:22 102:1 109:9,12 109:13 110:9 121:14,22 155:18 165:12 173:25 179:18 204:24 288:18
2709940 178:17	297 9:11	311 9:24	4/16 27:13 [REDACTED] [REDACTED] [REDACTED] [REDACTED]
2709984 8:9 178:20	2:04 233:19 2:12 233:22 2:32 250:3 2:41 250:7 2nd 2:11	312 5:13	412-263-4397 4:6
	3	312-566-4808 3:16	44 6:6 13:2
	[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]	316 2:15	45 180:10
		318 5:15	47 95:6,6
		31st 12:16,24 225:19 259:7	477553 8:7 172:8
		320 5:16	
		320-19-04 9:11 297:2	
		322 5:18	
		323 5:19	
		324 5:21	
		325 5:22	

[483 - accept]

Page 4

483 299:5	195:15 197:4	7890a 311:23	155:17
49 6:21	250:8 252:17	79755 6:16	abbreviations
496154 8:12	252:22 256:16	27:17	141:24 216:4
188:8	261:8 285:19	8	aberrant 156:9
496156 8:15	288:18 300:13	8 6:23 37:2	170:20 262:1
188:21	300:15	80:24 81:1,3	ability 329:7
4:12 291:7		109:13 154:17	able 17:3 22:2
4:55 326:24	600 4:22	225:16,20	49:25 74:7
327:3	601 4:11	81 6:23	109:4 175:15
5	60606 3:15	8101 2:19	200:15 292:10
5 6:15 27:15	65 148:9	82 301:3	292:16 303:15
29:1 108:15		850-435-7013	308:16,17
185:20,20	66210 2:20	2:16	325:11
186:1 205:3	678-553-2100	8:18 1:16 10:2	above 1:11
250:4	3:7	8:30 21:4 154:9	142:25 143:10
5,000 171:5	6th 1:14 11:5	9	absence 176:1
283:24 284:4,9	7	9 7:4 120:13,15	275:19
5,502,191 6:23	7 6:21 13:15	90 301:4	absolutely 47:8
81:4	49:8 155:23	91 301:1,2	54:19 61:13,14
5,700 210:13	156:25 159:19	913-385-5400	99:22 118:12
	160:6 179:1	2:21	118:16 123:7
518-724-2207	198:2,4 225:16	9251 329:12	132:5 143:15
3:11	225:20 260:8	926 167:11	143:16 144:4,7
53 140:9,16	285:23 286:25	973-228-9898	145:11 211:16
	287:2,4	2:12	307:8,14
5700 210:24	704-444-3475	973-757-1100	320:24 326:8,9
211:5	4:23	3:22	abstract 82:11
6	73119 6:19	9:00 154:10	305:14 306:12
6 6:6,18 12:16	34:15	9:21 63:9	318:19 324:16
12:23 13:1,15	75 71:25	9:33 63:13	324:17,22
34:11,13	76 216:25	a	abstracts 146:3
155:23 160:7	760 216:24	a.m. 1:16 10:2	146:6
164:18,19	217:9	63:9,13 114:14	academic 144:1
170:15 173:12	777 4:16	114:18 155:13	accept 225:6

[access - agree]

Page 5

<p>access 68:20 263:24 264:9 302:25 317:18 326:7,9 accessible 321:18,21 accomplishm... 293:25 account 69:4 75:11 96:25 accurate 12:5 265:18 284:12 286:2 329:5 accurately 228:1 acid 28:20 29:6 31:13 33:10 43:3 44:16 60:2 84:1 85:12,12 acidified 83:25 acknowledge 139:16 acknowledged 232:18 233:11 234:2 acknowledging 154:20 acquire 144:2 actavis 3:2,3 283:4 action 10:22 298:11 329:8 329:10</p>	<p>activation 247:11 actual 65:25 309:7 actually 31:9 63:3 66:18 67:1 114:9 139:6 178:13 181:17 195:8 196:9 199:15 200:14 203:24 221:14 223:23 228:1 247:21 275:25 285:4 307:1 308:18 325:12 326:14 adam 2:9 12:23 25:15,18 68:25 75:10,25 81:12 85:4 91:5 93:1 108:9 115:15 115:15 116:16 120:10,11,12 141:7 152:3,5 152:25 153:21 172:22 204:13 223:16 232:4 232:24 239:13 291:25 296:20 306:3 310:16 314:24 add 87:13,15 103:1,2 247:22 269:11 270:3</p>	<p>added 28:16 40:6 87:10 88:3 220:25 221:2,8 242:4 269:23 adding 28:6 85:20 86:19,24 119:7 130:22 addition 62:7 87:19 92:23 additional 70:9 174:8 176:23 182:2 185:4,7 202:11,12 235:14,16 259:25 289:14 289:17 298:3 address 7:10 36:24 75:12 76:21 123:20 196:22 253:3 addressed 162:5 306:9 addresses 228:14 adds 83:17 adequate 299:10 adequately 297:6,16 adjust 11:12 administration 19:17 adopted 37:12 63:23</p>	<p>adopting 26:7 32:1 advance 140:10 306:3 advances 135:11 advent 137:19 137:22 adverse 110:10 aero 283:4 affect 117:14 117:17 afternoon 205:5,5,6 250:10,11 agency's 7:10 123:20 agents 127:7 agilent 311:22 311:22 ago 15:17 67:10 92:20 174:7 194:18 207:19 240:2,4 246:23 249:8 287:8 293:19 312:22 agree 10:9 15:25 16:6 23:11 24:16 26:25 29:4 41:24 45:17 51:20 56:25 64:12 65:1,7,9 74:3 75:25</p>
--	---	--	---

[agree - answer]

Page 6

76:8,14 78:17 97:9 100:24 101:6 104:8,16 105:18,20 110:15,19 112:2 113:6,19 113:24 114:21 117:11 118:3 118:10,17,23 121:16 125:2 130:7 132:20 132:23 133:16 133:22 134:8 134:13 136:6 139:5 140:13 141:5 142:13 142:16 165:13 166:15 168:23 179:11,14,15 183:2 194:5,16 196:20 202:11 210:25 211:1 213:14 218:5 222:12 227:24 245:8 247:15 252:9 272:19 297:15,20 305:21 319:17 319:24 agreed 134:25 agreeing 166:9 agreement 298:14 agrees 221:9	ahead 76:12 77:8 85:18 90:6,11 124:12 150:25 165:10 231:19 253:21 260:8 298:21 309:16 aiding 306:19 al 330:2 albany 3:10 albertson's 4:19 alfano 4:3 allow 292:5 allowed 180:13 273:8 alphabetically 210:17 amarego 9:5 206:19 amazing 51:9 ambiguous 116:12 313:16 amendment 6:15,18 27:13 27:15,23 34:11 34:13 35:6 108:15 american 128:12 145:2,5 146:3 282:18 amine 95:3 222:20 amines 126:16 126:20 131:3	221:12 296:1 amount 24:3 30:17 38:19 41:10 65:15 80:11,17 85:22 94:15 amounts 53:1 60:1 217:20 analyses 129:21 170:11 272:10 analysis 9:18 66:5,10,21 191:9,9,13 270:19 271:3 273:13,13 274:15 276:4 307:17 308:5 308:12,23 309:2 318:24 319:20 analyst 184:7 analyte 134:5 analytes 133:10 analytic 133:9 134:11 analytical 132:15 135:8 138:17 147:25 298:3 309:5 311:17 318:23 319:20 321:16 analyze 171:5 265:6 278:12 317:7	analyzed 170:21 306:15 analyzing 108:25 132:16 133:18 319:4,6 anda 263:5,11 263:16 264:9 277:19 andas 263:13 263:25 264:18 265:11 277:21 279:11 280:19 annual 282:19 answer 16:25 17:3 20:11 23:25 24:10,20 25:1,25 26:10 26:18 29:21 30:20 31:23 32:4 33:2 36:22 39:20 40:10 41:13 42:13,25 44:5 44:13 46:4 47:4 48:1,17 52:23 54:24 55:19 56:13 57:7 59:6,11 59:21 64:24 68:11 71:13 73:18 74:23 75:24 76:18,24 76:25 79:1 80:1,9 84:7 86:17 87:23
--	--	--	--

[answer - appreciate]

Page 7

93:12 94:5	251:22 257:15	142:24 143:1	90:1,12 92:8
98:15 100:9	258:10 265:20	143:13 161:5	92:15 93:21
102:25 105:9	266:3,22	168:22 170:2	94:1
112:6,15	267:20 270:25	170:21 197:10	apparently
113:13 114:3	274:25 277:1	198:15 202:8	189:25 305:9
115:1 116:7	280:15 281:18	203:4,12 226:3	319:18
117:20 118:8	282:6,15 286:5	230:2 231:23	appear 121:20
119:2,20 123:3	287:22 313:11	232:9,19	176:4 182:3
125:15,17,25	315:16,23	251:10 253:11	273:14
138:6,8 139:2	316:18 317:1	258:7,23 265:3	appearances
139:11,12,21	318:7	268:1,10	2:1 177:17
146:8 149:1,21	answered	269:12,13	appeared 174:8
153:17 157:9	71:19 94:4	270:9,11,16,20	appears 71:11
158:1,10,11,18	138:7 153:10	270:22 271:4	123:4 179:25
160:11 162:11	153:20 202:19	271:20,23	191:8 194:6
163:4 168:20	234:24 236:9	272:24 273:3	197:1 198:1
170:18 171:24	263:21	273:23 276:22	241:18
175:9 177:24	answering	277:20 278:3,6	applicable
179:20 182:6	43:20 244:12	278:13 279:3	280:18
182:18,25	anticipate	279:13,19	application
183:6,17,23,25	306:9	280:9,10,19,24	262:5
184:8 185:13	anticipated	281:16,23	applications
187:3 196:25	122:8,13,19	290:14 298:5	263:6
197:15 202:15	298:24	apis 279:11	applied 63:22
203:9 209:8,21	anybody 12:9	apologies	269:11 295:7
212:7 213:19	12:10 51:4	256:17 268:4	300:8
214:21 215:12	213:23 257:16	274:2 283:7	apply 64:21
218:12 221:6	275:24	303:7	252:11 257:11
221:22 227:12	anymore 135:3	apologize 56:12	295:18 312:12
228:9 230:13	163:1	261:9,18 269:1	321:2
230:19 231:19	anyplace	273:1 277:15	appraisal
240:16 245:3	218:24	318:21	294:14 295:19
245:18 246:19	api 13:19,22	apparent 64:2	appreciate
247:20 248:2	16:8 122:15	64:8,9 65:3	47:14,16 56:18
248:22 249:3	130:16 140:21	79:7 89:24	68:25 88:24

[appreciate - assessing]

Page 8

93:1 116:8,16 219:22 247:25 310:15 approach 102:5 approached 175:8 appropriate 15:11 26:15 110:1,2,18 112:14 113:23 appropriately 183:14 298:4 approved 277:19,22 283:25 298:6 approving 263:5 279:11 approximately 70:19 146:24 149:23 april 6:16 7:16 8:21 27:2,16 136:20 192:25 193:10,12,21 195:7 301:3 arb 7:10 123:19 area 131:21 204:9 208:3 256:13 263:12 271:22 279:14 areas 252:11 270:18,23	arguing 182:9 argument 51:14 argumentative 25:2 75:4 armarego 206:14 arps 2:3 article 7:13 9:14 60:18 95:15,19,21,23 98:6 134:18 135:20,23 136:3,16,22 137:4,6 138:4 138:24 302:5 304:10,18 305:1,24 306:4 314:19,22 315:3,17,18 316:20 317:25 318:16,17 319:17 320:14 322:22 323:4,7 323:11,25 324:5,14,20,23 324:24 325:1,3 325:6,7,12 326:13 articles 58:2,11 59:16 79:19,22 98:6 134:9 136:4 212:17 242:14	aside 160:6 218:6 asked 62:22 73:6 92:19 93:8,10 94:3 100:9 102:24 116:11,12 138:7 171:21 176:21 212:4 236:5 244:18 246:25 266:15 279:1 286:4 287:9 291:10 294:6 296:14 296:16 312:4 asking 12:1 13:11,13 14:6 14:23 36:9,11 43:7,10 45:10 51:10,19 53:17 62:11 64:9,10 64:14 69:11 74:2 80:3 90:5 91:22,23,24 92:1 93:8 100:5,6 107:20 115:8,11 117:12 135:25 136:2,3 138:22 138:25,25 139:15,18 141:3,8 145:12 145:13 149:4 149:11 151:15 151:16,18,19	152:15 166:3 168:19 177:1 180:21 190:24 191:16,22 221:7 226:18 226:22 228:6,7 230:6 231:17 235:17,19 236:14 238:4 241:2,21 242:1 243:19 244:7 249:17 256:7 266:13 267:4 267:11 278:7 286:19 293:2 308:3 312:22 313:18,23 323:2,3 326:11 aslater 2:12 asms 145:6 146:4,15 282:8 282:15,18 aspect 112:2 128:8 aspects 25:5 40:3 98:17,22 99:9,21 113:2 assay 284:5,10 assays 283:16 assess 107:10 107:16 297:7 297:17 assessed 294:22 assessing 294:11
--	--	---	---

[assessment - back]

Page 9

assessment 29:3 64:3 79:8 92:10 93:23 94:2 98:8,12 104:1,7,12,17 104:20,23,25 105:6,21,23,24 106:9,13,14,17 106:19,22,24 107:1,25 108:3 109:22 110:9 111:5,10,14 238:18,20,22 295:16 299:18 300:1,8 assessments 124:20 assigning 19:17 associated 294:16 assume 12:1 14:3 26:2 42:14 48:11 89:4 119:11,13 136:4 187:12 205:13,14 211:5 214:13 214:14 266:5,9 266:16 267:4 267:11 268:9 270:8 278:7 280:6,12,22 281:4 283:25 293:8	assumed 208:22 209:4 assuming 84:23 84:25 265:23 266:18 281:11 284:12 assumption 39:24 48:20 119:15 266:25 266:25 268:16 270:9 271:19 271:21 285:6 atlanta 3:6 atmospheric 216:24 aton 3:19 attach 224:23 attachment 194:12,21 195:6,7,7 attachments 193:25 attend 128:11 145:2,5 attended 128:10 146:15 attending 11:1 attention 225:24 245:22 286:24 288:12 attorney 329:8 329:9 audio 10:8 23:19	august 7:6 9:24 120:14,18 121:2 311:9,11 author 246:5 authored 71:11 authors 209:16 210:12 305:8 availability 294:25 312:7 315:8 318:2 321:18 324:2 available 63:20 64:1,21 78:5 140:19 144:5 208:10 262:11 262:15 263:10 264:16,22 265:4,10 268:13,16 269:10 271:12 271:16 304:21 306:24 307:10 309:2,13 311:2 312:1 316:1,4 317:5,7,9,13,16 317:21 318:5,8 321:21 322:8 322:14 avenue 4:11 average 148:8 avoid 23:18,20 40:13 avoided 88:6 aware 98:17 99:8,20,21	100:16,16 121:8 126:24 127:7,8 128:15 128:16,17 202:24 210:8 212:9 222:1 227:9 256:25 258:5,22 267:25 270:10 277:17,18 283:15,19 284:3 290:12 awareness 98:15 99:5,11 99:12 120:3,4 295:13 azide 17:10,19 29:7,10,14 30:7 37:10 38:9,13 45:23 48:5,9 55:5 83:18,21 86:20 87:11,11,13,14 202:4 300:21 300:23
			b
			b 3:14 4:21 7:1 8:1 9:1 153:6,7 216:4,8 254:20 back 30:22 39:7 41:2 48:3 56:14,17 60:21 62:20 63:12 77:11 78:11 79:9,17 88:23

[back - bernardo]

Page 10

89:18,20,23	85:1 86:11	13:1,6 18:18	103:21 112:8
90:22 101:21	105:9 112:2	19:4,7 22:16	164:6 199:11
101:25 109:20	124:20 125:3	27:16 34:15	199:15 205:25
112:18,19	126:1 136:18	49:10 120:19	216:10 233:1
114:17 115:17	136:24 142:18	123:21 163:23	234:20 247:9
129:17 140:6	146:12,14	164:25 167:11	252:17 253:19
143:22 144:23	157:21 169:19	167:15 168:3	255:3 259:21
155:16,21	179:23 183:2	172:8 178:17	260:6,7,13
156:21 169:5	220:1,5 262:4	178:20 188:8	263:21 265:13
171:4 173:3,5	265:3,9 279:12	188:20 190:16	265:22 266:11
181:3 191:6	281:14 282:1	193:12 195:3	268:11 270:20
192:6,22 205:1	295:7 308:14	206:19 297:3	271:4 272:8
205:8 209:23	309:7,11	308:6 310:2	281:24 284:17
212:1,5 213:12	313:24	311:8,11	284:17 285:12
225:15 233:21	baseline 275:8	bausch 3:18	288:2 292:2
236:9 250:6	basic 47:8	baylen 2:15	318:9 319:10
251:14 254:24	94:12 99:23	bear 49:20	believed 306:24
256:16 257:5	213:9 271:19	bearing 208:20	bernardo 2:3
257:24 260:4	basically 73:8	beauty 129:9	5:6,7,13,18,21
261:8 270:13	101:22 222:16	beginning 37:3	11:8 12:19,22
285:9,21 286:8	basis 37:14	56:11,12 63:14	14:17 15:18
290:22,22,23	57:24 61:2	114:19 122:3	18:5,12,16,23
291:6 308:15	75:14 84:16	149:11 155:18	19:5,8 21:1,5,8
308:18	230:17 235:1	173:6 198:12	21:21 22:4,9
background	237:6 266:8	205:3 250:8	22:13,19 23:7
82:20 83:1	batch 74:14	261:23,25	25:14,18 27:8
backwards	176:20 269:12	285:23 300:4	27:12 28:2,5
272:6	300:9 309:2	305:16	28:13 34:10
bad 214:11	batches 171:5	begins 137:19	35:18 36:11
218:16	bates 6:6,9,11	259:9 286:25	37:8 41:1,15
bain 153:19	6:13,16,19,22	behalf 286:20	43:10 44:2,8
bain's 153:3,12	7:6,12,18,23	believe 22:23	49:4,7,17
based 7:15	8:4,6,9,12,14	48:22 60:17	56:10 58:8
23:18,21 41:17	8:19,21,24 9:5	66:11 101:17	60:20 62:11,15
69:25 82:24	9:12,20,22,24	102:19 103:18	62:17,24 63:15

[bernardo - blocking]

Page 11

68:25 69:13	167:12,25	303:16,19	bily 18:15 22:2
75:9 77:9	169:10,23	305:23 307:6	292:10,20
78:12 79:13	172:5,21 173:3	307:11,19	303:12
80:21 81:12,14	173:5 175:11	309:14 310:5,5	binder 224:8
81:17 82:17	176:10 178:16	310:11,15	224:10,21
83:9 84:18,22	178:23 182:11	312:17,19	binders 9:7
85:3,6 89:16	184:5 186:17	314:23 321:23	67:15,19,24
89:19,22 91:1	187:7,14 189:3	322:16,17	68:1,4,18,19
91:5,9,24 92:5	189:4,12,17	323:19 324:10	70:3,7,17
92:25 93:14	190:9,13 191:6	324:12 325:8	71:16,18,25
100:5 101:2	193:9,19,22	326:19	72:3,8,11,19
106:4 107:21	194:12,15,22	best 139:8,14	146:22,23,25
108:1,5,9	194:25 195:16	139:14,17	150:10 199:23
109:1,20	198:9 204:11	175:9 223:8	199:24 200:10
112:12,17	204:16,21	224:18 229:2	201:6 223:8
114:9,20	205:4 206:10	317:5,6 328:5	224:13 225:4
115:11,15,21	206:15 208:11	329:7	225:11 286:5,9
116:7,16,20	210:5 211:24	better 18:25	bio 155:7
117:3,10 120:9	212:1 213:12	25:15 37:20	biology 94:24
121:22 122:1	215:20 223:16	40:12 41:20	bipc.com 4:23
123:15,25	224:1,14,24	124:16 139:23	bit 25:11 37:9
124:17 135:25	225:13 232:3	145:1 147:11	38:25 39:1
136:5,13	232:16,24	151:23 202:17	52:15 58:25
137:15 139:7	233:1,3,7,16,23	229:8 282:8,11	142:9 147:11
140:8 141:3,7	235:18 239:12	316:11,12,15	176:7 199:12
141:13,16	248:10 249:5	316:22	210:19 215:21
142:8 151:18	249:13 257:7	big 81:16 105:1	216:12 222:11
151:24 152:3,5	285:24 286:13	120:13 172:3	237:2 285:25
152:19,25	291:24 292:2	275:23	321:7
153:2,21 154:5	293:6,11 295:3	bigger 169:8	blah 148:4,4,4
154:18 155:2,6	295:21 296:5	184:19 215:21	blanked 210:4
155:19 156:3,5	296:20 297:18	biley 10:20	220:9
163:16,19	298:16 299:2	billed 241:18	block 36:8
164:8,17,24	299:14 300:6	241:19 242:5	blocking 303:4
166:7,22 167:5	302:15 303:1		

[blow - case]

Page 12

blow 37:9 141:16,17 308:22 blue 195:24 bobber 4:15 body 255:23 258:3 261:8 boehringer 305:10 boffetta 246:5 bogdan 3:9 boil 216:17 boiling 90:3 92:11 93:24 95:23 100:17 216:8,13,15,20 216:23 217:15 218:8,8,9,25 book 206:25 207:2 208:5,13 208:19 209:2,5 209:17,17 210:8,15,25 211:8 213:11 213:22,25 214:19 215:23 221:17 books 207:10 208:7 bookshelves 208:2,10 bosick 4:3 bottom 36:7 63:18 129:20 137:10,16	180:20 209:25 215:8 255:24 257:2 272:8 288:17 300:14 321:10,11 boulevard 2:19 bowry 10:17 box 3:10 break 21:12 63:5 114:11 153:25 154:15 154:22 155:7 180:12 205:7 224:15,18 249:19,25 250:1 285:14 285:25 286:7 breaks 154:12 brett 2:19 brief 63:5,11 114:16 155:7 155:15 233:20 250:5 253:8 285:20 286:19 291:5 bring 181:8 188:3,17,24 194:22 241:13 307:22 brittney 4:10 286:14,17 brittney.nagle 4:12 broad 39:1	broken 288:17 brought 245:22 bsn 2:19 buchanan 4:20 bulb 202:5 263:3 bulk 66:1,19 bullet 28:9 30:9 30:23 bulletproof 211:23 bullets 28:4 business 227:4	capability 312:10 carbon 17:8 133:23 217:21 carcinogenic 247:12 carcinogenicity 127:1 128:14 carcinogens 54:12 126:4 care 132:10 160:13,16,25 161:4,12 168:10 171:25 176:1 182:22 188:3 231:19 carillon 4:21 caring 182:15 182:19 carolina 4:22 carried 105:5 carryover 141:21 case 12:15 14:1 15:1,12,22 20:7 56:8 60:18 66:17 69:21 70:22 96:24 118:9 119:7 132:5 147:3 148:15 152:17 214:17 237:14,22 238:25 241:25 244:20 250:17
		c	
		c 2:19 3:1 4:1 4:15 5:4 11:5 94:23 329:1,1 call 132:21 158:22 206:14 225:4 called 18:8 29:2 109:21 120:10 163:21 206:25 210:18 246:5 275:11 calls 52:8 244:1 camden 1:2 10:16 camera 10:5 camping 216:16 cancer 254:16 capabilities 311:16,17	

[case - check]

Page 13

254:25 258:21 263:14,18 276:23 279:8 279:25 282:24 285:8 290:11 306:13 321:2 330:2 cases 126:15 casual 211:16 catalyst 17:22 23:14,17,18,20 23:21 25:21 37:25 50:18 catalyzed 45:18 45:22 48:4,8 catch 301:13 category 132:6 causation 254:16,21 cause 86:24 161:9 300:17 300:18 301:20 302:2 caused 50:22 226:3 248:6 254:14 270:3 causes 7:11 123:20 causing 198:14 254:15 caution 15:4 ccr 1:12 celsius 205:22 217:16,24 218:14 219:10	center 3:21 centigrade 221:19 central 1:16 10:2 63:9,13 114:14,18 155:13,17 204:23 205:2 233:19,22 250:3,7 285:18 285:22 291:4,7 326:24 centre 4:4 certain 13:13 14:24 57:21 58:12 77:21 78:1 79:9 80:17 129:10 129:11 140:12 140:14 147:17 279:17 316:14 certainly 97:15 97:21 131:21 138:12 144:3 189:13 211:14 212:9,13 213:6 215:3 270:10 317:6 certainty 291:16 certified 329:2 329:14 certify 328:3,5 329:3,5,7	cgannon 3:23 cgeddis 2:13 cgmp 238:10 chain 7:18 8:6 8:8,11,18,21 163:22 172:7 178:19 179:1,2 179:16 188:6 190:15 191:5 193:11 challenge 61:22 219:24 230:7 chance 84:15 118:4,14,15,19 118:24 211:7 change 24:2 26:7 27:24 29:17 30:3,15 30:15 31:20 32:1,8 34:1,25 35:1,2,9,24 38:15 39:5,14 39:18 40:12,17 40:20,23 41:4 41:9,18,24 42:7 45:5 97:1 97:3,8 100:20 107:10,12 109:8 110:2,6 110:10 155:20 162:4,8,12,15 162:19 187:21 188:1 284:13 284:19 298:6 330:5	changed 30:6 35:20 39:10 40:5 changes 20:7,8 24:24 32:13 36:24 39:8 44:21 45:13 105:13,14,18 105:19,22 107:10,17 109:8 110:16 110:17,18,22 112:4 113:7,8 113:15,18,22 298:8 changing 105:11 113:20 113:21 characterizati... 106:23 113:25 140:22 141:4,5 151:25 307:12 characterize 38:14 213:15 characterized 112:7 charlotte 4:22 chart 8:23 195:2 chat 12:10 292:21 302:11 302:18,20,22 cheaper 135:12 check 161:6 162:2 211:14
---	---	--	---

[check - citation]

Page 14

215:13	219:16 220:12	[REDACTED]	274:7,15 275:4
checked 65:24	223:2 229:4,15	[REDACTED]	279:5 281:15
66:11 215:4,7	240:4,6 257:17	[REDACTED]	308:18 310:22
215:10	chemists 61:7	[REDACTED]	chromatograph
chemical 52:17	99:25 127:6	[REDACTED]	191:22
128:12 145:3	128:9 132:24	[REDACTED]	chromatogra...
146:17 210:17	133:18 257:12	[REDACTED]	318:25 319:22
220:5 262:4	294:10 295:6	[REDACTED]	chromatogra...
294:15 305:10	295:11,15	[REDACTED]	7:14,15 9:16
306:18	306:18 317:5	[REDACTED]	132:14,15
chemicals 9:4	cherry 171:20	[REDACTED]	136:17,19,23
206:18 207:1	175:16	[REDACTED]	136:25 156:10
214:3	chicago 3:15	chopped 31:16	240:9,13,18
chemist 53:20	chief 146:16	chris 291:21	272:23 273:3,9
53:20,22 61:4	chinese 7:18,22	292:5,25	274:17 275:13
61:6 62:2 64:3	8:11,14 73:14	302:17 304:9	276:5,21
64:6 65:4 79:7	73:16,21,24	307:16,21	277:20 278:5,7
89:25 90:2,6,7	74:4,10 77:3	314:24 320:10	278:8,11,12
90:9 91:13,16	163:23 166:11	321:8	304:13 305:5
91:18 92:9,16	167:14,18	christine 3:20	319:23 320:4
93:22 94:1,12	172:15 188:7	christopher	circumstance
94:14 96:7,19	188:19,23	2:10 4:21	158:16 181:20
97:15 98:7,11	189:7 226:16	306:5	187:20 201:21
120:7 125:20	226:25 227:3,7	christopher.h...	274:21
140:20 210:23	227:18 228:2,4	4:23	circumstances
228:24 256:24	228:18 229:3	chromatogram	87:7 119:17
chemistry 47:8	229:10,24	9:19 274:19,23	139:16,22
48:12 52:12	230:8,14,24	275:6,20	158:21 163:11
91:20 94:13	[REDACTED]	281:12 308:6	170:14 175:20
99:6 106:9	[REDACTED]	308:13 309:1	186:7 207:21
126:22 127:15	[REDACTED]	chromatograms	248:6 315:12
128:14 129:9	[REDACTED]	129:22 160:5	315:14 316:7
132:16 138:17	[REDACTED]	160:18,21	316:14
207:12 213:9	[REDACTED]	170:20 184:22	citation 96:21
213:16,17	[REDACTED]	272:11 273:23	171:21 212:19

[citations - commissioner's]

Page 15

citations 320:18 cite 147:10 156:17 157:12 158:3,5 165:12 179:9 182:2,4 188:10 206:12 237:1,7 312:25 cited 58:5 60:8 96:16,18 147:17 158:25 164:11 165:1,6 167:8 168:6 175:19 179:17 185:25 186:16 187:8,11,12 210:7 235:3,8 325:13,16 cites 74:1 citing 313:20 civil 152:17 claimed 174:7 clarification 13:20 14:3 15:19 18:4 29:25 38:10 43:21 46:20 47:15 55:22 59:7 68:12 90:10,20 94:22 100:11 103:23 126:18 146:1 216:7 217:11 277:14 288:9 303:6 310:4,10	318:14 clarified 91:21 clarify 12:2 13:10 15:5 43:23 51:13 111:20 116:11 205:11 256:20 257:24 268:7 276:18 322:18 323:9 clarifying 55:9 class 7:10 123:19 240:3 clean 175:10 cleaning 259:4 clear 14:6 15:2 42:6 62:20 79:4 86:9 89:1 91:2,25 92:3,7 105:9 115:23 116:14 144:8 145:21 185:5 189:9 226:21 231:6 232:14 236:13,20 249:16,18 255:4 257:25 259:5 261:2 263:22 271:20 276:4,15 285:15 312:4 323:24 clearer 198:19 clearly 152:16 181:19 276:14	315:19 317:9 client 116:18 clients 176:12 close 117:5 clunky 109:3 cn 17:8 coast 154:11 coffee 78:19 coincidence 226:1 colleague 21:9 21:22 122:3 124:15 225:22 colleagues 228:4 249:7 282:3 collect 207:10 college 2:19 240:7 colloquy 57:6 176:9 column 7:15 136:19,25 137:19 195:14 195:23 combination 133:16 combined 141:23,24 combustion 133:13 come 62:20 72:24 120:4 135:9 143:22 144:23 146:6	146:19 151:23 152:18 178:6 182:12 232:2 248:24 270:13 290:22,23 comes 239:13 249:20 275:8,9 292:23 coming 257:8 comma 261:24 commencem... 329:3 commencing 1:16 comment 176:22 commentary 144:10,11 287:20 commenting 24:24 comments 21:16 commercial 37:17 commercially 60:1 commission 330:25 commissioner 121:9 122:18 122:22 124:5 126:7 commissioner's 123:6
--	--	--	---

[committees - conclusion]

Page 16

committees 127:9	company 17:6 17:7 18:13	177:21 189:22 190:4 198:3	computer 231:25 232:4
common 299:21	24:4 26:6 27:10 29:5	complaints 156:8,15	235:21
commonly 133:17 207:11 210:24 247:13 318:23 319:19	41:17 61:12 67:25 68:2,5,6 68:8,14 69:19 69:19 70:9,20 71:9,12,20 72:1,4,7,12,15 72:21,25 73:15 97:16 105:13 109:14,25 126:8 131:7,14 149:18 151:2 158:7 160:25 162:5 164:2 174:14,17 214:24 238:15 309:19 311:25	158:23 159:4,6 159:22 160:3 162:21,22,25 168:10 170:16 171:7,9 183:4 183:8 186:9 197:3	computers 213:1
communicate 12:9 209:3		complete 76:2 197:19	conceivable 114:23 115:3
communicated 42:21 43:2 44:19		completed 236:8	concept 96:18
communicating 44:4		completely 175:6,7 276:1	concern 24:2,8 24:11,12 36:4 45:5 161:9,14 161:17 162:6 163:7 197:11 197:12 223:2 267:10
communication 43:12 44:10 174:22 177:20 192:12 193:10 196:8 202:13	compare 322:4	complex 325:19	concerned 77:6 85:22
communicati... 12:10 43:8,24 43:25 185:4,8 192:8,22 196:17 197:22 202:12	compared 184:24 229:5 275:21 277:10	compliance 238:10	concerning 161:22
companies 4:19 26:12 125:7,12 126:21,23 127:7 128:9,10 138:14 143:24 161:23 197:10 203:18 270:15 285:4 304:20 307:1,9	compartment... 89:2	complicated 223:1,5	concerns 32:23 33:5,8,16,21 34:1 36:18,25 42:11,21 43:2 43:13 44:11,19
	compendium 210:16	comply 174:6,9	concierge 10:19
	compiled 109:14	composite 9:7 225:3,10	conclude 169:3
	complained 162:7	compound 17:10,14 57:5 134:15 295:22	concluded 66:9 161:16 327:3
	complaint 165:17 166:18 174:20 176:12	compounds 33:14 132:17 133:13,19 184:21 210:18 257:18,20 322:2 325:24	concludes 326:24
			conclusion 138:2 143:20 178:6 229:23 230:7 269:9

[conclusions - continue]

Page 17

conclusions 255:7,12 269:7	301:5 309:11 316:5 325:11	consequences 99:10	contained 169:1,16
conditions 53:23 54:8,15 57:21 59:17 77:21 78:2 79:9 99:11 128:19 129:11 130:23 211:9 215:17 217:3 222:3	confirmatory 324:1	consider 98:23 98:25 99:1,3 105:2 117:13 239:20 297:11	287:16 containing 133:23
conduct 104:12 104:17,20 203:11 253:17 254:2 287:20	confirmed 37:17 199:10 199:10 237:9 301:8	consideration 26:15 29:24 203:13 262:22	contains 57:12 60:1 288:4
conducted 10:4 37:17 105:21 201:16 203:4 238:14,18 309:4	confirming 226:2 266:17 324:1	considerations 30:1	contaminant 53:4 56:5 119:25
conference 128:25 129:3 145:5 244:1	confirms 309:17 316:3,4	considered 32:8 67:7 105:4 160:8 270:5	contaminants 325:24
conferences 127:2 128:17 145:2	conflict 245:5	considering 266:7	contaminate 115:6 117:17
confidential 15:10,23	confused 210:10 235:20 236:15 277:15 288:19 326:11	consistent 212:21 237:19 298:22 299:22 307:14 309:18 310:25 317:11 320:21 322:6 323:4,25	contaminated 54:17 65:15 88:6
confines 15:2 40:2	confusing 14:11 64:11	constituent 96:20	contamination 94:7,16 223:3 232:19 233:12 233:15,25 234:4,7,11,16 234:19 235:3 235:13 236:22 237:3,8,13 252:5 254:14 262:3
confirm 103:19 166:14 191:17 211:2 237:5 258:4 260:17 287:14 291:11	confusion 14:22 181:19	constituents 325:25 326:1	content 303:3,9
	connected 320:5	consult 207:22 214:8,9	contentious 43:22
	connecticut 305:11	consume 100:2	context 112:21 157:13 179:23 182:1 296:13
	connection 10:6 60:15 67:7 149:7,16 159:3,4 165:16 173:11,17 245:10 257:8 279:8,25 283:17 289:15 315:4 326:12	contain 53:1 65:20 76:16 199:24 214:6 254:1,10 256:9	continue 10:8 55:23 142:9

[continue - correctly]

Page 18

174:19	207:14 225:7,8	108:22 109:22	238:13,16,17
continued 3:1	225:8 251:15	110:6,12	238:19 239:2,6
4:1 5:7 6:1 7:1	302:16	111:17 113:3	239:9,10,18,22
8:1 9:1 205:4	core 55:7,10	122:20 124:9	239:23 240:22
continuing	56:18	125:3 127:19	240:25 241:20
124:8	correct 11:21	130:9,17 131:7	241:23 242:14
contribute	12:17 17:11	131:9,11,15,16	242:15,21,24
294:17	18:9 23:4,15	133:5 134:11	244:5 245:5
contributing	23:16,22 24:5	134:22 136:9	247:9 252:3,15
254:16	25:23 28:21,24	139:3 140:23	253:10,12,18
contribution	28:25 29:8,11	151:2,3 153:13	254:22 255:9
205:14	29:12 30:13	156:15 157:1	256:5 258:8,24
control 9:14	31:1,4 32:15	158:16 159:18	259:2,13,16,23
196:1 304:11	32:19 34:20	163:13 165:2	260:2 261:6
305:2,17	35:7,10,16,22	168:6,24	264:25 265:4
318:21	36:2,5,19,25	174:14 177:11	268:14 271:8
controlled	39:12,15 40:8	177:14,15,18	271:13,17
298:5	40:15 41:7,8	178:3 179:9,13	272:16 274:10
convenient	41:11 42:1,8	179:18 180:23	284:20 286:10
208:14,19	42:11 45:2,6	181:5 184:10	286:12 287:6
conversion	45:20,24 46:2	191:13,14,18	287:17,20
37:25 38:5,11	47:11 48:9,22	193:1 194:19	288:7 289:10
convert 31:12	49:14 53:11	195:9,20 196:2	290:15,16
134:5	54:22 55:17	198:6 202:13	293:11 301:6
conviction	59:3 60:10,16	205:22 207:3	301:21 305:21
61:22	64:19,22 65:9	210:13,15	313:1 315:6,9
convince 76:5	65:16 70:4	211:7 217:16	315:11,21
cooled 83:24	73:22,24 74:4	217:25 218:15	316:15 322:24
85:13	74:7,15 75:1	220:3 226:12	322:25 323:5
coordinate	77:18,22 79:24	226:15,25	323:17,18
223:8	82:8,14 83:18	227:4,7,8,15	324:15,25
copies 9:7 13:9	84:24,25 85:13	228:12,19,22	328:5
225:11 286:6	97:19 101:18	228:24 232:24	correctly 17:25
copy 68:20	103:13,21	233:12 235:5	64:13 141:2,8
155:21 206:22	104:12,18	236:24 237:22	142:2 143:3

[correctly - davis]

Page 19

230:22 254:18 262:7,12 269:16 272:14 284:18 correspondeen... 196:8 cost 25:22 31:21 32:2 costs 26:14 98:25 counsel 11:1,4 18:15 21:18 73:9 76:20 157:5 175:25 180:12 189:8 204:20 249:7 290:24 292:24 296:14 308:17 323:1,16 329:8 329:9 counsel's 322:21 couple 81:22 133:3 147:5 192:22 269:19 283:2 291:10 293:3 294:5 314:20 coupled 319:25 course 12:11 51:6 117:22 149:7 154:5 209:15 213:21 213:24 227:4 238:7 239:25	249:9 267:23 270:10 287:25 316:9,13 court 1:1 10:15 10:19 11:3 13:20 18:4 38:10 43:21 46:20 47:15 55:22,24 59:7 59:10 68:12 77:9 90:10,20 94:22 100:11 103:23 117:6 126:18 146:1 151:22 216:7 277:14 288:9 303:6 310:4,10 329:14 courtesy 117:7 courtroom 11:20,21 cover 150:5,5 188:14 256:13 crcr 1:12 create 167:8 296:3 created 251:24 creation 301:20 critical 111:3 305:18 criticism 253:17 criticisms 250:22 252:10 254:2,11 256:9	cross 232:19 233:12,15,25 234:4,7,11,16 234:19 235:3 236:22 237:3,8 237:13 crude 28:8 38:1 38:18 52:25 101:18,19 cst 327:4 curing 127:22 current 7:6 120:18,24 299:9,22 currently 282:23 283:25 curriculum 9:9 293:14,20 customer 156:8 156:15 158:23 159:4,21 162:7 162:21,22 164:4 165:17 166:17 168:10 170:16 183:4,7 186:8 190:4 193:6 196:21 197:3 198:3 customers 162:24 174:18 cut 56:12 61:23 114:12 167:4 cv 291:23 293:8 293:13,18 325:17	d d 5:1 30:13 38:13 40:25 41:6 216:9 d'souza 190:19 190:21,23 192:3 d.d. 9:5 206:19 d5191-15-359 8:23 195:3 damn 211:21 dangerous 254:14 daniel 2:15 data 109:13,14 274:16 275:4 275:14 278:12 database 322:4 date 53:7 156:24 242:2 243:24 293:20 329:6 330:3 dated 6:6,8,16 6:18,21 7:6,11 9:11,24 12:15 12:16 13:1,5 27:13,16 34:14 49:9,13 120:18 123:21 296:22 297:2 308:19 310:20 311:9 311:11 329:15 dates 308:19 davis 3:5
--	--	--	---

[day - deposition]

Page 20

day 67:9 69:9 241:9 328:15 330:22 days 138:17 293:19 deal 60:15 191:3 234:10 dear 176:11 decades 126:2 129:16 december 6:18 6:21 8:6,18 34:14,19 49:9 49:13 148:17 172:8,11 174:1 180:16 189:22 190:16 191:21 192:2,13,17 decide 155:8 197:19 decided 106:19 296:6 decision 295:7 decompose 55:4 86:20 87:11,15 decomposed 202:3 decomposes 217:14 decomposition 50:22 51:4 52:7 87:8 132:18 133:20 205:9	decrease 30:11 41:6 decreased 30:8 40:24 deep 229:4 defendants 250:14,15 282:24 285:12 286:18 303:20 defense 290:24 296:14 302:7 308:17 defer 303:20 define 71:6 277:2 defined 180:22 defining 71:7,9 definitely 96:24 135:4 144:16 170:20 201:3 277:7 definition 71:8 degradant 297:14 degradants 297:13 degradation 46:13 61:10 78:6 80:6 86:14,25 87:20 89:8 95:23 104:1 205:15 205:25 212:20 219:1 294:18	degrade 52:19 53:24 57:11,21 59:18 61:5 77:21 78:2 79:9 84:12 85:9 90:3 92:10 93:23 100:16 211:10 221:19 243:12 degraded 47:1 47:6,22,23 205:18 217:6 degrades 111:16 degree 291:15 degrees 94:11 95:12 205:21 216:5,18,21,25 217:16,24 218:9,13,14,17 218:20,20 219:6,10,18 220:2 delamination 40:14 delay 63:4 delineate 139:18 199:25 demonstrate 160:15 183:13 demonstrated 56:7 262:1 306:16 demonstrates 109:25 161:11	183:3 221:10 demonstrating 306:25 density 216:9 depart 133:25 department 305:10 depending 231:1 depends 10:5 71:6 153:25 213:20 277:2 277:11 278:17 278:24 depo 156:24 depose 152:22 deposed 11:23 189:7 deposition 1:5 10:3,12 91:10 91:15 117:9 146:21 147:3 147:12,21 149:11,18 150:19 154:7,9 154:16 156:22 157:12 158:24 167:6 171:22 172:19 186:15 187:11,13 189:6 223:7,17 244:18 259:18 259:22 294:20 295:11,12,25 299:17 301:2,8
--	--	---	---

[deposition - difficult]

Page 21

304:1,19 306:1 306:3,6,10 314:20 322:7 323:2,17 324:2 328:4 330:3 depositions 147:6 149:24 derive 165:25 190:5,7 describe 20:20 27:24 34:25 38:23 104:5 107:16 170:16 293:23 described 23:12 31:3 44:22 58:12 83:18 102:21 143:10 182:16 306:14 describes 253:11 describing 35:1 35:2 84:4 170:5 241:6 253:23 description 7:2 8:2 9:2 83:2 86:11 175:22 194:7 descriptions 20:13,15,17 despite 112:13 318:2	destroy 29:6 detail 39:3,5 106:14 199:14 234:10 detailed 208:23 details 186:13 208:22 244:3 detect 133:22 298:7 detected 130:8 274:20 278:6 298:5,10,24 detecting 133:12 detection 134:3 134:15,21 137:24 273:8 274:21 276:12 276:21 277:18 277:18 316:13 320:1,2,6,7 detector 7:15 133:4 136:18 136:24 137:23 142:12 148:10 240:14 320:5 detectors 133:3 determination 309:6 determine 57:25 62:1 74:13 92:14 93:16,25 109:15 110:1 113:22 176:2	198:14 214:9 238:25 264:15 300:17 305:25 323:4 324:20 324:22 determined 74:14 145:24 162:23 178:2 178:12 determining 280:18 develop 124:21 273:11 developed 294:22 307:4 309:6 322:11 developing 98:16 294:11 298:7,8 development 6:13 9:15 18:14 22:16 23:1 64:3 79:8 91:17 92:9 93:22 94:2 96:8 98:8,12 128:4,5,18 183:20 237:20 295:16 299:10 304:12,24 305:3,10,18 307:2 311:16 319:9 320:17 321:1 322:9	deviation 235:4 devoted 241:25 dialects 229:12 diethylnitros... 234:14 difference 32:7 140:15 218:19 219:18 220:23 differences 232:8 278:20 different 15:20 32:12 42:3 45:13 47:17 58:11 91:23,25 103:9,10 105:6 111:1 117:22 119:12 127:14 127:24,24 148:2,11 179:22 181:17 183:11 204:9 207:9 210:3 216:9,11 227:10 229:12 229:19 231:22 231:24 232:12 235:22 236:1 277:6 283:3 311:19 314:18 differentiates 120:6 differently 265:14 difficult 120:12 300:17
---	---	---	---

[digits - distributed]

Page 22

digits 81:18	221:10 222:14	disclose 244:25	254:6 257:6
dimension	263:1 297:14	245:4,23	discussion 70:1
299:8	dimethylene	246:21,25	96:6 101:14
dimethylalam...	214:7	247:5,16 248:4	149:10 243:16
46:11	dimethylfor...	disclosed	255:7 292:3
dimethylamine	39:11 46:7	244:19 246:10	302:23 307:24
46:2,6,18,24	55:2 56:5 88:1	246:12 306:2	discussions
47:2,8,20,24	219:12,15	disclosure	208:24 243:11
53:1,3,4 54:7	220:8	245:9	282:2
54:22 55:2	dimethylnitro...	disconnect	dishwashing
56:1,4,22,23	54:18 55:3	68:23	238:6
57:8,12,12,22	56:2,8,15 88:5	discovered	disposal 25:5
57:22 59:18	129:15 220:25	171:2 262:3	dispute 42:1
60:2,16 61:5	221:9 234:13	300:16	50:24 79:21
65:5,13,15,21	234:22 262:19	discovery	80:2,5 84:12
65:25 66:12,25	314:6 325:21	121:18 296:25	84:16 99:24
74:13,21 76:16	direct 21:10	discuss 59:17	134:22 137:13
77:16,22 78:2	43:8 141:24,25	109:8 205:8	138:2,9 174:21
78:7,20,22	249:10	223:17 224:2	180:17 203:3
80:7,7,12,17	directed 43:25	224:17 264:5	229:23 230:7
85:22 86:14	directly 20:12	discussed 30:3	230:17 319:1
87:9,21,24,25	298:1	31:25 34:2	disputing 42:4
88:2,10,17	disagree 51:20	45:6,16,20	42:6
89:5,7 90:3	51:21 74:3	77:17 101:22	dissipates
92:11 94:8,8	106:13 113:19	128:10,14,18	326:21
94:10,17,18	123:5,7 135:18	128:20 217:15	distinct 16:7
95:5,10,11,22	140:14 151:24	248:19 256:20	65:12 187:15
96:5 129:16	152:10,19	258:2,6 271:3	distinctions
205:12,19	179:24 220:13	278:2 301:15	229:18
206:1 213:7,8	220:16 236:10	308:18	distinguish
214:7,24 215:5	267:10 299:10	discusses 95:21	98:9 140:15
215:13,17	299:12	95:23	distracted
217:20 219:2,5	disagreement	discussing	151:12
219:7,10,20	180:10	23:10 179:13	distributed
220:7,24 221:2		179:17 212:20	211:19

[district - documents]

Page 23

district 1:1,1 10:15,15 disturbing 40:14 dmf 27:13 39:11 42:22 43:13 44:11 45:24 46:14,25 47:1,8,21,23 50:19,23 51:5 52:8,17,18,25 52:25 53:2,4 53:23 57:11,20 58:4 59:18,25 60:6,16 61:4,5 61:10 62:3 65:4,14,20 66:12,18,24,24 67:1 74:13,19 76:16 77:16 78:6,18,20,22 79:8,24 80:6 80:12,16 83:20 84:11 85:8,23 86:14 87:8,20 88:15,16 89:6 89:8 90:2 92:10 93:23 94:7,9,10,16 95:5,8,10,11,16 95:22 96:5 100:16 103:25 111:15 205:10 205:12,14,18 211:10 212:21	213:2,6 214:4 214:8,10,14,18 215:5,13 217:5 217:13,14 219:5,13 220:2 220:4 222:15 243:12 263:1 263:25 264:10 268:13 297:13 297:13 dmfs 263:5 dna 247:12 dnigh 2:17 docs 143:22 doctor 55:25 56:6 57:4 59:8 62:6 64:14 76:18 81:2 86:5,5 90:11 92:18 99:16 100:22 106:3 109:2 112:6 115:21,22 129:5 131:6 140:25 154:14 154:21 158:12 168:15 171:17 171:18 175:3,4 206:21 246:16 263:4 267:9 270:17 277:4 277:15 279:2 282:17 283:6 291:9 293:17 298:17 304:7	304:17 312:3 314:2 320:13 326:10 doctor's 303:24 document 7:22 8:14 9:18 19:1 19:13,16,22,23 20:5,12 22:5,6 22:7,12,21 23:12 25:20 26:3 27:20 28:3 34:22 35:4 36:2,10 36:12 37:3,23 60:7 68:21 71:6,8,9,10,10 71:12 81:8,21 83:7 84:10,11 84:15,17 85:8 108:22 109:2,9 109:24 113:9 121:5,12,14,16 122:17 158:5,7 164:9,11 165:5 165:11,18 166:1,11,15 167:7,14,18 168:5,9 169:12 169:17 172:6 172:10,15,20 172:22,22 173:4,7,9,10,25 177:5,6,7,11 178:11,17 179:8,24 180:4	180:10,11 181:8,10 182:4 182:14 187:5,8 187:11,12,20 188:10,13,19 189:19 190:3,7 190:10,19 200:13 226:24 229:24 235:3,6 237:6 258:21 290:12 292:6 292:25 296:10 307:17 308:4 308:15 312:22 313:4 documentation 16:25 27:10 32:14,18,22 33:3,7,15,20,24 41:25 42:7,20 43:2 44:18 105:14 documentatio... 43:11 documented 320:17,23 documents 17:7 18:13 20:16,20 21:9 21:14,23 24:5 41:18 46:8 60:13 65:22 67:4,5,6,10,22 67:24,25 68:2 68:5,6,6,8,14
--	---	---	--

[documents - dr]

Page 24

68:18,19 69:19	116:25 135:24	307:9	114:21 116:5,5
70:9,17,20,25	138:17 154:4,6	dr 9:7 10:12	117:11 119:12
71:20 72:2,4	175:16 176:6	11:9,18 12:14	120:8,21 121:9
72:12,15,21,25	207:23 212:12	13:8,24 14:21	132:7 135:1
72:25 73:3,6,9	212:13 215:18	15:8 16:6	136:6 137:25
73:15 74:2,7	241:7,8 245:10	20:18 21:23	139:25 140:6
75:1 76:20	257:16 285:25	22:21 25:9	140:11,13
77:3 88:22	323:8	27:22 29:25	141:21 142:20
107:9,15,22	dose 250:16,23	33:4,25 34:5	143:8 144:8
109:5 146:25	250:24 251:2	35:25 41:5	145:18 146:2
156:17 158:15	251:11,19	43:18 44:4,9	146:20 147:16
158:24 163:12	252:12,23	45:11 47:17	148:12,14
168:18 175:18	255:16 256:5	48:23,24 49:12	151:19 152:24
175:24 176:3	256:10,15,21	49:21,24 50:1	153:3,3,12,19
182:1,1 185:25	257:13 263:10	51:7,11,17	154:1,4 155:4
185:25 186:4	263:17,23	52:14 53:6	155:9,20 156:6
186:15,25	264:8,17,22	55:9 56:17	162:18 164:1
187:15,23	265:7 267:14	58:7,16,19	164:12 165:7
189:7 200:17	267:15,18,22	60:22 61:22	168:12 169:11
200:21,22	267:24 268:14	62:3 63:1,16	170:3 171:11
202:11 234:9	269:12,21,22	63:25 67:19	173:2 174:24
235:17 259:13	270:3,7,12,21	69:3,16 73:23	175:18,21
259:16,25	271:3,7,12,17	75:8,13 78:13	179:3 180:9
260:14,18,22	271:21 273:22	81:20 82:18	181:23 182:13
260:25 261:5	274:6,7,8	85:7 86:11	182:20 185:2
264:15 268:12	275:14 276:6	87:6 89:18	185:18,22
288:24 289:5	276:22 278:9	92:1,6 93:2,12	186:21 189:15
289:10,12,14	278:13 280:11	95:13,19 96:2	198:11 201:11
290:3,4,6	280:25 281:3	96:9 97:2,9	205:6,11 207:3
293:4 316:21	287:5	99:24 100:22	210:16 212:4
318:1	double 42:4	102:25 103:8	212:15 214:12
doing 12:8	81:18	103:24 107:9	219:24 222:5
13:24 14:21	doubt 61:20	108:4,19 109:4	223:6 225:4,9
54:8 66:1 76:6	94:10 144:17	111:25 112:15	225:11,15
91:10 116:19	144:19,21,22	113:18 114:4	226:7,18

[dr - electronically]

Page 25

228:12,18 233:8,24 237:15 239:25 242:8 243:20 244:17 246:5 248:13 249:20 250:10 254:24 256:12 259:3 260:4 261:7,18 266:10 268:18 269:8,20 276:15 277:13 281:11,24 282:20 283:6 284:7 285:1,10 285:24 286:17 286:21 287:4,8 287:14 288:12 289:9,13,18 290:10,17 291:23 306:1,6 312:17 313:14 313:15,20,24 314:9,11 316:5 317:20 318:12 318:14 319:16 322:18 324:13 325:11 326:20 326:25 draft 151:9 draw 114:5 225:24 286:24 driving 139:13 dropbox 302:11,19,20	302:21 303:4 303:10 308:1 dropout 23:19 dropped 302:18 drug 6:10,15 6:18 9:15 18:8 18:18 19:17 27:15 34:11,13 35:6 99:3,4 108:15 120:1 122:23 126:13 128:9 231:22 251:11 258:8 258:24 263:9 266:1 267:17 283:13 285:4 288:6,10 290:14 294:17 298:12 304:11 304:20 305:2 305:17 306:20 306:25 307:9 318:24,24 319:20,21 320:16,17,25 321:1,12 322:9 322:9 drugs 283:13 299:24 due 53:3 94:18 321:17 duly 11:6 329:4 dump 102:3	dumped 204:2 dumping 55:4 80:13 85:11 118:11 202:4 duration 218:25 e e 3:1,1 4:1,1 5:1 5:4,4,4 7:1 8:1 9:1 11:5,5,5 38:13 48:24 227:10 329:1,1 earlier 21:16 101:23 148:19 157:4 205:20 238:22 257:23 265:13,22 272:18 286:4 287:15 294:25 296:16 311:25 324:2 early 317:13 easier 152:9 easily 56:2 228:5 262:3 east 154:10 easy 122:2 144:1 215:14 eat 154:25 204:10 eating 152:25 edition 9:5 206:18 207:1 209:24,25 210:3,6	editor 146:16 education 245:13 293:23 effect 57:17 86:21,23 87:17 87:19 efficient 13:25 21:11,25 25:22 26:13,19 31:21 32:2 96:2 134:19 135:18 136:14 effort 306:19 ehs 36:4,7 eight 67:15,18 67:24 68:1,4 70:3,7,16 71:18,25 81:12 286:5,9,12 309:1 einstein 2:4 eisenhower 2:10 either 12:10 15:4 21:21 52:20 102:18 152:16 178:10 185:6 215:5 243:24 244:3 255:15 280:19 325:13 326:13 electro 317:14 319:9,12 electronically 223:14,23,25
---	---	---	--

[eleven - evaluation]

Page 26

eleven 154:4	enabled 306:17	196:18 248:15	321:16
eliminate 143:6	encompassed	entities 283:3,3	esq 2:3,4,4,9,10
306:20	294:19 295:9	entitled 1:11	2:15,19 3:4,5,9
eliminated 24:2	encyclopedia	7:4,8,13 9:14	3:14,20 4:4,10
ellen 1:12 10:19	210:20	9:18 97:5	4:15,21
56:10 112:18	ended 234:13	120:16 123:18	establish 23:11
211:24 329:2	enforcement	136:16,22	103:7,12 110:5
329:13	239:4	247:11 287:5	128:2 234:1
ellis 4:10	english 7:20	304:10 308:4	established
email 7:18 8:6	8:4,16 73:20	entries 210:13	52:24 53:2,5,6
8:8,11,18,21	166:24 167:19	210:24 211:5	53:10 74:25
12:10 163:22	168:1,2 172:16	entry 193:3	93:20 98:11
172:7,12 174:1	172:25 188:12	environment	126:3 227:6
178:19,22,25	188:24,25	29:19 30:2	243:22 271:5
179:6,16	189:7 226:15	129:13	ester 31:12,15
180:19 181:9	226:19 227:10	environmental	31:19 41:20
188:6 190:15	227:21 228:21	24:11 25:5	estimate 70:6,8
191:5 192:13	230:20,23	36:15,18,25	70:12 71:24
193:11,21	231:4	99:1	97:10
194:9,21 226:1	enhance 29:18	epidemiologist	et 330:2
226:7,9 228:15	29:22 30:1	239:14,17,19	evaluate 110:5
229:25 230:4	40:17	epidemiology	110:22 111:2
230:24 231:20	ensure 15:24	239:22	111:15 112:4
247:24 292:20	65:19 74:20	equally 257:12	113:7 296:1
300:18 301:8	76:15 88:17	equipment	298:2,11
301:11,14	214:6,16 298:3	131:25 304:22	evaluated
employee 150:2	298:11,23	equipped	74:19 110:16
150:3 329:8,9	enter 120:5	143:23 144:16	evaluating
employees	entered 15:14	equivalent	100:1 136:8
24:17 148:24	15:22 112:9	109:15	271:13 279:19
149:19,23	entire 150:2	errata 246:24	295:20
151:2	174:25 175:5	330:1	evaluation
emulsification	324:20	esoteric 55:17	131:13 238:10
40:14	entirety 13:12	especially	295:19
	14:5 147:7	79:15 219:18	

[evaluations - expert]

Page 27

evaluations 113:9	324:12 325:10 329:3	27:15 34:11,13 49:5,8 80:24	exhibits 6:2 12:20 15:9,11
events 199:11	examinations 5:3	81:1,3,10,19,24 83:8 108:15	224:23
everybody 52:18 204:18 221:9 292:15 302:13	example 59:24 60:4 66:4 83:3 95:13,14,16 98:2 127:17 128:23 144:24 145:1 156:23 157:16 158:4 181:25 182:15 185:7,10 186:8 243:8 244:14 246:3 276:10 282:8,11,13	120:10,13,15 123:16,17 136:16 163:17 163:22 166:24 167:6,11,13,14 168:2 172:7,11 178:18,19 188:6,19,25 190:13,15 192:7 193:11 193:17,20 194:24 195:1,2 206:16,17,25 225:3,4,10,10 225:11 252:18 259:9 260:5,7 260:7,10,11,21 286:3 288:13 288:20,21,22 289:11,11,23 291:22 293:13 293:14,18 296:23,24 297:1 303:12 303:13 304:8 304:10,18 308:4,9,11 309:25 310:1 310:19 311:6 311:10	expand 18:23 166:7 expect 86:13 119:18 154:18 210:23 248:18 309:19 expectation 125:6 212:22 expected 97:16 114:22 118:6 125:21 130:5,7 209:18 294:7 304:20 311:24 expensive 98:20 135:10 144:3 experience 219:4,9,9,14,16 220:2,5 239:3 242:10 278:18 293:24 experiment 211:16 expert 6:21 35:14 48:24 49:8 69:7 73:24 75:22 77:2 131:18,23 132:5 153:4 239:21 244:8 244:15 246:13 247:17 279:22
evidence 44:9 142:21 143:8 144:9	examples 50:21 83:2 161:16 182:16 185:11 197:3		
evolution 135:7	exceed 281:12		
evolves 135:14	exceeded 280:9 281:1		
exact 52:16 53:7 59:23 71:1,2 243:24 244:2 266:11	excerpt 9:4 158:24 206:17		
exactly 17:25 46:10 54:1 64:9 103:11 122:1 144:13 167:5 170:24 170:25 201:7 206:13 207:9 223:20 234:17 235:18 257:25 275:10 321:25	excerpts 156:23 163:11		
examination 1:6 5:6,7,9,10 5:12,13,15,16 5:18,19,21,22 11:8 205:4 250:9 286:16 291:8 312:19 318:15 320:12 322:17 323:22	excess 29:7 87:11 exclude 275:17 excuse 130:4 exhibit 9:7,7 12:25 13:4,12 18:13,17 22:14 22:15,20 27:13		

[expert - falkenbergives.com]

Page 28

280:23 283:23 284:25 299:13 experts 140:18 141:6,22 142:5 152:2,15,22 expires 330:25 explain 58:21 69:11 75:7,9 87:6 160:6,8 160:15 166:16 170:14 176:6 186:7 189:20 241:5 explained 142:25 222:24 237:2 299:17 explanation 180:25 182:2 explicitly 122:18 exploded 319:8 explore 55:10 69:1 exploring 78:9 explosion 87:12 explosive 29:11 export 228:12 exposed 126:5 247:13 expressing 43:12 44:10 extending 119:4 extent 117:8 171:14 189:15	249:10 270:4 278:24 extra 299:8 308:25 309:3 extracting 88:4 88:7 f f 94:23 329:1 face 82:8 182:4 facilitate 39:14 fact 32:17 49:19 50:11,15 50:16 53:2 54:13,16 55:17 96:17 97:20 98:9 104:17 112:9 139:8 145:19,21,22 145:23,23 160:24 197:22 211:4,8 213:6 233:14 234:7 245:22 246:13 267:2 275:17 286:8 288:2,3 300:19 301:11 316:3 factor 160:8 162:25 203:13 factors 105:2,4 facts 256:11 285:9 319:13 factual 253:14 253:23 254:7 256:10 287:17	288:5 fahrenheit 218:17,21 failed 104:5,12 106:8 297:6 298:2,23 failure 296:1 297:16 fair 12:2,12 16:8 24:8,14 25:9 26:8,16 29:15,19,25 30:3,18 32:24 35:13,15 37:22 38:2,14,18 39:2,17 40:18 41:17 47:2,24 48:15 51:19 52:14 53:9 55:14 58:19 60:24 61:2 73:8,10,16,21 74:6,17 78:24 84:5,18 94:15 97:13,18,23 100:2 101:10 102:12 109:24 114:23 117:18 118:25 119:18 127:15,25 128:6 131:6,17 132:1,18 136:10 139:15 140:22 141:3 142:5 150:16	150:23 151:1 158:6 163:12 165:6 166:11 170:16 173:8 177:22 181:17 181:21,24 182:23 183:12 183:21 186:21 188:15 191:2 192:9 194:6 196:11 197:21 209:5,19 210:20,22 211:11 212:10 212:17 213:17 215:25 218:10 221:20,23 227:19,20,22 229:1,14,17 230:17 231:21 237:24 238:12 239:1,5,15 242:6,11 243:1 243:9,11 244:24 249:1 252:14 314:12 315:5,14 316:24 318:5 fairly 91:9 falanga 3:20 falkenberg 3:14 falkenbergiv... 3:16
--	---	--	---

[fall - finished]

Page 29

fall 135:9 256:13 familiar 15:13 19:21 20:1 21:14 27:19 121:6 207:2,5 208:23 209:4 209:13,18 213:6 250:15 263:4 270:8 279:2,10,15,16 279:21 283:7 283:14 far 133:24 158:19 160:1 160:21 165:23 199:2,6 201:4 210:7 233:25 274:2,5 279:3 283:12 fashion 258:1 fast 189:23 faulty 251:24 favor 25:11 116:23 fda 6:10 7:4,4,8 7:8 9:11 18:8 18:17 27:1 32:14,18,21 33:4,8,15,19,20 33:25 34:18 35:3,10,14 41:25 42:8,10 42:21 43:2,12 44:10,19 45:5	99:25 100:13 100:15 105:15 108:22 113:9 113:15 120:14 120:15,16,22 120:22 121:9 121:17 122:17 122:23 123:5 123:10,17,18 124:3,7 126:7 127:9,10 243:15,22 244:20 245:4 296:10,18,21 297:1,5 298:1 299:4,6,20 300:1 fda's 120:23,24 263:4 296:14 fda's 7:4,6,9 120:16,18 123:18 february 8:8,11 178:20 188:7 federal 152:17 feed 93:2 feedback 193:5 feeding 93:3 feel 82:5 117:4 117:6 270:2 fell 222:6 fengtian 6:21 49:9,12 fewer 71:4 72:12,17,19	fid 133:7,9,12 133:17,22 134:10 138:20 139:8,23 140:1 148:2 276:11 277:9,17,23 316:12 field 239:21 315:24 319:11 323:10 fields 94:20 fifth 195:13 311:15 figure 180:6 189:10 200:15 200:19 223:7 252:2 figured 109:1 199:5,16 200:15 201:4 203:25 262:21 262:25 figures 138:11 file 6:11,15,18 18:8,18 27:16 34:11,14 35:7 108:16 263:10 292:17 filed 10:14 18:7 26:25 34:17 files 263:17 316:21 filings 239:8 filtering 303:9	final 29:14 254:4,13 financially 10:22 329:9 find 59:17 65:23 66:4,12 146:8 147:21 163:1 181:4 203:12,15 208:1,5,13 212:19 216:18 228:5,6 250:20 272:19 finding 220:24 findings 7:6 120:18,25 fine 169:13 187:1 236:15 finish 25:12 62:16 77:1 84:24 116:21 145:17 152:7 175:3,4 224:3 224:4 248:2 finished 58:7 236:2 250:16 250:23,24 251:2,11,19 252:12,23 253:7 255:16 256:5,10,15,21 257:13 263:10 263:17,23 264:8,17,22 265:7 267:14
--	--	---	--

[finished - form]

Page 30

267:15,18,22	188:10 192:11	flom 2:3	forever 154:11
267:24 268:5,6	197:16 199:4	floor 2:11 3:21	forget 59:1
268:14 269:12	204:20 207:5	4:5	108:17 243:23
269:21,22,24	207:14,17	florida 2:16	247:22
270:3,7,12,21	213:13 229:9	fmoc 94:21,23	forgetting
271:3,7,12,17	236:23 253:4	95:4	258:19
271:21 273:22	255:1,5 256:16	focus 45:15	forgot 26:5
274:3,6,7,8	257:2 259:12	57:10,14 63:17	247:6
275:14 276:6	266:24 271:2	63:24 83:11	forgotten 71:19
276:22 278:9	275:22,24	96:5,9 121:13	form 17:10
278:13 280:11	286:21 288:1	156:6 273:19	20:6,9 47:2,23
280:25 281:3	291:13 293:7	focused 120:3	48:10 55:3
287:5 288:6,10	305:15 308:1	242:20	56:2 57:5,12
290:25	312:20 313:3	focusing 108:4	57:21 59:18
firm 2:18 10:17	314:22 324:19	folder 292:19	61:5 77:21
73:2 148:7	fishy 53:2	304:2	78:6,22 80:7
250:13	94:18	folks 249:15	86:14 87:8,20
firmament	fit 164:3	follow 121:18	90:3,17 92:11
257:20	five 7:12 27:14	130:2 193:6	95:11 100:18
first 12:22 14:5	27:14 62:22	312:18 320:9	102:6 113:11
14:18 16:10	82:12,13 91:14	followed 133:2	115:24 118:4
36:11 48:7	123:22 129:20	following	118:14,16,25
49:18 51:11	140:17,19	169:16 214:13	119:14,22
54:21 55:13,15	141:9,14,19,21	222:14	148:14 200:8
56:21 65:1	142:4 146:17	follows 11:7	205:18 219:1
77:25 88:5,8	249:25 306:13	food 19:16	222:19,24
101:22 109:8	309:7	129:12	243:12 262:19
117:11 135:10	fixed 81:19,24	foods 127:23	265:16,24
136:6 141:10	flame 7:14	127:23	266:13,17,19
156:23 157:16	133:3,14	footnote 141:12	267:16 268:12
158:4 163:20	136:17,23	141:15	284:22 295:3
164:10 165:1	137:22 240:14	forced 37:1	295:21 296:5
165:11 166:10	274:20	forefront 264:6	297:13,18
181:7 187:7,9	flip 188:13	foregoing	298:16,19
187:11,20,20		328:4 329:5	305:23 307:6

[form - gas]

Page 31

307:11 309:14 309:22 321:23 324:21 formation 13:15,19,21 23:14 28:7 29:8 30:12 33:22 35:22 38:1,8 39:10 40:24 41:6 44:21 45:19,23 46:25 48:5,8 50:20 52:17 54:15 56:24 60:16 89:13 94:8 104:14 111:8 112:23 124:9 127:25 128:11,13,13 128:22 129:8 129:15 130:6 130:24 206:1 215:16 222:2 222:10,13,14 230:1,5,9 231:14 238:1 243:3 258:23 265:3,9 296:8 297:7 299:7 formed 47:21 65:5 79:23 80:18 85:23 87:25 88:5,10 89:7 101:17 102:13,14,19	118:20 126:6 127:22 131:5 133:13 148:21 215:6 219:20 220:7 221:2 263:1 former 282:2 282:12 formic 60:2 forming 37:13 56:8 67:7 69:20 70:21 73:1 147:2 149:17 203:14 247:8 257:9 261:2 270:5 281:14 322:24 forms 102:3 103:1,4,14,15 formula 82:13 formulation 252:24 287:6 290:13 forth 115:17 181:3 192:22 291:19 329:6 fortunate 154:8 forward 106:20 300:10 found 33:3,7,19 42:20 43:1,11 44:9 59:23 66:16 95:5,14 95:21 96:17 162:6 168:25	169:14 171:5 177:10 178:3,4 197:9 234:23 256:4 323:2 foundation 75:5 87:2 100:4,8 116:12 168:17 171:23 175:5 179:19 297:19 298:20 309:15 321:24 326:4 foundational 101:5 four 16:6 17:15 45:12 72:8,11 72:19 91:14 105:12 146:24 195:13 259:18 259:21 284:9 290:4 fourth 9:4 16:19 170:15 173:17 206:18 207:1 209:24 209:25 288:2 289:2 296:12 311:15 fragmentation 322:1 francis 190:19 190:21,23 192:2 frankly 154:25 304:18 305:15	free 88:17 180:11 freeman 2:9 friday 1:15 friend 25:16 302:14 front 95:20 178:23 216:4 full 207:8 239:25 257:2 262:10,15 321:6 fully 75:10 174:5,9 298:10 298:22 function 216:15 functions 133:12 fundamental 312:6 further 20:25 22:7 135:11 191:23 193:5 198:10 205:8 249:5 255:6 273:6 318:11 321:9 323:20 326:17 329:5,7 furthermore 56:7
			g
			gannon 3:20 gas 7:14,15 132:14 133:10

[gas - go]

Page 32

134:5 136:17 136:18,23,24 240:9,13,18 gateway 3:21 gc 9:15,19 132:14,21,23 133:2,17,22 134:6,7,10 135:5 138:10 138:12,17,20 138:21 139:8 139:23,23 140:1 143:15 148:2,10 215:14 240:20 241:9 262:5 273:12 276:10 276:10,11 277:5,9,17,23 277:24 278:1 282:1,11 284:4 284:10,14 304:12,21 305:3 306:15 307:1 308:6,13 309:1,7,8,12 310:21,22 311:1,22 316:12 317:16 319:7 321:16 322:3 325:20 326:5 gears 204:6 geddis 2:10 292:8,12	302:10,19 306:5 general 15:4 43:24 108:2 113:24 115:11 129:8 134:4 147:19 160:13 243:6 254:20 264:13,20 305:20 generalize 32:11 generally 97:13 124:22 125:7,9 128:3,7 132:7 147:2 241:14 242:17,24 251:8 252:8 255:3 264:7,21 270:1 271:16 generated 50:19 276:24 generation 306:19 generic 231:23 georgia 3:6 getting 37:19 98:13 115:16 117:4 159:7 161:5 261:16 267:1 274:12 292:18 303:3,9 giant 169:17 gist 18:1	give 14:17 70:11,12 82:18 82:21 97:25 98:2,20 101:14 116:1,10 119:10 175:11 184:21 186:11 186:15 216:12 217:20 224:22 237:12 252:6 298:17 302:7 307:22 given 189:8 214:23 219:19 236:11 242:16 326:25 gives 83:2 98:19 109:13 156:24 181:12 196:10 glean 168:8 glenmark 185:20,23 186:7 187:10 189:22 190:4 191:16 192:9 192:17 193:4 194:11 195:8 196:9 glenmark's 191:9 193:4 go 10:9 11:24 14:2,12 21:1,7 21:18 22:4,7 23:7 29:1	30:22 39:7 48:3 60:21 61:11,25 66:3 76:12 77:8 78:11 79:17 82:18 85:18 86:20 88:23 89:18,23 90:6 90:11,22 98:5 101:21 106:5 106:18,20 115:17,25 116:1 121:23 127:23 129:17 133:24 134:6 134:20 137:18 140:6 146:3 150:25 151:21 155:7 156:21 161:20 165:10 169:5,6,7,23 171:4 173:5,25 175:15 178:23 179:1 180:3 181:7,24 191:4 191:7 192:6 194:9,10 204:19 205:8 208:5,11,12 209:23,24 213:12 216:16 216:17 219:3 224:25 225:15 225:22 231:18 233:16 234:10
---	---	--	--

[go - guy]

Page 33

236:9 252:6	93:7 98:20	286:19 291:3	308:9,10,22
253:21 254:6	99:4 101:15	293:3 296:9,11	greatest 100:14
256:17 257:5	106:2 108:1,11	296:18 297:15	greenberg 3:4
257:23 260:8	108:13 114:10	298:12 299:11	250:13
290:21 296:11	114:13 116:8	300:9 301:2	grilling 127:22
298:21 300:13	129:18 133:6	302:7 305:14	grinberg 305:9
306:3 307:16	141:20,23	307:20,22	ground 92:24
308:18,20	148:9 150:4,15	309:10 311:6	93:1 152:6
309:16,23	151:13 152:15	326:8	group 17:8
311:6,13 321:5	153:22 154:17	good 10:1 11:9	41:20 94:21
321:8	155:4,5,12,24	107:13 118:2	95:4
goal 40:1,1	158:3 161:6	144:24 153:24	gs 140:4
97:3	162:1,2,12	176:19 204:9	gsmc 325:23
godino 1:12	164:22 171:10	205:5,6 211:7	gtlaw.com 3:7
10:19 329:2,13	180:7 181:19	215:22 250:10	3:8
goes 14:22	181:24 184:21	250:11 282:13	guarantee
82:20 192:21	186:19 187:12	299:22 302:12	162:16 219:19
192:25 200:14	188:24 199:17	gordon 4:3	220:6
216:19 220:14	200:18 203:20	gotten 91:3	guess 35:11,12
260:18 275:8,9	203:21 204:8	303:5	36:15 58:24
308:15	204:12,22	gottlieb 121:3,9	70:13 97:24
going 10:2	211:19 219:4,6	124:4	119:21 141:18
11:24,25 12:9	219:20 220:10	governed	165:24 179:22
13:10,11,12	220:23 223:21	116:17	227:5 235:20
14:11 15:9	225:2 232:1	governs 15:23	241:23 246:20
21:3,14,20	233:18 236:1	grade 91:20	251:25 264:12
27:24 36:17	237:12 238:21	grant 4:5	266:23 267:5
37:7,21 40:7	241:11 249:23	graph 275:14	296:23 302:6
51:21 59:11	249:25 250:2	graphic 275:6	guessing 81:8
62:8,20 63:4,8	250:20 257:5	graphical	guidances
66:22 69:14	257:23 259:8	275:5,7	270:2 279:16
73:12 78:9	264:14 271:10	gray 256:13	280:20
81:18 82:21	272:7 275:21	great 89:15	guy 144:6
84:22 89:4	277:9 280:6,22	98:20 104:4	145:9 147:13
91:15 92:24,25	281:4,9 285:17	234:10 303:17	147:24 200:11

[guy - hecht]

Page 34

204:1 220:14 262:21 273:16 278:19 guys 293:9 308:2	happy 17:1 75:6 152:20 255:20 261:25 303:23 hard 37:7 68:20 120:12 138:16 139:12 206:22 harder 50:3,4 208:16 harding 3:9 harkins 3:4 5:9 5:15,22 249:21 249:24 250:9 250:12 261:12 268:22 269:5 272:3 285:10 287:9 303:3,7 303:8,23 304:2 309:22 310:6,8 310:8,12 318:13,15 319:3 320:8 325:9,10 326:17 harkinss 3:7 harmful 24:17 hash 244:21 haverford 240:6 hazards 98:23 257:18 hcl 23:13 he'll 124:16 308:1	head 141:23,25 309:6 header 260:15 260:18 heading 252:22 259:13 health 36:15 59:25 hear 11:11,13 42:17 125:17 158:11 245:19 251:6 heard 10:7 11:1 284:18 hearing 115:18 304:5 heat 89:12 94:11 95:11 219:5 220:8,19 221:18 heated 83:21 90:2 205:21 217:23 220:19 220:20 heating 52:25 88:1,10 89:14 219:10,12,13 220:2 hecht 1:7 6:5,6 6:8,8,10,13,15 6:18,21,23 7:4 7:8,13,18,20,20 7:22 8:4,4,6,8 8:11,14,16,16 8:18,21,23 9:4	9:7,9,9,11,14 9:18,22,24 10:12 11:9,17 11:18 12:14,20 12:25 13:1,4,5 13:8,24 14:21 15:8 16:6 18:17 20:18 21:24 22:15,21 25:9 27:15,22 29:25 33:4,25 34:5,13 35:25 41:5 43:18 44:4,9 45:11 47:17 48:23 49:8,21 50:1 51:7,11,17 52:14 53:6 55:9 56:17 58:7,16,19 60:22 61:22 63:1,16,25 67:19 69:3,16 75:8,13 81:3 81:20 82:18 85:7 86:11 87:6 89:18 92:1,6 93:2,12 95:13,19 96:2 96:9 97:2,9 99:24 100:22 102:25 103:8 103:24 107:9 108:4,19 109:4 111:25 112:15
h			
h 5:4,4,4 7:1 8:1 9:1 11:5,5 11:5 half 71:25 72:5 92:20 154:7 hand 137:19 231:2 handful 259:16 handle 148:7 handy 164:13 164:15 hang 116:6,6,6 154:2,2 happen 77:7 89:10 186:19 221:14 happened 76:22 89:9,12 89:14 154:8 162:13 166:17 197:23 204:5 221:9 237:2 282:14 312:7 happening 59:8 243:23 306:10 316:3 happens 145:6 222:19			

[hecht - hours]

Page 35

113:18 114:4	212:4,15	hecht's 9:7 62:3	122:3 124:15
114:21 116:5,5	214:12 219:24	78:13 169:11	195:23 225:23
117:11 119:12	222:5 223:6	225:11 291:23	highlighting
120:8,15,21	225:4,9,10,15	306:1	26:4 83:7
123:17 132:7	226:7,18 233:8	heewon 305:8	hill 4:15
135:1 136:6,16	233:24 237:15	held 1:13 292:3	hillwallack.c...
137:25 139:25	239:25 242:8	302:23 307:24	4:18
140:11 143:8	243:20 244:17	help 15:5 18:24	hint 199:8
145:18 146:2	248:13 249:20	36:14 71:13	hit 81:17
146:20 147:16	250:10 254:24	116:13 143:19	hoc 66:5,21
148:12,14	256:12 259:3	148:12 151:8	74:11,15
151:19 152:24	260:4 261:7,18	209:5 285:14	hold 63:2 80:22
153:3 154:1,4	266:10 268:18	helped 41:5,19	173:1 233:16
155:4,9,20	269:8,20	helpful 44:3	267:14 287:23
156:6 162:18	276:15 277:13	164:12 251:15	291:18 302:1
163:22 164:1	281:11,24	helping 116:21	holds 273:21
164:12 165:7	282:20 283:6	henry 4:21	hollis 2:18
166:24,25	284:7 285:1,10	hereinbefore	honestly
167:14 168:2,3	285:24 286:17	329:6	175:14
168:12 170:3	286:21 287:4,8	hetero 4:14	hope 290:22
171:11 172:7	287:14 288:12	260:22	326:20
173:2 174:24	289:9,13,18	hey 25:10	hopefully 291:1
175:18,21	290:10,17	232:22 292:24	hoping 264:13
178:19 179:3	293:14,15	hi 286:17	hour 63:5
180:9 181:23	297:1 304:10	high 7:13 91:19	92:20 114:10
182:13,20	306:6 308:4	98:19 136:17	153:24,25
185:2,18,22	310:1 311:10	136:23 319:22	154:7 155:8
186:21 188:6	312:17 316:5	320:3	241:19
188:19,25	317:20 318:12	higher 298:9	hours 83:22
189:1,15	318:14 319:16	highlight 37:4	89:12 93:15,15
190:15 193:11	322:18 324:13	50:2 122:2	94:11 95:12
195:2 198:11	325:11 326:20	233:3 235:9	150:20 154:19
201:11 205:6	326:25 328:11	highlighted	218:1,3,7
205:11 206:17	329:4 330:3,21	36:8 63:19	219:6,11,19
207:3 210:16		83:12 86:12	220:3,3 221:19

[hours - impacted]

Page 36

242:3 249:14 249:16 housekeeping 286:1 how's 155:8 hplc 318:25 319:23,25 320:3,5 hrms 141:25 huahai 2:2 huahai's 23:9 huge 105:25 hum 84:2 89:21 123:24 humana 3:13 3:13 94:25 humans 126:5 247:13 hundred 70:8 71:4 72:13,13 72:17,19 123:9 143:16 144:4 212:16 216:18 220:6 282:9 hundreds 97:11 117:16 118:1 126:25 145:3,7 146:5 242:13 hydraulic 83:25 hydrochloric 28:20 29:6 33:9 43:3 44:16 83:25	hydrochloride 23:13 25:21 35:21 hydrogen 133:14 hydrolysis 31:19 40:24 41:5,18 47:7 51:5 58:4 hydrolyze 31:15 94:10 hydrolyzed 213:8 [REDACTED] [REDACTED] [REDACTED] hypothetical 119:10 hypothetically 130:5 203:7,10 203:11 i ich 279:16 280:20 idea 45:7 67:13 72:23 105:7 106:16,22 214:1 224:5 229:13 230:15 230:25 284:6 identical 225:8 identification 9:14,19 13:3,7 18:20 22:18 27:18 34:16	49:11 81:5 120:20 123:23 136:21 159:18 163:25 167:1 167:17 168:4 172:9 178:21 188:9,22 189:2 190:17 193:13 195:4 206:20 225:12 279:4 293:16 297:4 304:11,15 305:2,16 306:15,17 307:18 308:5,8 308:13 309:3 310:3 311:12 320:15 321:17 identified 129:22 141:22 143:8 159:24 160:1,19 161:16 172:22 173:21 198:5 198:14,18,21 200:12 202:10 253:20 261:12 262:9 272:11 272:23 273:4 273:23 274:9 274:14 275:15 275:18 276:4,7 276:17,23 278:14 279:13 290:11 300:3	300:11 314:5 322:23 323:16 326:12 identifies 195:12 196:9 283:24 identify 63:22 150:8 197:17 221:11 262:5 323:15 325:12 325:14,20,24 326:1,12 identifying 190:24 identities 191:17 idiots 126:24 ignore 274:23 276:1 ignored 62:21 ii.2 13:14 iii 13:18,21,23 14:15 illinois 3:15 imagine 29:23 31:24 137:2 138:16 264:1 imaging 274:16 274:18 immediate 121:1 impact 99:2 impacted 176:5 296:2
---	---	--	---

[impacts - information]

Page 37

impacts 32:9 189:21	281:2 294:16 297:8,12 298:4	inclusion 190:4	individually 32:9
implemented 297:8	298:8,10,11 304:11 305:2	incoming 278:13	individuals 190:20 314:15
important 56:23 75:16,20 113:5 245:8,15 245:20	305:17 306:14 320:15	inconsistent 182:3	industrial 211:18
importantly 50:21	impurity 30:12 40:25 41:6	incorporate 162:2	industries 3:2 143:24
impossible 99:19	109:16 110:11 114:23 115:3	incorporated 3:18	industry 132:11 138:15 142:21 143:10 143:16,22 144:3,4,15 145:4,8,14 146:19 147:24 256:24 279:18 282:1,4,10 284:15,24 285:7 299:9,21 315:13 316:2 317:6,18 318:2 319:14 322:10 323:12 325:18 325:23 326:6 326:15
improper 75:5	118:4,6 124:24 124:25 161:11	increase 38:17 219:1	
improperly 116:11	294:17 306:17 306:18,20 318:23 319:20	increased 37:15 38:1,3,7 38:11	
improve 40:20	inappropriate 112:11 175:7	incumbent 52:20	
improved 37:25	inartfully 275:2	index 6:1 216:10 224:4	
improves 26:7 32:1	include 68:5 95:5 141:22 146:24 209:11 209:12 283:3	indicate 160:23 176:23 183:9 256:24	
impurities 7:5 7:10 9:14 30:17 36:1 41:11 95:4 115:6,7 117:13 117:17,23 120:17,24 123:19 124:21 131:18 140:1,3 161:9,13,17 195:24 196:2,5 197:9 237:16 238:1 256:4 258:7 262:2 279:4,12,19	included 70:22 154:22 260:1 289:15	indicated 160:12 174:8 250:25 278:4 310:23	
	includes 156:10 179:5 195:22 209:17 259:13 269:20 290:4	indicates 46:8 160:25 253:19 255:11 258:21 290:12	information 15:23 58:13 61:17 98:5 144:7 145:10 157:13 196:10 199:25 202:16 209:3 211:9 262:10,15 263:9 264:8,16 264:22 265:3,9
	including 62:9 141:11 171:22 255:16 265:7 297:13 325:21	indicating 33:25	
		indication 45:4	
		individual 313:1	

[information - issue]

Page 38

268:10,12 271:11 275:19 287:16,17 288:5 294:20 294:25 295:10 301:6 ingelheim 305:11 ingersoll 4:20 ingesting 254:17 initial 191:13 261:3 268:20 271:24 initiate 105:2 injected 240:20 240:24 241:1 injection 141:24,25 input 152:23 inquiry 183:14 instance 32:6 instances 197:9 institutions 144:2 instrument 133:9 instrumentati... 315:10 316:1 317:19 319:15 326:5,7 instruments 7:16 136:20 144:5 241:10 311:17	int3 37:10 intend 146:9 intended 31:20 40:17,20 41:10 209:2 253:16 256:8 269:21 287:16 intending 15:25 96:3 251:18 intent 198:1 interactions 247:12 interest 184:22 245:6 interested 10:22 329:9 interface 319:9 intermediate 40:13 international 3:18 internet 10:6 interpretation 209:6 interrupt 152:6 231:5 interrupted 117:12 152:13 186:18 interrupting 184:6 interruption 152:13,14,14	interview 151:1 interviews 313:7 invading 117:8 invent 48:14 invented 48:13 invention 82:21 inventory 224:16 investigate 65:19 124:8 158:21 159:3 163:10 178:6 234:7 235:14 237:8 273:6 investigated 162:22 197:23 198:13,18,21 231:13 233:14 investigating 191:22 investigation 7:5,9 120:17 120:23 123:19 161:10 175:21 191:23 235:4 investigational 276:16 investigators 128:8 investment 144:1 invoice 241:17 invoiced 241:22	invoices 241:12 involve 126:15 involved 30:24 45:23 64:3 79:7 91:17 92:9,16 93:22 94:1 96:8 98:11,24,25 251:2 283:4 294:11,15 295:6,16 involvement 237:14,22 involves 96:20 251:9 involving 247:17 ion 277:6 ionization 7:14 133:3 136:18 136:24 137:23 240:14 274:21 ions 133:12 irbesartan 1:4 10:13 231:7,9 231:15,22 232:9 235:23 ireland 199:3 200:11 irrelevant 52:3 148:4,5 171:4 171:7,9,15 185:17 issue 51:5 127:11,12
---	---	---	--

[issue - know]

Page 39

158:8 162:13 170:4 172:3 174:23 175:2 179:6,12,16,25 194:3 235:13 issued 6:24 81:4 121:17,17 124:3,7 246:24 issues 7:11 15:4 35:14 84:10 123:21 162:23 245:21 258:4 281:8,10 314:20 item 170:15 173:17 items 223:4 ives 3:14,14	313:17 jinsheng 226:2 jmr 4:6 john 4:15 jordan 2:4 josh 22:10 41:2 49:17 78:13 80:22 82:17 106:5 109:20 120:11 122:2 140:8 141:17 142:9 164:8,17 164:25 166:8 166:23 173:6 194:13 206:11 208:13,14 213:13 joshua 2:4 journal 9:16 247:22,23 248:4 304:13 305:4 jr 4:15 judge 115:18 july 6:6 12:15 12:16,23 13:1 226:1 241:20 241:24 242:1 252:17 256:16 260:5,8 261:8 261:19 268:20 271:24 286:22 286:22 288:11 288:22 289:16 300:13,15,17	312:21 313:4 jump 124:12 jumped 236:17 jumping 25:11 june 258:5,24 259:1 290:14 jury 58:22,22 75:17,20,23 justification 29:2,3 109:21 177:17 190:25 justify 191:17 justin 10:20	131:13 171:3,6 207:8 233:15 238:15 245:9 259:4 kinds 71:22 111:1 127:14 208:7 kirkland 4:10 kirkland.com 4:12 kirstin 3:14 knew 148:22 know 11:23
j		k	12:7 20:13,20
j 1:12 2:4,10 328:1 329:2,13 january 1:15 7:11 10:3 18:9 19:18 123:21 124:1,4 jason 4:4 jbobber 4:18 jenny 174:3,13 176:11,17 180:5 jersey 1:1 2:11 3:22 10:15,18 95:1 329:3,14 jin 301:8 312:21 313:5,8		kansas 2:20 katz 2:9 kbi 3:16 keep 51:22 69:14 93:7 155:4,5 208:13 208:19 249:23 249:25 kentucky 91:20 kevin 199:3 200:11 201:5 key 31:8 kidding 220:22 kilograms 37:15,16 211:14 kind 20:5,16 41:24 43:11 66:5 71:10 80:15 126:22 127:18 131:13	20:23 24:12,21 24:23 25:7,19 32:5,7,11,11 38:4,4 39:21 39:25 42:16,18 42:19 46:5,10 46:23 47:6,19 48:2,11,18,21 52:18 53:3,12 55:1,20 58:4 58:10 59:23 60:5 61:6,7,16 62:3 66:1,6,17 66:21 67:12,14 67:16 68:16,22 69:8,10,12 70:19 73:14,20 75:17 76:4,4,5 76:12 77:4,4,7 77:12 78:21 80:4,16,17

[know - known]

Page 40

81:9,17 85:21	149:5,25 150:1	209:10,11,12	281:19,20,22
85:24 88:14,22	150:10,20,22	210:18,24	281:22 282:12
90:9,19 91:19	151:23 153:8	211:4,13,17,18	282:21,24
94:7,9,14,19,20	153:11,14,16	212:11 213:6	284:23,23
94:21 95:7	153:17 159:7	213:23 214:22	285:3,3,5
97:16,22 98:13	159:13,17	214:24 215:2	289:24 294:7
98:22 99:7	160:2,12,18,20	216:16 218:20	296:10 303:14
100:10,12,13	160:22 161:5	219:17 221:8	311:14 312:22
100:15,19,21	161:14,15,21	221:25 222:1	314:4 316:11
101:16 104:25	161:22 162:1	222:17 226:20	317:8,15
105:1,4,5,5,23	163:6,7,7	226:21,24	319:11,13
105:24 106:16	164:1,3 165:22	227:14 228:11	320:2 322:2,5
106:19,21,25	168:22 170:1,1	228:17 229:7,9	323:10,14
107:4 113:14	170:3,9,22	229:10,11,13	325:2 326:3,5
114:4 115:2,19	173:19,20,22	230:21 231:3,7	knowable
117:16,21,25	173:23 176:4	231:11,18,22	55:16
119:3,4,4,6,11	176:24 177:1,5	234:18 241:9	knowing
119:21,23	178:5,9,14	242:3 243:5,6	102:11 227:25
120:1,2,6,10	179:21 182:7	246:21,21	knowledge
121:6 124:12	183:7,24,25	251:25 252:1,2	57:11 63:21
124:25 125:16	184:1,20	252:3,8 253:6	64:1,22 74:18
125:18,21	189:25 190:21	257:20,25	76:14 78:1,5
127:13 131:2	193:16 194:8	259:10 262:22	96:6 119:13
131:20,22	197:8,19,25	262:24 263:2	120:4,5 125:11
132:4,9 135:3	199:2,4,12,15	264:4 266:24	126:1 128:6
135:5,7,8,11	199:16 200:2	267:6,6 268:3	171:11 221:15
137:3,7 138:11	200:12,16,21	268:15 271:18	257:18 258:3
138:12,16	200:24 201:4,8	271:19 273:10	262:4 264:21
139:13,19,19	201:12,16,19	273:12,13,15	269:10 273:16
140:13 141:15	201:21 202:7,9	274:18,23	315:24 328:6
143:7,21 144:6	202:17,22,25	275:7,11	knowledgeable
144:15 145:1,9	203:2,6,8	276:11 277:9	120:7
146:16 147:9	207:8,11,12,20	277:11,22,23	known 16:10
147:13,21	207:24,25	278:18,20	16:13 30:12
148:1,3,23	208:2,3,4,9,16	280:4,17	48:12 53:11,12

[known - lin]

Page 41

53:16,21,23 54:11 55:16 56:1,3,4 57:17 57:20,25 58:1 58:13,16,17,20 59:19 60:24 61:5,9,13,13 62:2 64:20 65:2 86:15 96:7,19 98:7 125:20 127:4 127:12 129:16 130:25 211:10 212:8,11 271:7 294:21 299:19 300:19 knows 100:6	lack 100:4 116:12 160:13 160:16,23,25 161:3,3,4,4,12 168:10 171:25 172:1 224:14 309:15 language 7:18 7:22 8:11,14 83:12 91:6 163:23 167:15 188:7,20 229:11 233:4 309:12 large 273:3,7 larger 184:21 203:21 273:19 274:22 277:8 318:20 late 204:14 laughable 317:19 laura 283:23 law 2:18 73:2 152:18 250:12 lawyer 306:5 lawyers 151:19 154:21,25 302:7 layperson 38:2 layperson's 37:22 lc 9:15 138:18 141:25 143:15 241:9 273:13	276:11,11 282:11 304:12 304:21 305:3 306:15 307:1 311:22 316:12 317:13,14 319:8,11 320:16 325:20 325:24 326:5 leading 99:25 309:22 leads 109:15 leave 154:3 lecture 116:24 lee 10:17 172:12 189:6 305:8 left 36:7 137:10 137:16,19 192:12 210:8 legitimate 130:3 length 220:8 letter 6:5,8,10 9:11 12:25 13:4 18:17 296:11,19,22 297:1,6 298:2 letters 299:5 level 39:5 levels 109:16 122:14,19 148:8 253:20 254:6,14 256:4 279:12 298:10	levin 2:14 levinlaw.com 2:17 lexington 4:11 li 156:24 301:2 301:7,15 313:1 313:4,14,20,24 314:9,11 li's 313:15 liability 1:5 10:14 libraries 321:19,21 322:1 library 195:16 208:4 license 329:2 life 32:23 light 202:5,12 263:2 likely 206:4,6 208:20 209:12 233:11 234:3 272:25 likes 47:6 limit 93:15 157:23 limitation 196:4 197:13 limits 151:14 152:16 lin 226:2 301:9 312:21 313:5 313:17 314:13
l			
lab 132:12 207:24 208:1,3 209:3 210:23 213:24 228:5 241:8 278:19 278:21 labeled 289:4 290:3 laboratories 4:2 207:12 laboratory 9:4 206:18 207:1,9 207:10 208:21 213:21,24 214:3 labs 4:14			

[lin's - look]

Page 42

lin's 313:8	210:17 290:7	244:9,15	91:9 95:9
line 4:16	308:6,13 309:3	245:23 246:14	154:15 202:7,9
115:16 117:5,5	listen 221:23	247:17	240:4 291:1
140:16 156:25	listening	little 18:25	longer 82:2
156:25 174:22	245:11	25:11 37:9	190:18
175:1,6 193:24	listing 184:12	38:25,25 52:15	look 12:9 13:16
198:11 215:8	311:15,16	63:4 115:16	14:12 17:3
236:23 246:17	lists 195:8	120:3 137:12	21:12 22:7
252:2 261:24	289:9 311:19	141:17 142:9	23:9 28:2,4
287:15 301:3,4	literally 92:19	147:11 153:23	35:18 39:3
306:8 330:5	93:6 138:24	176:7 182:24	52:13 60:20
lines 129:20	282:9	191:7 198:10	66:6,7,23,24
232:20 234:11	literature	199:12,14	74:6 80:21
234:19 294:8	49:19 50:16	205:7 210:19	81:21 82:11,19
306:13	52:16,25 58:3	215:21 216:12	82:23 83:1,15
link 302:11,20	58:11 62:9	222:11 235:20	93:7 109:2,7
liquid 9:16	79:22 92:21	237:2 268:1	109:12 110:8
40:14 304:13	94:6,16,19	285:25 321:7,9	112:3,12 113:5
305:4 319:23	96:17,18,21	liu 174:3,13	114:7 121:6
320:3	97:12,17,23	176:17 180:5	123:13 124:11
liquids 238:7	98:10 99:13	llc 3:3 4:19	129:19 135:19
list 60:18 69:8	126:2,24	330:1	137:9,11,17
95:17,18	130:25 134:10	llp 2:3 3:4,9,14	144:15 146:5
156:11 169:21	256:25 257:7	3:20 4:3,10,15	150:5,9 155:3
185:10 197:3	258:2,5,11,12	located 1:14	155:22,22
259:8 260:1,6	258:13 295:1	locations 1:13	157:6,11
260:24 288:14	306:23,25	lockard 3:5	158:15,24
289:15,24	307:9 312:8	lockardv 3:8	163:11 164:9
290:2 303:24	320:18,23	logic 267:14	164:14 165:13
listed 9:19 60:9	litigation 1:5	logical 26:11	165:19 166:2
67:8 158:23	10:14 15:10,14	logistical	166:12,22
171:11,12	69:6 72:22	224:18 323:14	167:7,10
173:7,16	112:10 227:3	lomb 3:18	169:22 175:25
177:13 193:14	239:7 243:10	long 21:15,22	176:3,18
196:19,19	243:19,21	60:6 84:14	177:13 178:16

[look - make]

Page 43

179:11 180:5 180:14,19 181:25 182:24 183:1 184:18 185:19,20,24 189:10 190:9 193:9 199:7 200:18 204:1,4 208:16 211:25 212:13 214:18 215:1,16 230:23 232:11 253:3,22 255:20 260:9 273:11,17 275:23 278:21 286:21 289:2 289:22 311:18 looked 20:6 32:17 39:4 41:25 46:9 58:3 61:14 65:22 67:22,22 68:7,13 69:3 72:25 73:8 74:15 75:15 80:4 94:6 109:11,12 111:18 157:16 158:7 162:5 179:2 186:3 187:22 189:15 192:7,13,21 193:16 194:17 197:22 199:15	200:17,23 201:25 203:19 210:10 243:15 265:12 275:20 looking 14:20 53:21 69:11 70:7 71:11 72:9,18 77:3 95:15,20 112:2 113:10 129:23 136:7 143:1 147:20 150:19 158:14 164:16 165:8,8,21 166:4 168:24 168:25 178:12 180:15 184:19 186:24 187:25 196:16 202:1 202:13 203:16 203:24 208:18 214:19 215:24 221:16 241:17 251:13 252:16 255:1 259:6 272:12,20 273:24 274:7,9 275:16 288:11 288:16 300:14 301:14 306:12 310:19 318:16 322:22 325:19 looks 124:2 157:17 188:11 249:21	losartan 1:4 10:13 330:2 lost 104:19 261:10 313:17 lot 20:20 52:23 160:4 161:24 222:21 238:7 242:9 248:15 312:4 lots 219:16 lower 218:9,13 218:14,17,25 luck 303:15 lunch 153:25 154:23 155:8 205:7 luncheon 204:25	maintain 307:1 maintained 218:7 227:3 majority 126:15 make 14:11 26:14 31:21 32:6,8 36:24 41:23 42:5 44:3 45:17 46:11,15 51:22 51:25 56:19 60:25 62:20,21 64:12,17 76:9 86:9 88:11,25 96:13 101:12 101:15,16 103:12 105:8 105:18 106:3 110:15,16,18 116:13,24 130:12 135:1 138:23 149:9 152:8 161:1,6 162:3 169:8 171:13 173:16 176:6 189:9,13 200:3 201:9 211:21 215:4 215:21 218:5 226:21 233:6 234:25 235:11 236:21 249:15 253:1 256:12 259:5 266:4
		m	
		m 2:9 3:4 4:4 94:23 216:4,6 m.d. 124:4 330:3,21 made 21:16 24:24 39:14 105:13,17,19 107:11 121:14 135:11 171:3,6 200:4 271:20 mahoney 199:3 mail 227:10 main 130:22 162:13 243:6 250:19 252:9 282:21	

[make - material]

Page 44

267:7,8 268:4	160:16 214:14	122:20 124:22	189:1,2 190:17
268:19 270:17	250:16 263:11	124:24 125:21	192:7 193:13
273:1 274:12	263:23 264:9	126:14 217:5	195:4 206:11
309:24 312:3	264:23 269:21	217:24 238:11	206:20,25
318:20	270:7 271:17	270:20 280:10	225:12 252:18
makes 32:2	271:21 316:8	294:13 298:9	286:3 293:16
50:4 87:4	manufacturer's	299:8,22	296:24 297:2,4
109:3 208:16	238:10	322:10	303:12 304:14
229:25 230:7	manufacturers	march 6:24	308:7 310:3
making 26:14	36:23 114:22	81:1,4 82:8	311:12
82:12,13 88:24	122:15,24	mark 12:19	market 300:5
99:3,4 101:7	125:22 250:23	18:13 22:20	marking
107:10,17	250:25 251:2	27:12 34:10	308:11
110:17,23	251:20 252:12	49:5 80:25	martin 3:9
113:8 173:11	255:16 256:10	107:23 108:14	mass 135:5
211:13 221:12	256:15,21	114:8 120:13	138:10,12,18
256:2 295:7	257:13 263:17	136:14 167:12	138:18,21
298:8	264:17 265:7	178:18 206:15	139:23 140:4
managing	267:14,15,18	223:8,20,24	142:12 143:25
294:11	267:23,24	224:22 291:22	144:16 145:6
manhattan 2:5	268:14 269:23	marked 7:21	146:4 148:10
manipulative	270:3,22 271:4	7:23 8:12,14	240:19 277:5
208:22	271:7,12	8:17 9:12 13:2	282:10,18
manner 44:19	273:22 274:7	13:6 15:10	285:5 311:18
manual 214:9	275:14 276:6	17:2 18:19	311:20,23
manuals 207:9	276:22 278:9	22:17 27:18	315:25 320:7
manufacture	278:13 280:11	34:16 49:10	322:1,4 323:12
45:14 269:24	280:25	81:5 108:14	master 6:11,15
281:3,23	manufacturing	120:20 123:15	6:18 18:8,18
manufactured	16:7 20:7	123:22 136:21	27:16 34:11,14
19:20 115:9	24:17 29:19	163:24 166:25	35:7 108:16
198:15 253:11	30:2 38:15	167:1,15,16	263:9
269:13 300:9	39:18 40:5,21	168:4 172:9,11	match 322:5
manufacturer	45:20 100:23	178:21 188:8,9	material 17:9
118:5 160:14	102:7 122:14	188:20,21	72:7 132:12

[material - metadata]

Page 45

159:5 177:8	70:14,24 75:4	243:7,24 245:4	114:15,19
200:3 251:23	75:4 76:4,11	245:13 248:24	155:14,18
251:24 258:20	80:11 87:24	251:23 252:1	204:24 205:3
306:2	94:9,12,13,20	262:16 264:2,5	250:4,8 285:19
materials 60:9	95:8 96:18	266:5,8 267:21	285:23 327:1
69:7 71:22,23	101:19 102:1	270:14 274:18	meeting 128:12
75:18,18,19	102:23 105:24	275:24 276:9	282:19
146:25 189:16	106:17 109:6	278:16,17	meetings
193:15 196:20	115:2,3 116:2	285:3 292:14	127:10 128:10
211:19 221:24	119:5,6,24	313:18 314:4,6	146:15 282:8
226:12 259:9	127:9 130:22	317:2,4,16,17	memo 230:24
260:1,6 288:13	132:9,9 138:16	319:14,25	312:21 313:9
289:24 290:11	139:13,14	321:20,25	313:15,21,25
294:16 325:13	143:25 145:9	323:8	314:11,13,16
matter 1:11	147:12 148:5	meaning 313:8	mention 52:7
10:13 31:11	149:2 153:16	meaningless	52:11 80:6,10
129:11 161:14	153:19 159:6	111:2,6,7	84:11 85:8,20
209:10,13	159:25 160:3	112:22,23	184:17 255:15
299:13	163:5 170:19	113:1	mentioned
matters 76:1	170:22 171:6	meanings	50:21 68:15
101:14	177:25,25	229:19	74:11 80:19
mazie 2:9	178:7 182:10	means 169:18	96:16 170:12
mazieslater.c...	182:22 183:8	177:2 313:21	249:7 262:20
2:12,13	183:24,25	313:25 314:4	282:7
mazzotti 3:9	184:13 198:17	314:16	mentioning
mdl 1:3 10:16	202:2 204:14	meant 162:19	141:19
meagher 2:3	209:9,13 211:9	217:10	mentions
mean 14:13	212:16 213:8	measures	234:19
20:13 27:6	213:20 214:22	133:10	mercury 217:2
31:7,8 32:5	216:5,13 217:9	meats 127:22	mere 96:21
38:21 47:5	219:12 220:14	mechanism	message 303:9
51:2,9,10 52:6	220:22 222:8	127:24 129:8	metabolic
53:15,15 54:1	231:12 232:11	196:1	247:11
58:19 60:4,6	235:21 238:3	media 10:11	metadata
61:16 63:4	238:20 240:20	63:10,14	308:15

[metal - mtbe]

Page 46

metal 23:18,21 24:7 metals 24:3 methanol 60:1 method 50:17 82:10,11,12 134:3 139:8,14 139:14,17,23 141:23,25 142:1 168:17 184:24 273:11 276:13,21 277:18,19,23 278:5,8,11 308:24 309:5,7 310:22 318:25 319:22 methodologies 304:21 306:16 methodology 148:13 271:19 312:10 methods 94:21 94:23 135:8 140:17,19 141:9,14,19,21 142:4,11,17,18 143:9 145:8 147:25 207:10 276:16 278:2 298:3,7 325:17 methyl 41:19 micro 7:15 136:18,24	middle 49:18 114:12 261:23 320:13 millimeters 216:24 217:2 million 148:9 millions 61:7 min 301:2,7,15 313:1,4 mind 56:11 67:23 206:8 208:20 264:6 267:2 mini 7:14 136:17,23 minimize 29:13 41:19 minimum 281:1 minneapolis 1:15 11:6 minnesota 1:15 11:6 205:6 minor 39:8 229:17 325:24 326:1 minute 14:17 21:2 49:20,23 50:8 67:4 83:14 106:2 189:19 194:18 218:7 249:25 298:17 minutes 62:22 153:23 249:8	287:8 290:21 309:1,8 324:14 mischaracteri... 62:14 168:17 221:5 mischaracteri... 116:15 mischaracteri... 85:16 mischaracteri... 75:6 265:1 misleading 75:6 171:23 175:6,17 misled 68:17 missed 203:19 261:11 269:19 mixed 261:17 268:25 mixture 72:5 83:20 88:3 89:13 296:7 mixtures 131:4 325:19 molar 30:6 molecular 94:23 216:6,8 molecule 231:23 molecules 133:23 moment 63:17 81:20 82:19 129:18 231:25 235:9 253:3	312:22 money 26:8 326:4 monitored 277:6 monographs 283:7,8,12,17 283:19,24 284:4,9 monoxide 217:21 monroe 3:15 month 226:4 months 124:3 morning 10:1 11:9 154:10 176:19 205:9 mountain 216:17 275:10 mouth 60:25 88:13 161:1 322:20,21 move 34:8 76:9 77:15 103:25 103:25 116:2 117:9 142:8 151:16 152:10 152:11,20 153:1 moved 77:25 148:12 236:3 moving 100:22 194:25 303:22 mtbe 40:8,12
--	---	---	--

[mulberry - new]

Page 47

mulberry 3:21 multiple 91:22 108:24 127:1 222:12,17 277:6 multistep 100:24 101:9 mutagenic 297:7,12 muted 302:14 mylan 4:2,2 253:12 254:7 260:22 mysterious 47:7 67:21	native 228:18 229:3,11 naturally 197:11 nature 24:23 181:1 311:24 nd 174:6,9,10 176:14,23,24 176:25 177:2 178:13 181:12 181:13,16 ndea 63:22 103:4,5,15 125:8,13,22 128:18 130:16 142:19 143:1 148:7 159:18 160:19 254:6 262:6 269:12 269:15 298:24 300:3,11 312:11 ndma 63:22 102:13,14,19 103:1,1,14 122:14,19 125:7,12,22 128:18,23 129:22 130:16 142:19 143:1 148:3,7 159:18 160:19 171:2,5 198:5,15,18 199:5,9 200:12 203:13,15,17	203:21 204:4 222:10,13 226:2 243:3 247:8 253:20 262:6 269:11 269:14 272:11 272:19,23 273:9,23 274:9 274:14,20,24 275:15,20,25 276:7,23 277:8 278:6,14 281:2 281:21 298:24 299:7 300:3,11 300:16,19 301:20 312:11 ne 3:6 near 69:13 necessarily 66:25 113:1 153:19 208:3 215:1 316:22 necessary 126:13 222:23 need 16:24 31:12,18 75:9 78:18 79:18 82:5,23 85:10 116:17 117:2,6 124:11 147:17 183:1 203:16 206:22 224:19 224:25 226:21 236:10 241:13 241:16 253:3	272:20 292:24 293:4,8 298:3 300:22 302:7 323:7,10 325:2 needed 64:20 needs 59:12 75:23 124:23 154:15 negative 42:4 neglected 247:5 neither 116:24 316:20 317:25 329:7,8 nelu 305:9 never 24:15 76:23 106:21 118:9 131:6,12 222:3 237:20 237:24 238:9 238:14,18,24 239:7 240:5 243:2,5,11 262:18,20 new 1:1 2:5,5 2:11 3:10,22 4:11,11 10:15 10:18 25:20 35:20 92:22 93:9 95:1,8,9 114:11 135:9 135:10 241:11 294:17 297:8 298:9 301:13 329:2,14 330:1
n			
n 3:1 4:1 5:1,4 11:5 137:16 153:6,7 247:12 301:16 n203 222:19,20 n25 216:10 nagle 4:10 5:10 286:15,16,18 287:2 288:10 290:17 name 10:17 11:10,15 153:19 250:12 286:17 330:2,3 named 199:3 201:5 279:22 narrow 78:8 narrower 258:1			

[newark - number]

Page 48

newark 3:22	nitrosamine	196:13 198:5	note 10:3
newly 40:6	33:21 44:21	204:4 237:21	225:25
niche 127:11	46:25 54:15	242:10,14,17	noted 11:2
nigh 2:15	104:14 124:8	242:20,24	94:17
night 154:8	128:11,12,13	243:13 247:12	notes 1:10
nine 9:9 50:19	128:13,14	252:23 257:21	notice 203:24
50:21 293:15	130:6,24	265:16,17,24	236:18 273:18
nitrate 28:19	183:20 184:23	265:25 266:13	noticeable
29:5 33:9	221:12 222:2	266:19,20	273:8
102:3,11	222:20 229:25	267:16,18	noticed 275:22
118:11	230:4,9 231:14	281:14 287:5	novartis 159:19
nitrite 27:6	252:4 258:6,23	296:3	160:1 171:2
28:15 33:9	262:2 265:2,9	nitrosated 54:8	198:4,12,13,17
43:3 44:15	290:13 296:8	56:2	198:24,24
54:5,14 55:4	nitrosamines	nitrosodimet...	199:2,10,14,25
56:3 80:14	13:15,19,22	301:16	200:11 201:4
85:21 86:19,24	47:21 54:11	nnk 242:20	201:12,16,20
87:10,13,14,16	56:24 78:23	nnn 242:20	201:22 202:7
87:20 88:4	101:17 111:8	nobel 319:10	202:22 203:4
102:8 103:2,2	111:18 112:24	nodding 217:16	203:11,25
111:21 119:8	118:12,19	non 38:19	204:1 262:10
126:16 130:23	119:9,14,22	222:1	262:21,21
199:18 202:4	121:18 125:8	nonfunctional	268:2 270:13
204:2 220:25	125:13 126:3,6	31:4,6	270:14 273:16
221:3,8 222:18	126:9,11,12	nonsense	274:1 276:13
226:4 294:12	127:1,9,10,15	319:15	317:2
296:2,6 297:22	127:18,21,23	normally	november 9:11
300:20 301:12	128:4,5 130:20	217:14	296:11,22
301:17,23	131:5 132:13	normative	297:2 310:20
302:1 307:3	140:19,21	177:5,6,10	310:20
312:13 322:11	142:19 159:23	181:10	number 7:2 8:2
nitrogen 17:8	159:25 177:14	north 4:22	9:2 10:16
nitrogens 17:15	177:22 184:1	notary 328:17	11:23 19:4,7
17:20	184:10,13,14	330:25	19:17 29:1
	184:23 195:19		35:19 58:10

[number - observed]

Page 49

59:23 70:7,9 70:19 71:1,2 72:21 80:23 81:10 95:6 105:3 117:21 120:11 157:17 159:19 160:6 163:17 164:25 165:12 167:13 171:22 178:17 181:12,12,13 185:20,20 186:1 190:10 190:20 193:17 198:4 204:24 311:8,14 327:1 numberdescri... 6:4 numbers 26:1 81:16 120:13 160:7 164:14 286:2	295:21 296:5 297:18 298:16 298:19 305:23 307:6,11,12 309:14,22 321:23 objected 310:12 objecting 92:4 175:25 281:7 objection 20:9 23:24 24:9,19 24:25 25:24 26:9,17 29:20 30:19 31:22 32:3 33:1 34:3 36:21 39:19 40:9 41:12 42:12,24 43:5 44:12,23 46:3 46:17 47:3,25 48:10,16 52:22 53:25 54:23 55:18 57:2,5 59:5,9,20 60:11 62:5,7 64:23 68:10 71:5 72:14,16 73:17 74:22 75:3,3,10,21 78:25 79:25 80:8 84:6,13 85:14 86:4,6,7 86:16 87:1,22 90:16 91:4,12	99:15 100:3,3 100:18 102:16 102:22 103:17 107:2 113:11 114:2,25 115:8 115:24 117:19 118:7 119:1,19 123:2 125:14 125:24 129:1 130:10 131:19 132:2,8 134:24 138:3,5 139:10 139:20 143:14 148:25 149:20 151:13,21 157:8,25 158:9 158:17 160:10 162:10 163:3 166:20 167:23 168:16 170:17 171:19 174:25 175:12,14 177:23 179:19 182:5,17 183:5 183:16,22 184:11 185:12 186:22 187:2 194:4 195:10 196:24 197:5 197:14 200:8 202:14 209:7 209:20 211:12 212:6 213:18 214:20 215:11 218:11 221:4	221:21 227:11 228:3,8 229:5 229:20 230:3 230:12,18 245:2,17,25 246:7,11,17 247:19 248:21 249:2 251:21 257:14 258:9 265:19 266:2 266:21 267:19 269:18 270:24 276:25 280:14 281:17 282:5 284:22 287:21 298:17 299:2 299:14 300:6 304:5 305:24 313:10,16 315:15,22 316:17,25 318:6 323:6 objections 10:24 115:16 116:25 175:15 obligations 256:14 oblivious 76:11 111:24 112:1,8 222:8 observations 146:13,14 observed 308:25 309:1
o			
o 94:23 199:3 o'clock 154:17 o'mahoney 200:11 201:5 o'reilly 3:20 oath 11:19 object 28:17 76:19 85:2 91:11 93:10 94:3 100:7 108:10 112:6 176:8,9 295:3			

[obtained - okay]

Page 50

obtained 170:21	offer 251:19	38:24 39:7,22	108:24 110:4,8
obvious 232:11	offered 291:14	40:23 41:3	110:9,14,25
obviously 40:1	291:15	42:15,20 46:1	111:4,9,14,20
86:8 209:10	offering 224:20	47:9 48:19,22	111:23,25
227:17 228:21	287:19	49:3,16,19,22	112:12,16
249:8 263:2	offhand 243:8	50:7,13 51:7	116:21 117:24
293:4	office 67:15	51:11,16,24,25	118:3,17,22
occasion 137:3	223:9 278:19	52:2 54:2,20	119:3,14,17
137:6	oh 21:5 36:13	57:10,16,24	120:21 121:8
occur 122:14	53:7 82:2	59:16 60:3,13	121:11,15,21
122:19 198:25	98:18 104:25	60:20 61:9,15	122:12,17
222:13 234:8	123:25 141:10	61:19,21 63:8	123:5,8,10,13
235:2 300:19	150:20 172:25	64:17 65:1,9	125:6,11
occurred 40:6	207:7 208:14	65:18 66:3,14	126:10,22,24
46:11,13,14	211:17 223:12	68:4 69:25	127:3,11 128:2
205:21 206:2	223:13,22	72:4,6,11,18	128:8,11 129:8
233:15 301:22	240:5 246:15	73:23 76:7,12	129:9,9,13,17
304:24	248:11 257:4,4	76:13 77:13,20	130:2,15
occurrence	261:8 278:23	77:24 78:11	131:17 132:14
233:11 234:3	282:25 287:3	79:3 80:3,20	132:20 133:2,6
occurring	289:1 302:12	80:25 81:7,23	133:7 134:2,13
124:24	okay 11:15	82:2 83:3,10	134:18 136:1,5
occurs 301:16	12:3,7 14:8	83:16,17,24	136:12 137:9
october 6:8	15:7,18 16:2,3	84:3 85:25	137:10,21
12:16,24 13:5	16:22 17:13	88:18,23 90:6	139:5 141:14
148:17 225:18	18:11 19:1	96:1,11,12	141:20 142:7
225:19 232:14	20:2 22:3,13	97:15,25 98:15	142:15 143:6
251:14 254:25	23:17 24:13,16	100:15,20	143:24 144:7
255:22 259:7	24:22 25:6	101:12 102:4	144:20,24,25
261:14 269:3	26:5,12 27:4,9	103:3,22	145:4,7,12,20
289:19	27:19,22 28:1	104:11,16	145:21,22
odor 24:14	29:1,10,17	105:10,17	146:7,9 147:2
53:3 94:18	30:15,22 32:21	106:6,12,23	147:10,23
	35:6,11,12,17	107:7,19	148:21 149:6,8
	36:4 38:6,17	108:12,13,21	149:16,23

[okay - opinion]

Page 51

150:1,8,12,18	196:1,7,16	251:2,3,6	192:20 203:20
150:21 151:24	197:2 198:2,8	256:18 257:4	268:3
152:12,21	198:23 199:13	260:14 261:15	ongoing 7:4,9
153:10 155:4,6	199:19 200:2	261:21 268:23	120:16,23
155:11,25	200:24 201:1	269:6 272:5	123:18
156:14 158:20	201:16,21	274:20 278:17	online 70:25
159:11 161:10	202:10 203:7	281:5 284:1,2	208:8
163:14,19	205:18,24	284:17,23	open 303:4
164:7,22 165:4	206:5,9,12	285:16 286:13	operator
165:10,15,22	207:17 208:12	288:4,8 289:3	278:17,25
166:6,8,14,21	208:15 209:23	289:4,7,8,9,18	281:13,19
167:2,10 168:5	210:22 212:10	289:21 290:2	opinion 52:18
168:8 169:7,15	213:4,23 214:2	290:19 291:11	53:10,18,22
169:19,22	215:15 216:3	291:12 293:12	54:2,2,4 55:7,7
170:13,23	217:8 218:19	294:2,8,9	55:10 56:18
172:1,4,10,13	218:24 220:11	295:15 300:14	57:20 58:20
173:21 174:1,3	220:13,23	302:12 303:17	60:23 61:1,3,3
174:13,19	221:25 222:25	303:17,21	61:10 74:4
176:10,17	225:21 226:11	304:5 310:17	78:5 79:5,6,10
177:4,9,13,16	226:19,20,23	311:4 312:25	88:9 90:4
177:20 178:5,9	227:2,6,14,17	313:13 314:18	91:22 93:21
178:15,22,24	227:24 228:11	315:11 321:10	96:21,23,25
179:5,8,11	228:17 229:14	old 92:24,25	97:3,5,5,8
180:3,8,19,25	229:17,22	older 135:8	101:16 102:7
181:15,16	230:21 231:21	omitted 208:21	102:12 103:3
183:19 184:9	233:10 234:6	209:4	103:13 111:15
185:16,18,24	235:11 236:4	once 32:22	112:1,8,21,21
186:3 187:6,17	237:18 239:3	200:18 263:2	117:8 118:6,13
188:4,17 190:2	239:11 240:16	300:16	119:12 125:19
190:8,18,23	241:3 242:5,8	ones 68:14	126:1,5 130:19
191:12,20	243:1,10 244:4	73:19 135:8,9	145:18,19
192:6,11,20,25	244:14,17,24	135:10 146:23	160:7 161:11
193:3,24 194:2	245:8,21 246:3	147:17 149:13	162:4,9,12,15
194:6,9,15	246:24 247:4,7	157:3,5 160:3	162:19 163:1
195:5,12,22	247:15 248:9	184:12,22	168:9 185:11

[opinion - page]

Page 52

185:15 187:22 188:1,5 189:21 197:4 203:14 205:12,20 209:10,14,15 221:3 253:16 254:21 257:9 257:11 263:22 264:7,11,21 265:1 268:12 269:22 270:6 272:16 276:2 276:20 284:14 285:8 294:19 295:9,15,18 297:22 298:23 300:2,10 309:18 319:19 320:21 322:7 322:24 324:1,7 324:21 opinions 14:1,1 14:24,25 20:6 60:15 67:7 69:20 70:21 73:1 75:14,20 101:13 103:24 104:4 147:3 148:15,17,21 148:23 149:12 149:16,17 162:20 250:22 251:19 254:2 254:10 255:8 255:12 256:9	261:3 271:15 280:3 281:25 284:20 291:13 291:19 312:6 312:11 315:5 322:24 325:14 opportunities 252:7 opposed 43:25 optimization 300:22 optimize 38:15 39:18 40:2 oral 1:6 order 15:12,13 15:22 16:25 23:18 64:20 78:17,22 118:23 148:6 203:15 272:19 312:9 ordinary 227:4 organic 53:20 53:22 54:1 62:2 64:2,6 65:3 79:7 89:24 90:2,5,7 90:9 91:13,16 91:18 92:9,16 93:22 94:1,12 94:13 96:7,19 97:15 98:7,11 99:6 127:6 132:16 133:13 133:18,23	134:14 140:20 207:12 213:16 219:16,16 220:5,12 221:25 240:3,6 256:24 257:12 257:17,20 320:15 organization 59:25 orient 49:24 50:9 origin 190:25 191:17 195:24 196:22 200:14 original 27:1 34:17 227:18 229:24 230:8 originally 226:25 ought 53:22 118:24 270:10 outcome 10:23 outfit 221:24 output 37:14 38:2,18 322:3 outside 68:4 70:6,16,16 71:15 72:11 239:7 overall 32:10 32:10 40:21 41:20 257:19 overland 2:20	oversight 91:17 295:17 own 109:3 237:7 253:6 270:21 oxford 4:4 p p 3:1,1 4:1,1 5:4 11:5 p.m. 205:2 233:19,22 250:3,7 285:18 285:22 291:4,7 326:24 327:3 p.o. 3:10 pace 253:6 page 5:3 6:4 7:2 8:2 9:2 14:16,18 19:9 20:22,24 22:9 23:7 28:3,5 29:1 30:22 35:18 37:2 39:7 49:18 64:18 82:22 95:3 106:4 109:9,9,13 110:9 121:14 121:22 124:12 129:19 137:10 138:24 140:9 140:16 156:25 164:15,17,18 164:19 165:5 169:3,5,6,20,21
--	---	--	---

[page - peak]

Page 53

169:24,25	166:5,19,23	263:15	165:17 179:15
170:15 173:12	190:14 192:23	park 2:20	194:17 208:6
173:25 178:23	206:20 225:16	parkway 2:10	214:19 229:18
179:1,18	293:15 311:14	part 17:16	237:16,18
180:10,20	paid 246:13	32:13 39:24	315:13
181:8 189:18	panel 243:15	45:19 46:24	parties 10:9
191:4 194:10	243:22,25	47:20 50:25	329:8
195:15 197:4	244:11,20	53:9 56:13,23	parts 108:3
198:2,3 213:13	245:1	57:8 83:1 99:6	148:9 157:12
215:20 225:20	panels 245:11	102:13,14	171:20
232:15,22,25	papantonio	142:15 143:7	party 10:21
233:1,2 236:23	2:14	160:13,16	198:25 201:13
252:22 255:24	paper 18:7 27:1	167:20 178:25	passing 257:17
256:17 257:3	34:17 246:4,8	194:12 223:18	past 77:25
259:12,15	247:6,7,16,23	224:17 226:11	148:12 208:9
260:19 261:19	papers 80:5	234:22 254:20	patent 6:23
268:20 269:2	126:25 145:3	267:7 268:17	80:22 81:1,3
271:24 272:1,8	146:18 245:10	271:16 282:2	82:7 84:3 86:8
286:25 287:2	282:9	306:2	86:18
288:15,18	paragraph	partial 51:4	patients 298:12
289:2 296:12	37:3,6,23	participants	pattern 322:2
300:14,15	49:18 63:18	10:6	pause 59:9
301:3,4 305:15	94:20 137:17	participated	253:8 292:25
308:21,21	137:18 215:23	243:25 244:2	pc 4:20
311:15 320:11	253:4,10,14,19	244:20	pdf 224:4,9,11
320:13,14	253:23 254:1,4	participating	pdfs 224:21
321:5,10,11	254:5,8,13	245:1	peak 9:18
330:5	255:1,5,11	particular 32:6	156:9 163:6
pages 6:6,9,22	256:8,23 257:3	33:14 45:15	192:9 196:10
7:7,12 9:5,9	261:23 288:3	52:3 73:3	203:17,21
13:2,6,15	321:6,6,12,15	96:24 99:6,10	273:11,14
21:11 49:10	paragraphs	99:22 111:15	274:20,24
82:18 120:19	255:17 288:1	119:7 150:4	275:20,25
123:22 155:23	pardon 11:11	157:23 158:8	276:7 277:8,9
157:17,24	17:24 226:8	162:21 165:16	278:22,23

[peak - pharmacy]

Page 54

281:21 307:18 308:5,12 peaks 129:24 148:2,3 156:9 160:4,17,21,24 161:16,19,24 163:5 170:20 170:24 174:8 175:22 176:23 177:17,21 178:1,3 179:6 180:7,21,22 181:1,5 183:15 183:20 184:1 184:10,16,19 184:21,23 190:1,24 191:10,14 193:25 194:11 194:19 195:8 195:13 196:10 196:23 197:16 198:13 203:17 203:21 262:1 272:12 273:2,2 273:5,6,7,19,25 274:19,22 275:5,7,11,12 275:16,21,24 276:24 277:11 278:14 308:25 309:3,4,7 peer 134:10 pennsylvania 4:5,17	pensacola 2:16 people 61:12 114:4 126:23 128:8 209:16 209:18 232:6,6 245:11 278:21 294:21 295:5 peptide 94:24 percent 71:25 123:9 143:17 144:5 220:7 percentage 71:24 285:4 perfect 54:15 130:23 224:24 320:11 321:8 321:10 perfectly 161:10 perform 104:5 106:8 283:16 284:5,10 304:22 performance 7:14 136:17,23 319:22 320:3 performed 106:13 238:9 283:12 294:13 300:1 309:8 performing 277:20 period 56:5 118:14 136:9 304:23	permission 292:19 perrin 9:5 206:19 person 150:5 162:7 199:6 214:23 230:21 292:5 person's 209:12 personal 52:1,2 personally 69:20 70:20 146:10 240:9 240:10,20 perspective 256:22 303:19 pertain 158:15 159:21 175:19 pertaining 67:25 181:20 185:4 248:18 pertains 174:22 pertinent 172:2 173:17 185:11 185:14 pfizer 3:18 ph 54:14 55:5 56:3 118:11 119:8 126:17 126:20 130:23 202:4 204:3 222:19 ph.d. 5:4 11:5 13:1,5 49:9	226:2 293:15 329:4 pharma 3:2,19 4:8 pharmaceutical 2:2 3:2 114:22 117:14,15 118:5 125:7,12 126:21,23 127:6,7 128:9 129:12 131:7 131:14 132:11 138:14 143:23 143:24 144:4 144:15 164:2 238:15,19,24 239:1,4,8 243:4,13 279:18 282:1,4 282:10 284:15 284:24 285:7 305:18 316:2 317:18 323:11 325:18,23,25 326:6,15 pharmaceutic... 3:2,18 4:2,8 100:2 125:23 128:5,7 131:18 132:7 237:16 237:17,21 238:2,3,5,8,12 305:11 pharmacy 3:13
--	--	--	--

[pharmtech - potential]

Page 55

pharmtech 174:14,16 180:6 phd 1:7 6:6,8 6:21 9:9 philip 279:22 280:24 phone 117:6 phrase 238:22 phrased 266:11 picked 171:20 picking 175:16 picture 120:5 piece 77:15,25 78:15,16 98:5 113:5 276:6 pieces 97:17 156:11 piedmont 3:6 pietragallo 4:3 pietragallo.co... 4:6 pin 69:1 pink 83:7,12 86:12 pinpoint 306:18 pittsburgh 4:5 pizzi 3:20 place 10:9 49:22 63:11 91:11 114:16 127:2 129:10 129:14 155:15 175:15 204:25	233:6,20 250:5 255:21 257:19 257:21 279:11 280:8 281:13 285:20 291:5 329:6 plaintiff's 73:9 140:18 141:6 141:22 142:5 157:5 279:21 280:23 283:23 322:20 323:1 323:16 plaintiffs 2:8 244:19,25 245:14,23 246:14 play 160:7 please 10:3,25 11:3,10,15 17:1 25:12 37:5 55:24 70:11,13 89:22 93:12 101:4 116:9,15 169:9 174:10 176:22 177:16 204:21 213:13 217:17 248:3 289:20 300:14 303:1 308:21 309:24 320:11 plenty 243:16 plunkett's 283:23	plus 72:19 point 14:22 49:21 50:5 57:11 68:24 69:14 88:9 89:9,10 90:3 92:11 93:24 95:24 100:17 102:20 103:4 110:14,19 143:18 145:23 148:6 154:20 165:24 166:9 173:16 183:12 187:19 189:13 202:17,20 205:24 208:17 210:12 216:9 216:14,15,20 216:23 217:15 218:8,8,9,21,25 234:1 292:24 325:15 pointed 142:5 162:17 pointing 25:14 144:9 186:9 225:24 313:19 points 171:13 173:11 248:18 portion 70:2 75:18 76:3 148:18 149:8 149:13 150:2,9 212:20 248:14	portions 13:13 147:7 150:6,7 150:11,14 166:10 208:14 position 143:7 170:14 229:2 299:12 possibility 46:9 52:21 54:6,13 66:7 104:14 232:18 262:18 possible 26:20 98:22,23,25 99:9 120:5 161:8 229:21 229:25 230:9 230:22 277:7 294:18 322:5 possibly 95:4 116:2 119:25 131:5 266:9 267:2 post 66:5,20 74:11,15 143:21 [REDACTED] [REDACTED] potent 126:4 potential 25:4 30:12,17 32:9 33:21 41:10 44:20 53:4 56:4 115:5 117:14,16 231:14 245:5
--	--	---	---

[potential - procedures]

Page 56

252:4 258:6,22 262:4,6 265:2 265:8 290:13 295:8 296:1 297:7,12 powerful 54:11 321:16 powerpoint 9:24 311:7,9 311:10 practice 299:9 299:21,22 practices 238:11 preamble 11:25 precedes 287:10 precursor 38:8 38:12 predict 129:13 predicting 299:7 preface 208:12 209:23,24 210:4 prefaces 210:11 preferred 37:12 preliminary 191:8,9 premise 267:10 prepare 146:20 267:25 270:9 271:20	presence 17:22 40:6 54:21 56:22 65:24 95:22,25 96:4 126:16,20 202:5 296:1 300:16 present 46:6,14 47:21 54:7 65:4,5,8,13 80:12 88:2,15 126:4 128:19 131:3 239:1 presentation 9:24 311:11 presentations 145:7 242:16 presented 145:4 presents 252:4 press 94:25 pressure 216:16,19,22 216:24 217:1,4 217:9 pressures 216:9,12 presumably 39:23 52:13 63:25 165:5 presumed 266:25 pretty 114:5 134:3 135:10 204:12 229:16	231:6 249:18 prevalent 281:25 prevent 12:4 previous 169:5 169:20,25 315:5 previously 7:21 7:23 8:12,14 8:17 9:12 166:25 167:15 188:7,20 189:1 201:17 238:25 245:21 254:21 278:3 297:2 primary 297:13 principle 305:20 326:2 princeton0007... 6:19 34:15 princeton0007... 6:16 27:17 printout 310:21 prior 16:8 33:5 33:10,17,22 34:5,5 43:16 44:11,16,20,24 45:14 69:20 70:21 82:24 85:16 107:9,17 113:8 125:11 144:12 202:23 203:4,12	237:14,21 243:10,19,21 244:8,25 258:5 258:24,25 264:18 290:14 304:22 307:2 307:13 329:3 priorities 115:4 prize 319:11 probably 72:5 72:17 97:10 119:23 126:13 126:14 184:18 186:5 189:10 204:9 207:19 208:8 209:22 211:3 229:1,15 240:1,12 247:5 247:6 267:21 273:10,18 274:1,11 275:1 problem 25:3 57:8 78:4 106:20 162:17 163:8 170:22 176:13 197:20 222:3 252:4 303:2 procedure 28:7 28:14,23 152:17 201:25 204:2 312:10 procedures 267:25
---	--	--	--

[proceed - products]

Page 57

proceed 11:4 303:18 304:5 proceeding 10:25 168:18 proceedings 1:11 253:8 327:3 process 16:11 16:14,17,20,23 17:5,6,7,21 18:6,9 19:19 20:8 23:10,12 23:19 24:18 26:7,24 27:2,6 27:7 29:18 30:2,6 31:1,21 32:2,8,10,13 34:1,9,18,25 35:2,3,20 37:13,16 38:1 38:15,20 39:5 39:9,18 40:2,4 40:5,15,18,21 40:24 41:5,9 41:18 43:9 45:5,13,20 46:2,25 47:7 47:20,23,23 52:17,19 54:22 55:11 56:23 58:18 61:25 65:6,14,25 66:6,19 67:1 78:23 79:8,16 79:23 84:4,5	85:12 86:13,18 87:7 88:1,11 89:10,14 91:18 93:19,24 94:2 96:19,20 97:4 98:8,13,16,18 98:18,24 99:1 99:2,9,22 100:23,24,25 101:3,7,8,9,10 102:7,13,15,20 102:21,23 103:6,10,15,16 104:1,15,18,21 104:24 105:3 105:20 107:17 109:15 110:16 111:2 124:22 124:25 125:21 126:8,14 128:23,24 129:7 132:10 142:22,23 143:11,12 145:24 151:8 198:16 199:7 199:16 200:17 200:18 205:21 205:25 207:23 208:6 211:15 211:18,23 215:3,6 217:5 217:24 222:7,9 222:11,14 230:1,2,9,10	234:16,23 252:2 262:19 262:23 263:5 264:16 265:10 266:7 268:10 268:13 269:14 270:8,19 271:4 271:7,13,16 281:23 294:22 295:17 297:8 297:10,21,24 298:6 299:8,9 300:21,23 301:25 305:18 306:14 312:5 312:12,13 processes 16:7 16:22 20:14,17 34:9 36:24 43:16 44:1 63:23 64:4 92:10 93:23 96:8 98:12 105:12,12 128:19 234:12 234:17 269:13 294:13,22 295:7,9,17,20 298:9,25 300:4 300:11 304:24 307:3 322:11 produce 16:7 299:24 produced 76:23 227:2	producing 221:24 product 6:13 18:14 22:15 23:1 26:14,15 29:14 32:10,23 54:16 56:9 80:18 88:4,6,7 98:21 111:8,19 112:24 115:7,9 129:12,12,21 135:13 151:14 151:22,23 162:2 174:5,9 182:22 202:5 232:20 238:19 243:4,13 251:11 253:11 253:21,21 254:7 256:5 258:24 264:18 266:1 269:24 270:4 272:10 274:6,8 288:6 288:10 290:14 320:17 321:1 production 24:4 37:18 50:17 142:24 143:13 232:20 products 1:5 10:14 130:8 234:13 238:16 258:8 281:2 294:18 317:7
--	--	--	---

[products - putting]

Page 58

318:24 319:21 325:25 326:2 professional 221:24 293:24 293:25 317:4 profile 110:11 294:17 program 131:14 promise 285:1 pronounce 40:8 48:25 206:13 pronouncing 17:24 pronunciation 35:25 proper 286:3 propose 317:17 319:14 326:6 proposed 37:13 105:17 proposition 326:14 protective 15:12,13,22 protocols 94:24 prove 221:1 proved 220:24 provide 41:20 177:16 181:13 181:14 182:1,2 245:9 255:6 provided 32:14 32:18 40:12	67:9,12,14 72:21 73:2,10 163:12 167:3,6 168:25 172:17 176:20 227:22 241:18 254:21 293:18 322:7 provides 17:19 225:7 providing 12:5 public 123:11 328:17 330:25 publication 60:3 207:6,22 212:20 publications 59:2,16 85:10 97:12 206:12 245:11 293:24 published 7:16 94:19,25 126:25 134:9 135:20 136:20 146:5 242:13 243:2 247:7 258:11,12,13 305:4 317:10 pull 16:24 18:12 21:22 27:10 34:12 49:4 63:1,6,16 78:12 80:22,25 106:1,2 107:21 107:21,22 108:11 109:4	135:18 136:13 163:16 164:22 167:25 172:5 172:14,16,24 173:3 180:11 187:7 198:9 206:10,22 232:16 314:23 315:1 pulled 164:23 172:19,21 304:18 305:25 305:25 306:5 314:19,22 pulling 108:13 314:24 purchased 214:5,15,15 purchasing 197:10 214:4 pure 161:7,25 162:3 purely 72:3 238:4 purification 9:4 206:18 207:1 214:3,8 214:9,18 purifications 221:17 purify 214:10 214:18 purity 132:24 160:23 161:3,4 214:16	purport 97:22 purpose 24:23 34:24 67:20 97:7 140:11 177:5 255:6 purposes 30:16 35:3 75:14 89:4 101:14 205:10,15 266:14,15 280:7,12,23 281:5 284:1,7 284:13 322:23 pursuant 214:15 pursue 159:16 put 22:14 41:1 47:10 60:25 68:19 79:18 88:12 89:19 101:25 106:7 118:2 120:9 127:5 129:18 140:7 155:21 218:6 224:5,12 270:11 279:11 292:6,12,14,20 298:17 302:4 302:19 304:17 305:24 308:1 putting 161:1 302:10,11,21 307:25
---	---	--	--

[qualification - questions]

Page 59

q	104:21 105:19	124:14 130:4	323:21 326:11
qualification	105:20 107:14	136:1 137:1	questioned
47:16 88:25	142:23 143:12	139:12 140:11	304:19 306:7
qualified	226:3 230:1,10	149:9 153:10	questioning
256:24	294:12 297:22	153:20 157:14	175:1,6 221:13
qualifier 134:2	300:21,23	161:18 162:18	221:14 244:22
qualify 241:5	301:22 302:1	168:16 171:19	246:18 250:19
qualitative	307:3 312:13	171:24 178:8	290:25 296:13
9:22 110:11	question 19:25	182:13 185:2	306:8
309:24 310:1	20:10 28:12	187:24 194:2	questions 12:1
310:20	36:18,19 37:22	202:19 212:2,4	12:12 13:10
quality 10:4,5	44:6 47:17	214:11 218:4	14:24 17:1
176:13 214:6	48:14 52:4	231:19 234:24	43:17 51:16,19
299:24 305:19	53:13 62:10,13	241:4,15	69:3 75:11
quantified	62:18,23 70:14	244:12 247:20	81:22 82:4
197:24	70:23 71:13,14	248:12 253:22	89:5 96:3,4
quantify	71:15,17 75:5	256:7 258:16	149:12 151:13
197:18	75:6,21 76:21	260:16 261:13	154:19 168:19
quantitation	76:24,25 77:10	261:18 264:13	175:9 182:25
148:7	78:9 82:22	264:14,20	186:18 192:3
quantitative	84:14 85:1	266:4,11,14,16	205:10,15
110:11	87:2,3,5 91:2	267:11,13	222:22 236:8
quantity 37:11	91:12,23,25	270:1 271:10	236:14 249:6
37:14	92:1,6,19,22	273:21 274:25	249:15,17,22
quarter 71:25	93:8,9,9,10,13	277:16 278:22	285:11,13
quench 28:22	93:18 100:8,8	278:25 280:7	286:19 287:9
quenched	101:4,6 102:17	280:13,23	290:18,24
301:17	102:24 105:8	281:5,8,10	291:9 293:9
quenching	107:6,13 108:5	282:20 284:1,8	294:5,6 296:16
16:16 26:24	108:9 112:10	284:13 295:4,5	312:4,15
27:2,5,7 28:7	112:14,16,17	295:22 297:19	318:12 320:8
28:14,20,23	113:12 115:12	298:19 301:13	322:15 323:3,3
30:6,16,24	115:22,22,25	307:12 309:15	323:20 324:9
40:6 101:9	116:2,11,12,14	316:25 319:16	326:17,18
103:16 104:18	119:13 122:11	321:24 323:13	

[quiangming - really]

Page 60

quiangming 156:24	raw 274:16 278:12 294:16	142:2 143:3 147:3,5,6,7,7	reagent 45:24 48:6,9 207:25
quick 114:5 249:24 285:14	reaching 218:8	149:24 150:1,4	211:15
quicker 114:5 290:22,23	react 87:14	153:3 157:20	reagents 33:14
quickly 204:13 253:5 292:21	reaction 28:8 28:15,24 29:8	159:13 178:10	real 267:1
quite 144:3 274:22 275:21	30:7 38:1,8,12	189:23 200:2	realized 66:21
277:10	39:11 41:21	201:3,3 208:25	really 14:23
quote 94:13	45:19,23 48:5	212:1,5,25	15:1 24:12,21
quotes 51:3	48:8,15 50:20	220:21 227:7	25:7 35:14
quoting 294:14	50:22 54:5	227:14,18	38:22 39:21
r	55:4 80:14,15	228:12 229:24	42:16,19 46:5
r 3:1 4:1 328:1 329:1	83:20 88:3	230:8,14	48:18,21 56:19
racemization 36:1	89:13 99:10	234:18 247:24	57:10 72:9
rafferty 2:14	110:10 129:14	253:4,5 254:18	73:5,7 76:1
raise 33:4,8,16 33:21 65:12	131:4 222:25	261:25 262:7	84:13 96:1,5,9
181:23	223:4 296:7	262:12 269:16	96:13,14 97:7
raised 14:23 33:25 36:18	reactions 108:4 129:10 220:6	272:14 280:5	101:13 107:18
187:18 195:8	223:1 262:5	287:23 296:18	110:5 121:13
309:7	294:15	306:21 313:6	135:23 136:7
range 71:3 275:10	reacts 222:20	314:14 315:3	138:21 139:12
raspanti 4:3	read 15:24 20:13 37:5,24	315:17,18	147:9,18
rather 136:3 276:11 318:4	48:23 49:2,14	318:18 319:18	148:13 149:5
322:20	49:25 50:3,10	323:10 324:13	152:1 154:16
ratio 30:6 37:11	50:14,25 56:14	324:17,19,21	159:7,8 170:8
	64:5,12,15	324:23,24	175:17,17
	66:20 74:9,10	325:1,6,7,12	183:8 191:16
	77:11 84:15,17	326:14 328:3	194:5,8 218:16
	86:8 112:17,19	readily 63:20 64:1,21 306:24	222:22 229:12
	121:24 122:6,9	reading 50:12	244:23 245:7
	124:16,18	56:11 142:10	266:23 268:1,3
	130:24 137:21	157:21 199:22	278:16,24
	141:1,8,14	199:22,23	279:14 282:7
		235:16	282:11,13,15
			285:5,9 306:9
			317:4

[reason - referred]

Page 61

reason 14:21 20:7 22:1 42:1 50:24 51:2,3 52:11 80:5 84:12 85:20,21 85:24 119:22 119:24 122:23 130:7 134:22 137:13 138:1,9 142:25 144:21 174:21 179:24 180:17 200:15 203:3 214:8,17 215:1 229:22 230:6 265:16 265:17,23,24 266:13,16,19 266:20 267:15 267:17 281:13 281:20 330:5 reasonable 26:22 62:23 70:12 84:14 93:11,16 118:4 118:14,15,19 118:24 140:20 291:15 312:8 reasons 131:4 294:24 295:24 299:16 recall 74:16 158:19 160:21 170:25 187:18 219:15 228:15 242:19 244:22	245:24 246:6 248:7 287:9 289:13 recalling 186:21 recalls 7:5 120:17,24 receipt 6:10 18:17 22:6 receive 72:24 received 13:2,6 18:19 22:17 27:17 32:22 34:15 49:10 81:4 120:19 123:22 136:20 156:8 159:22 163:24 166:25 167:16 168:4 172:9 174:20 176:12 178:21 188:9,21 189:1 190:17 193:13 195:4 206:20 225:11 251:23 253:12 293:15 297:4 304:14 308:7 310:2 311:12 recent 60:5 241:17 recently 241:19 247:7 recess 63:11 114:16 155:15	204:25 233:20 250:5 285:20 291:5 recheck 174:10 recipients 172:12 recognized 124:23 265:2,8 recollection 108:19 155:24 173:10 313:14 record 10:2,10 11:2,10,16 15:3,19 21:1,3 21:7,18,20 37:6 42:5 50:15 63:9,13 76:2,3 83:7 114:14,18 122:7,10 137:12 155:12 155:17 172:23 204:20,22 205:2 223:18 223:19 224:17 226:22 233:17 233:18,22 236:12,20 250:2,7 258:1 285:18,22 286:1 291:4,7 292:3 293:12 298:18 302:23 307:24 311:7 318:14 322:19	326:23 recorded 10:8 10:12 106:21 recording 10:5 10:8 recounted 286:8 redirect 248:11 249:9 reduce 30:17 35:24 36:1 38:19 41:10 306:19 reduced 36:4,6 reducing 26:14 reefer 4:4 reenergized 243:22 refer 133:6,17 156:14 217:12 241:13,16 271:24 reference 17:8 157:16 167:7 208:4 218:21 229:25 230:8 255:23 278:3 301:1 309:9 314:3 referenced 60:8 86:15 98:5 references 95:6 208:10 referred 146:24 177:4
---	---	---	---

[referring - report]

Page 62

referring 15:1 66:10 104:13 187:14 251:1 299:5 refers 17:6 264:10 300:18 reflect 286:2 refractive 216:10 refresh 108:18 155:23 regard 156:9 251:19 256:3 276:3 294:10 297:21,23 299:25 300:9 301:19,25 312:6 regarding 18:14 78:6 158:22 312:12 324:2 region 308:25 registration 169:17 regular 69:6 regularly 125:12 284:14 regulation 239:4 regulators 243:12 regulatory 35:14 40:3 239:8	reiterate 21:16 relate 99:10,21 179:25 194:7 related 9:16 10:21 50:16 72:7 159:6,9 159:10 161:17 184:20 258:14 304:13 305:5 320:16 relates 79:15 179:12,16 194:3,8 relationship 164:4 247:2 relative 329:8,9 relatively 203:21 release 121:1 279:3 280:9,19 released 232:5 relevance 160:9 162:20 162:25 173:22 relevant 52:12 80:11,13,18 125:19 148:5 157:22 190:3 197:4 207:11 208:10 215:24 277:21 reliance 60:18 69:8 95:17 196:20 303:24 306:2	relied 60:9,14 60:15 227:21 288:14 315:4 relies 325:17 rely 171:14 324:6,21 relying 235:12 282:22 315:19 315:24 319:18 remainder 249:9,11,13 remember 19:11,12 31:11 53:7 66:9 67:2 70:25 71:1 73:5,7 101:24 137:2 148:16 149:10 153:9 153:18 161:19 165:19 166:2 170:8,12 173:13 176:5 186:10,13 187:4 199:6 201:7,15,20 207:20 244:2 245:7 246:8,9 287:12 296:15 313:12 314:17 remind 299:20 reminded 248:8 remotely 11:2 removal 24:7	remove 79:13 95:4 180:21 removing 24:3 94:21 repeat 70:14 77:10 93:18 101:4 202:3 212:12 265:21 271:9 280:16 307:19 rephrase 92:6 149:2,5 157:15 323:24 replacement 30:24 31:4,6 replies 193:5 reply 176:22 report 6:5,8,13 6:21 9:18 12:22,25 13:4 13:11,14 14:2 14:5,5,19 15:1 18:14 22:16 23:1 48:23 49:8,12,13 50:9 52:6,13 52:21 60:8,12 60:14 63:1,2,6 63:17 64:15 67:8 74:1 89:19 104:9 106:1,2 129:17 140:6 148:18 148:18 149:8 149:13,14
---	--	---	---

[report - responds]

Page 63

151:6,15,22	283:23 286:22	250:13 277:25	resolve 21:8,12
153:4,12,12,18	286:25 288:12	283:22 284:8	resolved
155:21,22	288:13,22	286:18 308:14	162:24
156:1,7 158:23	289:16,19,23	representation	respect 23:4
164:11,13,15	300:13,15	225:7 275:5,7	33:13 34:1
164:19 165:6	307:17 308:5	representing	86:1 97:4
167:8 171:12	308:12,23	76:22 185:5	104:22 105:21
171:23 173:8	309:24 310:20	196:17	111:7 112:23
173:12 179:9	313:20 314:2	require 284:4,9	113:2 125:20
179:18 185:21	315:4,7	required 299:8	126:6 128:3
186:9,16	reported 51:6	requirements	147:2 158:8
187:10 196:19	94:9 106:18	299:23	159:1,22
198:2,8 204:7	reporter 10:19	research 126:2	166:17 170:15
213:24 220:15	11:3 18:4	146:10,12,17	177:21 179:17
225:15,19	46:20 55:24	232:8,10	186:1 187:19
228:12,14	59:10 77:9	237:15 311:16	187:21 189:21
232:13,14,23	90:20 94:22	researched	216:13,22
235:4 236:23	103:23 126:18	237:20 322:23	235:2,13 237:3
242:2 248:14	216:7 277:14	researchers	238:11 239:4
248:15 250:20	288:9 329:2,14	52:20	243:3 246:4
250:21 251:13	reporting	reserve 223:21	254:11 255:8
251:18 252:8,9	330:1	225:2	288:5 290:7
252:10,16,18	reports 9:22	reserving	295:8 314:20
252:22 253:2	12:14 13:9	248:10 249:8	315:20
254:24 255:6	50:19 52:15	residual 24:3	respected
255:19,21,22	70:22 152:4,23	174:6 193:25	97:21
255:24 256:4,8	159:13 199:22	308:24 309:5	respond 32:21
256:16,17	248:14 261:17	residue 277:10	42:10 152:8
257:11 259:4,6	291:19 310:1	residues 168:21	responded 33:4
259:7 260:5,8	326:13	169:1,4,14	33:8,16,20
261:3,4,8,9,13	represent	170:2,6,11	183:14 193:4
261:14,19,20	19:15 84:9,19	273:20	responds
268:20,21	84:20,22,24	resolution	176:17 181:9
269:1,3 271:24	85:7 116:18	170:25	191:20 192:3
271:25 283:23	175:20 216:21		

[response - right]

Page 64

response 36:19 152:7 170:4 211:1 268:8 299:4,5,6 responses 192:16 responsibility 98:17 99:21 209:16 251:25 responsible 120:6 298:6 299:23 rest 171:21 result 124:21 124:24 229:19 246:25 300:20 resulted 56:24 78:23 206:1 results 176:21 201:17 274:16 retained 201:13 244:4 244:15 247:17 327:1 retention 244:8 revealed 269:14 review 7:16 49:19 136:19 137:4,6 148:23 149:17 150:15 157:23 226:12 258:20 263:5 271:6,11,14,16 275:13 281:15	290:10 312:8 318:18 reviewed 67:6 67:11 69:20 70:10,21 72:1 134:10 153:11 159:5 165:5 226:7,9 239:8 257:8 259:9 260:2,6,14 261:5 263:13 263:16 264:15 268:11 270:5 279:7,24 288:24 289:14 289:24 290:7 318:17 reviews 127:2 rich 14:9 15:16 19:3 25:10 27:6 43:7,19 60:17 68:16 83:6 90:16,16 100:21 107:24 156:2 210:2 223:10 310:14 richard 2:3 310:5 richard.berna... 2:6 rid 87:13 riddell 3:9 ridgefield 305:11	right 16:21 21:18 22:13 23:6 27:3 28:5 28:23 30:9 34:19 35:11,13 40:16,19 41:3 43:9,16 45:21 46:18 49:21 62:19 63:19 64:5 70:24 74:11 75:25 76:7 80:11 82:6,15 91:20 92:17 100:24 105:12,15 108:8,14,15 109:9,13 110:24 114:13 115:13 118:20 120:12 121:19 125:1,4 127:8 131:1,10,20,23 133:8 135:15 136:11 141:20 142:3,14 147:21 157:18 159:14 165:14 166:4 174:1 175:23 178:4,5 178:13 179:6 179:10 181:1 187:16 189:13 190:19 191:1,4 191:15,15,25 192:1,14,23	193:5 194:1 196:6,14,15 202:21 203:16 204:12 206:14 207:4 218:18 218:22 221:25 223:15 224:23 224:25 225:1 226:17 228:25 231:6 233:5,6 234:4 235:9,24 237:3,10 240:17 242:7 242:12,22 244:16 246:15 247:3 249:4,19 250:17 251:8 251:11 252:15 253:13,17 254:2,3,8,9,12 254:23 255:17 255:18 256:6 256:12 257:9 260:3,12,20,23 261:1,7 264:10 269:4 270:23 271:14 272:15 272:21 274:13 275:18,22 278:10 280:20 280:21 281:6 281:19,24 282:4,15 285:10,17 286:15 289:1
---	---	---	---

[right - says]

Page 65

289:13,18 290:20 291:3 292:23 293:7 294:2 304:4 309:12 313:21 316:19 317:15 317:23 318:10 321:3,8 ring 17:16 79:24 82:14 risk 29:3,14 87:12 104:1,6 104:12,17,20 104:23,25 105:5,21,23,24 109:21 111:5 111:10,14 113:2,14 120:4 124:23 219:1 238:21 254:15 risks 112:4 113:7 120:5 238:25 295:8 295:20 312:9 rn 2:19 road 3:6 4:16 role 245:12 250:16 roman 13:14 13:18 14:15 rooney 4:20 root 7:11 123:20 300:17 300:18 301:20 302:2	roseland 2:11 rosemarie 3:9 rosemarie.bo... 3:11 rough 72:9,10 roughly 72:2,8 115:5 241:25 route 23:10 routine 130:14 272:23 273:2,9 273:12 276:5 276:21 277:3 278:5,6,8 281:11 316:24 routinely 132:24 rpr 1:12 rules 152:6,17 run 277:7 running 175:11 175:13 278:19 292:5 rush 147:15 russ 279:22,24 280:4,5,7,24 russ's 280:3 russian 169:16 176:12	safe 298:12 safety 7:11 24:8,11 29:18 29:23 30:1 36:16 123:21 305:19 sake 154:13 salt 23:13 25:21 35:21 sample 66:11 240:21,24 241:1 samples 168:25 176:20 saponification 31:1 saponify 31:12 sartan 231:8 sartans 17:17 satisfaction 162:24 satisfied 162:8 saved 222:21 saves 26:8 saw 20:23 126:8 132:10 153:15 160:17 160:20,20 161:7 163:5 169:21 170:1 202:2,3 204:2 207:18 263:2 324:16 saying 14:10 44:2 46:12	58:15 62:7,9 89:3 90:6 92:23 103:18 104:11 113:4 119:6 122:21 122:23 123:1 128:22 129:2,8 130:3 141:1 142:20 144:8 146:12 152:13 176:9 177:9 181:18 191:21 196:18 199:24 205:16 209:19 232:1 264:11 275:19 282:21 292:16 307:15 317:12 320:2 says 26:3 36:12 50:11,15 63:20 64:15 88:16 95:3 110:9 121:1 140:16 141:21 142:11 156:7,23 174:20 176:11 176:19 177:16 180:20 181:11 181:16 193:4 195:24 208:19 209:9,25 210:14 216:3 217:12 220:18 221:18 228:18 229:11 254:13
	s		
	s 1:7 3:1 4:1 5:4 6:5,8 7:1 8:1 9:1,9 11:5 13:1 13:5 153:7 293:15 330:5		

[says - see]

Page 66

261:25 262:9	scope 69:2,18	168:14,14,15	75:23 76:22
272:9 299:20	scott 121:2	171:17 173:1	79:5 81:2 82:1
305:15 306:13	124:4	187:12 188:17	82:5,7,25 83:3
309:12 311:18	screen 10:7	197:17 231:16	83:17,22 84:1
314:7 317:8	18:13,21 21:23	232:1 246:16	88:19 94:6
318:22 321:16	50:1 81:2 82:1	255:11 259:15	102:4 104:9
321:25	82:3 129:18	261:24 267:6	106:10 107:8
scale 87:12	140:7 156:5,7	271:22 287:24	107:15 109:17
105:3 212:13	165:8 216:1	301:12 302:25	110:17 113:18
schoch 2:4	221:17 292:6,9	308:21 318:18	120:21 121:3
22:11 49:6	292:10,13	318:22 320:13	124:5 129:25
80:24 89:21	293:17 302:5	321:6	137:13,14
108:12 123:24	304:17 305:1	secondary	142:15 145:3
163:18 164:18	307:22 308:1	126:16,20	146:18 156:12
190:12 194:14	scroll 19:6	131:3 221:12	156:18 157:21
195:15 224:8	20:24 22:5	section 13:14	161:23 167:24
school 91:19	109:20 121:12	13:18,21,23	168:23 169:13
science 135:14	121:13 164:24	14:13,15 22:8	169:13 172:14
229:18 295:7	165:4 168:11	29:2,4 30:23	172:20 173:9
scientific 7:16	168:12 180:4,7	39:8 41:3	173:22 174:1
52:16 62:9	189:19 191:6	109:21 124:13	174:11 176:15
63:21 64:1,21	288:25 320:10	153:22 225:24	179:2,2,5
79:22 85:10	321:7	250:21 252:21	180:5 181:11
97:12 98:10	search 50:16	253:4 269:7	181:14 184:17
99:13 130:3	195:16 212:16	286:25 287:2,4	185:21 186:1
134:10 136:19	second 14:5	287:10,10,16	191:10,21
142:25 258:3	16:13 57:4	287:19 288:4	192:4,11,18
291:15 294:14	62:6,6 76:17	289:4 290:3	193:7 194:10
295:1,19	76:17 77:15,20	sections 14:4	194:16 195:12
306:25 312:8	77:24 85:15	108:24 252:7	195:17,23
scientist 97:21	86:5 90:25	see 18:21 19:3	197:16 198:3
scientists 26:12	92:18 99:16,18	19:16 20:3	200:7 203:23
100:1,14,15	112:5 129:5	26:4 28:6,9	208:25 209:25
scifinder 50:18	137:10 140:24	30:8 60:19	211:17 226:5
	151:11,12	66:24,24 67:22	232:21 233:8

[see - showing]

Page 67

236:10 252:9 255:22 260:25 266:5,9 267:7 270:14 282:9 287:4 289:4 290:2 300:24 302:15 303:15 305:6,12 306:21 308:16 308:17,19 310:22 311:19 320:18,19 321:9,13 seeing 144:9 seem 32:6 seems 174:5 176:22 183:18 197:25 286:11 seen 10:6 19:1 19:12 20:19 22:22 26:1 33:6,15,23,24 34:22 43:24 44:17,18 45:7 46:7 48:2 70:24 74:24,25 75:17 76:2,5 81:7 88:15 108:18,21 121:5,7 130:13 137:8 142:20 172:23 173:10 173:13 176:4,5 258:21 276:14 277:8 296:10	302:8 323:23 sees 28:14 select 150:14 selected 73:9 75:19 124:20 150:12,16 157:5 selling 214:23 214:24 send 180:12 223:12,14,23 224:6,11 292:21,25 sense 71:3 87:4 130:12 147:19 266:4 267:7,8 sensitive 142:19 sent 19:16 42:7 73:4 150:13 223:14,24 226:12,14 303:11 sentence 50:11 50:14 63:24 89:23 121:24 122:10 123:4 124:18 141:12 141:21 261:24 269:9 272:9 318:18,22 319:1 321:15 separate 187:15 224:8 224:11	separately 288:17 separating 132:16 133:18 separation 40:15,18 320:4 sequence 199:11 series 156:8 274:19 serious 281:8,9 seriously 183:4 183:8 set 87:7 271:5 279:17 283:11 286:19 291:19 329:6 setting 160:6 seven 49:6,7 93:14,15 156:11 158:22 249:14,16 286:7,9,12 289:9,11 309:8 327:1 seventh 159:17 several 59:1,22 64:19,25 98:6 124:3 150:20 212:16 shanghai 174:13,16 180:6 share 21:9,23 81:19,24	169:12 251:16 292:5,9,11,16 292:17,19 303:12 shared 232:19 shed 202:12 sheet 330:1 shelf 207:8 shen 305:9 sherry 305:8 shiang 301:8 312:21 313:5,8 313:17 shift 204:6 shocked 285:7 shorthand 329:2 show 21:11,23 124:13 135:22 136:3 164:10 164:25 165:22 166:5 171:25 172:1 175:21 176:1 185:6 264:5 279:4 284:19 310:21 310:25 316:22 318:1,4 322:1 showed 148:1 168:10 315:21 316:21 showing 33:4,7 33:15,20 42:21 43:2 44:18 86:22 107:9
--	---	--	--

[showing - slater]

Page 68

172:10 175:18 210:6 shown 275:3 shows 34:19 82:14 180:15 183:19 196:21 shut 232:1 shy 153:23 sic 37:11 46:11 140:4 side 50:22 240:23,23 sign 15:8 174:10 signature 329:12 signed 15:11,16 15:25 176:14 significant 143:25 similar 79:23 84:4 86:12 190:1 256:7 260:5 295:5 similarly 85:12 254:7 289:22 simple 17:13 91:12 222:25 223:4 simpler 149:9 176:7 simplest 223:1 simply 23:11 64:10 110:15 117:7 137:10	139:15 146:10 149:4 151:19 154:20 185:2 189:14 223:18 226:18 235:11 237:5 323:13 simultaneous 55:21 68:9 90:8,13,18 91:8 93:5 107:5 129:6 130:11 132:3 145:25 184:4 single 68:21 117:14 158:5 224:21 sit 76:9,13 137:25 150:3 170:13 186:6 186:20,23 229:23 230:16 248:25 sitting 227:24 situ 40:13 situation 264:23 296:15 situations 126:5 six 7:7 120:19 129:20 156:11 159:21 163:10 308:25 size 18:23 49:25 166:7 208:14,20	209:5 273:11 skadden 2:3 skadden.com 2:6 skills 229:3,10 skip 141:23 slate 2:3 slater 2:9,9 5:12,16,19 12:21 14:9,16 14:18,23 15:16 19:3,6,10 20:9 21:16,19 23:24 24:9,19,25 25:10,16,19,24 26:9,17 27:5,9 28:12,17 29:20 30:19 31:22 32:3 33:1 34:3 36:9,21 39:19 40:9 41:12 42:12,24 43:5 43:7,15,19,22 44:5,12,23 46:3,17 47:3 47:25 48:10,16 50:3,10 51:14 52:22 53:25 54:23 55:18 57:2,4 58:6 59:5,8,14,20 60:11,17 62:5 62:13,16,19 64:14,23 68:10 68:16 69:5	70:2,11 71:5 72:14,16 73:17 74:22 75:3,21 76:17 77:1 78:25 79:25 80:8 81:10,13 81:15 83:6,10 84:6,13,20,23 85:5,14 86:4 86:16 87:1,4 87:22 90:5,11 90:16,24 91:3 91:7,11 92:3 92:17 93:3,6 94:3 95:17 99:15,18 100:3 100:7,12,18,21 100:25 101:25 102:16,22 103:17 107:2,7 107:24 108:2,7 112:5 113:11 114:2,25 115:8 115:13,20 116:4,6,19,23 117:19 118:7 119:1,19 123:2 125:14,24 126:19 129:1,5 130:10,12 131:19 132:2,8 134:24 135:22 136:2 138:3,5 139:10,20 140:24 141:11
---	--	---	---

[slater - sodium]

Page 69

143:14 147:14	221:4,21	304:8,16 306:4	281:21 308:22
148:25 149:20	223:10,22	306:11 307:16	326:3
151:4,10,21	224:3,10,20	307:21,25	smart 61:8
152:1,4,12,21	227:11 228:3,8	308:9,20	204:1
153:14 154:2,6	229:5,20 230:3	309:23 310:6	smell 25:8
154:24 155:3	230:12,18	310:11,17,18	smelled 24:15
156:1,4 157:8	231:16 232:2,5	311:5,13	smokeless
157:25 158:9	232:22,25	312:15,21	246:4,14
158:17 160:10	233:2,5 235:16	313:10,16,19	snow 326:20
162:10 163:3	241:21 245:2	314:18,19	society 128:12
165:7 166:20	245:17,25	315:1,15,21,22	145:3,5 146:4
167:4,23	246:7,11,16	316:17,21,25	282:18
168:14 169:8	247:19 248:2,8	318:6,11 320:9	sodium 17:9,19
170:17 171:17	248:21 249:2	320:12 321:7	27:6 28:15,19
172:18 174:25	249:10,11	322:15 323:6	28:22 29:5,7
175:3,13 176:8	251:21 257:14	323:21,22	29:10,14 30:7
177:23 179:19	258:9 261:10	324:9 326:18	30:25 31:10
182:5,9,12,17	265:19 266:2	slater's 225:6	33:9 37:10
183:5,16,22	266:21 267:19	slides 9:25	38:9,13 43:3
184:5,11	268:21,23	311:12	44:15 45:23
185:12 186:11	269:3,18	slightly 217:14	48:5,9 54:5,14
186:14,22	270:24 272:1,4	258:1	55:5 56:3
187:2,9,16,17	276:25 280:14	slower 82:12	80:13 83:17,21
187:24 189:4	281:7,17 282:5	small 18:22	85:21 86:19,20
193:17,20	284:22 285:25	53:1 85:22	86:24 87:10,11
194:4,24 195:5	286:6 287:1,3	129:24 148:3	87:11,13,13,14
195:10 196:24	287:21 290:20	184:23 203:17	87:14,15,20
197:5,14 200:8	291:8,21 292:1	203:22 217:20	88:4 103:2
202:14 204:8	292:4,14,23	272:13 273:5,6	111:21 119:7
204:14,17	293:7,12 294:3	273:14,25	126:16 202:4
206:21 209:7	296:21 302:6	274:22,24	226:4 294:12
209:20 210:2,9	302:12,17,21	275:16,21,25	296:2 297:22
211:12 212:6	302:24 303:2	276:8,24	300:20,21,23
213:18 214:20	303:14,17,21	277:10 278:15	301:12,17,22
215:11 218:11	303:25 304:4,6	278:22,23	302:1 307:3

[sodium - specifics]

Page 70

312:13 322:10 solco 19:8 311:8 solco00032578 6:11 18:18 sold 59:25 254:17 solid 188:5 solubility 40:13 solution 28:15 29:6 33:10 43:4 44:16 solvent 17:23 39:10 40:7 45:24 47:22 50:20,23 52:8 80:16 168:21 168:25 169:4 169:14 170:2,6 170:11 184:20 190:1 207:24 208:6 273:20 277:10 308:24 309:4 solvents 9:19 33:14 169:21 174:6 176:21 203:19 308:6 308:14 309:6,9 somebody 55:14 150:15 151:7,20 214:17 221:15 240:24 241:7 249:20 264:4	270:15 319:10 sophie 172:12 sorry 12:15 19:3 23:19 31:16 34:5 35:25 41:2 46:19 49:20 56:6 58:6,8 63:3 65:4 66:3 71:16 76:12 78:2 81:11 82:11 83:25 92:8 101:2 107:13,18 109:12 110:10 120:10 121:2 122:6,9 123:25 125:17 130:6 135:22 140:17 140:24 142:9,9 142:17 150:24 158:11 162:14 164:8 172:18 172:25 184:5 186:14 189:3 189:23 191:6 210:2 214:12 219:13,13 225:18 231:5 232:7,14,22,25 236:16 244:11 248:11 253:5 254:5 255:8 257:2 263:16 266:14 283:6	296:21 303:3 303:23 304:2 307:19 318:13 318:17 325:8 sort 45:17 109:3 181:8 218:19 258:3 283:4 320:6 sorted 109:5 sound 294:14 295:18 sounds 26:11 26:22 27:3 47:6 142:3 source 234:20 301:6 south 2:15 space 141:23 141:25 309:6 spaced 172:19 speak 11:13 59:11 73:21 91:7 227:7 281:9 315:11 speaker 228:18 speaking 55:21 68:9 90:8,13 90:18 91:8 93:5 107:5 129:6 130:11 132:3 145:25 184:4 229:3 251:8 270:1 speaks 73:23 73:24 228:21	spec 135:5 138:10,12,18 138:18,21 139:24 148:10 277:5 320:7 322:1 special 257:21 specific 43:8,16 43:25 44:1 98:16 99:8 108:3 127:18 149:12 175:20 219:14 242:20 252:7 264:12 264:14 276:13 283:16 325:20 specifically 65:24 73:6 76:21 104:13 126:11 128:4 129:4,7,23 220:4,18 258:7 258:13,22 259:8 261:19 272:12 273:12 273:17,24 274:9 279:9 281:14 297:11 300:19 specifications 214:16 277:19 279:10 280:8 281:1,12 specifics 147:18 159:15
---	---	--	--

[specifics - steve]

Page 71

187:4 specified 283:16 284:5 284:10 spectral 321:18 321:21 spectrometer 143:25 spectrometers 311:23 323:12 spectrometry 140:4 142:12 144:16 145:6 146:4 240:19 282:10,19 285:5 311:19 311:20 315:25 316:6 spectrum 322:4 spell 153:5 spelled 48:24 spend 171:9 326:4 spent 150:19 spray 317:14 319:9,12 st 2:15 stage 87:8 stamps 6:6,9 13:2,6 stand 203:18 219:21,22 standard 11:24 142:21 143:10 143:16 145:14	145:16 196:4 197:13 207:7,8 315:13 318:3 standards 214:23,25 270:2 279:3,17 280:18 standing 220:1 241:7 standpoint 323:14 stands 320:3 start 16:23 78:22 107:13 236:7 238:1 308:3 started 47:20 127:10 154:10 starting 17:9 77:5 81:15 128:21 starts 252:21 261:23 269:9 321:12 state 10:25 11:10,15 14:4 60:14 140:18 255:5 300:15 329:2,14 stated 47:5,13 56:17 134:20 268:9 301:11 statement 7:4,4 7:8,9 50:25 51:12,15 63:2	73:10 78:13,14 78:16 79:20 97:13,18 112:7 114:24 117:18 120:14,15,16 120:22,22 121:14,17 123:6,14,17,18 124:2,7 141:2 256:2,19 257:6 262:14 269:20 288:3 299:25 301:19,21 319:17 statements 268:19 288:2 313:8 states 1:1 6:23 10:15 36:5 59:25 74:2,3 81:1,3 299:6 301:15 308:24 320:14,25 stating 122:18 306:24 321:22 stenographer 13:20 38:10 43:21 47:15 55:22 59:7 68:12 90:10 100:11 146:1 303:6 310:4,10 stenographic 1:10 11:2	stenographic... 329:6 step 17:8 28:8 28:10 32:12,12 37:14 46:1 54:21 55:13,15 56:21 101:13 101:18,20,22 102:1,6,23 111:22 135:21 217:4 222:16 306:18 stephen 1:7 6:5 6:8 9:9 10:12 11:17 13:1,5 293:15 326:25 328:11 329:4 330:3,21 steps 7:10 55:11 57:25 60:22 65:19 74:12 76:15 92:14 97:6 101:7 107:16 109:25 110:4 110:21,24 111:1,3,5 112:4 113:7,22 123:20 158:21 159:1,3,12 170:3 198:23 199:25 214:5,6 222:13,17,23 steve 272:2 303:7,21 310:6
--	--	---	--

[steve - sure]

Page 72

310:8,12,13 325:8 steven 3:4 250:12 sticker 224:5 stickers 224:12 stipulated 112:9 stipulation 112:9,13 stop 86:5,5 90:24 92:18 99:18 151:11 231:16 293:4 297:15 298:12 299:11 309:10 straightforward 104:6 106:9,24 269:11 stream 133:10 134:5 street 1:14 3:21 4:5,22 11:5 stretch 326:4 strike 261:16 strong 229:16 structural 232:8 structure 17:16 17:16 232:11 301:17 309:10 students 143:21 144:10 144:11,22 242:23 282:2	282:12,22 studied 146:22 231:9,11 238:24 studies 51:3 213:5 306:13 study 238:6 299:10 studying 242:10 stuff 161:24 171:3 229:12 259:4 273:20 325:2 subject 128:24 151:17 155:24 193:24 237:25 237:25 247:18 248:5 290:25 subjects 248:19 submission 6:11 18:7,18 19:18,19 27:1 33:16 34:17 submit 263:11 263:25 submitted 35:9 41:24 83:8 105:15 108:22 113:8,15,17,19 146:18 250:21 251:14 252:17 254:25 255:22 259:7 263:14 263:17 264:17	265:11 279:25 submitting 264:9 subscribed 328:14 330:22 subsequent 193:6 substance 9:15 132:25 188:14 267:17 294:18 304:12 305:3 320:16 321:1 substances 38:20 126:13 283:13 297:23 305:17 306:20 318:24 319:21 321:12 325:20 substantially 254:15 substantively 165:25 substituted 82:12,13 sudden 235:25 suggest 118:22 suggesting 77:6 152:21 200:4 201:11 suitability 37:17 suitable 298:7 suite 2:20 3:6 3:15 4:16,22	summarize 236:20 summary 38:2 82:21 192:8,18 192:21 196:8 255:12 supplement 255:8 supplemental 95:18 250:20 251:13 252:10 255:12,22 259:6,8 260:1 261:4,9,13 269:1 289:23 supplemented 67:9 70:1 supplementing 304:1 support 74:3 324:7 325:13 325:15 326:14 supports 168:9 suppose 139:22 179:21 supposed 161:24 sure 14:13 18:5 19:5 22:11 28:17 29:22 31:9 37:1 41:24 42:5 44:3 45:17 46:12,15 48:25 51:22 53:8
---	---	---	---

[sure - talk]

Page 73

56:19 60:25 62:21 64:12,17 64:25 73:19 76:9 79:17 81:14 86:23 87:6 88:11,25 89:17 95:6 96:11,13 97:14 101:5,12,15,16 102:16,19 103:12 104:20 105:8,9 106:3 110:15 115:3 128:1,21 135:1 135:14 138:13 138:21,23 157:14,15,19 159:25 160:2 161:1,6 162:3 165:11 169:10 169:17 178:7 182:21 200:16 200:20,22,25 202:16 204:21 206:13 211:21 215:4 221:7 223:16 231:24 233:6 234:17 234:25 235:12 236:21 237:20 243:7 246:8 253:1 256:12 259:5 260:17 264:3 265:22 266:6,23	267:24 268:4,8 268:19 270:18 273:1 274:12 315:1 surprised 212:23 surprising 268:1 surrounding 258:4 suspect 281:21 suspected 199:4 swear 11:3 switch 18:6 237:12 switched 31:9 236:2 sworn 11:6 301:7 328:14 329:4 330:22 sympathy 267:22 symposium 244:1 syncor00001... 9:22 310:2 synthesis 26:20 39:15 54:9 66:1 94:24 215:18 219:17 221:25 294:15 synthetic 50:17 system 7:15 136:18,24	320:1,2,4 systemic 131:13 t t 2:3 5:4,4 7:1 8:1 9:1 11:5,5 328:1 329:1,1 tab 18:15,16 22:14 164:9 172:5 190:10 table 108:6,10 109:12,13 195:22 take 10:9 13:16 21:15 22:7 23:9 28:2 35:18 41:15 49:23 50:8 54:3 56:16 57:25 60:20 63:5 69:3 73:4 75:11 80:21 81:20 82:19,23 83:14,14 89:16 92:14 109:7 110:4,24 111:1 111:3,13 112:4 113:7 114:7,11 123:13 124:16 129:10,14,19 132:12 135:12 135:19,21 137:9 139:7 147:14 150:9 153:25 154:12	154:13,14,15 154:22 155:6 155:22 157:6 158:21 159:2,2 159:12 163:14 163:20,20 164:9,14 167:10 169:22 178:16 180:4 185:19 186:3 189:19 193:9 193:15 197:2 204:18 225:23 226:11 249:19 249:24 250:1 253:3,22 255:20 260:8 285:14 289:19 290:20,21 294:3 298:11 311:5 322:3 324:10 taken 1:12 96:24 111:11 111:22 112:20 127:2 135:5 299:12 329:6 takes 63:11 114:16 155:15 204:25 233:20 250:5 285:20 291:5 talk 16:22 17:5 26:23 34:8 52:14 53:14
---	--	---	---

[talk - tested]

Page 74

56:21 59:10	136:10 148:8	142:23 143:11	166:16 167:19
61:1 66:3 67:3	148:16 152:7	230:1,9 234:16	168:11 175:23
67:18 77:24	155:25 174:23	234:23 294:12	177:3 183:1
78:1,3,4 87:18	180:1 182:7	297:21 301:25	186:24 190:2
89:6 105:18	187:10 194:3	307:2 312:13	219:4,9 241:16
206:7 218:6	194:11,18	322:10	272:1 323:11
222:11 223:7	203:20 214:2	teach 213:16	telling 117:4,7
224:15 225:14	221:18 222:9	teaching 91:20	temperature
236:22 241:12	233:24 235:6	213:21,24	217:23
241:14 252:7	235:22,22,25	technical 292:4	ten 70:8 290:21
275:3 312:20	242:17 244:11	technician	tens 97:11
314:21	256:14 274:15	209:3	term 276:19
talked 41:4	275:4 276:16	technique	terminology
43:13 49:14	278:4 297:9	318:23 319:20	274:13
77:18 92:20	298:25 307:21	321:17	terminus 3:5
105:11 147:25	312:23 317:20	technologies	terms 16:1
148:19 149:8	317:21 321:2	9:16 304:14	17:13 69:7,9
157:3 205:9	324:15	305:5 320:16	128:6 131:24
217:22 242:9	talks 28:6	324:3	164:3 295:25
248:15,19	82:10 230:4	technology	299:17 301:19
270:18 271:23	247:8 315:7	12:8 135:15	301:22 302:2
314:21	target 279:17	146:19 180:13	terribly 20:1
talking 15:4,9	task 305:18	269:10 307:2	tertiary 131:3
21:24 25:12	taught 237:25	307:10 309:13	test 114:23
28:18 43:15,23	239:24 240:5,6	309:20 311:1	118:6,12,23
46:22 48:4	242:23 243:2	317:5,7,9,12,14	119:18,24,24
49:25 54:20	tea 16:13,16	318:1,5 320:22	125:7,12,22
58:3 59:13	18:6,8 23:10	322:8	126:9 132:12
63:25 71:4,16	23:12,13,19	tell 22:24 54:2	132:24 140:21
77:2 91:16,18	26:23 27:1	82:5,22 89:9	176:21 265:17
101:1 107:12	30:5,16,23	92:1 115:24	265:25 266:20
107:19,24	33:5 101:9	126:8,19	267:18 312:10
108:3 115:10	103:15 104:18	140:10 143:23	tested 88:16
116:8 117:15	104:21 105:19	144:13 153:17	119:8 124:25
128:3 132:6	105:19 107:14	161:20 164:20	125:4 126:12

[tested - thing]

Page 75

139:25 140:3 testified 11:7 265:13,15,22 268:11 272:22 279:22 280:8 280:17,24 281:25 287:15 300:2 311:25 313:14 314:9 314:15 324:6 testify 248:18 329:4 testifying 11:20 122:24 testimony 12:5 56:14 77:11 82:24 85:17,25 88:12 89:1,8 96:12 106:12 111:4 112:19 118:20 147:4 148:23 149:18 149:18 150:2,3 150:11,15,19 156:18,22 157:20,22 171:22 172:20 178:11 186:15 187:11,13,15 187:19,25 188:11 189:10 205:20 212:5 215:25 236:11 248:5 257:22 266:8,18	272:18 291:14 301:7 307:13 312:25 313:6 313:15,20,24 314:14 315:20 323:5 326:25 328:4 329:5 testing 63:21 64:2 122:16,25 123:12 130:9 130:14,16,20 131:13,14,18 132:7 139:9 140:19 148:13 181:4 201:12 201:14,22 202:8,23 203:4 203:11,16 238:14 253:21 254:6 269:11 269:22 270:4 270:11,21,22 271:23 272:20 272:24 273:3,9 274:2,5 276:5 276:24 278:5,7 278:8,12 281:15 283:12 284:4 315:8 316:6,7,23,24 317:22 318:3 tests 124:20 201:17,18 283:15	tetrazole 17:10 17:14,15 23:14 28:7,15,24 29:7 35:21 37:13,25 38:4 38:7,12 39:10 45:18,23 48:5 48:8 50:20 79:23 82:14 89:13 tetrazoles 50:17 82:13 teva 3:2,2 250:13,15 251:1,10 252:23 253:12 253:20 254:11 254:17 255:16 255:23 256:3 257:13 258:22 259:25 260:24 261:4 263:18 263:24 265:8 270:15 283:3,3 287:10 303:8 310:9 teva's 253:17 254:2 263:13 text 12:11 59:2 194:7 textbook 61:17 210:16 213:15 textbooks 59:24	texts 58:12 thank 12:22 15:7 16:5 18:3 19:10 25:9,12 26:21,23 30:5 36:17 37:9,21 42:10 45:8,11 52:1 55:8 56:6 56:16 67:3 69:25 77:13 79:12 81:13 82:16 84:9 89:15 92:13 102:9 103:22 120:8 124:17 131:12 132:23 134:8 138:22 139:5 142:10 153:20 155:11 156:4 162:18 166:21 185:18 188:2 189:3 215:19 216:3 217:10,11,19 222:21,24 244:17 272:4 286:13 293:6 312:16 323:19 326:19,22 thanks 25:14 141:17 290:18 theoretical 208:23 thing 31:8 52:3 58:24 88:7
---	---	---	--

[thing - time]

Page 76

157:4 159:9	91:25 92:3	245:15 249:1	217:22 220:21
171:1,20	94:13,17 101:6	249:17 257:16	222:4 223:13
173:23 197:16	101:15 104:6	257:22 258:18	262:18,20
197:18 210:7	110:21,25	259:24 265:14	267:3 270:14
220:9 236:17	112:10,14	265:16,23	296:7 299:18
259:3 282:21	114:10 115:15	266:12,13,16	thousands
294:4 312:4	115:17,20,24	266:19 267:5,6	97:11,11
325:19	116:1,2,22	267:8,16,21	117:16 118:1
things 21:12	117:1 118:2,17	268:2 269:18	322:2
64:20,25 65:2	118:18 119:22	270:16 275:1,1	three 3:21
69:8 105:6	123:10 125:2,9	276:2,19 280:4	17:19 28:10
119:5 136:4	134:25 138:10	281:13 282:25	174:7 176:20
140:12,14	138:13 140:12	291:22,24	185:25 189:18
161:21 177:10	151:20 153:6	293:19 295:13	194:18 195:13
209:17 226:21	154:24 156:14	302:8,18 310:6	288:1 306:13
256:21 257:24	157:3 159:24	311:14 313:5	thrust 250:19
278:19 291:10	160:2,3,12,17	322:19 325:17	252:9
291:11 293:2	160:18,19,22	326:10	time 1:16 10:2
294:8 297:5	163:9,21	thinking	10:25 21:4,15
319:4,5,5	164:12 165:7,8	127:12 153:24	26:13 59:10
think 14:9,10	166:9,15,18	204:11	60:6 63:9,9,13
14:11 17:2,25	171:1,8 182:14	thinks 115:23	63:13 69:6
21:8,13,21,24	184:8 185:10	third 16:16	89:6 93:11,17
33:11 35:5	185:14,17	28:9 30:23	95:9 114:14,14
38:22,22 42:4	186:19 189:5	190:9 191:4	114:18,18
48:12 51:4,19	200:13 206:11	198:11,24	121:9 136:10
52:4 59:2	211:1 212:3	201:13 254:5	142:22 143:2
62:23 65:12	213:2 214:25	260:19 272:9	143:11 147:14
66:15 69:13,25	219:8 220:15	thoroughness	150:18 151:10
71:18 73:5,14	227:6 228:17	106:14	151:10 153:1
74:12 75:16,19	229:15 233:25	thought 25:3	153:24 154:20
75:22 76:1,8	234:1,2,15,24	54:6,9,10,12,13	155:13,13,17
76:20 77:16	236:7,9,20	54:16,18,25	155:17 159:25
79:18 82:23	237:2,9,18	55:1,6,14 58:8	160:20 171:2
85:11,24 90:22	242:8 243:8	61:17 180:13	171:10 176:19

[time - translation]

Page 77

181:9 184:7	246:4,14 326:2	tool 134:11,14	toward 142:19
204:9,17,23,23	today 11:19	134:21 137:24	towards 321:11
205:2,2 207:17	12:5 46:23	top 168:24	tower 4:21
218:6,25 220:8	47:19 70:4	181:7 198:3	township 4:16
232:2 233:19	76:13 128:20	216:17 261:22	toxic 297:12
233:19,22,22	137:25 138:25	305:16 310:23	301:18
239:24,25	146:21 154:7	topic 49:24	toxicity 99:4
240:8 241:5,19	170:13 186:7	114:11 148:11	toxicology
241:24 242:6	186:20,24	157:23 205:9	146:17
243:23 248:10	229:23 230:17	225:14 236:2,3	trace 60:1
249:6,9,12	248:20,25	241:11 253:24	80:11
250:3,3,7,7	257:23 265:23	314:19	tracking
255:20 265:10	266:18 272:18	topics 155:20	320:15
285:18,18,22	284:18,20	237:12 243:6	trade 4:22
285:22 291:4,4	286:20 290:18	248:16	trained 208:21
291:7,7 304:23	291:14 312:4	torrent 4:8,8	transcript 1:10
316:2 322:12	315:5	251:1,10	301:3 328:4
324:11 326:7	today's 326:24	255:23 256:3	329:5
326:20,24	told 62:8 70:2	257:13 259:16	transcripts
329:6	144:22,23	263:18 286:18	259:19,22
timeframe	294:20,24	286:20 287:5	transition
219:19	295:10,11,24	289:5,14 290:3	236:19 241:12
times 11:24	toluene 39:11	290:7,12	transitions
91:14,22 139:6	tonight 154:17	torrent's	277:6
202:2	took 55:11	287:20 288:5	translate
tin 16:10,23	60:22 65:19	total 210:1,13	230:22
17:5	74:12 76:15	326:25	translated 77:5
title 19:18	97:6 107:16	totality 67:10	230:21
120:22	109:25 110:21	69:19 185:6	translating
titled 8:23	111:5 113:22	235:12	228:1
13:15,19,21	170:4 183:4,7	totally 76:11	translation
195:2 252:23	198:24 199:7	171:7 172:18	7:20 8:4,16
305:1 308:12	200:1 214:5	191:12 267:11	37:23 166:12
tobacco 127:18	262:17 317:15	totowa 94:25	166:23,24
238:7 242:20	319:11		167:2,19 168:1

[translation - under]

Page 78

168:2 172:16 188:25 227:15 227:21,25 230:20,23 231:4 translations 73:20,20 189:8 227:10 transmittal 188:14 traurig 3:4 250:13 treated 17:9 tri 23:19 trial 251:9 324:7 tributyltin 17:22 18:2 23:15,21 24:13 25:4,22 27:24 trick 51:17,23 108:8 tricky 51:1,23 tried 109:6 116:13 183:3 230:14 triethylamine 23:13 25:21 27:25 35:20 103:5 trip 216:16 trouble 81:18 266:24 267:1,1 292:18	troubled 51:12 51:15 true 52:6,7,9,10 240:6 243:14 267:14,21 268:15 273:22 276:9 291:18 302:1 316:19 328:5 329:5 trust 12:8 224:12,15 truth 161:20 329:4,4,4 truthful 12:5 try 25:15 26:19 40:7 46:21 96:1 97:2 105:10 149:5 180:6 211:17 trying 43:23 44:3,3 57:13 61:21,23 67:20 69:16,22 96:13 96:15 97:7 98:1,4 101:12 102:10 103:7 103:11 106:15 108:7 110:14 115:17 116:7 134:19 135:17 136:14 140:15 144:14,21 145:14,20 146:10 147:11 147:18 163:1	171:12,13 173:24 175:24 176:2 184:25 185:1,2,6 186:25 189:14 200:5 201:1 219:23,24,25 222:22 241:5 249:15 276:18 303:4 turn 20:22 22:8 37:2 49:17 114:11 140:9 153:22 167:21 204:7 215:20 225:19 249:6 255:24 256:15 261:7 288:12 289:19 turned 163:6 184:10 turning 248:11 254:24 255:19 260:4 268:18 271:2,22 twenty 190:12 two 12:14,20 58:5 60:13 65:12 77:16 82:18 105:12 130:20,22 159:15 165:5 166:5,19,23 174:6 195:13 210:10 216:9	216:11 246:2 248:13 251:1 255:17 269:1 270:18,23 291:10 294:8 298:25 300:4 309:7 311:19 type 19:21,23 132:15 207:22 264:23 270:4 306:23 307:8 311:24 315:8 316:6,7,22,23 317:22 318:1,3 types 128:17 131:25 264:8 264:22 283:15 311:20 316:14 typical 208:9 typically 131:25 317:22 u u 48:24 328:1 uh 84:2 89:21 123:24 un 122:2 unacceptable 254:15 unaccounted 262:2 unanticipated 298:4 unaware 120:7 under 11:19 28:10 30:9
--	---	--	---

[under - update]

Page 79

39:8 53:23	107:18 110:25	171:10 189:6	250:4,8 285:19
54:8 57:21	113:3 118:20	199:20,21	285:23
59:18 77:21	129:2 130:2	205:19 216:12	united 1:1 6:23
78:1 79:9	135:23 138:1	223:19 229:4,8	10:14 81:1,3
109:19 119:17	140:15 143:19	235:1 237:6	universities
128:18 129:10	144:10,20,21	245:12 262:18	138:13
152:16 157:17	145:15,17	262:25 263:9	university
187:10 195:16	147:11 148:14	263:20,23	239:25 242:23
211:9 215:17	151:8 157:14	264:3,4 266:12	unknown 156:9
222:2 252:22	161:2,18	280:2 311:1	175:22 177:21
259:12 280:19	165:15 171:12	313:3,7,13,15	178:1 183:14
316:7,23	178:7,10	313:24 314:8	183:19 184:1,9
317:22	186:23 189:14	322:8	184:9,16
underlying	196:22 199:1	understood	190:24 191:12
187:22	200:5 201:2	60:7 67:18	192:9 193:25
understand	205:11,16	88:20 112:25	194:18 196:9
11:18 12:1	206:6 213:10	203:10 215:9	196:22 198:13
13:8 15:3 20:3	219:23,25	217:10 218:2,4	279:4,12,19
21:19 24:23	226:20 227:18	220:17 295:12	281:1 306:14
37:12 43:17	229:2 242:10	undertake	306:17
44:7 55:8,11	251:9 252:13	271:6	unknowns
56:19 57:13,19	253:2 257:22	undertaken	321:17
58:15,17,18,21	264:25 265:14	265:6	unnumbered
58:22 60:21	266:10 267:9	undo 208:15	260:13
61:1,21,23	267:12 269:8	undoubtedly	unpackage
67:21 69:2,17	270:18 276:2	318:25 319:21	58:25
69:18,22,23	278:9 283:11	unexpected	unpleasant
70:23 74:8	286:7 290:24	47:7	24:14
75:10,15,17,20	312:9	unhydrolyzed	unreasonably
78:8,14 79:19	understanding	41:19	254:14
86:1 89:3	22:24 46:12	unit 10:11	upcoming
96:10,12,14	48:25 66:20	63:10,14	251:9
97:6 98:1,4	72:20 75:14	114:15,19	update 7:6
101:13 102:17	88:11 103:13	155:14,18	120:18,24
103:20 106:15	140:12 169:11	204:24 205:3	

[upload - valsartan]

Page 80

upload 292:6 292:19,21	23:20 28:19 29:6,7 30:7	317:2,22 318:8 318:23 319:19	utilizes 100:1 uv 276:11 316:12 320:6
uploading 292:8	45:13,18,24 46:15 47:22	322:12 325:25 326:9 327:1	v
upper 192:12	50:19 59:1	useful 167:9 208:7	v 330:2
ups 312:18	65:14 66:19	users 208:20	vague 115:25 295:22
usa 3:2	67:1 74:14,19	uses 85:12 214:14	valeant 3:18
usable 116:14	78:21 85:11	using 9:15 17:22 37:24	validation 37:16 177:7
usage 23:18,20	86:13 89:6	48:5,9 50:18	valsartan 1:4 6:13,18 7:5,9
use 15:23 33:5 33:9,13 42:21 43:3,13 44:11 44:15 48:7 52:20 55:1 69:7 83:2 93:11,16 104:6 126:15,22 136:8 139:17 142:12 145:8 146:19 148:10 199:17 207:24 213:21,24 238:21 241:9 270:16 276:20 279:11,18 280:19 284:9 293:3 296:6 300:20 305:24 314:2 315:13 316:23 317:5 318:3 319:8 320:22 324:3 325:23	95:14,20 109:14 111:16 131:25 132:1 132:15,24 133:17 134:14 134:17,21 135:2,3,4 137:24 138:11 138:13,21 140:20 145:13 148:1 167:3,6 167:20 207:11 207:25 211:15 211:22 213:2 213:16 234:3 234:11 249:14 251:10 252:3 266:7 267:25 270:8 276:10 276:10,12,19 277:5,9 280:10 280:25 281:2 281:23 284:14 285:6 295:13 297:23 315:12 316:6,9,13	54:14 56:2 62:2 65:20 69:9 80:16 91:5 99:2,11 111:21 140:1,4 173:15 178:13 181:10 184:25 199:7 208:6 214:4 215:3,4 269:13 270:22 278:2,4,11 282:10 298:7 304:12 305:3 306:15 320:16	9:18 10:13 13:19,22 16:7 19:19 22:16 23:4 24:4 28:8 30:13 34:14 38:19 40:25 41:6,19 45:14 66:2 74:20 100:23,23 101:8,18,19 120:17,23 121:19 122:15 122:20 123:19 124:9 140:21 142:24 143:1 143:13 176:13 176:20 178:13 181:12,13,16 202:23 203:4 203:12 211:14 217:4,23 226:3 230:2,11 231:10,23
used 16:6 20:14 20:17 23:12,17		usp 283:7,8,12 283:17,19,25 usually 135:10 utilize 64:21 utilized 79:24 142:23 143:12 240:9 322:9	

[valsartan - want]

Page 81

232:9,19 247:8 251:11 253:20 254:17 258:7,8 258:14,23,23 264:18 265:25 267:16 269:24 272:19 276:22 277:20 279:3 280:9 290:13 290:14 298:5 299:7 300:20 300:22 301:16 301:21 307:17 308:5,12 309:2 314:6 316:24 330:2 value 309:9 vaporized 132:17 133:19 variety 172:12 various 1:13 58:2 105:6 126:4 147:25 148:1 156:17 210:17 216:4 223:4 234:12 257:18 vast 126:15 321:18,21 322:1 vaughn 2:19 vein 51:23 venture 126:22 veritext 10:18 10:20 327:2	330:1 version 226:14 288:16 versions 77:5 116:1,10 versus 219:18 vertex 163:21 164:1 165:12 165:14 166:17 174:7,23 175:2 176:13 178:12 179:17 180:20 180:21 181:4,9 181:20 187:21 vicinage 1:2 10:16 victoria 3:5 video 10:8,12 videoconfere... 1:13 videographer 10:1,18 21:3,6 21:10,17 22:3 63:8,12 114:13 114:17 155:12 155:16 204:19 204:22 205:1 233:18,21 250:2,6 285:17 285:21 291:3,6 326:23 videotaped 1:5 view 62:3 113:4 views 79:19 296:14	virtually 10:4 vitae 9:9 293:14,21 voc 134:21 137:24 volatile 134:1,6 134:14,16,17 319:7 volume 11:12 11:13 94:24 95:2,3 w w 3:15 w.l.f. 9:5 206:19 wait 62:16 77:1 146:2,2 151:10 151:10 210:2 302:25 walk 63:6 183:3 198:23 walked 182:14 185:9 wallack 4:15 walsh 3:20 walsh.com 3:23 want 11:25 13:16 14:2,3 14:22 15:2,18 15:24 21:6,9 23:11 24:22 26:13 27:12 28:13 34:10 41:1,23 42:5 45:14 46:11,15	49:21 50:10 51:12,22,25 55:10 56:19,21 57:10,19 58:16 58:17,22,25 60:21,24,25 62:19,21 63:24 64:17 67:19,21 68:17,22 69:1 69:2,10,10,12 69:18 70:19 71:2,3 75:13 75:15,23 76:19 77:24 78:1,3,4 78:11 79:3,4 79:14,17 80:21 80:25 81:21 82:17,24 83:11 84:20,24 85:1 86:9 88:11,12 88:23,25 89:2 89:6,18,23 90:22 96:1,2,5 96:9 97:6 101:6,16,21,25 103:12,19,19 103:25,25 104:8 105:8 106:3 110:5 112:6 113:18 114:7 119:10 119:11,12 120:9,13 121:12,13,24 124:13 128:2
--	---	--	--

[want - widely]

Page 82

129:2,17,19	244:22 248:17	watson 283:4	week 279:22
130:4 135:1	249:19,25	way 37:8 38:23	weight 216:6,8
137:13,15	252:8,13 253:1	42:3 47:5,11	welcome
138:1,23 140:6	253:3 255:4	47:13,13,18	137:11 182:24
142:9,15 143:6	256:20 257:24	74:18 100:8	went 45:12
143:7 146:9	258:4 259:5	102:2,5 106:25	92:21 93:19,24
148:13 149:9	260:17 268:4,7	118:2 121:17	105:13 154:9
152:1 154:3,13	268:19 269:8	127:5 135:21	154:11 199:14
154:16,22	270:17 273:1	147:16 158:4	202:6 212:23
155:20,21,23	274:12 276:4	168:19 175:7	235:21 263:3
156:6 160:25	276:15 285:2	179:23 183:11	286:8 300:5
161:2,23 164:8	286:1,21	189:4 192:25	west 2:5 4:22
164:10 165:15	287:14 289:22	197:1 202:25	wet 37:14
166:14 167:25	292:12 294:7	221:11 223:8	whatsoever
170:1 171:9	301:5 302:24	224:18 227:25	33:25 43:12
172:24 175:13	312:3,20 314:3	234:12 236:12	45:4 62:1
175:14 176:6	314:21 317:5	266:11 284:14	76:14 104:23
180:4,14	321:9 322:18	ways 65:13	110:22 161:11
182:25 183:25	323:9 324:10	77:17 276:3,17	whoops 137:18
186:11,14,17	324:19	wayside 135:9	wide 128:6
186:23 188:12	wanted 21:11	we've 32:17	widely 53:11
189:9 194:10	75:7 82:3	34:1 44:21	53:12,15 55:16
198:9,25 204:6	180:25 208:17	63:4 93:20	55:20 56:1,3,4
204:18 205:8	233:6 234:1	114:10 128:19	57:16,20 58:1
205:11,13,13	236:8 237:5,11	149:8 174:23	59:19 60:23
206:6,10 208:1	323:14	179:12,16,25	86:15 98:7
213:10 214:13	wants 154:14	185:3,9 194:3	125:20 127:4
214:14 218:5	154:15 317:6	205:6 206:11	134:14,17,21
222:11 223:18	warning 9:11	208:21 212:15	135:2,3,4
223:20,22	296:10,19,22	215:24 221:18	137:24 138:10
224:1,4,6,12,16	297:1 298:2	222:9 236:7	138:12,20
224:24 225:14	watch 155:1	238:7 248:13	211:10 212:8
225:15,19,23	water 60:2	271:4 292:15	212:11 285:6
232:16 235:11	216:18	303:5 304:17	316:1
241:12 244:21		314:21 324:14	

[widespread - yeah]

Page 83

widespread 326:15	79:4 88:12 106:7 124:22	worry 278:23 wrap 286:20	144:8 220:14 228:18
withdraw 71:17 107:6,6 176:14	161:1 162:21 234:3,15 269:19 276:12 322:20	write 151:6,7 151:20 247:21 247:23 248:4 313:4 314:11	xue's 140:6 228:12 xxxv 94:24 xylene 17:23
withdrawing 62:17	work 21:15 134:4 151:14 151:22,23 155:9 169:12 197:19 241:25 244:19,25 245:9,14,23 277:12 279:8 325:16,22	writes 174:3 writing 151:15 152:23 writings 212:21 written 12:14 71:12 151:23 153:12 212:16 226:1,4,25 314:13 325:3	y
withdrawn 42:6 62:15,25 67:5 73:13 78:3,18 98:3	worked 131:7,9 131:21 180:5 240:23 282:3 282:23 305:9	wrong 26:6 32:1 48:23 123:10 144:7 145:10,11 181:10 189:5,9 220:15 261:12 268:3 276:19 326:8	yardley 4:17 yeah 11:14 18:25 19:11 28:11 30:21 49:2 50:13 58:10 65:22 68:3 69:5 71:14 73:22 74:5 83:4,19 94:13 97:24 104:3 109:10 113:15 119:16 119:21 120:11 122:1,5,8 124:19 125:4 138:9,20 141:10,18 142:3 147:20 148:11 149:15 150:25 154:5 157:2 159:12 163:5 164:21 165:22 166:13 167:22 169:14 174:2,4,12 176:8,16 179:7 180:24 181:2,6 181:22 182:21
witness 1:14 10:7 11:4 50:12 55:23 59:13 64:16 90:21 248:5 249:23 250:1 285:16 286:11 290:19 326:22	working 61:4 91:19 99:7 196:21 257:12 306:6	wrote 151:9,16 151:19 152:4 246:4 247:6 313:5	
witnesses 157:12 259:22	works 98:19 163:19 211:18	x	
witnesses' 330:3	world 59:25 115:7,9,10 117:13 258:2	x 1:8 5:1 7:1 8:1 9:1 48:24 xl0l6l8 329:2 xue 6:21 48:24 49:9,13,24 73:23 140:13 141:21 142:20	
wondering 303:10	world's 97:12 97:22 99:25 100:14		
word 38:5 42:17 59:1 74:12 95:14,21 104:6 105:1,25 182:20 239:13 295:13	worldwide 211:20		
wording 229:18	worried 174:9		
words 37:19 57:17 60:25			

[yeah - zhp's]

Page 84

183:8 187:2	240:1 246:23	19:18 20:20	197:10 198:15
192:15,19	278:18 323:8	22:6,15 23:2	199:7 202:8
193:23 194:14	yellow 195:23	26:25 33:4,8	204:2 232:18
200:6 204:11	yep 32:20 36:3	33:20 34:17	233:10 234:2
204:16,16	40:22 59:14	42:7 43:8,12	234:19 235:4
205:5 209:9	73:25 83:13	43:24 44:10,20	251:9,24,24
210:21 211:25	124:6 130:1	45:13,18 46:8	252:10 253:12
224:1 226:19	135:16 142:6	48:7,14 62:2	253:21 255:7,9
227:5 229:7	148:20 165:3	65:14,19 67:25	255:13 259:13
235:10 236:16	177:19 191:19	68:5,6 69:19	259:22 260:18
237:4 238:4	191:24 192:5	70:9,20 71:9	262:11,15,18
241:23 242:7	193:8 195:11	71:12,12,20	263:24 264:16
243:21 246:15	195:25 196:12	72:22 73:14	265:1,4,15,15
246:20 247:1	218:18,23	74:12,19 76:15	265:17,23
247:21 248:8	226:6 233:9	78:17 86:13	266:18 267:23
249:23 252:20	247:10,14	104:4,11,16,20	272:16,22
253:9 255:2	256:1 268:24	106:8 107:9,16	273:4 278:3,5
257:16,19	274:4 302:24	110:15 111:5	280:10,24
259:11,20,24	312:24 317:24	119:13 127:12	294:6 296:24
267:5 268:15	320:20	130:5,15,19	297:3,6 298:1
268:16 271:1	yield 37:20	142:25 146:25	298:2,23 299:5
278:10 280:21	38:3,7,11,17	148:22,23	299:12 300:1
284:11 286:11	41:20 98:19,20	149:12,18	300:18 308:24
286:23 287:7	yielded 46:2	156:8 161:6	309:4,12,19
289:3 292:14	yields 109:15	164:4,5 166:25	311:1,9,17,25
302:17 303:2	york 2:5,5 3:10	167:15 168:10	314:15 316:8
306:4 314:10	4:11,11 330:1	170:4 171:4	318:1
315:1 319:25	yup 137:20	178:5 180:5,21	zhp's 33:16
321:9 323:7	z	181:9,16	43:3 44:11
year 145:2,6	z 38:13	182:15 183:4	48:24 73:23
146:5 247:9	zhejiang 2:2	188:8,11,18,20	84:5 100:23
year's 232:23	zhp 6:10,13	189:1 190:24	226:3 265:10
years 15:17	7:21,23 8:12	191:16,20	268:13 271:13
127:3 146:17	8:14,17 9:12	192:8,16 193:4	295:11 316:21
174:7 207:19	16:6 18:7,18	194:11 196:21	

[zhp00496153 - zoom]

Page 85

zhp00496153	142:22 143:11
8:12 188:8	198:15 222:10
zhp00496155	230:2,10
8:15 188:20	294:12 297:9
zhp01344159	307:3 312:5,12
9:12 297:3	322:11
zhp01710663	zoom 1:13 82:1
6:13 22:16	82:3
zhp01746277	
9:20 308:7	
zhp02118680	
8:21 193:12	
zhp02118709	
8:24 195:3	
zhp02118712	
8:19 190:16	
zhp02630924	
7:19 163:23	
zhp02630926	
7:23 8:4	
167:15 168:3	
zhp02709940	
8:9 178:20	
zhp0477534	
8:6 172:8	
zinc 16:19 34:9	
34:18 35:21	
37:10,24 39:9	
39:22 40:4	
45:18,19,22	
48:4,8 50:18	
83:21 84:5	
87:7 101:2,8	
102:14,21	
103:14 128:23	

Federal Rules of Civil Procedure

Rule 30

(e) Review By the Witness; Changes.

(1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:

(A) to review the transcript or recording; and

(B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.

(2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1, 2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS
COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.